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Abstract 
Antibiotics are a cornerstone of modern medicine and have drastically reduced the burden of infectious 
diseases. Unfortunately, resistance to all clinically used antibiotics has become a major challenge that is 
exacerbated by numerous difficulties surrounding the development of new drugs. However, inventive 
strategies to overcome resistance as well as discover novel antibiotics are increasingly being explored. 
Whereas traditional antibiotics were generally designed to directly kill as many species of bacteria as 
possible, several new approaches have focused on narrower spectrum agents that have significant 
potential benefits. Antibiotics active against only one or a small group of pathogens would spare the 
microbiome, which may decrease the risk of secondary infections and slow the spread of resistance. One 
such narrow-spectrum strategy is to target the virulence factors employed by pathogens during an 
infection. In chapter 2, I demonstrate that the FDA approved HIV protease inhibitor nelfinavir can be 
repurposed as an inhibitor of the biosynthesis of the Streptococcus pyogenes cytolytic toxin streptolysin 
S. Nelfinavir was utilized to explore the proteolytic processing step in streptolysin S biosynthesis and was 
also shown to inhibit toxin production in other pathogens known to harbor similar biosynthetic clusters. 
Another approach to the problem of finding new antibiotics can be found in facilitating natural product 
discovery. Many antibiotics are derived from natural products but continuing to find new compounds has 
become increasingly difficult, especially due to rediscovery of known natural products. To help 
circumvent this problem, I developed a probe for identifying natural products containing aldehydes and 
ketones from microbial extracts based on the chemical reactivity of those carbonyl functional groups 
(chapter 3). This method is agnostic to the activity of the product and allows for the rapid identification of 
low abundance compounds that may be missed through activity-based screening. I demonstrate the utility 
of this probe by screening a collection of bacterial extracts, leading to the discovery of an analog of the 
protease inhibitor antipain. 
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Chapter 1: Introduction 
This chapter is taken in part from Maxson and Mitchell
207
 and is reproduced with permission from 
Tetrahedron. 
 
1.1 The impetus for antibiotic research 
 The advent of antibiotics in the early twentieth century catalyzed a medical revolution, drastically 
reducing mortality due to bacterial infections. Along with numerous other advances in healthcare, such as 
vaccines and improved sanitation, antibiotics have contributed to an extension in the average life 
expectancy in the USA from 59.7 years in 1930 to 78.7 years in 2010.
1
 Antibiotics are a critical 
component of a number of modern medical procedures, including many surgeries and transplants, as the 
rate of severe complications and death from infection would otherwise be unacceptably high. Decades of 
research into antibiotic development have produced highly effective and safe antibiotics, giving clinicians 
a wide range of tools to prevent and fight bacterial infections. However, resistance has inevitably 
followed the release of each new drug,
2-7
 and the rapid propagation of resistant pathogens has become a 
serious issue, resulting in at least 23,000 deaths in 2013 in the United States alone.
8
 Of particular concern 
are the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) which have high levels of 
resistance and frequently “escape” eradication by antibiotics.9, 10 While drug resistance or insensitivity can 
arise in other therapeutic areas, only in infectious diseases is that resistance known to be directly 
transmissible from person to person. Conservative use of antibiotics to slow resistance can be beneficial 
to society by extending the lifetime of current drugs
11
 but doctors still use them liberally to treat 
individual patients if alternative options are not available. This has created a unique situation where 
everyone is at risk of having fewer treatment options than in previous decades unless the development of 
new antibiotics keeps pace with the development of resistance. 
 Unfortunately, bringing new antibiotics into the clinic has proven to be challenging for a number 
of reasons. The most fruitful strategy to discover novel antibiotics has been natural product screening, but 
it is increasingly rare to find compounds with new scaffolds, with rediscovery of known antibiotics 
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posing a significant challenge.
12, 13
 Synthetic small molecule libraries have not fared better as effective 
antibiotics tend to have different properties than drugs in other therapeutic areas. Antibiotics often contain 
complex structures with multiple stereocenters and can be much larger than the usually small, flat 
compounds that dominate synthetic libraries.
14
 Thus, compound collections designed around Lipinski’s 
“rule of five” are poor sources for lead compounds.15 This has been especially evident in screening 
campaigns against essential targets identified through genomics in which hits from in vitro screens 
frequently failed to display activity in whole cell assays.
16
 A frequently cited factor for the decline in 
antibiotic development is the potential for low financial returns.
17-19
 Bringing new antibiotics to market is 
seen as a poor investment as they are often reserved as drugs of last resort with a short duration of 
treatment, yet are subject to a pricing scheme dictated by a market saturated with the generics of older 
antibiotics that are often still effective.
20, 21
 Additionally, FDA regulations have made clinical trials for 
antibiotics difficult and expensive to perform.
22
 Non-inferiority trials are usually required due to the 
ethical constraints of withholding antibiotics from patients with serious infections, and the very low non-
inferiority margin requirements result in the need for large patient populations.
20, 22
 This is exacerbated by 
the disqualification of patients who have received any prestudy antibiotic, although the FDA has started to 
ease the regulatory restrictions for antibiotic clinical trials over the last several years. These factors had 
two major consequences. First, pharmaceutical companies interested in antibiotic development focused 
more on broad-spectrum agents to widen the potential market. Second, there has been an overall drop in 
approvals for new antibiotics over the last 30 years (Figure 1.1), which is concerning since resistance to 
available drugs is rapidly climbing leading to some experts calling this a “perfect storm”.23-26 However, 
this drop in approvals may not be as dire as it initially appears. Only looking at the trend in the number of 
approvals conceals the fact that many of the antibiotics released in the 1980s and 1990s were perhaps 
rushed through development too quickly and have since been discontinued while newer drugs have thus 
far fared much better (Figure 1.1). Many of the second and third generation cephalosporins approved in 
the 1980s had overlapping clinical utility with better selling family members and were withdrawn due to 
poor sales, while several fluoroquinolones approved in the 1990’s were withdrawn for safety reasons.27 
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Despite the declining trend in antibiotic approvals, 2014 witnessed an uptick with four new molecular 
entities receiving FDA approval (1. dalbavancin, 2. oritavancin; both vancomycin derivatives, 3. 
ceftolozane; a 5
th
 generation cephalosporin, and 4. tedizolid; an oxazolidinone related to linezolid). 
 
Figure 1.1. US FDA approval and discontinuation of antibiotics from 1980 to 2014. Approvals are shown 
in black. Discontinued antibiotics are shown in red as negative values.
27
 Approvals are split by clinically 
useful activity into broad-spectrum, narrow-spectrum that target Gram-positive species only, and all other 
narrow-spectrum drugs (includes antimycobacterials). No narrow-spectrum antibiotics were discontinued 
during this time period. 
 
 The uptick of new approvals may have been spurred in part by a heightened academic and media 
interest in antibiotic development and conservation as a response to the dire consequences of antibiotic 
ineffectiveness. More recently, government organizations have been promoting antibiotic discovery as 
well. The United States congress passed the Generating Antibiotic Incentives Now (GAIN) Act in 2012 to 
financially incentivize antibiotic development
28, 29
 followed by Executive Order 13676 (Combating 
Antibiotic-Resistant Bacteria), which directs government agencies to promote the development of new 
drugs and diagnostics, identify means of slowing resistance, and strengthen surveillance efforts for 
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resistant bacteria.
30, 31
 A number of specific suggestions have been put forward to stimulate antibiotic 
development, including providing further financial incentives like research and development tax credits 
and grants, easing regulatory constraints, and promoting industry-academic collaborations.
23, 32, 33
 New 
ideas to identify novel antibiotics are also appearing in the literature. Given previous successes with 
natural products serving as antibiotic lead structures,
34
 strategies promoting natural product discovery 
with new cultivation techniques and molecular methods to reconstitute or activate specific gene clusters 
are especially promising.
15, 35-42
 Beyond representing a promising source of new antibiotics, natural 
products have also served as drugs or inspirations for drugs for many other diseases
34
 and have been used 
extensively as biological probes.
43, 44
 Another potentially successful approach for antibiotic discovery is 
reexamining old drug leads that were previously abandoned during development, often because they were 
not considered broad-spectrum enough at the time.
45
 Repurposing drugs designed for other indications 
can also produce new antibiotics or anti-virulence agents, with the added benefit of known safety and 
pharmacokinetic profiles.
46, 47
 
 Expanding the focus of antibiotic development to narrower spectrum compounds opens the door 
to the development of previously discarded leads, and makes it easier to find new ones by removing the 
requirement that a compound is growth inhibitory towards evolutionarily diverse bacterial pathogens.
15
 
Additional benefits associated with narrower spectrum drugs range from the possibility of slower 
resistance generation
48-50
 to the demonstrated decreased risk of antibiotic-associated colitis (i.e. 
Clostridium difficile infections).
51-53
 However, efficacious use of narrow-spectrum antibiotics requires 
rapid and sensitive diagnostics to identify the bacterial cause of infection. The current gold standard 
diagnostic is still traditional culture-based clinical microbiology, which is slow and often insensitive, such 
as with blood culture for sepsis patients.
54-57
 Furthermore, determination of an antibiotic resistance profile 
adds even more time to this process. Ironically, the ready-availability of numerous, effective broad-
spectrum drugs that saved so many lives also contributed to a stagnation in diagnostic advances for 
decades.
58
 Only in the past 15 years have improved diagnostic techniques begun to gain momentum. The 
introduction of new molecular techniques, especially those that are polymerase chain reaction (PCR)- and 
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mass spectrometry (MS)-based, have primarily driven this innovation and, along with several as yet 
clinically unevaluated technologies, have already resulted in tests that shave hours or even days off 
traditional diagnostic methods.
59
 The benefits and disadvantages of currently used molecular diagnostics, 
as well as several that are still in development, are discussed in Appendix A in this thesis. 
 Looking to the future, every avenue of antibiotic discovery and development will need to be 
explored in conjunction with efforts to conserve our current arsenal of therapeutics. Effective broad-
spectrum antibiotics will likely always be needed for emergency empirical treatment and for 
polymicrobial infections. Introducing a wider variety narrow-spectrum drugs that do not disturb the 
microbiome to the clinic may provide an alternative, safer option. Ideally, narrow-spectrum antibiotics 
and rapid diagnostic tests will co-evolve. The effectiveness of this strategy has already been demonstrated 
in cancer therapy with companion diagnostics
60
 and we argue that a similar effort is needed for bacterial 
infections. Regardless of the specifics of the approach, however, efforts to address antibiotic resistance 
are worthwhile and necessary endeavors that will hopefully maintain or enhance our ability to fight 
bacterial infections. 
1.2 Narrow-spectrum antibiotics 
1.2.1 Definition and therapeutic benefits 
 As a preface to a discussion on the benefits and drawbacks of antibiotics with different spectra of 
activity, it is important to define what exactly is meant by the terms “narrow-spectrum” and “broad-
spectrum”. The terms were introduced in the 1950’s as comparators to describe the obvious differences 
between the original penicillins, such as penicillin G, and the broader spectrum tetracyclines and 
chloramphenicol.
61
 When used to compare two antibiotics with different spectra of activity, broad- and 
narrow-spectrum are relatively easy to define. However, the terms have evolved over time into sweeping 
categories into which compounds with very different activities are lumped.
61
 This has resulted in 
discrepancies in the literature wherein an antibiotic described as broad-spectrum in one paper may be 
called narrow-spectrum in another, often with no explanation as to why the label was chosen in either 
case. The phenotypic Gram stain is also frequently used as part of descriptions of narrow-spectrum 
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antibiotics; for instance, many agents act selectively on Gram-positive bacteria because the drug cannot 
penetrate the outer membrane of a Gram-negative organism. However, this can be misleading in the case 
of organisms that lack an outer membrane but are still phenotypically Gram-negative (e.g. 
mycobacteria).
62
 Additionally, many antibiotics that target only Gram-positive or Gram-negative species 
are still broadly active within that category. We will reserve the term narrow-spectrum for antibiotics that 
have a reasonable likelihood of only affecting one or a small handful of species when administered to a 
patient, either through specifically targeting a single species or by targeting virulence factors that would 
be generally absent from non-pathogenic bacteria. However, we include a discussion of antibiotics that 
are selective for a single Gram stain phenotype as these are often considered to be narrow-spectrum
63, 64
 
and are certainly narrower spectrum than many other available agents.  
 Historically, the development of broader spectrum drugs by synthetically modifying existing 
antibiotics was the goal of pharmaceutical companies.
4
 This can be readily seen with beta-lactam 
antibiotics, which were designed to achieve broader activity with the second and third generation 
compounds.
65
 This approach is logical from a number of standpoints, most notably offering 
pharmaceutical companies the highest potential return on investment, as the drug could theoretically be 
used for multiple types of infections. Furthermore, broad-spectrum drugs allow doctors to treat infections 
empirically with a higher likelihood of success.
66
 This is critical in life-threatening situations and broad-
spectrum antibiotics will likely always have a place in medicine for this purpose.
66
 The simplicity of the 
“one drug treats all” approach is appealing, but retrospectively we can no longer ignore antibiotic 
resistance and other associated problems like C. difficile infections. While a number of factors contribute 
to the rate at which resistance appears and spreads, including the frequency of use and misuse, the type of 
resistance mechanism required, and the fitness of resistant organisms,
67, 68
 the use of broad-spectrum 
antibiotics appears to be correlated with increased emergence of resistance.
48-50, 69
 Accumulation of 
resistance to antibiotics other than the one employed in treatment has been observed as well,
49
 resulting 
from horizontal gene transfer (HGT) of DNA cassettes containing multiple resistance genes.
70-72
 
Administration of several broad-spectrum antibiotics, especially those that accumulate in the intestines, 
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can have a devastating impact on the microbiome that persists for months or even years after cessation of 
treatment.
73-76
 As alluded to in section 1, disturbances of the gut microbiome can lead to a number of 
issues, most notably C. difficile infections.
77, 78
 C. difficile thrives in the human colon when other bacteria 
are not present to suppress its colonization and growth.
79, 80
 Secondary infections like those caused by C. 
difficile are directly linked to antibiotic usage, especially broad-spectrum cephalosporins, 
fluoroquinolones, and clindamycin.
77
 Thus, C. difficile is difficult to eradicate with antibiotics owing to a 
catch-22-like scenario. As such, healthcare-associated strains of C. difficile have quickly become a global 
problem.
23
 Additionally, antibiotics may be contributing to other issues linked to changes in the gut 
microbiome including chronic inflammatory diseases, diabetes, and asthma.
81-85
 It is becoming 
increasingly obvious that the health of the microbiome must be taken into consideration during the 
development of future antibiotics. 
 Due to the drawbacks of broad-spectrum antibiotic usage and the general difficulties associated 
with finding new drugs capable of inhibiting the growth of a range of evolutionarily diverse bacterial 
pathogens, there have been calls in the literature to give renewed consideration to narrow-spectrum 
compounds.
58, 86
 A number of possible benefits to using narrower spectrum drugs have been postulated, 
including those mentioned above, although some of the benefits are either theoretical, anecdotal, or are 
based on limited clinical data. In contrast to broad-spectrum treatment, the use of narrow-spectrum drugs 
may slow the spread of resistance through a lessened impact on the human microbiome, leading to 
reduced HGT of pre-existing resistance mechanisms.
50, 76, 87
 Further studies are needed to confirm the 
trend, but large scale correlative evidence of this can be seen in Europe, where northern European 
countries tend to prescribe narrow-spectrum antibiotics more frequently than their southern neighbors on 
a proportional basis.
87-89
 However, it is difficult to determine the direct impact of narrow- versus broad-
spectrum antibiotic usage on a large scale since resistance rates also correlate heavily with frequency of 
usage. Countries that take a narrower spectrum approach also tend to be more conservative towards 
antibiotic usage overall and an increase in use with possible new narrow-spectrum antibiotics could still 
potentially cause a rapid rise in resistance. Sparing the gut microbiome has also been shown to correlate 
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with a lower rate of childhood obesity as compared with the use of broad-spectrum drugs.
90
 Although 
direct evidence for the impact of broad- versus narrow-spectrum antibiotics on other conditions associated 
with the human microbiome is scarce, it is not difficult to imagine that significant links exist. As for the 
treatment efficacy, numerous studies have demonstrated that narrow-spectrum drugs can be just as 
effective as broad-spectrum ones in certain circumstances, especially in prophylaxis.
91-94
 
 Narrow-spectrum drugs have been developed and marketed since the advent of antibiotics, 
starting with salvarsan for syphilis. However, there has been a recent uptick in FDA approvals of 
antibiotics with narrower spectrums of activity, especially drugs targeting Gram-positive bacteria (Figure 
1.1). Pathogen-specific antibiotics that target only one or a small set of species are also receiving 
increased interest, with fidaxomicin being recently approved as a selective agent for C. difficile that 
permits the gut microbiome to recover.
76, 95
 Other strategies for fighting bacterial infections, such as 
targeting virulence
3, 96, 97
 or treatment with antibodies or phage,
58, 98
 are alternatives to growth-suppressive, 
small molecule antibiotics that spare the microbiome and possibly slow resistance. However, these 
approaches must be demonstrated to cure patients as effectively as traditional antibiotics or they will not 
gain FDA approval, let alone find clinical utility. Even if treatment with a broad-spectrum antibiotic leads 
to the spread of resistance in the longer-term, the immediate need of the patient will likely outweigh what 
may be best for the community at large.
99, 100
 
1.2.2 Antibiotics selective for one Gram stain group 
 Until recently, narrow-spectrum generally meant that an antibiotic was only considered to be 
active against either Gram-positive or Gram-negative bacteria, with the exception of drugs for 
tuberculosis (TB) and salvarsan for syphilis. However, as noted in section 2.1, many of these drugs are 
still rather broad-spectrum within one Gram stain grouping. Many of the early antibiotics are Gram 
selective, but this shifted to a trend of even broader spectrum compounds in the 1980s and 1990s as 
medicinal chemists continuously tinkered with the properties of existing drugs.
4
 This resulted in the 
release of ever more broad-spectrum fluoroquinolones and second and third generation cephalosporins 
during that time period.
34
 More recently, there has been a shift towards the approval of more antibiotics 
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active only against Gram-positive bacteria (Figure 1.1), spurred in part by the prevalence and threat posed 
by multiple drug-resistant (MDR) S. aureus and Streptococcus pneumonia. These two pathogens alone 
were responsible for over 75% of deaths from antibiotic-resistant infections in the United States in 2013.
8
 
Discovering compounds with Gram-positive-only activity is theoretically easier than for Gram-negative 
activity, since the outer membrane present in most Gram-negative bacteria presents a formidable 
barrier.
101, 102
 Focusing on a subset of bacterial species helps circumvent problems posed by the diversity 
among species that must be considered when attempting to develop broad-spectrum antibiotics,
103
 though 
targeting an entire Gram stain grouping may not be specific enough to reap the potential benefits of 
narrow-spectrum agents. 
  Two notable examples of the renewed interest in narrowing the spectrum of antibiotics by 
targeting Gram-positive pathogens are the oxazolidinone and lipopeptide classes (exemplified by the first-
in-class agents linezolid and daptomycin, respectively) (Figure 1.2).
103
 Intriguingly, both compounds had 
been identified as potential leads, but discarded because of toxicity concerns.
104-106
 However, in both 
cases, different pharmaceutical companies picked up the development of the compounds, overcame the 
toxicity issues, and brought them to market.
104, 106
 Although both drugs are still broad-spectrum enough to 
be clinically useful in a number of infections, the fact that both have achieved blockbuster status is a 
testament to the potential for financial success with emerging narrow-spectrum antibiotics. A number of 
other Gram-positive selective antibiotics have been successfully released since, including glycopeptide 
and oxazolidinone family members. 
10 
 
 
Figure 1.2. Structures of linezolid and daptomycin. 
 Despite clinical and financial success, drugs targeting a single Gram stain grouping share the 
limitations of broader spectrum antibiotics. For example, the clinical appearance of resistance to linezolid 
and daptomycin was not significantly slower than for other antibiotic classes.
5, 6
 This may partly be a 
consequence of the success of the drugs, with high usage leading both to blockbuster status and the rapid 
development and dissemination of resistance. In theory, narrower spectrum antibiotics should have a 
reduced impact on the human microbiome, although this does not always appear to be the case for Gram 
selective drugs. Oral vancomycin treatment, although rare and generally reserved for C. difficile-
associated diarrhea/colitis,
76
 induces dramatic changes in the gut microbiome similar to broader spectrum 
antibiotics.
74, 107, 108
 Indeed, orally administered vancomycin kills Bacteroides species that are not 
susceptible in vitro
109
 which has been attributed to vancomycin concentrating to unusually high levels in 
the gut due to poor oral absorption;
110, 111
 however, this may also stem from the knock-on effect of wiping 
out a subset of the microbiome that produces factors that other members rely on for stable colonization.
76
 
The latter possibility is potentially an issue for all narrow-spectrum antibiotics that affect even a single 
off-target species.
107, 112
 Moving forward, the impact of Gram selective versus broader spectrum drugs on 
the human microbiome, as well as on resistance, will need to be examined in detail on a compound-by-
compound basis to determine if they do provide an advantage. 
11 
 
1.2.3 Pathogen-specific antibiotics 
 In contrast to Gram selective antibiotics, pathogen-specific narrow-spectrum antibiotics would 
theoretically be used against a specific pathogenic species/genus rather than a general disease category 
like sepsis or urinary tract infections (UTI). This would constitute a type of personalized medicine with 
clear parallels to newer cancer drugs that are marketed with companion diagnostics. In cancer therapy, the 
diagnostic serves the purpose of determining whether the genotype of the patient’s cancer cells is a match 
for the drug, while with an infectious disease the specific invading pathogen would be identified.
60, 113
 The 
main advantage of such a personalized strategy is that treatment would be expected to minimize collateral 
damage to the microbiome
95, 107, 112
 and perhaps even delay resistance acquisition by HGT. Pathogen-
specific drugs have been used for decades in the treatment TB, with a number of FDA-approved drugs 
that are only active against Mycobacterium tuberculosis and other related mycobacteria (isoniazid, 
ethambutol, etc.).
114
 The focus on TB stems in part from the staggering number of people infected (an 
estimated 2 billion worldwide) and the difficulty in treating the disease (6 months with multiple drugs).
114
 
While mycobacteria-specific antibiotics are effective at treating TB, a cocktail of several drugs that 
usually includes broad-spectrum antibiotics as well is necessary to prevent the rapid generation of 
resistance.
114
 Thus, TB presents a well-studied counter-point to the idea that pathogen-specific antibiotics 
may help to slow the spread of resistance. Nonetheless, the other potential advantages to pathogen-
specific treatment discussed in section 2.1 may still be beneficial, especially given the extended duration 
of treatment.
114
 Since TB does not kill quickly in most cases, there is time to accurately diagnose the 
disease through culture-based methods and begin a treatment regimen that includes TB-specific 
antibiotics. It should be noted though, that the existence of TB-specific drugs certainly had more to do 
with clinical efficacy rather than with a conscientious attempt to spare the microbiome. Mycobacteria 
contain a number of unique targets related to the cell wall that facilitated the development of specific 
antibiotics.
115
 Generalizing beyond TB selective drugs, there is no reason to think that pathogen-specific 
antibiotics couldn’t be developed for other pathogens as well, although it is likely that differentiating 
between two Gram-negative species, for example, would be more difficult than differentiating between 
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mycobacteria and other pathogens. Very narrow-spectrum antibiotics are anticipated to be useful 
primarily for mono-microbial infections, and only then if the infecting pathogen can be rapidly and 
accurately identified. Identification would either be through standard clinical microbiology or the 
observation of symptoms unique to a pathogen. If multiple antibiotics targeting a specific pathogen could 
be developed, they could be used as part of a cocktail therapy to help extend the lifetime of the drugs, 
similar to the treatment regimens for TB. 
 Partly because the pharmaceutical industry preferentially develops (and doctors prescribe) the 
most broad-spectrum agents possible, the targets of current antibiotics are ubiquitous in the domain 
bacteria. Antibiotics that target a single Gram stain grouping share the same targets and are only selective 
due to the presence of other cellular features like the outer membrane of most Gram-negatives and efflux 
pumps that prevent the accumulation of therapeutic concentrations inside the cell. To develop an 
antibiotic against a specific species, unique targets that are not only essential to cell survival but also do 
not exist or can be compensated for in other bacteria are required. The presence or absence of important 
enzymes, unique cellular components, and key metabolic pathways are possible future drug targets. 
Additionally, specific protein folds or 3D structures unique to a single species in the otherwise common 
targets of other antibiotics could also be investigated. Prodrugs that are only activated once taken up by a 
specific pathogen would also impart specificity to compounds that become toxic when metabolized, such 
as with isoniazid in the treatment of TB.
116
 Designing antibiotics around a specific target in one pathogen 
may even prove to be advantageous in that drug leads would not be required to have activity against 
distantly related homologs in other species. However, targets would need to be chosen carefully to ensure 
that sufficient differences between homologs exist and it remains to be seen if this is going to be a viable 
strategy. 
A bountiful source of pathogen-specific drug leads may remain to be discovered in the realm of 
natural products. Some of these yet-to-be-discovered compounds may specifically interact with 
ecologically neighboring species while leaving others unaffected, either as signaling molecules or as 
mechanisms to fend off competitors. A compound that acts as a signaling molecule for a specific species 
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at environmentally relevant concentrations may kill the recipient outright while still maintaining 
specificity at higher concentrations. Even in the absence of co-evolution of species, microbial natural 
products are endowed with properties that render them better able to enter bacterial cells and interact with 
efficacious target(s).
117, 118
 In addition to whole-cell screening with new compounds, pathogen-specific 
antibiotic discovery can also occur through screening against unique targets either in vitro or in silico, 
though serious pitfalls exist for these methods as discussed in section 1 and reviewed by Payne et al.
16
 To 
date, few pathogen-specific antibiotics have been reported and still fewer have been followed up on to 
any significant extent. The scarcity stems in part from the limited antibiotic testing performed on many 
new natural products. Often, only common pathogens such as S. aureus and Escherichia coli are screened 
during testing so select activity against rarer pathogens is undetected (although the financial realities of 
developing such a compound would likely be limiting). Conversely, if only a small handful of organisms 
are used, a compound with activity against only one tested strain may also have activity against other 
untested pathogens or against the multitude of species in the human microbiome. As always, the 
researcher can only detect what he/she screens for. 
Outside of TB-specific drugs, the only pathogen-specific antibiotic in use with FDA approval is 
fidaxomicin for the treatment of C. difficile (Figure 1.3),
95
 which is ironic given that the explosion in C. 
difficile cases is the direct consequence of widespread use of broad-spectrum antibiotics. Although 
fidaxomicin does display some activity against other species, the minimum inhibitory concentrations in 
these cases tends to be 10-100 fold higher than for C. difficile,
119
 allowing for the specific treatment of 
that pathogen with minimal effects on the gut microbiome.
76
 Fidaxomicin has been shown to reduce 
recurrence rates of C. difficile in comparison to vancomycin, likely by allowing the gut microbiome to 
recover.
120, 121
 The deployment of fidaxomicin to treat C. difficile infections represents an important 
milestone; however, the cure rates are still significantly lower than those achieved by fecal transplant.
121, 
122
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Figure 1.3. Structure of fidaxomicin. 
A number of other pathogen-specific antibiotics have been reported in the literature but have not 
yet found clinical use. The following examples are not meant to be an exhaustive list of pathogen-specific 
agents and additional examples can be found in other reviews.
123, 124
 Microcins are ribosomal peptide 
antibiotics, some of which are extensively post-translationally modified and display exquisitely selective 
activity.
125
 A notable example is microcin B17 (Figure 1.4), exerting activity against only a handful of 
related gamma-proteobacteria that lack the associated immunity gene that protects the producing 
strains.
125, 126
 The microcin B17 peptidic framework is decorated with a number of side chain-derived 
thiazole and oxazole rings
125
 that rigidify the conformation of the peptide and provide an interaction 
surface to inhibit DNA gyrase.
127, 128
 While microcin B17 does not exhibit the type of small molecule 
structure typically associated as being “drug-like”, other peptides (and even larger biologics) have found 
clinical utility, such as the HIV fusion inhibitor enfuvirtide (Fuzeon) or insulin for diabetes.
129
 Several 
other ribosomal peptides have been recently reported with pathogen-specific activity including the natural 
product plantazolicin (Figure 1.4), which, as another thiazole/oxazole-containing peptide, is 
biosynthesized in a similar manner to microcin B17 by Bacillus amyloliquefaciens and Bacillus 
pumilus.
130, 131
 Plantazolicin has selective activity against Bacillus anthracis but the biological target has 
not yet been reported.
132, 133
 The semisynthetic lanthipeptide NVB302 (from the natural product 
deoxyactagardine B) is another example of a ribosomal peptide-derived, pathogen-specific antibiotic 
(Figure 1.4);
134
 it has recently completed a phase I clinical trial for the selective treatment of C. 
difficile.
135
 Looking to more traditional, small molecule antibiotics, promysalin (Figure 1.4) is a novel 
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type of amphipathic salicylic acid-containing antibiotic produced by Pseudomonas putida with 
exquisitely selective activity against only other members of the Pseudomonas genus including P. 
aeruginosa, an ESKAPE pathogen.
136, 137
 Yet another example is the pyloricidins (Figure 1.4), a family of 
peptide-like small molecules produced by Bacillus sp. HC-70 and HC-72.
138, 139
 These compounds were 
discovered by screening specifically for activity against Helicobacter pylori, a traditionally difficult to 
treat gastric pathogen.
140
 Like the example provided by M. tuberculosis, the selective targeting of other 
traditionally difficult pathogens may be the ultimate niche for further pathogen-specific antibiotic 
development. 
 
Figure 1.4. Structures of pathogen-specific antibiotics. 
Most of the above examples demonstrate selectivity and potency in vitro which does not 
necessarily mean they would translate well into drugs. Additional studies are required, including 
determination of safety and pharmacokinetics, and the compounds (or derivatives) would need to meet all 
the stringent requirements for development into a drug. Whether this will happen is questionable given 
the high cost of drug development and the relatively small market for an antibiotic specific against rarer 
pathogens. A serious impediment in the development of pathogen-specific antibiotics is recruitment of 
sufficient patient populations known to be infected with the targeted pathogen, adding complexity to the 
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clinical trials. Granting orphan drug status to these compounds may help but additional financial 
incentives would likely also be required for pharmaceutical companies to proceed with development. 
Governmental agencies may have an interest in providing incentives for pathogens of homeland security 
concern, like B. anthracis. In the absence of subsidies however, it is probable that only pathogen-specific 
antibiotics against ubiquitous pathogens like methicillin-resistant S. aureus (MRSA) will attract interest 
from industry, analogous to the case of fidaxomicin for C. difficile. 
1.2.4 Anti-virulence agents 
 An alternative strategy for treating disease caused by a particular bacterial pathogen is to interfere 
directly with pathogenesis. Such an anti-virulence strategy is anticipated to reduce the pathogen’s ability 
to cause disease, rather than be growth suppressive. This entails targeting molecular entities that are not 
essential for the survival of the pathogen in vitro but are required for invasion and/or survival in the host.
3, 
96, 97
 A number of virulence targets have been explored, including inhibition or over-activation of quorum 
sensing,
141, 142
 inhibition of bacterial adhesion,
143, 144
 and inhibition of toxin production or delivery.
96
 Since 
virulence factors are often unique to a single or small set of pathogens, agents that target them will 
intrinsically be pathogen-specific, although there are certainly cases in which members of the microbiome 
have similar factors that help them stably colonize a host without causing disease.
145
 Targeting virulence 
rather than viability has also been postulated to cause slower resistance development due to the fact that 
the agent is not growth suppressive and thus elicits less selective pressure for acquiring resistance.
3, 96, 146
 
However, this prediction has not been sufficiently investigated and recent studies involving quorum 
sensing inhibition have cast some doubt on the idea.
147
 We postulate that the propensity to develop 
resistance with anti-virulence agents will depend strongly on a number of factors, including how critical 
the virulence factor is to the pathogen for maintaining fitness in the host. If the virulence factor is 
essential to survival in the host, one would expect resistance to rise at approximately the same rate as if 
the cell wall or the ribosome were being targeted. Although it remains to be tested, anti-virulence agents 
also may not deliver clinical efficacy if supplied to patients as a monotherapy.
86
 Formulating anti-
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virulence agents with immune-stimulating drugs,
148, 149
 or even a more conventional antibiotic, could 
prove to be the best future strategy for the patient and for the community. 
 A number of compounds that interfere with virulence through a wide array of pathways have 
been reported in the last decade. One of the first notable examples was virstatin (Figure 1.5).
150
 It was 
found to transcriptionally prevent cholera toxin and pili production in Vibrio cholerae without causing 
any growth effects.
150
 An in vivo infection model in mice demonstrated that virstatin treatment achieved a 
significant decrease in the bacterial burden.
150
 Interestingly, virstatin was also recently found to inhibit 
biofilm formation in the ESKAPE pathogen A. baumannii through inhibition of pili biogenesis.
151
 
Another example of an anti-virulence agent that showed efficacy in vivo is BPH-652 (Figure 1.5), which 
was originally designed to inhibit cholesterol biosynthesis by targeting human squalene synthase. BPH-
652 was also found to block a homologous enzyme in S. aureus, dehydrosqualene synthase, leading to 
inhibition of the oxidative stress-protective pigment staphyloxanthin.
152
 Without the protection of 
staphyloxanthin, S. aureus was much more susceptible to the reactive oxygen species delivered by host 
immune cells and was cleared more efficiently in a mouse model of infection.
152
 In addition to 
compounds that inhibit pathogenesis, there have been efforts to develop strategies to counteract toxins 
such as those produced by B. anthracis and Clostridium botulinum,
153, 154
 similar to existing antibody 
based anti-toxin therapies (e.g. raxibacumab for anthrax toxin).
155
 These types of compounds would not 
necessarily prevent or clear an infection alone but would rather reduce the damaging effects of the toxins 
and increase the chances of patient recovery. This is particular important for the pathogenic mechanism of 
diseases like anthrax and botulinum, which can cause mortality even if the causative pathogen is 
eradicated.
156, 157
 It may also be possible to develop pseudo broad-spectrum anti-virulence antibiotics by 
purposefully targeting virulence factors that are employed by multiple different pathogens, such as the 
streptolysin S family of cytolytic toxins.
158
 We found that the HIV protease inhibitor nelfinavir (Figure 
1.5) blocked the proteolytic maturation of streptolysin S in Streptococcus pyogenes as well as related 
cytolysins from other pathogenic Firmicutes.
159
 Such an approach may addresses the niche marketability 
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issue associated with pathogen-specific antibiotics while still providing the benefit of not disturbing the 
human microbiome. 
 
Figure 1.5. Structures of anti-virulence agents. 
 Despite the potential benefits of anti-virulence antibiotics, the fact that they don’t suppress 
growth directly could also prove to be a major pitfall. Some pathogens deploy large arsenals of virulence 
factors
160-162
 and inhibiting a single one may not sufficiently reduce their pathogenicity. Not all virulence 
factors are important throughout the course of infection either, with some required only for initial 
invasion or for dissemination to other body sites. This could prove to be an issue if treatment isn’t started 
until symptoms appear and the infection is well underway, although utilization in prophylaxis for immune 
compromised individuals or surgery patients could still be helpful. A further complication is that many 
pathogens have variant strains that don’t produce specific virulence factors and yet still cause disease; 
virulent strains of V. cholerae that do not produce cholera toxin and non-hemolytic strains of S. pyogenes 
that lack streptolysin S are examples of this.
150, 163, 164
 If advances in diagnostics can overcome these 
challenges, however, anti-virulence agents could be an excellent avenue for treating bacterial infectious 
disease. Additionally, coupling anti-virulence drugs with conventional agents in a multicomponent 
cocktail, as is done in HIV, cancer, and TB therapy, could serve to significantly improve patient outcomes 
by directly reducing bacterial counts with the survivors more vulnerable to the host’s immune system. 
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 An additional benefit stemming from the development of anti-virulence agents are opportunities 
to use these agents as tools to study pathogenesis. Traditional methods for determining the roles of 
virulence factors include reconstitution of the factor’s activity in vitro and generation of genetic deletions 
followed by in vivo infection models.
165, 166
 While reconstitution of the activity of a virulence factor in 
vitro can provide a wealth of knowledge regarding the interaction of the factor with its cellular target or 
its effect on a single cell in culture, the role of the factor in the context of the array of other virulence 
factors and their global effects on the host are lost. Genetic deletion allows these effects to be more 
effectively investigated in certain situations but is a heavy-handed approach to a complex question; the 
importance of the virulence factor at different time points during the infection is impossible to explore 
and the quantity produced cannot be modulated beyond a simple on or off. Additionally, deletion of some 
cellular components that are recognized as important for virulence also causes detrimental effects on the 
pathogen when grown in vitro, such as with modulins.
165
 Inhibitors of virulence factor production or 
action offer additional tools that help address these short comings. Anti-virulence agents can be used in 
vitro and in vivo to offer more temporal control over virulence factor action and provide a method to tune 
the activity of virulence factors through concentration-dependent inhibition. Anti-virulence compounds 
can also be useful in elucidating the biosynthesis of virulence factors, as is demonstrated in the second 
chapter of this thesis. Anti-virulence agents are simply one additional tool, however, and their use 
alongside other methods for probing pathogenesis is likely the best approach to providing useful insights 
into the mechanisms of infection. 
1.2.5 Alternative narrow-spectrum therapeutic approaches 
 Another unconventional method for designing narrow-spectrum antibiotics is to attach broad-
spectrum antibiotics, or even broadly toxic compounds, to a narrowly specific targeting domain.
167
 This 
strategy has been employed in cancer therapy with several FDA-approved antibody-drug conjugates 
[brentuximab vedotin (Adcetris), trastuzumab emtansine (Kadcyla)].
168
 Examples of targeting domains 
include peptides,
169, 170
 antibodies,
171
 and phage.
172
 The conjugates are intended to bind specifically to the 
pathogen of interest and thus create a locally high concentration of the antibiotic that is sufficient to kill 
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the target. This strategy theoretically prevents non-targeted bacteria (and host cells in the case of general 
toxins) from experiencing harmful concentrations of the toxic payload. Oral administration of these 
antibiotic conjugates would likely be infeasible due to stability and bioavailability issues. The 
requirement of successfully targeting the pathogen and then delivering a sufficiently toxic payload also 
presents two different routes for resistance generation. Attempting to fight the pathogen outright with 
antibodies or bacteriophage may be more realistic. Both strategies have historical precedent and have 
been reviewed extensively elsewhere.
173-175
 The use of bacteriophage to deliver CRISPR-Cas (CRISPR, 
clustered, regularly interspaced, short palindromic repeats; Cas, CRISPR-associated protein) systems for 
selective bacterial killing is also beginning to be explored.
176
 Cas proteins are nucleases capable of 
cleaving DNA in a site-specific manner dependent on targeting by ~20-40 nucleotide RNA guides 
(CRISPR units).
177, 178
 Cleavage of the bacterial genome by Cas nucleases has been shown to be lethal
179
 
and antimicrobials utilizing this strategy are currently in development by Eligo Bioscience.  
1.2.6 Challenges facing narrow-spectrum therapy 
 If narrow-spectrum antibiotics manage to overcome the technological and financial hurdles to 
their development, they still face significant challenges in the clinic. An accurate and sensitive diagnosis 
would be required to rule out the possibility of a polymicrobial infection, otherwise a patient’s condition 
may only worsen as an undetected pathogen flourishes during treatment of the known one. Additionally, 
immunocompromised patients are more susceptible to secondary infections that could be suppressed by a 
prophylactic broad-spectrum antibiotic but would be unaffected by a narrow-spectrum agent. 
 One of the intended benefits of narrow-spectrum antibiotics is that they would be less likely to 
disturb the human microbiome. However, there are an estimated 800 or more species in the gut
180
 and 
new antibiotics are unlikely to be tested against a vast majority of these, especially given the difficulty in 
culturing many species in the microbiome. Even a pathogen-specific antibiotic may have unanticipated 
effects on some of these species, which could end up impacting the entire microbiome with deleterious 
effects. The argument that resistance may be slower to develop due to less possibility for HGT also loses 
some of its relevance if this is the case. The spectrum of activity of antibiotics against the gut microbiome 
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could be tested indirectly through metagenome analysis of fecal samples however, and this approach 
would also provide a more realistic picture of the effect of narrow-spectrum antibiotics in the context of 
the host. Regardless, resistance will always develop as bacteria eventually find a way to survive. Given 
the difficulty in finding novel antibiotics, strategies that provide new avenues to discovery or slow the 
spread of resistance are welcome and will hopefully be successfully combined in the future with other 
methods of fighting infections, such as boosting the human immune system or improved sterilization and 
sanitation in hospitals. 
1.3 Reinvigorating natural product discovery as a source of new therapeutics 
 Natural products have historically served as important sources of drugs leads and as inspirations 
for synthetic or semisynthetic drugs.
34, 181, 182
 Beyond the realm of antibiotics, drugs for other indications 
such as anticancer and immunosuppressive therapies have also had great success in coopting natural 
products.
183-185
 The chemical diversity offered by collections of natural products has been recognized as 
an important factor in the hit rate of high-throughput screening campaigns for new drug leads
186
 and 
compound libraries are starting to be designed to be more “natural product-like” in acknowledgement of 
this.
187-189
 Natural products have also been extensively utilized as biological probes, aiding in the 
elucidation of enzyme activity and other cellular functions.
43, 44
 For these reasons, continuing to expand 
our knowledge base of natural products is a worthwhile undertaking that will likely translate into 
medically and scientifically useful compounds. 
Traditional methods for natural product discovery such as the Waksman platform for antibiotic 
discovery generally revolved around screening for a particular bioactivity from a culture or extract 
followed by isolation of the active compound by tracking the activity through purification steps.
15, 182, 190
 
While this strategy has resulted in the rapid discovery of a great many medically important natural 
products, there are significant flaws in the method that have become more apparent over time. The 
rediscovery of highly active compounds that are produced by a wide array of species results in wasted 
effort towards the isolation and characterization of known natural products.
191
 For example, random 
screening of soil actinomycetes for antibiotic activity will yield streptomycin from roughly 1 in 100 
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strains.
13
 Natural product discovery based on bioactivity screening will also only provide compounds that 
are active in the assay utilized. This can be a positive outcome in some cases, as any compounds found 
will have the desired activity, but also presents the drawback of missing any natural products with 
alternative activities that are not screened for. Compounds that are weakly active may also be missed due 
to insufficient abundance or interference from other components of the extract,
182
 but these compounds 
could potentially be interesting as lead structures for further drug development. Therefore, novel methods 
for natural product discovery have been introduced and are continually being expanded. 
Several strategies for natural product discovery that utilize bioactivity based screening but offer 
advantages such as more sensitive detection of low abundance compounds have been frequently 
employed. Prefractionation of extracts can remove many of the interfering or nuisance compounds that 
would otherwise interfere with the detection of weakly active or low abundance compounds in 
bioassays.
192, 193
 Desired physicochemical properties that are known to make better drug leads can also be 
selected for during prefractionation, helping to eliminate active yet undesirable scaffolds.
194
 Another 
method for improving discovery through bioactivity based screening is the use of novel cultivation 
techniques to stimulate robust natural product production or to successfully culture organisms that 
previously could not be cultivated in laboratory settings.
15, 195-197
 Growing microorganisms in the context 
of their natural environment provides access to the myriad of factors normally present during growth and 
facilitates the culture of the roughly 99% of species that cannot be easily cultivated, many of which will 
hopefully provide new natural products.
42, 198
 
Alternative strategies of natural product discovery that are independent of activity have also been 
developed. These methods often have the advantage of reduced rediscovery rates at the expense of 
potentially providing products with cryptic activity. Genomics has been extensively utilized in many of 
these methods to garner a sense of the biosynthetic potential of organisms and to provide initial clues as 
the structure of a natural product prior to isolation and characterization.
199, 200
 Access to information about 
the natural product biosynthetic gene cluster of interest also allows for targeted strategies to stimulate 
production or facilitate isolation. Silent clusters can be activated through manipulation of promoters, 
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utilization of signaling molecules such as γ-butyrolactones, or expression in a heterologous host.201, 202 
Mass spectrometry guided methods have also been used not only for the detection of natural products 
with structural motifs predicted from genome mining but also to aid in final structural elucidation of the 
products.
203, 204
 Another strategy is to employ chemoselective enrichment for functionality suspected to be 
present on the natural product of interest.
205
 Similar to chemoselective enrichment, unique and reactive 
functional groups can be used as handles for tagging natural products as a method of reactivity-based 
natural product discovery.
206
 The discovery of natural products with aldehyde or ketone functional groups 
via reactivity-based screening with an aminooxy probe is the focus of the third chapter in this thesis. 
1.4 Summary and outlook 
 The golden age of antibiotics has ended and new strategies to develop antibiotics and fight 
resistance are needed. However, academia has fervently taken up the call and industry is starting to follow 
suite with prodding from public concern and government incentives. While the studies discussed in this 
thesis may not directly have an impact on the development of a new antibiotic, they help build the 
groundwork for future research in these areas. Developing a better understanding of virulence in S. 
pyogenes will be beneficial towards future endeavors to develop treatment strategies against this common 
pathogen, whether they are the design of new antibiotics or vaccines or simply more intelligent utilization 
of our current drugs. 
 History tells us that natural products are one of the best sources of new drugs, especially 
antibiotics, and continuing to launch new discovery efforts is a worthwhile pursuit. Reactivity-based 
natural product discovery is a relatively new endeavor so its utility towards large scale discovery is as yet 
untested. However, it offers another potentially useful set of tools for natural product screening. As 
additional reactivity-based probes are developed, they will hopefully allow the majority of natural 
products to be labeled selectively by at least one probe, adding in isolation and also potentially providing 
useful structural information. 
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Chapter 2: HIV protease inhibitors block streptolysin S production 
This chapter is taken in part from Maxson et al.
1
 and is reproduced with permission from ACS Chemical 
Biology. 
 
Douglas Mitchell generated 
35
S-labeled SagA, performed membrane cleavage assays, and tested general 
mechanism based protease inhibitors. Andrew Markley and Shaun Lee (Lee lab) performed E. coli 
pETDuet experiments. Evelyn Molloy tested nelfinavir in L. monocytogenes. Caitlin Deane tested 
nelfinavir in B. amyloliquefaciens.  
 
Abstract 
Streptolysin S (SLS) is a post-translationally modified peptide cytolysin that is produced by the 
human pathogen Streptococcus pyogenes. SLS belongs to a large family of azole-containing natural 
products that are biosynthesized via an evolutionarily conserved pathway. SLS is an important virulence 
factor during S. pyogenes infections, but despite an extensive history of study, further investigations are 
needed to clarify several steps of its biosynthesis. To this end, chemical inhibitors of SLS biosynthesis 
would be valuable tools to interrogate the various maturation steps of both SLS and biosynthetically-
related natural products. Such chemical inhibitors could also potentially serve as anti-virulence 
therapeutics, which in theory may alleviate the spread of antibiotic resistance. In this work, we 
demonstrate that FDA-approved HIV protease inhibitors, especially nelfinavir, block a key proteolytic 
processing step during SLS production. This inhibition was demonstrated in live S. pyogenes cells and 
through in vitro protease inhibition assays. A panel of 57 nelfinavir analogs was synthesized, leading to a 
series of compounds with improved anti-SLS activity while illuminating structure-activity relationships. 
Nelfinavir was also found to inhibit the maturation of other azole-containing natural products, namely 
those involved in listeriolysin S, clostridiolysin S, and plantazolicin production. The use of nelfinavir 
analogs as inhibitors of SLS production has allowed us to begin examining the proteolysis event in SLS 
maturation and will aid in further investigations of the biosynthesis of SLS and related natural products. 
2.1 Introduction 
The ribosomally synthesized and post-translationally modified peptides (RiPPs) comprise a 
rapidly expanding class of natural products that includes a wide variety of structural modifications.
2
 
These modifications impart RiPPs with diverse activities, giving rise to a range of products from 
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antibacterials
3-5
 to anticancer agents.
6
 The installation of azole and/or azoline heterocycles is one such 
modification common to many RiPPs, forming a sub-class of natural products called the thiazole/oxazole-
modified microcins (TOMMs).
7
 The azoles are biosynthesized by the cyclodehydration and subsequent 
dehydrogenation of cysteine, serine, and threonine residues to form thiazole and (methyl)oxazole rings on 
the C-terminal portion, or “core”, of a ribosomally produced precursor peptide.7 The azole-containing 
peptides will often undergo further processing, including the proteolytic removal of the N-terminal 
“leader” portion of the peptide and export of the mature product.8 Although recent discoveries have shed 
light on the mechanism of azole formation,
9-11
 the proteolytic processing step of most TOMMs has yet to 
be investigated. 
Streptolysin S (SLS), a key virulence factor of Streptococcus pyogenes, is one such TOMM 
whose biosynthesis is incompletely understood.
12
 S. pyogenes is the causative agent of diseases ranging in 
severity from pharyngitis to necrotizing fasciitis
13
 and is a major global health burden, causing over 600 
million infections and 500,000 deaths annually.
14
 SLS is the cytolytic toxin responsible for the classic β-
hemolytic phenotype when S. pyogenes is grown on blood agar
15
 and has been shown to be critical to 
pathogenesis in mammalian infection models.
16-18
 Although a few strains of non-β-hemolytic, pathogenic 
S. pyogenes have been described, such as the Lowry strain,
19
 the vast majority of S. pyogenes isolates 
produce SLS.
20
 The toxin is biosynthesized by a 9-gene biosynthetic operon that encodes the precursor 
peptide (sagA), cyclodehydratase and dehydrogenase enzymes (sagBCD), a putative leader peptidase 
(sagE), a multicomponent ABC-transporter (sagGHI), and a protein of unknown function (sagF) (Figure 
2.1A).
15
 The SagBCD heterocycle synthetase is known to install azol(in)e rings on the core region of the 
precursor peptide,
21, 22
 which is followed by proteolytic removal of the leader peptide prior to export of 
the mature, bioactive natural product (Figure 2.1B,C). The final molecular weight of SLS has been 
inferred from classic gel filtration studies to be 2.8 kDa,
23
 which is consistent with the bioinformatic 
prediction of the scissile bond being C-terminal to a Gly-Gly motif based on the similarity to bacteriocins 
from other Gram-positive bacteria.
24
 Additionally, proteolysis following small residues is common in 
RiPPs with known cleavage sites.
8
 Although SLS was first defined nearly 80 years ago,
25
 with the β-
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hemolytic phenotype being known since the late 1800s,
26
 a detailed mechanism of SLS biosynthesis and 
the structure of the mature toxin remain elusive. Thus, effective SLS biosynthetic inhibitors could serve 
as powerful chemical tools to shed more light on the biochemistry of SLS and the infection biology of S. 
pyogenes. 
 
Figure 2.1. TOMM gene clusters and the biosynthetic pathway. (A) Open reading frame diagram 
showing the organization of several TOMM gene clusters, grouped by function of the mature TOMM. 
The letters over each gene correspond to the name of the sag genes in S. pyogenes. The function of each 
gene is color-coded in the legend. (B) Sequences of the precursor peptides from the clusters shown in 
panel A. The putative (*) or known (-) cleavage sites are shown. The residues substituted in SagA to 
generate SagA-VLPLL are shown in red. SagA, from S. pyogenes; ClosA, from C. botulinum; StaphA, 
from S. aureus; LlsA, from L. monocytogenes; BamA, from B. amyloliquefaciens. (C) Generalized 
mechanism of TOMM maturation with SLS as the example. The proteins putatively responsible for each 
step are shown above each arrow. 
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Gaining a better understanding of how pathogens employ their various virulence factors also aids 
in the development of selective treatment strategies that could help to increase the lifespan of clinically 
important antibiotics. Unlike traditional broad-spectrum antibiotic treatment, specifically targeting 
virulence would retain the human microbiota, helping to eradicate secondary infections and, in some 
cases, could theoretically reduce the evolutionary pressure for the development of resistance.
27
 Previous 
approaches to targeting virulence have included disruption of quorum sensing, which often regulates 
virulence factor expression, blocking toxin delivery or function, and inhibition of bacterial adhesion.
27
 
Several compounds designed around these approaches have been efficacious in vivo and have prompted 
further study,
27, 28
 but the selective nature of targeting virulence requires a tailored therapy for each 
pathogen, which when developed, would stimulate vast improvements in clinical diagnostics. SLS is an 
interesting anti-virulence target, as it plays a major role in paracellular invasion, immune evasion, and 
host-metabolism manipulation.
12, 29
 Furthermore, additional roles of SLS in iron acquisition have been 
suggested but require further confirmation.
12
 Due to the importance of SLS in a multitude of pathogenic 
processes, chemical inhibitors developed to probe the biosynthesis of SLS may find future roles in 
virulence attenuation strategies that protect the vital microbiota and limit the spread of antibiotic 
resistance in other pathogens that employ SLS-like toxins (i.e. S. pyogenes and specific strains of Listeria 
monocytogenes, Clostridium botulinum, and Staphylococcus aureus). 
In this study, we identified inhibitors SLS biosynthesis in S. pyogenes by searching for 
compounds that block an essential proteolytic maturation step. This proteolysis event has been proposed 
to be performed by SagE, a putative peptidase with homology to a large family of proteases referred to as 
the CaaX proteases and bacteriocin-processing enzymes (CPBP; often confusingly annotated as abortive 
infection proteins, Abi), which includes the eukaryotic type II CaaX proteases as well as prokaryotic 
proteins with putative bacteriocin-related functions.
30, 31
 The type II CaaX proteases are involved in the 
processing of a number of C-terminally prenylated proteins in eukaryotes and have been much more 
thoroughly studied than their prokaryotic counterparts.
32-34
 Type II CaaX proteases were initially believed 
to be cysteine proteases,
35
 but the presumed catalytic cysteine was later proven to be unnecessary for 
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activity.
34
 In contrast, conserved glutamate and histidine residues were shown to be important for activity, 
leading to the hypothesis that type II CaaX proteases were metalloproteases.
34
 Many of the prokaryotic 
members of the CPBP family, including SagE, have been annotated as immunity proteins due to the role 
in bacteriocin self-immunity of the family members in Lactobacillus plantarum and L. sakei.
36
 However, 
the production of viable allelic exchange mutants of sagE and the homolog in Listeria monocytogenes 
(llsP) indicates that SagE may not be serving an immunity role or may be redundant with other 
uncharacterized immunity mechanisms.
15, 37
 Thus, it is plausible that the prokaryotic CPBPs actually act 
as proteases and that this function is exploited to provide self-immunity in certain cases. The results 
presented herein support a role for SagE as a protease through the discovery and characterization of a 
family of small molecule inhibitors of SLS biosynthesis. Appealingly, these inhibitors were identified 
through the repurposing of existing drugs by an examination of known off-target effects. This approach 
facilitated the rapid identification of lead compounds without the need to perform expensive and laborious 
high-throughput screens, as well as aiding in the synthesis of analogs by leveraging previous work on the 
compounds.
38-40
 
2.2 Evidence for the role of SagE as a protease 
Reconstitution of SagE in vitro would be the most direct means of testing for the predicted 
protease activity and for the screening of inhibitors. Unfortunately, numerous attempts to heterologously 
express SagE proved unsuccessful and alternative assays were developed to address this issue. We 
attribute much of the difficulty in expressing SagE to the predicted transmembrane nature of the protein; 
topology modeling of SagE with SPOCTOPUS
41
 predicted five transmembrane helixes and an N-terminal 
signal peptide (Figure 2.2). With this in mind, crude membranes from S. pyogenes were prepared from 
total cellular lysates by ultracentrifugation. The resultant samples were then assessed for proteolytic 
activity towards 
35
S-labeled SagA, generated through in vitro transcription/translation. Robust proteolysis 
of SagA to the predicted molecular weight
23
 was observed after treatment with the membrane fraction 
(Figure 2.3A). SagA processing in the whole cell lysate and supernatant fractions was much less 
extensive and often not observable (Figure 2.4). To test the substrate specificity of proteolysis, a mutant 
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version of SagA with residues Ala20, Gly22, and Gly23 mutated to leucines (SagA-VLPLL) was 
generated (Figure 2.1B). These residues are directly N-terminal to the predicted leader peptide cleavage 
site and were expected to be important for protease recognition. Pro21 was left intact to avoid inducing a 
drastic structural change on the peptide. When treated with isolated S. pyogenes membranes, SagA-
VLPLL was processed at a rate slower than wild-type SagA (Figure 2.3A), suggesting that the cleavage 
was performed by a membrane protease specifically recognizing the SagA cleavage site (other 
membrane-bound proteases may also be minor contributors to the observed proteolysis). 
 
 
Figure 2.2. Hydropathy plot of SagE. The membrane topology of SagE was modeled using the 
SPOCTOPUS program
41
 and is predicted to be an integral membrane protease with 5 transmembrane 
helices. The eukaryotic homologue Rce1 from Methanococcus maripaludis is known to also be an 
integral membrane protein with eight transmembrane α-helices (PDB ID 4CAD).42 
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Figure 2.3. The role of SagE in the processing of pre-SLS. (A) Purified S. pyogenes membranes display 
proteolytic activity towards SagA. Both wild type (WT) SagA, and to a reduced extent, the predicted cut 
site mutant SagA-VLPLL, function as cleavage substrates. (B) Lytic activity of E. coli expressing the 
SLS biosynthetic machinery after a 2 h induction. The hemolytic activity of extracted SLS on 
erythrocytes is measured by a colorimetric readout of hemoglobin release. 
 
 
 
Figure 2.4. Cleavage of Flag-tagged SagA with the S. pyogenes membrane fraction. Proteins present 
within S. pyogenes membranes harbor proteolytic activity towards MBP-Flag-SagA (Flag tag is on the N-
terminus of SagA). A cleavage band is not seen for MBP-SagA-Flag as the Flag tag here is appended to 
the much smaller C-terminal core peptide, which migrates with the dye front. WCL, whole cell lysate; 
Sol, soluble fraction; Ins, insoluble (crude membrane) fraction. 
 
To provide additional evidence for the role of SagE, a previously reported multi-plasmid-based 
expression system for the generation of SLS in Escherichia coli was used. In that study, a lytic entity was 
generated by the expression of a maltose-binding protein (MBP)-tagged SagA in conjunction with SagB-
D from pETDuet vectors after extended induction times.
43
 SLS produced in this system could be extracted 
with bovine serum albumin (BSA) and applied to blood using procedures long established for S. 
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pyogenes.
44
 The heterologously produced SLS was presumably exported by generalized transporters after 
non-specific proteolysis of the MBP tag or was released via E. coli cell death following buildup of the 
toxin. Using this system, no lytic activity was observable after a considerably shorter induction time (2 h) 
from a strain expressing only SagA-D; however, E. coli expressing SagA-F was highly lytic after 2 h 
(Figure 2.3B), indicating that SagEF expedite SLS maturation. The additional inclusion of SagF was 
required for this effect, although its functional role is unknown. SagF shares no homology to any known 
proteins but has previously been demonstrated to be necessary for SLS biosynthesis
15
 and may aid in the 
folding or localization of the other modification machinery. To support the role of SagE as a protease 
involved in SLS maturation, two highly conserved glutamine residues (Glu131 and Glu132) that are 
critical for activity in mammalian CPBP family members
31, 34
 were mutated to alanine, resulting in the 
complete loss of the observed lytic activity. 
 2.3 Aspartyl protease inhibitors block SagA proteolysis 
A small panel of general mechanism-based protease inhibitors was screened for inhibition of 
SagA leader proteolysis using the membrane cleavage assay with S. pyogenes membranes. This assay was 
preferred over the E. coli multi-plasmid system to avoid potential issues with membrane penetration or 
general toxicity of the inhibitors. From the panel, only the aspartyl protease inhibitor pepstatin displayed 
inhibitory activity (Figure 2.5), which was unexpected given that SagE bears no similarity to known 
aspartyl proteases and that members of the type II CaaX protease family were previously hypothesized to 
function as zinc-dependent metalloproteases.
34
 However, inhibition of a metalloprotease by aspartyl 
protease inhibitors has literature precedent, as several inhibitors of HIV protease were found to also 
inhibit the type I CaaX protease ZMPSTE24, which is a known zinc metalloprotease.
45-47
 Lipodystrophy 
is a possible side effect of treatment with certain HIV protease inhibitors and also occurs from genetic 
deficiencies in ZMPSTE24, leading to the discovery of this off-target effect for these drugs.
45
 Although 
type I and II CaaX proteases do not share sequence similarity, they redundantly process some of the same 
substrates and share similar substrate-binding site architectures.
42, 48
 Given this, we reasoned that HIV 
protease inhibitors might be repurposed as inhibitors of SLS production. 
46 
 
 
 
Figure 2.5. Inhibition of SagA proteolysis by general-mechanism based inhibitors. Proteolysis of WT 
[
35
S]-MBP-SagA by S. pyogenes membranes treated with general mechanism-based protease inhibitors. 
Bestatin, metalloproteases; pepstatin, aspartyl proteases; pefabloc, serine proteases; E-64, cysteine 
proteases. 
 
2.4 HIV protease inhibitors block SLS production 
A whole-cell assay in S. pyogenes based on the extraction of SLS with BSA was used to screen a 
panel of nine FDA-approved HIV protease inhibitors (Figure 2.6). Nelfinavir, ritonavir, saquinavir, and 
lopinavir were found to inhibit the production of SLS when tested at 50 µM, while indinavir, amprenavir, 
atazanavir, and darunavir did not inhibit SLS production (Figure 2.7A). Interestingly, tipranavir caused 
significant growth suppression in S. pyogenes, and treated cultures never reached late exponential phase 
(Figure 2.8), which is when SLS becomes detectable in vitro.
49
 The efficacies of the HIV protease 
inhibitors shown to inhibit SLS production in the initial screen were evaluated by determining 50% 
inhibition concentration (IC50) values. The IC50 of nelfinavir (6 µM) was much lower than those of 
ritonavir (35 µM), saquinavir (25 µM), and lopinavir (25 µM). Owing to its greater potency, nelfinavir 
(Figure 2.7B) was selected for further study. 
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Figure 2.6. Structures of the FDA-approved HIV protease inhibitors. The structures of all FDA-approved 
HIV protease inhibitors are shown (U.S. brand name in parentheses) with the exception of fosamprenavir 
calcium (Lexiva), a pro-drug of amprenavir. Any previously reported activity for each drug on the CaaX 
protease ZMPSTE24 is listed,
46, 47
 along with the activity for SLS production inhibition. 
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Figure 2.7. Inhibition of SLS production. (A) Hemolytic activity of SLS extracts from S. pyogenes 
treated with HIV protease inhibitors. Tipranavir is shown separated by a dashed line due to significant 
growth effects during treatment (Figure 2.8). Asterisks indicate a P-value < 0.01 relative to the DMSO 
control. (B) The structure of nelfinavir (1). (C) The proteolytic effect of S. pyogenes membranes treated 
with nelfinavir on MBP-SagA, relative to a DMSO-treated control. 
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Figure 2.8. Growth effects of HIV protease inhibitors on S. pyogenes. S. pyogenes M1 5448 was grown 
in the presence of the indicated HIV protease inhibitor at 50 µM and the optical density at 600 nm was 
recorded. Tipranavir was found to significantly inhibit growth. 
 
Nelfinavir was evaluated in the membrane proteolysis assay to determine if the observed loss of 
β-hemolysis was due to inhibition of the proteolytic processing step of SLS maturation. As expected, 
treatment with nelfinavir greatly reduced the proteolytic activity toward SagA contained within S. 
pyogenes membranes (Figure 2.7C, the membrane fraction used in this experiment was prepared on a 
different day than the fraction used in Figure 2.3 and displayed much higher activity). Evidence that 
nelfinavir was not drastically perturbing normal cellular function came from the observation that the 
growth rates of S. pyogenes treated with nelfinavir were identical to the DMSO control (Figure 2.8). 
Additionally, minimum inhibitory concentration (MIC) testing revealed no growth inhibition up to the 
highest concentration tested (64 µM) for a range of bacterial species (Table 2.1). Transmission electron 
microscopy (TEM) was used to examine the morphology of S. pyogenes treated with nelfinavir, with no 
apparent changes compared to the control sample (Figure 2.9). The transcription levels of a panel of 
virulence factor genes, as assessed by qRT-PCR, were also not significantly impacted (Table 2.2). 
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Notably, the levels of sagA and sagB expression were unchanged. These data indicate that nelfinavir 
inhibited peptide processing directly, rather than through transcriptional regulation or by significantly 
perturbing other cellular processes. 
Bacterial strain MIC (µM) 
Streptococcus pyogenes M1 5448 >64 
Listeria monocytogenes 4b F2365 >64 
Clostridium sporogenes ATCC 19404 >64 
Staphylococcus aureus USA300 >64 
Enterococcus faecium U503 >64 
Bacillus subtilis 168 >64 
Klebsiella pneumoniae ATCC 27736 >64 
Pseudomonas aeruginosa PA01 >64 
Escherichia coli MC4100 >64 
 
Table 2.1. The minimum inhibitory concentrations of nelfinavir against a range of bacterial species, 
including Gram-positive and Gram-negative organisms, are shown. No growth inhibition was seen for 
any species up to the solubility limit of nelfinavir after 16 h of growth. 
 
 
 
Figure 2.9. Transmission electron microscopy (TEM) of nelfinavir-treated S. pyogenes. TEM images of 
S. pyogenes M1 5448 treated with (A) DMSO or (B) 25 µM nelfinavir. Scale bars are 100 nm. These 
images are representative of the entire sample, where more than 100 cells were closely examined. 
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Gene 
Log2 ratio 
(treated/untreated) 
Virulence factor 
emm49 -1.98 ± 0.77 M protein 
slo 0.02 ± 1.22 streptolysin O (SLO) 
sagA 0.32 ± 0.20 streptolysin S (precursor peptide) 
sagB 0.10 ± 0.70 streptolysin S (dehydrogenase) 
scpA -0.86 ± 0.26 C5A peptidase 
ska -1.23 ± 0.83 streptokinase 
speB 1.38 ± 0.92 streptococcal pyrogenic exotoxin B (SpeB) 
nga -1.30 ± 0.90 NAD glycohydrolase 
spd3 -0.83 ± 0.28 streptodornase 
 
Table 2.2. Changes in virulence factor expression as measured by qRT-PCR with S. pyogenes M49 
NZ131 during treatment with nelfinavir versus a DMSO control. Values are from three biological 
replicates averaged from three technical replicates each. The 16S rRNA gene was used as an internal 
control gene and relative gene expression was calculated by a comparative CT method.
50
 Positive and 
negative values represent up- and down-regulation upon nelfinavir treatment, respectively. The primers 
used are given in the supplemental methods. A transcription change was not considered significant if the 
log2 ratio was < 1.5 fold or if the P value was > 0.01. Based on these criteria, none of the genes were 
significantly altered upon nelfinavir treatment. Similar results were obtained for an additional strain, S. 
pyogenes M1 5448. 
 
2.5 Structure-activity relationships 
A series of nelfinavir analogs was synthesized to gain a better understanding of the structure-
activity relationships (SAR) for inhibition of SLS maturation. If nelfinavir were to interact with the SLS 
leader peptidase in a manner analogous to HIV protease, the secondary hydroxyl group would function as 
a tetrahedral intermediate mimic, as is the case for many aspartyl and metalloprotease inhibitors (Figure 
2.10). Synthetic routes to nelfinavir have been thoroughly explored and a route that allowed facile 
derivatization was adapted for this study (Scheme 2.1).
38
 The efficacy of each analog at 25 µM was 
evaluated using the hemolysis assay (Table 2.3 and Table 2.4). 
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Figure 2.10. Aspartyl and metalloproteases share a common intermediate. Both types of protease activate 
water, which performs a nucleophilic attack on the scissile amide bond. This attack results in a gem-diol 
intermediate shared between the two mechanisms, unlike the covalent acyl-enzyme intermediate formed 
by serine, threonine, and cysteine proteases. Nelfinavir and other aspartyl and metalloprotease inhibitors 
usually mimic the intermediate with the non-hydrolyzable secondary hydroxyl group. However, our data 
suggest that nelfinavir does not inhibit the SLS leader peptidase in this fashion. 
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Scheme 2.1. Synthesis of nelfinavir. a, i-BuOCOCl, Et3N, THF; CH2N2, Et2O (62%); b, HCl, Et2O; c, 
NaBH4, THF (62% over two steps); d, KOH, EtOH (91%); e, 6, KOH, IPA, 80 °C (84%); f, 3-hydroxy-2-
methylbenzoic acid, EDC, HOBt, THF (66%). 
 
Nelfinavir has peptidomimetic features, including an S-phenyl-ethyl group intended to replace the 
side chain of phenylalanine commonly found in the P1 position of the HIV protease substrate. Since the 
putative P1 position of SagA is a much smaller glycine residue (Figure 2.1B, Gly23), we surmised that 
smaller substituents at this location on nelfinavir might improve the observed anti-SLS activity. Instead, 
removal of the side chain (8) abolished detectable activity. It is possible that the cleavage site is closer to 
the N-terminus, however, and that Pro21 or an aliphatic residue preceding it resides in the P1 position. 
Accordingly, analogs mimicking these amino acids (9, 10) were synthesized, but these compounds did not 
exhibit detectable inhibitory activity. Even retention of the phenyl ring in a phenylalanine mimic (11) was 
insufficient to maintain activity. Conversely, a tryptophan mimic (12) was inhibitory, albeit weakly, 
suggesting that a relatively large group in that position may be necessary for activity. 
The lack of detectable activity with the series of P1 position analogs prevented the rigorous 
establishment of SAR. Modifications to other portions of the molecule were prepared in order to enhance 
the inhibitory activity to address this pitfall. As installation of the benzamide is the final step of the 
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synthesis (Scheme 2.1), preparation of analogs at this location was convenient. Initial analogs revealed 
that neither the hydroxyl nor the methyl groups (13–15) were important for activity but that the ring itself 
was necessary (16). Replacement of the ring with bulkier naphthyl and cyclohexyl groups (17, 18) 
provided >5-fold increases in potency, indicating that this part of the pharmacophore may reside in a 
hydrophobic pocket not fully occupied by the single planar ring. However, increasing the size of this 
moiety to an anthracene (19) greatly reduced activity. In general, electron-deficient rings had improved 
activity relative to electron-rich rings (Table 2.4), although hydrophobicity appeared to be a more 
significant contributing factor towards potency. 
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Table 2.3. Relative activity of nelfinavir analogs for SLS inhibition. 
a
The activity of each analog is reported qualitatively relative to nelfinavir due to variability in commercial 
blood lots and extraction effectiveness. Inhibitory activity that is >3-fold than nelfinavir is designated as 
(+++); activity that is equal to nelfinavir is (++); detectable activity that is <3-fold than nelfinavir is (+); 
non-detectable activity is denoted (-). 
56 
 
 
Table 2.4. Relative activity of additional nelfinavir analogs for SLS inhibition. The activity of each 
analog is reported qualitatively relative to nelfinavir due to lot variation in the commercial sources of 
blood and the BSA extraction efficiency. Activity >3-fold that of nelfinavir is designated as (+++); 
activity that is equal to nelfinavir is (++); detectable activity that is <3-fold that of nelfinavir is (+); non-
detectable activity is denoted (-). 
  
57 
 
Table 2.4 (cont.) 
 
 
Given the enhanced activity of the naphthylamide-bearing compound (17), this group was 
incorporated into the collection of P1 position analogs (Table 2.3; Table 2.4), increasing the activity of 
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these analogs to detectable levels. The tryptophan mimic with the naphthylamide (20) displayed 
considerably increased potency relative to the 3-hydroxy-2-methylbenzamide analog (12). Within the 
naphthylamide series, the phenylalanine and leucine mimics (21, 22) were equivalently active to 
nelfinavir, while the glycine mimic (23) displayed weak SLS-inhibitory activity. The proline mimic (24) 
remained devoid of activity, possibly due to structural perturbations enforced by the ring. These data 
support a trend of larger substituents imparting higher activity that was foreshadowed by the initial SAR. 
To further probe the pseudo-P1 position of nelfinavir, the stereochemical configurations of both 
the side chain and the secondary hydroxyl group were varied. Surprisingly, inverting stereocenters with 
this series of analogs (25–27) did not result in large changes in activity. Many of the derivatives were still 
highly potent, suggesting that nelfinavir may not inhibit SagE through mimicking the proteolytic 
tetrahedral intermediate (Figure 2.10). This is further supported by the retention of activity in acetylated 
derivatives (28, 29). Overall, the sum of the SAR analysis resulted in the development of an analog with 
significantly improved potency (17, IC50 = 1 µM). Additionally, the activity trends led us to believe that 
nelfinavir might serve as an inhibitor for the protease in other TOMM natural product biosynthetic 
clusters in which the precursor peptides do not always contain a predicted Gly-Gly cleavage motif (Figure 
2.1B). 
2.6 Biosynthesis inhibition of other TOMMs 
SLS is the best-studied member of a group of related cytolysins produced by a number of 
bacteria, including pathogens such as L. monocytogenes and C. botulinum.
12, 21
 The SLS-like biosynthetic 
gene clusters in these strains are highly similar to that of S. pyogenes and include orthologs of sagE 
(Figure 2.1A, Figure 2.11). The SLS-like toxin from L. monocytogenes, listeriolysin S (LLS), is known to 
be expressed during oxidative stress; therefore, a strain with LLS under the control of a constitutive 
promoter was used in the blood lysis assay to determine if nelfinavir could also inhibit LLS production.
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The strain was deficient in production of an unrelated cytolysin, listeriolysin O (LLO), to ensure any 
hemolysis observed derived from LLS production. When treated with nelfinavir, this strain produced 
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significantly less LLS (Figure 2.12A). The LLO
-
/LLS
-
 strain of L. monocytogenes was included as a 
negative control to demonstrate the observed hemolysis was indeed LLS-dependent (Figure 2.12A). 
 
 
 
Figure 2.11. Amino acid sequence alignment of select bacterial CaaX proteases and bacteriocin-
processing enzymes (CPBPs). A Clustal Omega alignment of SagE and related proteases in other natural 
product gene clusters is shown. Conserved residues shown to be important for catalysis in eukaryotic 
homologues are highlighted in yellow and their proposed role in catalysis is shown in Figure 2.18.
34
 The 
C-terminal 35 residues were manually aligned. Gene names and producing organisms: SagE, S. pyogenes; 
LlsP, L. monocytogenes; StaphE, S. aureus; ClosE, C. sporogenes/botulinum; BamE, B. 
amyloliquefaciens. 
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Figure 2.12. Inhibition of the biosynthesis of other TOMMs by nelfinavir. (A) Lytic activity of extracts 
from an LLS-producing strain (LLS+) of L. monocytogenes treated with nelfinavir relative to a DMSO 
control (n = 3). Extracts from a separate strain with llsA deleted (LLS-) were also used as a control. (B) 
Lytic activity of extracts from a CLS-producing strain of C. sporogenes treated with nelfinavir relative to 
a DMSO control (n = 3). (C) Production of PZN by B. amyloliquefaciens treated with nelfinavir relative 
to a DMSO control (n = 4). Nelfinavir was used at 50 µM in all cases. Excluding LLS- negative control, 
P-values < 0.05 were obtained for all nelfinavir-treated samples relative to the corresponding DMSO 
positive controls. 
 
Similar to SLS and LLS, clostridiolysin S (CLS) is a hemolysin from C. botulinum as well as 
from certain strains of C. sporogenes, which are nearly identical to C. botulinum but do not produce 
botulinum toxin.
22
 The presence of the CLS cluster in an unsequenced strain of C. sporogenes (ATCC 
19404) known to be hemolytic on blood agar was confirmed by PCR amplification of closC and closD 
(the cyclodehydratase genes). When C. sporogenes was grown in the presence of nelfinavir, the 
production of CLS was significantly reduced (Figure 2.12B). The inhibition of not only SLS but also LLS 
and CLS production suggests that nelfinavir would likely inhibit the production of additional TOMM 
cytolysins. 
TOMM biosynthetic gene clusters are wide-spread among bacteria and archaea, and the products 
of the vast majority of these clusters have not been structurally or functional characterized.
7
 A 
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bioinformatic analysis of TOMM clusters revealed that 22% (328 out of 1520 as of October 2014) 
contained a CPBP family member within the cluster, many of which are predicted or known to have non-
cytolytic products. The presence of a CPBP member in these clusters led us to postulate that nelfinavir 
would also inhibit TOMM production in these cases. Plantazolicin (PZN) is a TOMM produced by 
Bacillus amyloliquefaciens FZB42 with highly selective antibacterial activity against Bacillus anthracis 
and has a sagE-like gene (bamE) in its biosynthetic gene cluster (Figure 2.1A, Figure 2.11).
52
 The 
structure of PZN has been determined; thus the precise cleavage site is known (after Ala27, Figure 2.1B), 
although no biochemical studies have directly linked BamE to leader peptide cleavage. Methanolic 
surface extracts from B. amyloliquefaciens were analyzed by liquid chromatography-mass spectrometry 
and the nelfinavir-treated cultures were found to produce significantly less PZN than a DMSO control 
(Figure 2.12C). Unlike the cytolysins, PZN can be readily observed and quantified by mass spectrometry, 
which permitted confirmation of the nelfinavir dose-dependent inhibition (Figure 2.13). The nelfinavir-
dependent inhibition in divergent organisms of additional TOMM cytolysins, as well as a functionally 
distinct antimicrobial TOMM, not only supports the assignment of the CPBP protein being responsible 
for leader peptide removal during maturation, but also suggests that nelfinavir, and analogs thereof, could 
be generally useful for inhibition of TOMM production in a large number of hitherto uncharacterized 
clusters. 
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Figure 2.13. Dose-dependent inhibition of PZN by nelfinavir. The production of plantazolicin by B. 
amyloliquefaciens is reduced in a dose-dependent manner when treated with nelfinavir, relative to a 
DMSO control. *P<0.05, **P<0.005. 
 
Additional CPBP family members are also present in bacteria beyond TOMM biosynthetic gene 
clusters. One such family member is PrsW from Bacillus subtilis, which is involved in cleaving the 
peptide RsiW (anti-σ factor) during a signaling cascade following cell envelop stress.53 It is believed that 
PrsW is responsible for sensing antimicrobial peptides and other cell envelop stressing agents.
53
 Since 
PrsW is a more divergent CPBP family member and is not expected to be involved in TOMM 
biosynthesis, we were interested in determining if it would also be inhibited by nelfinavir. Previously 
reported strains of B. subtilis containing an IPTG inducible, FLAG-tagged rsiW with and without prsW 
genetically deleted
53
 were grown in the presence or absence of nelfinavir. After induction of prsW, the 
cells were treated with small amounts sodium hydroxide as a model cell envelop stressing agent. Rather 
than observing nelfinavir-dependent inhibition of PrsW, however, nelfinavir appeared to activate the 
protease even in the absence of sodium hydroxide (Figure 2.14). While this could indicate that nelfinavir 
is binding to the protease but resulting in activation instead of inhibition, it is also possible that nelfinavir 
is simply acting as a mild cell envelop stressing agent. This would result in non-specific activation of 
PrsW, complicating any attempts to determine the interaction between nelfinavir and the protease. 
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Nevertheless, it appears that the strong inhibitory activity of nelfinavir towards CPBP family members 
likely does not extend significantly beyond members in TOMM biosynthetic gene clusters. 
 
Figure 2.14. Cleavage of RsiW by PrsW. The CPBP family member PrsW cleaves RsiW under 
conditions of cell envelop stress, created here by sodium hydroxide. The WT strain is CDE743, 
containing a FLAG-tagged rsiW under IPTG controlled induction. The ΔprsW strain is CDE744, a 
modified version of CDE743 with prsW genetically deleted.  
 
2.7 Target validation studies 
Although the previous data strongly support SagE as the target of nelfinavir in SLS biosynthesis 
inhibition, we sought to further validate this hypothesis through affinity pulldown with a photoactivatable 
crosslinker probe. The previously described synthesis (Scheme 2.1) was utilized to install 
photoactivatable moieties as well as terminal alkynes for subsequent azide-alkyne cycloaddition click 
chemistry. As the most facile position to modify, replacement of the benzamide was initially investigated. 
The installation of a photoactivatable benzophone moiety at this position unfortunately yielded a barely 
active compound (140), but installation of the smaller aryl alkyne did not significantly affect activity 
(141). Thus, as leucine-mimic analogs of nelfinavir had been determined to be active (22, 89, 114), an 
analog derived from D-photo-leucine containing a photoactivatable diazirine moiety was synthesized with 
the aryl alkyne in the benzamide position. The D-form of photo-leucine was chosen rather than the L-
form as head-to-head comparisons of 22 and 114 consistently indicated that the R stereochemistry at the 
side chain of the P1 position was more active. The probe (150, Figure 2.15A) was determined to retain 
inhibitory activity via the hemolysis assay, albeit weakly, and was thus used for subsequent affinity 
pulldown studies. Cultures of S. pyogenes were treated with 150 before irradiation with UV light, cell 
lysis, and conjugation to biotin via copper mediated azide-alkyne cycloaddition. The lysates were then 
passed over streptavidin resin for affinity pulldown or were visualized directly by western blotting. 
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Unfortunately, it became quickly apparent that copious non-specific crosslinking was occurring due to the 
presence of numerous bands by western blot (Figure 2.15B), none of which were diminished in 
competition experiments with nelfinavir. As SagE was shown to be active in E. coli, a strain 
overexpressing SagE was utilized for labeling and also displaying non-specific crosslinking (Figure 
2.15C). A proteomics analysis of the labeled proteins revealed that several of the most abundant cellular 
proteins were crosslinking to the probe (150), including EF-tu and protein S9. These abundant 
housekeeping proteins overwhelmed the analysis and no proteins that would reasonably be expected to be 
involved in SLS biosynthesis were detected. It is probable that 150, as well as nelfinavir, non-specifically 
stick to many different cellular components, likely contributing to the range of known off-target activities 
of nelfinavir. 
 
Figure 2.15. Cell extracts photocrosslinked with 150. (A) Structure of probe 150. (B) Western blot of the 
insoluble fraction of lysates from S. pyogenes M1 WT cells labeled with probe 150. (C) Western blot of 
total lysate (lane 1) and the insoluble fraction (lane 2) from E. coli labeled with probe 150. 
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Although initial attempts to heterologously express and reconstitute SagE were unsuccessful, we 
believed it might be possible to generate properly folded SagE in the presence of lipid nanodiscs as the 
protein is expected to normally be membrane bound (Figure 2.2). Lipid nanodiscs are portions of lipid 
bilayer solubilized by the action of membrane scaffolding proteins that wrap around the hydrophobic tails 
of the lipids.
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 The nanodiscs have been shown to be effective platforms for stably reconstituting 
otherwise intransigent membrane proteins in vitro. SagE was generated through a coupled in vitro 
transcription/translation system in the presence of lipid nanodiscs. The reactions were then tested for their 
ability to cleave an MBP-SagA substrate. Although intact SagE could be visualized by western blotting, 
no cleavage activity could be detected (Figure 2.16). 
 
Figure 2.16. Representative example of the lack of MBP-SagA cleavage by SagE expressed in vitro with 
lipid nanodiscs. Each lane of the western blot represents a different reaction condition for the in vitro 
transcription/translation (TNT) of SagE or for the cleavage of MBP-SagA. (1) no DNA, 30 °C TNT, 37 
°C cleavage; (2) pET28-Mistic-SagE, 30 °C TNT, 37 °C cleavage; (3) pET28-Mistic-SagE, 18 °C TNT, 
37 °C cleavage; (4) pCOLA- SagE-SagF-Stag, 30 °C TNT, 37 °C cleavage; (5) pCOLA- SagE-SagF-
Stag, 18 °C TNT, 37 °C cleavage; (6) pET28-Mistic-SagE, 30 °C TNT, 18 °C cleavage; (7) pET28-
Mistic-SagE, 18 °C TNT, 18 °C cleavage; (8) pCOLA- SagE-SagF-Stag, 30 °C TNT, 18 °C cleavage; (9) 
pCOLA- SagE-SagF-Stag, 18 °C TNT, 18 °C cleavage. No cleavage is seen in any condition. 
 
In a final effort to validate SagE as the target of nelfinavir, sagE (with and without sagF) was 
cloned into the S. pyogenes overexpression vector pIB184 under constitutive control.
55
 If inhibition of 
SagE by nelfinavir causes a bottleneck in SLS biosynthesis, overexpression of SagE may abrogate the 
inhibition. The amount of SLS produced by strains containing the sagE vectors was compared to an 
empty vector control in the presence or absence of nelfinavir via the hemolysis assay. No difference in the 
amount of SLS produced between sagE-containing or empty vectors could be detected in any instance 
(Figure 2.17). Taking the opposite approach, overexpression vectors containing antisense sequences to 
sagE were created, transformed into S. pyogenes, and tested in the hemolysis assay. Again, however, no 
synergistic inhibition of SLS biosynthesis was observed (Figure 2.17). qRT-PCR analysis of strains 
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containing the overexpression vectors against empty vector controls indicated that the presence of the 
vectors was resulting in a several fold increase in sagE RNA quantities (Table 2.5). Therefore, it is likely 
that the levels of SagE were being effectively modulated but that this was having no effect on SLS 
biosynthesis in the presence of nelfinavir. It is possible that SagE requires other cellular components to 
function that are more limiting than the quantity of SagE. If nelfinavir only binds to SagE in the context 
of this interaction, modulating the expression of SagE would not be expected to have a significant effect 
on nelfinavir inhibition. However, it is also possible that nelfinavir does not directly inhibit SagE or that 
the inhibition of nelfinavir biosynthesis is achieved through the interaction of nelfinavir and a different 
target. Even in this latter scenario, it is still possible that nelfinavir inhibits proteolysis via SagE, but that 
this simply isn’t a limiting factor in the biosynthesis of the mature cytolysin. 
 
Figure 2.17. Over- and under-expression of SagE does not affect SLS biosynthesis inhibition by 
nelfinavir. Lytic activity of extracts from S. pyogenes containing pIB184 vectors with sagE/F or antisense 
sagE treated with nelfinavir relative to DMSO controls (n = 2).This subset of data is representative of the 
overall trend. 
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Vector Gene 
Log2 ratio 
(treated/untreated) 
pIB184-sagE sagE 4.54 ± 1.32 
pIB184-sagEF sagE 3.11* 
pIB184-sagEF sagF 2.55* 
pIB184-sagF sagF 4.63 ± 0.72 
pIB184-AntiEfull sagE 6.07 ± 0.41 
Table 2.5. Changes in SagE/F expression as measured by qRT-PCR with S. pyogenes M1 5448 
transformed with pIB184 vectors. Values are from three biological replicates averaged from three 
technical replicates each, except for the pIB184-sagEF vector which was only one biological replicate 
(indicated by a *). The sagB gene was used as an internal control gene and relative gene expression was 
calculated by a comparative CT method.
50
 Positive values represent up-regulation of the genes. sagE 
appears to be upregulated with the antisense vector as the primers used cannot differentiate between 
normal sagE RNA and antisense sagE RNA. The primers used are given in the supplemental methods. 
 
2.8 Discussion 
In this work, the FDA-approved HIV protease inhibitor nelfinavir was repurposed as the first 
small molecule inhibitor of SLS production in S. pyogenes, displaying low micromolar activity. 
Nelfinavir was identified as a lead compound by leveraging the extensive basic and clinical research data 
accumulated on the effects of the drug. Lipodystrophy, a known side effect of nelfinavir and several other 
HIV protease inhibitors, had been previously linked to the off-target inhibition of the CaaX protease 
ZMPSTE24. We surmised that the HIV protease inhibitors would also inhibit SagE due to its homology 
with CaaX proteases, allowing us to rapidly identify a lead compound for the inhibition of SLS 
production. This strategy for lead identification negated the need for high-throughput screening or for a 
crystal structure of the target for in silico and structure-based design. Utilizing a drug with synthetic 
routes that have been thoroughly explored also greatly accelerated the creation of analogs for SAR efforts 
that yielded compound 17, with an improved IC50 value of 1 µM. 
Nelfinavir and related compounds are inhibitors of SLS biosynthesis, most likely through 
inhibition of proteolytic cleavage of the protoxin by the CPBP family member SagE. Although in vitro 
reconstitution was unsuccessful, the necessity for SagE during SLS production in the multi-plasmid 
expression system in E. coli provides considerable evidence for its role in proteolytic processing. Like 
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many CPBP members, SagE is commonly referred to as an immunity protein in the literature,
15, 16
 but 
inhibition by nelfinavir did not have any effect on the growth of S. pyogenes, providing evidence that 
SagE is not involved in self-immunity. Alternatively, compensatory mutations that abolish SLS 
production may arise when SagE is inactivated, as has been previously suggested.
16
 The original 
annotation of SagE as an immunity protein stems from its similarity to PlnP from Lactobacillus 
plantarum. PlnP and several related proteins are found downstream of bacteriocin structural genes in L. 
plantarum and have been shown to provide immunity to the antibacterial effect of the respective 
bacteriocins.
36
 Yet, unlike these bacteriocins, SLS has not been demonstrated to possess any antibacterial 
activity against intact S. pyogenes cells. A large buildup of intracellular SLS might result in toxicity, but 
this would be expected to affect any S. pyogenes strains in which the transport machinery is inactivated as 
well, which has not been observed.
15
 Furthermore, treatment of SagA with the cyclization machinery 
(SagBCD) in vitro results in a lytic entity without cleavage of the leader peptide, indicating that while 
proteolysis is required for cellular export, it is unnecessary for lytic activity.
21
 These observations lead us 
to conclude that the principal function of SagE is to proteolytically mature SLS. 
In addition to experimentally supporting a biochemical role for SagE, we have also addressed the 
mechanism of proteolysis and the probable inhibition by nelfinavir. CPBP family members have been 
postulated to function through a zinc metalloprotease mechanism based on the presence of two 
glutamates, two histidines, and an asparagine residue that are conserved across the family (Figure 2.11).
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Mutation of these residues in the eukaryotic type II CaaX protease Ras-converting enzyme (Rce1) has 
also demonstrated that these residues are critical for activity.
34
 We found that Glu131 and Glu132 were 
critical for the activity of SagE. Thus, it was initially unexpected that proteolysis was inhibited by 
pepstatin, a general aspartyl protease inhibitor, but not by bestatin, a metalloprotease inhibitor (Figure 
2.5). However, a recent report detailing the crystal structure of Rce1 from Methanococcus maripaludis 
provides compelling evidence that this family of proteases actually functions through a novel glutamate-
dependent mechanism (Figure 2.18).
42
 The authors hypothesized that a glutamate residue extending into 
the active site is responsible for deprotonating a water molecule, activating it for nucleophilic attack. 
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Given the similarities between this proposed mechanism and the mechanism of aspartyl proteases, it is 
perhaps unsurprising that a CaaX protease homolog would be inhibited by aspartyl protease inhibitors, 
including nelfinavir. 
 
 
Figure 2.18. Proposed mechanism for glutamate-dependent proteases. A potential mechanism for 
glutamate dependent proteases based on the crystal structure of Rce1 is shown.
42
 Glutamate and histidine 
activate water for nucleophilic attack while a second histidine residue and an asparagine residue labeled 
“Oxy” comprise the oxyanion hole. A second conserved glutamate near the active site is thought to be 
structurally important. A general mechanism for aspartyl proteases is shown for comparison. 
 
In addition to increasing the potency of inhibition with compound 17, our synthetic effort also 
yielded information on how nelfinavir may interact with SagE. The SAR analysis revealed that a rather 
large side chain in the pseudo P1 position of the structure was required for potent activity, with the 
original S-phenyl-ethyl group displaying the greatest inhibition. This result was not anticipated, given that 
the P1 residue in the SagA substrate is putatively glycine. One possible explanation for this discrepancy is 
that the catalytic site architecture of SagE is highly conserved with the type II CaaX proteases, which 
normally cleave substrates with a prenylated cysteine in the P1 position. In this case, nelfinavir would be 
an ideal fit for the active site, as the core of the molecule closely resembles a cysteine with a hydrophobic 
group appended. An alternative explanation is that nelfinavir does not bind in the active site in the 
expected fashion (with the secondary hydroxyl interacting with the catalytic residues, Figure 2.10) or does 
not bind in the active site at all. These possibilities are supported by the potent activity of several analogs 
with different stereochemical configurations, as these molecules would likely be forced into different 
conformations that do not allow the same favorable interactions with active site residues. In this scenario, 
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binding of nelfinavir to the membrane protease may be driven by hydrophobic interactions. This 
explanation would also account for the attenuated activity of saquinavir, which is nearly identical to 
nelfinavir except for the presence of a more hydrophilic group at the benzamide position (Figure 2.6, 
XLogP3 values from PubChem for nelfinavir and saquinavir are 5.7 and 4.2, respectively). Comparisons 
to the other HIV protease inhibitors do not yield much additional information due to their low similarity 
to nelfinavir, as reflected in the Tanimoto similarity coefficients (Table 2.6). 
 
ampr ataz daru indi lopi nelf rito saqu tipr 
ampr 1.00 0.24 0.67 0.14 0.21 0.14 0.21 0.20 0.12 
ataz 0.24 1.00 0.22 0.15 0.20 0.13 0.21 0.20 0.11 
daru 0.67 0.22 1.00 0.13 0.20 0.13 0.20 0.19 0.11 
indi 0.14 0.15 0.13 1.00 0.15 0.18 0.14 0.22 0.10 
lopi 0.21 0.20 0.20 0.15 1.00 0.14 0.28 0.19 0.11 
nelf 0.14 0.13 0.13 0.18 0.14 1.00 0.10 0.40 0.09 
rito 0.21 0.21 0.20 0.14 0.28 0.10 1.00 0.17 0.10 
saqu 0.20 0.20 0.19 0.22 0.19 0.40 0.17 1.00 0.10 
tipr 0.12 0.11 0.11 0.10 0.11 0.09 0.10 0.10 1.00 
 
Table 2.6. The Tanimoto similarity coefficients for the FDA-approved HIV protease inhibitors. Higher 
Tanimoto coefficients indicate higher similarity. Compounds that inhibited the production of SLS are 
highlighted in green. Abbreviations: ampr, amprenavir; ataz, atazanavir; daru, darunavir; indi, indinavir; 
lopi, lopinavir; nelf, nelfinavir; rito, ritonavir; saqu, saquinavir; tipr, tipranavir. 
 
Unequivocal confirmation of the bacterial target of nelfinavir (and analogs) was unfortunately not 
possible in the present study, which can be attributed to the technical challenges inherent to the study of 
integral membrane proteins. Nelfinavir also likely interacts with multiple targets in S. pyogenes, as the 
drug is known to have multiple off-target effects in humans.
45
 A significant body of work in mammalian 
cell lines has demonstrated that nelfinavir displays promiscuous activity, such as interruption of Akt 
signaling and inhibition of the proteasome.
56
 Target promiscuity likely also exists in bacteria, so possible 
interactions of nelfinavir with additional targets cannot be ruled out. Thus, nelfinavir may be inhibiting 
71 
 
additional participants that indirectly result in the inhibition of SLS production in a mechanism unrelated 
to proteolysis. Further targets of nelfinavir may also exist that do not result in observable phenotypes. 
However, nelfinavir also inhibited the biosynthesis of other natural products that include a CPBP family 
member in the gene cluster (i.e. LLS, CLS, and PZN). The fact that this inhibition occurred in a range of 
disparate bacterial species decreases the probability that another protease is responsible and provides 
substantial, albeit indirect, support that SagE is the primary target of nelfinavir in S. pyogenes. Finally, the 
HIV protease inhibitors found to inhibit SLS production parallel those capable of inhibiting the human 
CaaX protease ZMPSTE24 (Figure 2.6),
46, 47
 providing additional evidence that nelfinavir and its analogs 
inhibit SLS production by blocking the action of SagE. 
2.9 Summary and outlook 
Despite their prevalence, prokaryotic members of the CPBP family have not yet been thoroughly 
investigated. Many of the family members are incorrectly annotated or have a predicted function based 
solely on distant homology. The discovery of nelfinavir as an inhibitor of CPBPs has provided evidence 
that SagE functions as a protease and will aid in the assignment of functions to other family members, 
including other human pathogens such as S. aureus. Additionally, nelfinavir is the first reported inhibitor 
of the production of SLS and related toxins. Nelfinavir and improved analogs will provide a new tool to 
investigate toxin function without the need to create genetic deletions while also allowing for temporal 
control over toxin production. Reversible control of SLS production with nelfinavir analogs will also help 
to clarify the precise contribution of SLS to virulence in in vivo models of infection and may open the 
door to the development of virulence-targeting strategies for the control of S. pyogenes infections. Finally, 
the chemical knockdown effect of nelfinavir can be utilized for the discovery of natural products from the 
22% of TOMM gene clusters that contain a CPBP family member, potentially accelerating the structural 
and functional characterization of these compounds. 
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2.10 Experimental 
2.10.1 Materials 
All chemicals were purchased from Sigma-Aldrich, VWR, Fisher Scientific, or Oakwood 
Products and used without further purification unless otherwise specified. HIV protease inhibitors were 
obtained from the NIH AIDS Research and Reference Program, Division of Aids, NIAID, NIH. 
Nelfinavir, ritonavir, saquinavir, indinavir sulfate, amprenavir, lopinavir, atazanavir sulfate, tipranavir, 
and darunavir were received through distribution by Thermo Fisher. 
2.10.2 Plasmid construction 
The genes encoding Flag-SagA and SagA-Flag were generated in pDCerm via PCR utilizing 
primers specific to sagA and containing the Flag tag sequence and XbaI (Flag-sagA) or BamHI (sagA-
Flag) restriction sites. For heterologous expression of these peptides in Escherichia coli, the genes of 
interest were subcloned into a pET28 vector containing an N-terminal maltose binding protein (MBP) 
fusion as previously described.
21
 The construction of the Duet vectors pETDuet-1-sagB-sagC and 
pACYCDuet-1-MBP-sagA-sagD has been previously described.
43
 The Duet vector containing sagE and 
sagF was constructed using the pCOLADuet-1 vector (EMD Millipore) in an analogous manner.
43
 Point 
mutations of SagA and SagE were introduced by the Quikchange site-directed mutagenesis kit (Agilent), 
following the manufacturer’s instructions. The genes encoding SagE, SagEF, and SagF were inserted into 
pIB184 using Gibson cloning following the manufacturer’s instructions (New England Biolabs) with the 
EcoRI cut site to generate pIB184-sagE, pIB184-sagEF, and pIB184-sagF respectively. Antisense RNA 
comprising the entire sequence of sagE and the first 150 bp of sagE was inserted into pIB184 in a similar 
manner to generate pIB184-AntiEfull and pIB184-AntiE150 respectively. 
2.10.3 Generation of SagA substrates 
35
S-Methionine-labeled MBP-SagA was generated as previously described (from rabbit 
reticulocyte, T7-coupled in vitro transcription/translation, Promega).
57
 MBP-Flag-SagA and MBP-SagA-
Flag were generated by heterologous expression and purification as previously described.
21
 
  
73 
 
2.10.4 Preparation of S. pyogenes membranes 
An overnight culture (5 mL) of S. pyogenes M1 5448 ΔsagA16, 21 was grown in Todd-Hewitt 
Broth (THB) at 37 °C and used to inoculate a 50 mL culture of THB. This culture was grown to an OD600 
of 0.6 and harvested at 4,000 x g (5 min, 4 °C), and the cell pellet was transferred to a 1.7 mL microfuge 
tube using 1 mL of cell lysis buffer [50 mM MOPS (pH 7.6), 50 mM NaCl, 5% (v/v) glycerol, 1500 U 
mutanolysin, and 5 mg lysozyme]. The cell wall was digested for 1 h at 37 °C with agitation before 
cooling to 4 °C, directly prior to cell disruption by sonication (3 rounds for 30 s each, 30% power using a 
microprobe). The sample was then subjected to 3 rounds of freeze/thaw cycling using liquid nitrogen with 
cap venting upon warming to room temperature. A final round of sonication was then applied and any 
remaining intact cells were removed by a low-speed centrifugation step (500 x g, 3 min, 4 °C). Omission 
of either the sonication or freeze/thaw cycling steps in this procedure gave poor membrane fraction 
preparations. The supernatant of the low-speed spin is referred to as the whole-cell lysate fraction. The 
majority of this fraction was transferred to a thick-walled microfuge tube prior to a subsequent high-speed 
spin (50,000 x g, 45 min, 4 °C), in which the membrane fraction was separated from the whole-cell lysate. 
The supernatant of this spin, referred to as the soluble fraction, was transferred to a clean microfuge tube. 
Proteins from the harvested membrane fraction were resolubilized in 300 µL of membrane extraction 
buffer [50 mM HEPES (pH 7.4), 125 mM NaCl, 5% (v/v) glycerol, and 1% (w/w) dodecyl maltoside] 
with light sonication (2 rounds for 1 s each, 10% power using a microprobe). The extraction was allowed 
to proceed for 1 h at 4 °C with rocking. Protein concentration in each sample (whole-cell lysate, soluble, 
and membrane fractions) were quantified using the Bradford assay, adjusted to the same concentration 
(3.8 mg/mL) and would typically produce a total of 1-2 mg of protein for each fraction. 
2.10.5 Localization of SagA/SLS proteolytic activity 
To S. pyogenes fractions (whole-cell lysate, soluble, and membrane, 13.2 µL, 50 µg protein 
each), was added TCEP (1 µL of 50 mM), purified 
35
S-methionine-labeled MBP-SagA, MBP-Flag-SagA, 
or MBP-SagA-Flag protein pre-diluted in membrane extraction buffer (1 µL of 90 µg/mL), and 14.8 µL 
of membrane extraction buffer for a total reaction volume of 30 µL. Aliquots were removed at specific 
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times of reaction at 25 °C and quenched with SDS-PAGE loading buffer. Proteins were separated on a 
10% SDS-PAGE gel with 25 ng of MBP-SagA protein loaded per lane. For samples utilizing 
35
S-
methionine-labeled MBP-SagA, the gels were dried and visualized by autoradiography (typically 
requiring ~10 h of exposure at -80 °C using a Kodak BioMax low-energy isotope intensifying screen). 
For samples utilizing MBP-Flag-SagA or MBP-SagA-Flag, protein was transferred to nitrocellulose 
membranes (Pierce) by electroblot. Membranes were blocked for 30 min at 25 °C in 4% non-fat milk in 
TBST [25 mM Tris (pH 7.6), 150 mM NaCl, 0.1% (v/v) Tween 20] before anti-Flag antibodies (M2, 
mouse monoclonal, Sigma-Aldrich) were added at a 1:5,000 dilution directly to the buffer and allowed to 
bind for 1 h at 25 °C. The buffer was discarded and the membranes were washed 3 times for 5 min each 
with TBST. The membranes were then treated with anti-mouse horseradish peroxidase (HRP, GE 
Healthcare) at a 1:5,000 dilution for 30 min at 25 °C followed by 3 washes for 5 min each with TBST. 
The membranes were then treated with the SuperSignal West Pico Chemiluminescent substrate (Pierce) 
prior to film imaging. 
2.10.6 Expression of SLS in E. coli 
The three vectors comprising SagABCDEF were co-transformed into BL21-DE3 cells 
(Invitrogen) and plated on LB agar plates with 100 µg/mL ampicillin, 35 g/mL chloramphenicol, and 30 
g/mL kanamycin. The resulting colonies were then chosen and tested for their ability to produce 
hemolytic activity. To perform hemolytic tests, 10 mL LB cultures with 100 µg/mL ampicilln, 35 g/mL 
chloramphenicol, and 30 g/mL kanamycin were grown overnight at 37C with shaking. Separate 10 mL 
LB cultures were inoculated 1:50 with each of these starter cultures and grown to OD600 0.7. Cultures 
were induced with 0.1 mM isopropyl--D-thiogalactopyranoside (IPTG) and bovine serum albumin 
(BSA, 10 mg/ml) was added to the induced cultures. An aliquot was removed at 2 and 8 h for hemolytic 
assay testing. Aliquots were centrifuged at 4,000 x g for 15 min and supernatants were collected and 
directly added to washed, defibrinated sheep blood. 
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2.10.7 Erythrocyte lysis assay 
Defibrinated sheep blood (Hemostat Laboratories) was rinsed by resuspension in phosphate 
buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4·2H2O, 2 mM KH2PO4, pH 7.4) 
followed by centrifugation at 300 x g for 10 min at 4 °C. The supernatant was discarded and the pellet 
was rinsed again, repeating until the supernatant was nearly colorless. The blood was resuspended in fresh 
PBS to a concentration within the linear absorbance range at 405 or 450 nm when treated with 0.1% 
Triton X-100. SLS extracts were applied to the blood in a 3:4 ratio and incubated at 37 °C for 30 to 120 
min. Lysed cells were removed by centrifugation at 300 x g for 10 min at 4 °C and hemoglobin release 
was measured by A405 (FilterMax F5 plate reader) or A450 (Cary 4000 UV-Vis). 
2.10.8 Membrane proteolysis inhibition 
Purified membranes from S. pyogenes M1 5448 were used to digest [
35
S]-MBP-SagA in the 
presence of nelfinavir or mechanism-based protease inhibitors. A typical reaction (25 µL total volume) 
consisted of 18 µL of S. pyogenes membranes (5.0 mg/mL protein concentration), [
35
S]-MBP-SagA, 
protease inhibitor, and TCEP (2 mM). The inhibitors tested were pepstatin A (for aspartyl proteases, 60 
µM), bestatin (for metalloproteases, 200 µM), E-64 (for cysteine proteases, 200 µM), and pefabloc (for 
serine proteases, 400 µM). Nelfinavir was also tested in subsequent assays. Aliquots were removed at 
specific times of reaction at 25 °C, quenched with SDS-PAGE loading buffer, and analyzed by SDS-
PAGE as described above. 
2.10.9 Effect of FDA-approved HIV protease inhibitors on S. pyogenes 
An overnight culture (5 mL) of S. pyogenes M1 5448 was grown in THB without shaking at 37 
°C and used to inoculate multiple, identical 50 mL cultures of THB. Upon reaching an OD600 of 0.2, the 
cultures were diluted two-fold using an equal volume of THB containing the desired concentration of 
protease inhibitor (initial screening was at 50 µM; nelfinavir analog screening was at 25 µM) from 10 
mM stock solutions in DMSO. An equal volume of DMSO was used as a negative control for these 
assays. The OD600 of these cultures was measured in triplicate every 30 min using a Cary 4000 UV-Vis 
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spectrophotometer. For the cultures that reached an OD600 of 0.6, any SLS present on the cell surface was 
isolated using a BSA extraction procedure. SLS activity was then quantified by erythrocyte lysis assay. 
2.10.10 BSA extraction of SLS 
S. pyogenes M1 5448 was grown in THB at 37 °C as described above to an OD600 of 0.6. Cultures 
were harvested by centrifugation at 4000 x g for 10 min at 4 °C and the supernatant was discarded. The 
pellets were resuspended in fresh THB containing 10 mg/mL BSA and incubated at 37 °C for 1 h. The 
cultures were harvested by centrifugation at 4000 x g for 10 min at 4 °C and the supernatant was 
subsequently used in the erythrocyte lysis assay either undiluted or at a 1:3 dilution in fresh THB 
containing 10 mg/mL BSA. 
2.10.11 Determination of IC50 values 
S. pyogenes M1 5448 was grown in the presence of inhibitors with a concentration range of 0.2 to 
64 μM. SLS extracts were applied to the erythrocyte lysis assay alongside a DMSO treated control. 
Samples were centrifuged at 300 x g for 10 min at 4 °C and the supernatants were assayed for hemoglobin 
release when DMSO control treated blood had reached roughly 90% lysis. IC50 values were defined as the 
concentration of inhibitor needed to prevent 50% of the hemolysis relative to the DMSO control over the 
given time course. 
2.10.12 Minimum inhibitory concentration (MIC) testing 
Cultures of Bacillus subtilis 168 and E. coli MC4100 were grown in Luria-Bertani (LB) broth; 
cultures of Listeria monocytogenes 4b F2365, Staphylococcus aureus USA300 (MRSA), and 
Enterococcus faecium U503 (VRE) were grown in brain heart infusion (BHI) broth; cultures of S. 
pyogenes M1 5448 were grown in THB; cultures of C. sporogenes ATCC 19404 were grown in 
anaerobically prepared THB supplemented with 5 mM L-cysteine; cultures of Bacillus amyloliquefaciens 
RS6, Klebsiella pneumoniae ATCC 27736, and Pseudomonas aeruginosa PA01 were grown in Mueller 
Hinton broth. All strains were started as overnight cultures, were incubated at 37 °C, and were used at 
1:100 dilutions to inoculate fresh cultures in the same media. The cultures were grown at 37 °C to mid-
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exponential phase prior to MIC testing. Nelfinavir was added to the cultures at 1 to 64 µM from a 10 mM 
DMSO stock. The treated cultures were incubated for 16 h at 37 °C and growth was visually examined. 
2.10.13 Electron microscopy 
An overnight culture of S. pyogenes M1 5448 was grown in THB at 37 °C and used to inoculate 5 
mL cultures of THB containing 25 µM nelfinavir (from a 10 mM stock) or an equivalent amount of 
DMSO at a 1:20 dilution. The cultures were grown to an OD600 of 0.6, harvested by centrifugation (5,000 
x g, 10 min, 25 °C), and fixed with a Karnovsky’s fixative in phosphate buffered 2% glutaraldehyde and 
2.5% paraformaldehyde. Microwave fixation was used with this primary fixative and the tissue was then 
washed in cacodylate buffer with no further additives. Microwave fixation was also used with the 
secondary 2% osmium tetroxide fixative, followed by the addition of 3% potassium ferricyanide for 30 
min. After washing with water, saturated uranyl acetate was added for enbloc staining. The sample was 
dehydrated in a series of increasing concentrations of ethanol. Acetonitrile was used as the transition fluid 
between ethanol and the epoxy. Infiltration series were done with an epoxy mixture using the epon 
substitute Lx112. The resulting blocks were polymerized at 90 °C overnight, trimmed, and ultrathin 
sectioned with diamond knives. Sections were stained with uranyl acetate and lead citrate and 
photographed with a Hitachi H600 Transmission Electron Microscope. 
2.10.14 qRT-PCR of virulence gene expression 
An overnight culture of S. pyogenes M49 NZ131 was grown in THB at 37 °C and used to 
inoculate 2 mL cultures of THB containing 25 µM nelfinavir (from a 10 mM stock) or an equivalent 
amount of DMSO at a 1:20 dilution. The cultures were grown to an OD600 of 0.8 before RNA was isolated 
using an RNeasy Protect Bacteria Mini Kit (Qiagen) following the manufacturer’s instructions, except for 
the lysis step, which was extended to 1 h with the addition of 250 U mutanolysin. The absence of DNA 
contamination was confirmed by PCR with primers to the 16S rRNA and sagA genes. Isolated RNA was 
used to generate cDNA using the ImProm II kit (Promega) following the manufacturer’s instructions, 
running reactions both with and without reverse transcriptase (RT). RT negative reactions again 
confirmed the absence of DNA contamination. qRT-PCR reactions were initiated with 2 uL of cDNA 
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(~2.5 ng/µL), 2 µL of 10 µM forward primer, 2 µL of 10 µM reverse primer, 10 µL of iTaq Universal 
SYBR Green Supermix (Bio-Rad), and 4 µL of water and were run on a Lightcycler 480 (Roche). The 
fold-change in gene expression was calculated using a comparative CT method.
50
 We defined a significant 
change in gene expression to be genes that were either up- or down-regulated by more than 1.5 fold (log2) 
with P-values <0.01. 
2.10.15 Inhibition of LLS production 
Overnight cultures (5 mL) of L. monocytogenes were grown in BHI media at 37 °C and used to 
inoculate a 50 mL culture of BHI at a 1:20 dilution. Upon reaching an OD600 of 0.2, the culture was used 
to create multiple, identical cultures diluted by twofold using an equal volume of BHI containing 50 µM 
nelfinavir from a stock solution of 10 mM in DMSO. An equal volume of DMSO was used as a negative 
control for these assays. L. monocytogenes F2365LLS
C
 Δhly (LLO genetically deleted, LLS constitutively 
expressed) was used as the “+LLS” strain and L. monocytogenes F2365LLSC ΔhlyΔllsB (LLO and LLS 
genetically deleted) was used as the “-LLS” strain51. LLS was extracted in a manner analogous to SLS 
and applied to the erythrocyte lysis assay. 
2.10.16 Inhibition of CLS production 
Overnight cultures (5 mL) of Clostridium sporogenes ATCC 19404 were grown in anaerobically 
prepared THB containing 5 mM L-cysteine at 37 °C in an anaerobic chamber (Coy Lab Products) and 
used to inoculate 5 mL cultures at a 1:40 dilution of anaerobically prepared THB containing 5 mM L-
cysteine. The cultures were incubated at 37 °C until an OD600 of 0.15, at which point 50 µM nelfinavir 
from a stock solution of 10 mM in DMSO was added. An equal volume of DMSO was used as a negative 
control. CLS was extracted in a manner analogous to SLS and applied to the erythrocyte lysis assay. 
2.10.17 Inhibition of plantazolicin production 
10 mL cultures of B. amyloliquefaciens RS6 (sfp::ermAM bac::cmR, deficient in lipopeptides, 
polyketides, and bacilysin)
58
 were grown in LB broth at 37 °C to an OD600 of 0.2 or 0.6 (early- to mid-log 
phase, respectively), at which point nelfinavir or an equivalent volume of DMSO was added to the liquid 
cultures. Following inhibitor addition, cultures were grown with shaking at 37 °C for 24 h. Cells were 
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harvested by centrifugation (4,000 x g, 10 min, 4 °C), washed with Tris-buffered saline (TBS, pH 8), and 
harvested again (8,000 x g, 10 min, 4 °C). PZN was obtained by a non-lytic, methanolic cell surface 
extraction, as described previously.
52, 59
 Briefly, cells were resuspended in MeOH (1 mL), agitated by 
vortex for 30 s, and equilibrated for 15 min at 22 °C. Cells were harvested by centrifugation (8,000 x g, 
10 min, 4 °C), and the MeOH supernatant was evaporated in a speed-vac concentrator with minimal 
heating. Dried, crude extracts were resuspended in 100 µL of MeOH and filtered through a 0.22 µm filter 
in preparation for analysis by liquid chromatography-mass spectrometry (LC-MS) using an Agilent 1200 
HPLC system coupled to a G1956B quadrupole mass spectrometer with an electrospray ionization (ESI) 
source. LC used a 4.6 mm x 250 mm Thermo Scientific BetaSil C18 column (100 Å, 5 µm) with a 
gradient of 40-90% MeCN (with 10 mM NH4HCO3 in the aqueous phase) over 25 min, with the analytes 
eluted directly into the MS. PZN was quantified by integrating the total area under the curve for the 
single-ion monitoring (SIM) trace of m/z 668 ([M+H]
2+
), normalized to a negative control sample 
included in each set. 
2.10.18 Bioinformatics analysis of CaaX-like proteins in divergent TOMM clusters 
All YcaO superfamily proteins (InterPro IPR003776, SagD-like) were obtained from UniProt on 
October 28, 2014. Genome clusters were defined by using regions of 1000 bp on either side of the YcaO-
like protein. Gene cluster families were created using MultiGeneBlast
11
 with a cutoff of total score above 
10. TOMM clusters were defined as containing both a YcaO-like protein and a SagC or SagA like 
ortholog. All gene clusters were manually examined with special attention toward stand-alone YcaO 
clusters such as bottromycin (i.e. lacking the C-protein). CaaX-like proteins were defined as being 
orthologous to the SagE protein and identified using a Hidden Markov Model (HMM) created with SagE 
orthologs from Clostridium and Bacillus. 
2.10.19 PrsW cleavage of RsiW 
B. subtilis strains CDE743 (B. subtilis PY79 amyE::Phyperspank-3xflag-rsiW) and CDE744 (B. 
subtilis PY79 amyE::Phyperspank-3xflag-rsiW  psrW::erm) were obtained from Craig Ellermeier 
(University of Iowa, Iowa City). Overnight cultures of CDE743 and CDE744 were grown in LB 
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containing 5 µg/mL kanamycin (for maintenance of the rsiW-containing vector) at 37 °C with shaking. 
An additional 25 µg/mL erythromycin was added to all cultures of CDE744. The overnight cultures were 
used to inoculate fresh 2 ml cultures in LB containing 5 µg/mL kanamycin at a 1:100 dilution. The 
cultures were grown at 37 °C with shaking to an OD600 of 0.1 before the addition of 1 mM IPTG and 
either 50 µM nelfinavir or an equivalent amount of DMSO. The cultures were then grown to OD600 of 0.7 
before 24 mM NaOH from a 100x stock was added to half of the cultures. The cultures were incubated at 
37 °C with shaking for an additional 1 h. The cultures were pelleted and the supernatant was discarded. 
The pellets were resuspended in 375 µL of TAE buffer (40 mM Tris HCl, 20 mM acetic acid, 1mM 
EDTA, pH 8.0) with 10 mg/mL lysozyme. After a 10 min incubation at room temperature, the samples 
were mixed with 4x reducing loading dye and heated at 65 °C for 10 min. The samples were run on 12% 
SDS-PAGE gels and protein was transferred to PVDF membranes (Pierce) by electroblot. Membranes 
were blocked overnight at 4 °C in 5% non-fat milk in TBST before horse radish peroxidase (HRP) 
conjugate anti-Flag antibodies (M2, mouse monoclonal, Sigma-Aldrich) were added at a 1:5,000 dilution 
directly to the buffer and allowed to bind for 1 h at 4 °C. The buffer was discarded and the membranes 
were washed 5 times for 5 min each with TBST. The membranes were then treated with the SuperSignal 
West Pico Chemiluminescent substrate (Pierce) prior to film imaging. 
2.10.20 Affinity labeling with crosslinking probe 
S. pyogenes M1 WT and E. coli BL21-DE3 were grown in THB and LB, respectively, as above. 
Overnight cultures of each species were used to inoculate fresh 50 mL cultures in the same media. The 
cultures were grown to an OD600 of 0.9 at 37 °C and then pelleted at 4,000 x g for 10 min. The 
supernatants were discarded and the pellets were washed with 2 mL water before being resuspended in 1 
mL of water. Probe 150 was added at 50 µM to each sample and the suspensions were incubated at 37 °C 
with shaking for 30 min. The samples were transferred to a 6-well plate and exposed to 365 nm light from 
a 4 W UV wand placed directly on the well for 20 min. The samples were transferred back to an 
Eppendorf tube and pelleted at 2,000 x g for 10 min. The pellets were resuspended in MOPS lysis buffer 
(50 mM MOPS, 50 mM NaCl, 5% glycerol, pH 7.0) containing 15 µL/mL protease inhibitor cocktail (2 
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µM leupeptin, 200 µM PMSF, 2 mM benzamidine, 2 µM E64) and either 200 U/mL mutanolysin (for S. 
pyogenes) or 15 mg/mL (for E. coli). For S. pyogenes samples, cell lysis was carried out by a one hour 
incubation at room temperature followed by freezing, thawing, and sonicating the cells for 30s, with the 
freeze/thaw/sonicate cycle being repeated 4 times total. For E. coli samples, cell lysis was carried out by a 
30 min incubation at room temperature followed by four rounds of sonication for 30 s each. Biotin-peg3-
azide (Jena Bioscience, Jena, Germany; 100 µM), copper sulfate (10 mM), and sodium ascorbate (20 
mM) were added to each sample. The samples were incubated for 1 h and were then used as total lysate or 
were centrifuged at 17,000 x g for 10 min. The supernatant was used as the soluble portion of the lysate 
while the pellet was used as the insoluble portion. The insoluble portion was resuspended in 100 µL 
MOPS lysis buffer with 1% CHAPS with a reducing loading dye before application to 12% SDS-PAGE 
gels. Protein was transferred to PVDF membranes (Pierce) by electroblot. Membranes were blocked 
overnight at 4 °C in 5% BSA in TBST before neutrAvidin-HRP (Pierce) was added at a 1:30,000 dilution 
directly to the buffer and allowed to bind for 1 h at 4 °C. The buffer was discarded and the membranes 
were washed 5 times for 5 min each with TBST. The membranes were then treated with the SuperSignal 
West Pico Chemiluminescent substrate (Pierce) prior to film imaging. 
2.10.21 Expression of SagE in lipid nanodiscs 
POPC lipid nanodiscs (disc concentration at 3uM, in 20mM tris, 0.1% NaCl, 15% glyercol) were 
obtained from Steven Sligar (University of Illinois, Urbana, IL). Coupled transcription/translation 
reactions were carried out with the Promega TNT T7 Coupled Rabbit Reticulocyte Lysate System 
(Progema product number L4610) following the manufacturer’s guidelines. Reactions contained 12.5 µL 
rabbit reticulocyte lysate, 1 µL TNT reaction buffer (supplied with kit), 0.5 µL T7 polymerase, 0.25 µL 
amino acid mix minus Met, 0.25 µL amino acid mix minus Leu, 0.5 µL RNasin, 6.5 µL POPC nanodiscs, 
and 1 µg DNA. The DNA used for each reaction was either pET28-Mistic-SagE or pCOLA-SagE-SagF-
Stag. Generation of the pCOLA is described above while the pET28 vector was generated in the Dixon 
lab (University of California, San Diego (UCSD), La Jolla, CA) by cloning from S. pyogenes M1 5448. 
The reactions were incubated at either 18 or 30 °C for 90 min before 2 µL of each reaction was mixed 
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with 3 µL of 33.3 ng/µL MBP-SagA in various cleavage buffers (50 mM tris, 50-125 mM NaCl, 0-20 
mM MgCl2, 0-50 µM ZnCl2, 2.5 mM TCEP or 10 mM DTT, 0-2.5% glycerol, 0-3 mM ATP, pH 7.5). The 
cleavage reactions were incubated at 18 °C or 37 °C for 2 h before being mixed with a reducing loading 
dye and applied to 12% SDS-PAGE gels. Protein was transferred to PVDF membranes (Pierce) by 
electroblot. Membranes were blocked overnight at 4 °C in 5% non-fat milk in TBST before anti-MBP 
primary antibodies (rabbit polyclonal, generated in the Dixon lab, UCSD) were added at a 1:2,000 
dilution directly to the buffer and allowed to bind for 2 h at 4 °C. The buffer was discarded and the 
membranes washed twice with TBST for 30 s each. The membranes were placed in 10 mL fresh TBST 
and 1.5 µL of anti-rabbit-HRP goat secondary antibodies were added to the buffer. The membranes were 
incubated for 45 min at 4 °C. The buffer was discarded and the membranes were washed 5 times for 5 
min each with TBST. The membranes were then treated with the SuperSignal West Pico 
Chemiluminescent substrate (Pierce) prior to film imaging. 
2.10.22 qRT-PCR of strains containing pIB184-sagE/F vectors 
Overnight cultures of S. pyogenes M1 5448 transformed with pIB184-sagE, pIB184-sagEF, 
pIB184-sagF, or pIB184-AntiEfull were grown in THB at 37 °C with 50 µg/mL kanamycin and used to 
inoculate 2 mL cultures of THB. The cultures were grown to an OD600 of 0.65 before RNA was isolated 
using an RNeasy Protect Bacteria Mini Kit (Qiagen) following the manufacturer’s instructions, except for 
the lysis step, which was extended to 1 h with the addition of 250 U mutanolysin. The absence of DNA 
contamination was confirmed by PCR with primers to the 16S rRNA and sagE genes. Isolated RNA was 
used to generate cDNA using the ImProm II kit (Promega) following the manufacturer’s instructions, 
running reactions both with and without reverse transcriptase (RT). RT negative reactions again 
confirmed the absence of DNA contamination. qRT-PCR reactions were initiated with 2 uL of cDNA 
(~2.5 ng/µL), 2 µL of 10 µM forward primer, 2 µL of 10 µM reverse primer, 10 µL of iTaq Universal 
SYBR Green Supermix (Bio-Rad), and 4 µL of water and were run on a Lightcycler 480 (Roche). The 
fold-change in gene expression was calculated using a comparative CT method.
50 
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2.10.23 Tanimoto similarity analysis 
The structure of each HIV protease inhibitor in ChemDraw (PerkinElmer) was converted to .sdf 
format. Tanimoto similarity coefficients were calculated in Discovery Study Client 2.5 (Accelrys) using 
the .sdf files as input reference ligands for the Library Analysis protocol “Find Similar Molecules by 
Fingerprints”. ECFP_6 was used and the minimum similarity was set at zero. The compounds were all 
compared pair-wise. 
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2.10.24 List of primers 
Primer Sequence (5’ to 3’) Description 
Construct Generation 
pDC-Flag-SagA-
fwd 
GAGTCTAGAATGGATTACAAGGATGACGACGA
TAAGTTCAAATTTACTTCAAATATTTTA 
Forward primer to append an N-
terminal Flag tag to sagA 
pDC-SagA-rev ACAGGATCCTTATTTACCTGGCGTATAACTTCC 
Reverse primer to append an N-
terminal Flag tag to sagA 
pDC-SagA-fwd 
GAGTCTAGAATGTTAAAATTTACTTCAAATATT
TTAG 
Forward primer to append a C-
terminal Flag tag to sagA 
pDC-SagA-Flag-
rev 
ACAGGATCCTTACTTGTCGTCGTCATCCTTGTA
GTCTTTACCTGGCGTATAACTTCC 
Reverse primer to append a C-
terminal Flag tag to sagA 
Flag-SagA-fwd AAAAGGATCCATGGACTACAAGGATGACGAC 
Forward primer to subclone Flag- 
sagA from pDCerm construct 
Flag-SagA-rev 
AAAAGCGGCCGCTTATTTACCTGGCGTATAAC
TTCCG 
Reverse primer to subclone Flag- 
sagA from pDCerm construct 
SagA-Flag-fwd 
AAAAGGATCCATGTTAAAATTTACTTCAAATA
TTTTAGCTACTAGTGT 
Forward primer to subclone sagA-
Flag from pDCerm construct 
SagA-Flag-rev 
AAAAGCGGCCGCTTACTTGTCGTCGTCATCCTT
GTA 
Reverse primer to subclone sagA-
Flag from pDCerm construct 
MBP-fwd ATGAAGCCCTGAAAGACG 
Sequencing primer for pET28-MBP 
constructs 
SagE-fwd AAAACCATGGCGCCTTTGTCCATCCAATGC 
Forward primer to clone sagE into 
pCOLADuet-1 
SagE-rev 
AAAGCGGCCGCTCATGTCACCTCCTTCTTCTTT
TTTG 
Reverse primer to clone sagE into 
pCOLADuet-1 
SagF-fwd 
AAAAAAAACATATGATGCTATTGGTTTTGCTG
TCG 
Forward primer to clone sagF into 
pCOLADuet-1 
SagF-rev 
AAAACTCGAGCTAATACTCTTTGCAACTAATC
ATCAAATAAGTC 
Reverse primer to clone sagF into 
pCOLADuet-1 
SagE-E131A-
fwd 
GGCTATCCTTTATTACTAGCTTTATTTgcaGAGA
CGATTTATCG 
Forward primer for incorporation of 
alanine at position E131 in sagE 
SagE-E131A-rev 
CGATAAATCGTCTCtgcAAATAAAGCTAGTAAT
AAAGGATAGCC 
Reverse primer for incorporation of 
alanine at position E131 in sagE 
SagE-E132A-
fwd 
CTAGCTTTATTTGAAgcgACGATTTATCGTTTTT
TGTGG 
Forward primer for incorporation of 
alanine at position E132 in sagE 
SagE-E132A-rev 
CCACAAAAAACGATAAATCGTcgcTTCAAATAA
AGCTAG 
Reverse primer for incorporation of 
alanine at position E132 in sagE 
SagA VAPGG-
VLPLL-fwd 
GCTACTAGTGTAGCTGAAACAACTCAAGTTcttC
CTctactcTGCTGTTGCTGCTGTAC 
Forward primer for incorporation of 
leucine at positions A20, G22, and 
G23 in sagA 
SagA VAPGG-
VLPLL-rev 
GTACAGCAGCAACAGCAgagtagAGGaagAACTTG
AGTTGTTTCAGCTACACTAGTAGC 
Reverse primer for incorporation of 
leucine at positions A20, G22, and 
G23 in sagA 
G184-SagE-fwd 
CCCGCGGTACCCGGGATGCCTTTGTCCATCCA
ATG 
Forward primer to clone sagE (and 
sagEF) into pIB184 
G184-SagE-rev 
AGATCTCGAGCTCTAGTCATGTCACCTCCTTCT
TC 
Reverse primer to clone sagE into 
pIB184 
G184-SagF-fwd 
CCCGCGGTACCCGGGATGATGCTATTGGTTTTG
C 
Forward primer to clone sagF into 
pIB184 
G184-SagF-rev 
AGATCTCGAGCTCTAGCTAATACTCTTTGCAAC
TAATCATC 
Reverse primer to clone sagF (and 
sagEF) into pIB184 
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2.10.24 List of primers (cont.) 
 
G184-AntiE-fwd 
CCCGCGGTACCCGGGTCATGTCACCTCCTTCTT
C 
Forward primer to clone antisense 
sagE into pIB184 
G184-AntiE-rev agatctcgagctctagATGCCTTTGTCCATCCAATG 
Reverse primer to clone antisense 
sagE-full into pIB184 
G184-AntiE150-
rev 
CCCGCGGTACCCGGGAATGTCATAAATCAGAG
TTGCTC 
Reverse primer to clone antisense 
sagE-150 into pIB184 
qRT-PCR 
q16S-fwd GAGAGTTTGATCCTGGC 
Forward primer for qRT-PCR on the 
16S rRNA gene 
q16S-rev TTGCCGAAGATTCCCTA 
Reverse primer for qRT-PCR on the 
16S rRNA gene 
qM49-fwd TTAGTTTTCTTCTTTGCGTTTTAGA 
Forward primer for qRT-PCR on 
emm49 
qM49-rev CGAAGCTAAGAAAAAAGTAGAAG 
Reverse primer for qRT-PCR on 
emm49 
qSLO2-fwd GATGTGTTTGATAAATCAGTGAC Forward primer for qRT-PCR on slo 
qSLO2-rev TCAGTTCTGTTATTGACACC Reverse primer for qRT-PCR on slo 
qsagA-fwd ATGTTAAAATTTACTTCAAATATTTTAGCT 
Forward primer for qRT-PCR on 
sagA 
qsagA-rev TATTTACCTGGCGTATAACTTC 
Reverse primer for qRT-PCR on 
sagA 
qsagB-fwd ATGTCATTTTTTACAAAGGAACAA 
Forward primer for qRT-PCR on 
sagB 
qsagB-rev ATTGACGATGACTTCTTCG 
Reverse primer for qRT-PCR on 
sagB 
qscpA-fwd TTAGAAGATCGTTTCTCTAGAGTA 
Forward primer for qRT-PCR on 
scpA 
qscpA-rev TACTGTTCCATTGAAAATGTCA 
Reverse primer for qRT-PCR on 
scpA 
qska-fwd ATGAAAAATTACTTATCTTTTGGGAT Forward primer for qRT-PCR on ska 
qska-rev CTTGCAAAATCAATGACCTC Reverse primer for qRT-PCR on ska 
qspeB-fwd CTAAGGTTTGATGCCTACAA 
Forward primer for qRT-PCR on 
speB 
qspeB-rev TGTTGGTATTTCAGTAGACATG 
Reverse primer for qRT-PCR on 
speB 
qnga-fwd AAACAAAAAAGTAACATTAGCTCAT Forward primer for qRT-PCR on nga 
qnga-rev GTATTTAACATCAGCCTTTGC Reverse primer for qRT-PCR on nga 
qspd3-fwd ATGTCTAAATCAAATCGTCGT 
Forward primer for qRT-PCR on 
spd3 
qspd3-rev GTCATTTAAGCCGCTAAATTG Reverse primer for qRT-PCR on spd3 
qsagE-fwd GCCTTTGTCCATCCAAT 
Forward primer for qRT-PCR on 
sagE 
qsagE-rev AATCGTCTCTTCAAATAAAGCT 
Reverse primer for qRT-PCR on 
sagE 
qsagF-fwd TGCTATTGGTTTTGCTGT 
Forward primer for qRT-PCR on 
sagF 
qsagF-rev ATACTTAAGACTGGTTTATCTTGT 
Reverse primer for qRT-PCR on 
sagF 
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2.10.24 List of primers (cont.) 
 
Gene Verification 
ClosC-fwd 
ATGGAAAATAATACTATATACAAATTAAGCAA
TAATTTAA 
Forward primer for confirming the 
presence of closC 
ClosC-rev 
TTAAGAATTAATATCTTCTAAAATTTCATCCAC
AA 
Reverse primer for confirming the 
presence of closC 
ClosD-fwd 
ATGATAAAATTTTACCCAAGTTTTAATAATATA
TTAGAG 
Forward primer for confirming the 
presence of closD 
ClosD-rev TTAAGGCATTGGGTGCG 
Reverse primer for confirming the 
presence of closD 
 
Primers used in this study. Restriction endonuclease recognition sites are underlined. Lower-case letters 
indicate bases targeted for mutagenesis. The function of each gene analyzed by qRT-PCR is given in 
Table 2.2. 
 
2.10.25 Compound Syntheses 
 
1
H, 
13
C, and 
19
F NMR spectra were collected on Varian Inova 400 and 500 MHz spectrometers. 
All 
1
H and 
13
C spectra collected in CDCl3 were referenced to an internal tetramethylsilane standard. All 
1
H and 
13
C spectra collected in (CD3)2SO were referenced to the solvent peak. All 19F spectra were 
referenced to an external CFCl3 standard. High-resolution mass spectrometry (HRMS) data were obtained 
on a Micromass Q-TOF Ultima tandem quadrupole mass-spectrometer at the University of Illinois at 
Urbana-Champaign Mass Spectrometry Laboratory. 
 
 
(R)-Benzyl (4-diazo-3-oxo-1-(phenylthio)butan-2-yl)carbamate (2) 
 To a stirred solution of N-Z-S-phenyl-L-cysteine (5.00 g, 15.1 mmol) in anhydrous 
tetrahydrofuran (60 mL) under nitrogen at -78 °C was added anhydrous triethylamine (3.14 mL, 22.7 
mmol) followed by isobutyl chloroformate (2.95 mL, 22.7 mmol). The reaction was stirred cold for 1 h 
and then warmed to room temperature for 1.5 h. The reaction was cooled to -78 °C before an ethereal 
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solution of diazomethane (100 mL, 32.4 mmol) was added in one portion and the reaction was then 
warmed to room temperature with stirring for 1 h. The reaction was evaporated to dryness, resulting in a 
yellow solid. The solid was taken up in ethyl acetate, washed twice with water, twice with a saturated 
solution of sodium bicarbonate, and once with brine. The organic phase was dried over sodium sulfate 
and concentrated by rotary evaporation. The product was purified by silica flash column chromatography 
(gradient of 0-4% EtOAc in CHCl3) to yield 2 as a yellow oil (3.33 g, 62%). 
1
H NMR (500 MHz, CDCl3) 
δ ppm 7.31 (d, J = 7.5 Hz, 2H), 7.29-7.17 (m, 6H), 7.13 (t, J = 7.5 Hz, 2H), 5.79 (d, J = 7.5 Hz, 1H), 5.39 
(s, 1H), 5.01 (s, 2H), 4.32 (br s, 1H), 3.20 (m, 2H). 
13
C NMR (500 MHz, CDCl3) δ ppm 130.05, 128.98, 
128.38, 128.09, 127.92, 126.79, 67.39, 60.64, 57.35, 55.15, 36.38, 21.38, 14.44. HRMS (m/z): [M + H]
+
 
calc. for C18H18N3O3S, 356.1069; observed, 356.1072. 
 
 
(R)-Benzyl (4-chloro-3-oxo-1-(phenylthio)butan-2-yl)carbamate (3) 
 To a solution of 2 (3.33 g, 9.37 mmol) in anhydrous tetrahydrofuran under nitrogen at 0 °C was 
added 1 M HCl in diethyl ether (14.1 mL, 14.1 mmol) dropwise. The reaction was stirred at 0 °C for 30 
min after complete addition. The solution was dried under reduced pressure to yield 3 as a slightly yellow 
solid (3.4 g). No further purification was made. 
1
H NMR (500 MHz, CDCl3) δ ppm 7.40-7.21 (m, 10H), 
5.77 (d, J = 7.5 Hz, 1H), 5.08 (s, 2H), 4.69 (q, J = 7 Hz, 1H), 4.24-4.08 (m, 2H), 3.35 (m, 2H). 
13
C NMR 
(500 MHz, CDCl3) δ ppm 199.52, 155.65, 135.76, 133.83, 130.64, 129.25, 128.46, 128.23, 127.99, 
127.30, 67.24, 57.03, 46.93, 35.42. HRMS (m/z): [M + H]
+
 calc. for C18H19NO3SCl, 364.0774; observed, 
364.0771. 
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Benzyl ((2R,3S)-4-chloro-3-hydroxy-1-(phenylthio)butan-2-yl)carbamate (4) and benzyl ((2R,3R)-4-
chloro-3-hydroxy-1-(phenylthio)butan-2-yl)carbamate (60) 
 To a solution of 3 (3.34 g, 11.06 mmol) in dichloromethane (25 mL) and methanol (15 mL) under 
nitrogen at 0 °C was added sodium borohydride (293 mg, 7.74 mmol). The reaction was stirred at 0 °C for 
1 h, then at room temperature for 1 h. The reaction was cooled to 0 °C and quenched with slow addition 
of 2 M HCl (6 mL). The reaction was evaporated to dryness and the solid was taken up in 
dichloromethane. The solution was washed twice with water followed by brine, dried over sodium sulfate, 
and concentrated by rotary evaporation. TLC analysis showed two diastereomers with the lower Rf 
compound being the (R,S)-isomer. The (R,S)-isomer was recrystallized in hexanes/ethyl acetate. The 
crystals were collected and washed with cold 2:1 hexanes:ethyl acetate. The filtrate was collected, dried 
to a solid, and recrystallized again in the same manner. Both diastereomers were then separated further by 
silica flash column chromatography (gradient of 0-40% EtOAc in hexanes) to yield (R,S)-isomer (4) as a 
white solid (2.51 g, 62%) and (R,R)-isomer (60) as a colorless oil (439 mg, 11%) over two steps. 
Characterization of the (R,S)-isomer (4): 
1
H NMR (500 MHz, CDCl3) δ ppm 7.41-7.15 (complex, 10H), 
5.15 (br s, 1H), 5.07 (s, 2H), 3.93 (m, 2H), 3.68 (dd, J1 = 3.5 Hz, J2 = 11.5 Hz, 1H), 3.60 (dd, J1 = 7 Hz, J2 
= 11.5 Hz, 1H), 3.30 (m, 2H), 2.81 (br s, 1H). 
13
C NMR (500 MHz, CDCl3) δ ppm 154.16, 130.11, 
129.17, 128.57, 128.29, 128.10, 127.92, 126.84, 120.32, 72.85, 67.17, 53.33, 47.45, 35.26.  HRMS (m/z): 
[M + H]
+
 calc. for C18H21NO3SCl, 366.0931; observed, 366.0928. Characterization of the (R,R)-isomer 
(60): 
1
H NMR (500 MHz, CDCl3) δ ppm 7.38-7.09 (complex, 10H), 5.52 (d, J = 9 Hz, 1H), 5.06 (dd, J1 = 
12.5 Hz, J2 = 16 Hz, 2H), 4.10 (m, 1H), 3.87 (m, 1H), 3.61 (d, J = 4 Hz, 1H), 3.46 (m, 2H), 3.18 (dd, J1 = 
6.5 Hz, J2 = 13.5 Hz, 1H), 3.04 (dd, J1 = 8 Hz, J2 = 13.5 Hz, 1H). 
13
C NMR (500 MHz, CDCl3) δ ppm 
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156.33, 135.90, 134.98, 129.26, 128.96, 128.39, 128.08, 127.88, 126.31, 70.71, 66.98, 52.04, 46.89, 
35.35. HRMS (m/z): [M + H]
+
 calc. for C18H21NO3SCl, 366.0931; observed, 366.0933. 
 
 
Benzyl ((R)-1-((S)-oxiran-2-yl)-2-(phenylthio)ethyl)carbamate (5) 
 To a solution of 4 (1.40 g, 3.83 mmol) in ethanol (60 mL) at 0 °C was added solid potassium 
hydroxide (237 mg, 4.22 mmol). The reaction was stirred cold for 15 min then warmed to room 
temperature and stirred for an additional 3 h. The reaction was evaporated to dryness and the solid was 
purified by silica flash column chromatography (gradient of 0-2.5% EtOAc in DCM) to yield 5 as a 
viscous yellow oil (1.15 g, 91%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.41-7.31 (m, 7H), 7.28 (t, J = 7.5 
Hz, 2H), 7.21 (t, J = 7.5 Hz), 5.36 (br s, 1H), 5.09 (dd, J1 = 12.5 Hz, J2 = 16 Hz, 2H), 3.72 (br s, 1H), 3.20 
(s, 2H), 2.99 (s, 1H), 2.76 (br s, 2H). 
13
C NMR (500 MHz, CDCl3) δ ppm 155.67, 136.02, 135.02, 129.69, 
128.95, 128.36, 128.03, 127.93, 126.53, 66.78, 52.51, 52.07, 46.55, 35.76. HRMS (m/z): [M + H]
+
 calc. 
for C18H20NO3S, 330.1164; observed, 330.1159. 
 
 
(3S,4aS,8aS)-2-((2R,3R)-3-amino-2-hydroxy-4-(phenylthio)butyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (7) 
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 To a solution of 5 (775 mg, 2.35 mmol) in isopropyl alcohol (15 mL) was added (3S,4aS,8aS)-N-
(tert-butyl)decahydroisoquinoline-3-carboxamide (6, 617 mg, 2.59 mmol). The solution was heated to 
reflux and stirred. After 5 h, 2 M KOH (5.9 mL, 11.8 mmol) was added and the reaction was stirred at 
reflux for an additional 14 h. The reaction was diluted with toluene (30 mL) and extracted with 1 M HCl 
(10 mL) three times. The aqueous fractions were combined and washed with toluene (15 mL) three times. 
The aqueous phase was adjusted to pH 12 with 5 M KOH and was extracted with toluene (20 mL) three 
times. The combined toluene fractions were washed with brine (15 mL), dried over sodium sulfate, and 
concentrated by rotary evaporation to yield 6 as a white solid (859 mg, 84%). No further purification was 
made. 
1
H NMR (500 MHz, CDCl3) δ ppm 7.39 (d, J = 7.5 Hz, 2H), 7.27 (t, J = 7.5 Hz, 2H), 7.17 (t, J = 
7.5 Hz, 1H), 6.63 (br s, 1H), 6.22 (s, 1H), 3.90 (q, J = 6 Hz, 1H), 3.49 (dd, J1 = 3 Hz, J2 = 14 Hz, 1H), 
3.11-2.98 (m, 3H), 2.72 (dd, J1 = 3 Hz, J2 = 6 Hz, 1H), 2.59 (dd, J1 = 8 Hz, J2 = 14 Hz, 1H), 2.46 (dd, J1 = 
5 Hz, J2 = 14 Hz, 1H), 2.29 (d, J = 11.5 Hz, 1H), 1.93 (q, J = 13 Hz, 1H), 1.85-1.14 (complex, 19H). 
13
C 
NMR (500 MHz, CDCl3) δ ppm 173.50, 134.80, 129.67, 129.06, 126.38, 69.89, 60.06, 59.20, 54.91, 
51.14, 36.41, 35.78, 33.03, 30.97, 30.39, 28.72, 28.61, 26.15, 25.60, 20.45. HRMS (m/z): [M + H]
+
 calc. 
for C24H40N3O2S, 434.2841; observed, 434.2841. 
 
General procedure for EDC coupling to compound 7 
 To a solution of 7 (1.0 eq) in THF (0.01-0.05 M) was added carboxylic acid (1.05 eq), 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide hydrochloride (1.05 eq), and hydroxybenzo-triazole hydrate (1.05 
eq). The solution was stirred at room temperature for 16-48 h. The reaction was taken up in ethyl acetate 
and washed once with saturated sodium bicarbonate and once with brine. The ethyl acetate fraction was 
dried over sodium sulfate, concentrated by rotary evaporation, and purified by silica flash column 
chromatography. 
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(3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-
(phenylthio)butyl)decahydroisoquinoline-3-carboxamide (1) 
 This reaction was performed according to the general EDC coupling procedure (0.083 mmol 3-
hydroxy-2-methylbenzoic acid for 16 h). Purification by flash column chromatography (gradient of 2-5% 
MeOH in DCM) yielded 1 as a white solid (31 mg, 66%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.43 (d, J = 
8 Hz, 2H), 7.30-7.7.14 (m, 4H), 7.02 (d, J = 4.5 Hz, 2H), 6.82 (t, J = 4.5 Hz, 1H), 5.87 (br s, 1H), 5.56 (s, 
1H), 4.45 (m, 1H), 4.07 (m, 1H), 3.86 (br s, 1H), 3.74 (dd, J1 = 9 Hz, J2 = 13.5 Hz, 1H), 3.41 (dd, J1 = 5 
Hz, J2 = 13.5 Hz, 1H), 2.92 (d, J = 11.5 Hz, 1H), 2.56 (dd, J1 = 9 Hz, J2 = 12.5 Hz, 1H), 2.44 (d, J = 11 
Hz, 1H), 2.28 (s, 3H), 2.24-2.17 (m, 2H), 1.97 (q, J = 12.5 Hz, 1H), 1.80-1.14 (complex, 11H), 1.09 (s, 
9H). 
13
C NMR (500 MHz, CDCl3) δ ppm 174.04, 171.76, 154.51, 137.42, 135.65, 130.14, 129.05, 127.92, 
126.53, 122.65, 119.96, 116.88, 70.66, 70.48, 59.76, 58.74, 54.60, 51.26, 36.08, 35.41, 33.72, 30.99, 
30.89, 28.41, 26.28, 25.98, 20.51, 12.50. HRMS (m/z): [M + H]
+
 calc. for C32H46N3O4S, 568.3205; 
observed, 568.3209. 
 
 
Benzyl (3-diazo-2-oxopropyl)carbamate (30) 
 To a stirred solution of Z-glycine (720 mg, 3.44 mmol) in anhydrous tetrahydrofuran (12 mL) 
under nitrogen at -78 °C was added anhydrous triethylamine (716 μL, 5.16 mmol) followed by isobutyl 
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chloroformate (672 μL, 5.16 mmol). The reaction was stirred cold for 1 h and then warmed to room 
temperature for 1.5 h. The reaction was cooled to -78 °C before an ethereal solution of diazomethane (25 
mL, 8.1 mmol) was added in one portion and the reaction was then warmed to room temperature with 
stirring for 1 h. The reaction was evaporated to dryness, resulting in a yellow solid. The solid was taken 
up in ethyl acetate, washed twice with water, twice with a saturated solution of sodium bicarbonate, and 
once with brine. The organic phase was dried over sodium sulfate and concentrated by rotary evaporation. 
The product was purified by silica flash column chromatography (gradient of 0-8% EtOAc in CHCl3) to 
yield 30 as a yellow solid (565 mg, 70%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.32-7.28 (complex, 5H), 
5.90 (m, 1H), 5.37 (m, 1H), 5.09 (s, 2H), 3.89 (bs s, 2H). 
13
C NMR (500 MHz, CDCl3) δ ppm 190.56, 
156.25, 136.01, 128.30, 127.97, 127.81, 66.79, 53.32, 47.93. HRMS (m/z): [M + Na]
+
 calc. for 
C11H11N3O3Na, 256.0698; observed, 256.0706. 
 
 
Benzyl (3-chloro-2-oxopropyl)carbamate (31) 
 To a solution of 30 (565 mg, 2.43 mmol) in anhydrous tetrahydrofuran (8 mL) under nitrogen at 0 
°C was added 1 M HCl in diethyl ether (3.65 mL, 3.65 mmol) dropwise. The reaction was stirred at 0 °C 
for 30 min after complete addition. The solution was dried under reduced pressure to yield 31 as orange 
solid (571 mg). No further purification was made. 
1
H NMR (500 MHz, CDCl3) δ ppm 7.35-7.28 
(complex, 5H), 5.64 (br s, 1H), 5.09 (s, 2H), 4.20 (d, J = 4.5 Hz, 2H), 4.10 (s, 2H). 
13
C NMR (500 MHz, 
CDCl3) δ ppm 198.61, 156.17, 135.97, 128.40, 128.10, 127.91, 67.01, 48.43, 46.03. HRMS (m/z): [M + 
H]
+
 calc. for C11H13NO3Cl, 242.0584; observed, 242.0585. 
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Racemic benzyl (3-chloro-2-hydroxypropyl)carbamate (32) 
 To a solution of 31 (571 mg, 2.36 mmol) in dichloromethane (7 mL) and methanol (4 mL) under 
nitrogen at 0 °C was added sodium borohydride (63 mg, 1.65 mmol). The reaction was stirred at 0 °C for 
1 h, and then quenched with slow addition of 2 M HCl (2 mL). The reaction was evaporated to dryness 
and the solid was taken up in ethyl acetate. The solution was washed twice with water followed by brine, 
dried over sodium sulfate, and concentrated by rotary evaporation. The product was purified by silica 
flash column chromatography (gradient of 0-8% EtOAc in DCM) to yield racemic 32 as a colorless oil 
(423 mg, 74% over two steps). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.33-7.28 (complex, 5H), 5.63 (t, J = 6 
Hz, 1H), 5.06 (s, 2H), 3.88 (s, 2H), 3.48 (m, 2H), 3.39 (m, 1H), 3.22 (m, 1H).
 13
C NMR (500 MHz, 
CDCl3) δ ppm 157.23, 135.93, 128.36, 128.06, 127.91, 70.52, 66.90, 46.44, 43.96. HRMS (m/z): [M + 
H]
+
 calc. for C11H15NO3Cl, 244.0740; observed, 244.0741. 
 
 
Racemic benzyl (oxiran-2-ylmethyl)carbamate (33) 
 To a solution of 32 (333 mg, 1.37 mmol) in ethanol (15 mL) at 0 °C was added solid potassium 
hydroxide (84 mg, 1.50 mmol). The reaction was stirred cold for 15 min then warmed to room 
temperature and stirred for an additional 3 h. The reaction was evaporated to dryness and the solid was 
purified by silica flash column chromatography (gradient of 0-6% EtOAc in DCM) to yield 33 as a 
colorless oil (237 mg, 83%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.35-7.28 (complex, 5H), 5.29 (br s, 
1H), 5.09 (s, 2H), 3.57 (dq, J1 = 3 Hz, J2 = 14.5 Hz, 1H), 3.22 (dt, J1 = 6 Hz, J2 = 14.5 Hz, 1H), 3.07 (m, 
1H), 2.74 (t, J = 4 Hz, 1H), 2.56 (dd, J1 = 2.5 Hz, J2 = 4 Hz, 1H). 
13
C NMR (500 MHz, CDCl3) δ ppm 
156.39, 136.23, 128.35, 127.99, 127.90, 66.66, 50.51, 44.87, 42.05. HRMS (m/z): [M + H]
+
 calc. for 
C11H14NO3, 208.0974; observed, 208.0982. 
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Benzyl ((S)-3-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-2-
hydroxypropyl)carbamate (34) and benzyl ((R)-3-((3S,4aS,8aS)-3-(tert-
butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)carbamate (35) 
 To a solution of 33 (237 mg, 1.14 mmol) in isopropyl alcohol (15 mL) was added (3S,4aS,8aS)-
N-(tert-butyl)decahydroisoquinoline-3-carboxamide (6, 327 mg, 1.37 mmol). The solution was heated to 
reflux and stirred. After 5 h, the reaction was cooled and dried to a solid. TLC analysis showed two 
diastereomers with the lower Rf compound being the S-isomer. The products were purified by silica flash 
column chromatography (gradient of 0-4% MeOH in DCM) to yield the S-isomer (34) as a white solid 
(205 mg, 40%) and R-isomer (35) as a white solid (205 mg, 40%). Characterization of the S-isomer (34): 
1
H NMR (500 MHz, CDCl3) δ ppm 7.35-7.25 (complex, 5H), 6.25 (m, 1H), 6.03 (s, 1H), 5.08 (m, 2H), 
3.85 (d, J = 3.5 Hz, 1H), 3.74 (s, 1H), 3.56 (m, 1H), 3.19 (m, 1H), 2.79 (d, J = 11.5 Hz, 1H), 2.52 (dd, J1 
= 2.5 Hz, J2 = 11.5 Hz, 1H), 2.44 (dd, J1 = 9 Hz, J2 = 12.5 Hz, 1H), 2.17 (m, 2H), 1.93 (q, J = 12 Hz, 1H), 
1.84-1.14 (complex, 20H).
 13
C NMR (500 MHz, CDCl3) δ ppm 173.98, 157.68, 136.46, 128.24, 127.75, 
127.72, 70.14, 68.27, 66.46, 58.99, 58.87, 50.92, 44.98, 35.71, 33.14, 30.71, 30.52, 28.53, 26.09, 25.44, 
20.25. HRMS (m/z): [M + H]
+
 calc. for C25H40N3O4, 446.3019; observed, 446.3023. Characterization of 
the R-isomer (35): 
1
H NMR (500 MHz, CDCl3) δ ppm 7.35-7.28 (complex, 5H), 6.34 (s, 1H), 5.61 (t, J = 
5.5 Hz, 1H), 5.06 (dd, J1 = 12.5 Hz, J2 = 14.5 Hz, 2H), 3.83 (s, 2H), 3.35 (dq, J1 = 3 Hz, J2 = 14 Hz, 1H), 
3.03 (m, 1H), 2.83 (d, J = 11.5 Hz, 1H), 2.62 (dd, J1 = 3 Hz, J2 = 11 Hz, 1H), 2.47 (t, J = 11 Hz, 1H), 2.14 
(dd, J1 = 3 Hz, J2 = 11 Hz, 1H), 2.01 (dd, J1 = 2 Hz, J2 = 13.5 Hz, 1H), 1.91-1.17 (complex, 21H). 
13
C 
NMR (500 MHz, CDCl3) δ ppm 173.48, 156.77, 136.33, 128.31, 127.90, 127.88, 69.54, 66.55, 66.39, 
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58.73, 58.05, 50.69, 44.70, 35.66, 33.09, 30.76, 30.73, 28.45, 26.16, 25.35, 20.12. HRMS (m/z): [M + H]
+
 
calc. for C25H40N3O4, 446.3019; observed, 446.3021. 
 
 
(3S,4aS,8aS)-N-(tert-butyl)-2-((S)-2-hydroxy-3-(3-hydroxy-2-
methylbenzamido)propyl)decahydroisoquinoline-3-carboxamide (8) 
 A solution of 34 (44 mg, 0.099 mmol) and 10% palladium on carbon (32 mg, 0.030 mmol) in 
methanol (10 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite 
and washed with excess methanol. The reaction was then dried to a solid and redissolved in THF (3 mL). 
3-hydroxy-2-methylbenzoic acid (17 mg, 0.109 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (21 mg, 0.109 mmol), and hydroxybenzotriazole hydrate (18 mg, 0.109 mmol) were added 
to the reaction and the solution was stirred at room temperature for 18 h. The reaction was taken up in 
ethyl acetate and washed once with saturated sodium bicarbonate and once with brine. The ethyl acetate 
fraction was dried over sodium sulfate, concentrated by rotary evaporation, and purified by silica flash 
column chromatography (gradient of 0-4% MeOH in DCM) to yield 8 as a white solid (24 mg, 54%). 
1
H 
NMR (500 MHz, CDCl3) δ ppm 7.45 (t, J = 5 Hz, 1H), 6.96 (t, J = 7.5 Hz, 1H), 6.91 (d, J = 6.5 Hz, 1H), 
6.80 (d, J = 7.5 Hz, 1H), 5.83 (s, 1H), 3.94 (m, 2H), 3.39 (dt, J1 = 5 Hz, J2 = 14 Hz, 1H), 2.76 (d, J = 10 
Hz, 1H), 2.51 (dd, J1 = 2.5 Hz, J2 = 11 Hz, 1H), 2.41 (dd, J1 = 9 Hz, J2 = 12.5 Hz, 1H), 2.18 (m, 4H), 2.00 
(q, J = 12 Hz, 1H), 1.86 (qd, J1 = 3 Hz, J2 = 12.5 Hz, 1H), 1.70 (m, 2H), 1.59-1.14 (complex, 18H). 
13
C 
NMR (500 MHz, CDCl3) δ ppm 174.19, 172.84, 154.81, 137.62, 126.32, 122.40, 119.02, 116.66, 70.42, 
96 
 
69.17, 59.46, 58.07, 51.35, 43.48, 35.93, 33.45, 30.90, 30.79, 28.45, 26.22, 25.50, 20.31, 12.51. HRMS 
(m/z): [M + H]
+
 calc. for C25H40N3O4, 446.3019; observed, 446.3021. 
 
 
(S)-benzyl 2-(2-diazoacetyl)pyrrolidine-1-carboxylate (36) 
 To a stirred solution of Z-L-proline (1.02 g, 4.10 mmol) in anhydrous tetrahydrofuran (12 mL) 
under nitrogen at -78 °C was added anhydrous triethylamine (853 μL, 6.15 mmol) followed by isobutyl 
chloroformate (800 μL, 6.15 mmol). The reaction was stirred cold for 1 h and then warmed to room 
temperature for 1.5 h. The reaction was cooled to -78 °C before an ethereal solution of diazomethane (25 
mL, 8.1 mmol) was added in one portion and the reaction was then warmed to room temperature with 
stirring for 1 h. The reaction was evaporated to dryness, resulting in a yellow solid. The solid was taken 
up in ethyl acetate, washed twice with water, twice with a saturated solution of sodium bicarbonate, and 
once with brine. The organic phase was dried over sodium sulfate and concentrated by rotary evaporation. 
The product was purified by silica flash column chromatography (gradient of 3-4% EtOAc in CHCl3) to 
yield 36 as a yellow oil (894 mg, 80%). 
1
H NMR (500 MHz, CDCl3, mixture of cis and trans isomers) δ 
ppm 7.38-7.26 (m, 10H), 5.50 (br s, 1H), 5.29 (br s, 1H), 5.19-5.05 (m, 4H), 4.33 (br s, 1H), 4.28 (br s, 
1H), 3.56-3.47 (m, 4H), 2.17 (m, 1H), 2.10-1.83 (m, 7H). 
13
C NMR (500 MHz, CDCl3, mixture of cis and 
trans isomers) δ ppm 194.95, 194.18, 154.92, 154.24, 136.30, 136.14, 128.24, 128.18, 127.80, 127.69, 
127.62, 66.88, 63.75, 53.02, 52.42, 47.09, 46.66, 30.93, 29.43, 24.09, 23.30. HRMS (m/z): [M + H]
+
 calc. 
for C14H16N3O3, 274.1192; observed, 274.1202. 
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(S)-benzyl 2-(2-chloroacetyl)pyrrolidine-1-carboxylate (37) 
 To a solution of 36 (894 mg, 3.27 mmol) in anhydrous tetrahydrofuran (8 mL) under nitrogen at 0 
°C was added 1 M HCl in diethyl ether (4.91 mL, 4.91 mmol) dropwise. The reaction was stirred at 0 °C 
for 30 min after complete addition. The solution was dried under reduced pressure to yield 37 as a slightly 
yellow oil (860 mg). No further purification was made. 
1
H NMR (500 MHz, CDCl3, mixture of cis and 
trans isomers) δ ppm 7.35-7.25 (complex, 10H), 5.15-5.01 (complex, 4H), 4.74 (dd, J1 = 4 Hz, J2 = 8.5 
Hz, 1H), 4.53 (dd, J1 = 4 Hz, J2 = 9 Hz, 1H), 4.31 (dd, J1 = 16 Hz, J2 = 21 Hz, 2H), 4.05 (dd, J1 = 16 Hz, 
J2 = 21 Hz, 2H), 3.59-3.48 (complex, 4H), 2.26-2.12 (complex, 2H), 1.99-1.81 (complex, 6H). 
13
C NMR 
(500 MHz, CDCl3, mixture of cis and trans isomers) δ ppm 201.36, 201.30, 154.79, 153.61, 136.12, 
135.72, 128.29, 128.21, 127.99, 127.81, 127.79, 127.50, 67.14, 66.92, 62.80, 62.50, 46.96, 46.94, 46.48, 
46.21, 30.08, 29.04, 24.32, 23.42. HRMS (m/z): [M + H]
+
 calc. for C14H17NO3Cl, 282.0897; observed, 
282.0894. 
 
 
(S)-benzyl 2-((S)-2-chloro-1-hydroxyethyl)pyrrolidine-1-carboxylate (38) and (S)-benzyl 2-((R)-2-
chloro-1-hydroxyethyl)pyrrolidine-1-carboxylate (39) 
 To a solution of 37 (860 mg, 3.05 mmol) in dichloromethane (7 mL) and methanol (4 mL) under 
nitrogen at 0 °C was added sodium borohydride (81 mg, 2.14 mmol). The reaction was stirred at 0 °C for 
1 h, and then quenched with slow addition of 2 M HCl (2 mL). The reaction was evaporated to dryness 
and the solid was taken up in ethyl acetate. The solution was washed twice with water followed by brine, 
dried over sodium sulfate, and concentrated by rotary evaporation. TLC analysis showed two 
diastereomers with the lower Rf compound being the (S,S) product. Both diastereomers were purified by 
silica flash column chromatography (gradient of 0-10% EtOAc in DCM) to yield the (S,S)-isomer (38) as 
a white solid (279 mg, 32%) and (S,R)-isomer (39) as a white solid (429 mg, 50%) over two steps. 
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Characterization of the (S,S)-isomer (38): 
1
H NMR (500 MHz, CDCl3) δ ppm 7.36-7.28 (complex, 5H), 
5.12 (dd, J1 = 13 Hz, J2 = 23.5 Hz, 2H), 4.04-3.95 (complex, 3H), 3.60-3.29 (complex, 4H), 2.08-1.74 
(complex, 4H). 
13
C NMR (500 MHz, CDCl3) δ ppm 156.01, 136.27, 128.32, 127.89, 127.67, 72.52, 66.98, 
61.04, 47.15, 46.84, 26.62, 23.92. HRMS (m/z): [M + H]
+
 calc. for C14H19NO3Cl, 284.1053; observed, 
284.1056. Characterization of the (S,R)-isomer (39): 
1
H NMR (500 MHz, CDCl3) δ ppm 7.37-7.28 
(complex, 5H), 5.13 (dd, J1 = 12.5 Hz, J2 = 16 Hz, 2H), 4.95 (d, J = 2 Hz, 1H), 4.11 (m, 1H), 3.81 (br s, 
1H), 3.72 (d, J = 11 Hz, 1H), 3.55 (m, 2H), 3.37 (m, 1H), 2.03 (m, 1H), 1.89 (m, 1H), 1.81 (m, 1H), 1.72 
(m, 1H). 
13
C NMR (500 MHz, CDCl3) δ ppm 157.52, 136.04, 128.27, 127.87, 127.65, 74.69, 67.22, 
60.57, 47.91, 47.05, 28.12, 23.94. HRMS (m/z): [M + H]
+
 calc. for C14H19NO3Cl, 284.1053; observed, 
284.1055. 
 
 
(S)-benzyl 2-((S)-oxiran-2-yl)pyrrolidine-1-carboxylate (40) 
 To a solution of 38 (297 mg, 0.983 mmol) in ethanol (15 mL) at 0 °C was added solid potassium 
hydroxide (61 mg, 1.08 mmol). The reaction was stirred cold for 15 min then warmed to room 
temperature and stirred for an additional 3 h. The reaction was evaporated to dryness and the solid was 
purified by silica flash column chromatography (gradient of 0-5% EtOAc in DCM) to yield 40 as a 
colorless oil (224 mg, 92%). 
1
H NMR (500 MHz, CDCl3, mixture of cis and trans isomers) δ ppm 7.38-
7.28 (complex, 10H), 5.17-5.06 (complex, 4H), 3.72 (d, J = 3.5 Hz, 1H), 3.59 (br s, 1H), 3.49 (br s, 3H), 
3.42 (m, 1H), 3.03 (s, 1H), 2.88 (s, 1H), 2.83 (t, J = 4.5 Hz, 1H), 2.78 (s, 1H), 2.65 (s, 1H), 2.49 (s, 1H), 
2.09-1.83 (complex, 8H). 
13
C NMR (500 MHz, CDCl3, mixture of cis and trans isomers) δ ppm 154.96, 
154.77, 136.57, 136.27, 128.28, 128.25, 128.01, 127.94, 127.72, 127.58, 66.89, 66.50, 58.87, 58.25, 
52.67, 52.26, 47.38, 47.18, 46.96, 46.52, 28.39, 27.07, 23.84, 22.95. HRMS (m/z): [M + H]
+
 calc. for 
C14H18NO3, 248.1287; observed, 248.1290. 
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(S)-benzyl 2-((R)-2-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-1-
hydroxyethyl)pyrrolidine-1-carboxylate (41) 
 To a solution of 40 (233 mg, 0.902 mmol) in isopropyl alcohol (12 mL) was added (3S,4aS,8aS)-
N-(tert-butyl)decahydroisoquinoline-3-carboxamide (6, 258 mg, 1.08 mmol). The solution was heated to 
reflux and stirred. After 5 h, the reaction was cooled and dried to a solid. The product was purified by 
silica flash column chromatography (gradient of 0-7% MeOH in DCM) to yield 41 as a white solid (211 
mg, 48%). 
1
H NMR (500 MHz, CDCl3, predominately one cis/trans isomer) δ ppm 7.38-7.29 (complex, 
5H), 6.31 (s, 1H), 5.12 (m, 2H), 4.18 (m, 1H), 4.02-3.87 (complex, 2H), 3.56 (m, 2H), 3.36 (m, 2H), 3.22 
(d, J = 11.5 Hz, 1H), 2.56-2.41 (complex, 3H), 2.22-1.00 (complex, 25H). 
13
C NMR (500 MHz, CDCl3, 
predominately one cis/trans isomer) δ ppm 174.04, 155.82, 136.46, 128.37, 127.87, 127.65, 71.05, 70.11, 
66.82, 61.80, 59.02, 58.73, 50.37, 47.43, 35.60, 32.88, 30.51, 28.57, 26.34, 26.08, 25.60, 25.21, 24.32, 
20.49. HRMS (m/z): [M + H]
+
 calc. for C28H44N3O4, 486.3332; observed, 486.3325. 
 
 
(3S,4aS,8aS)-N-(tert-butyl)-2-((R)-2-hydroxy-2-((S)-pyrrolidin-2-yl)ethyl)decahydroisoquinoline-3-
carboxamide (42) 
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 A solution of 41 (211 mg, 0.434 mmol) and 10% palladium on carbon (140 mg, 0.13 mmol) in 
methanol (16 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite, 
washed with excess methanol, and dried to a solid. The solid was taken up in ethyl acetate and extracted 
with 1 M HCl three times. The aqueous fractions were combined, adjusted to pH 12 with 10 M NaOH, 
and extracted with ethyl acetate three times. The combined ethyl acetate fractions were washed with 
brine, dried over sodium sulfate, and concentrated by rotary evaporation. The solid was further purified 
by silica flash column chromatography (gradient of 4-10% MeOH in DCM with 1% triethylamine) to 
yield 42 as a yellow solid (136 mg). The product was used without further purification. 
 
 
(3S,4aS,8aS)-N-(tert-butyl)-2-((R)-2-hydroxy-2-((S)-1-(3-hydroxy-2-methylbenzoyl)pyrrolidin-2-
yl)ethyl)decahydroisoquinoline-3-carboxamide (9) 
 To a solution of 42 (24 mg) in THF (3 mL) was added 3-hydroxy-2-methylbenzoic acid (11 mg, 
0.075 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (14 mg, 0.075 mmol), and 
hydroxybenzotriazole hydrate (12 mg, 0.075 mmol). The solution was stirred at room temperature for 16 
h. The reaction was taken up in ethyl acetate and washed once with saturated sodium bicarbonate and 
once with brine. The ethyl acetate fraction was dried over sodium sulfate, concentrated by rotary 
evaporation, and purified by silica flash column chromatography (gradient of 0-5% MeOH in DCM) to 
yield 9 as a white solid (27 mg, 73% over two steps). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.00 (t, J = 7.5 
Hz, 1H), 6.81 (d, J = 7.5 Hz, 1H), 6.66 (d, J = 7.5 Hz, 1H), 6.50 (s, 1H), 4.31 (t, J = 7.5 Hz, 1H), 4.16 (d, 
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J = 5 Hz, 1H), 3.48 (s, 2H), 3.31 (d, J = 11 Hz, 1H), 3.24 (t, J = 9 Hz, 1H), 3.12 (br s, 1H), 2.64 (m, 2H), 
2.26 (m, 2H), 2.12 (m, 4H), 1.89-1.21 (complex, 24H). 
13
C NMR (500 MHz, CDCl3) δ ppm 174.67, 
171.81, 162.54, 155.3, 138.36, 126.93, 115.81, 72.06, 70.15, 62.76, 59.41, 59.12, 50.75, 50.72, 35.77, 
32.88, 30.71, 28.71, 27.45, 26.23, 25.63, 24.70, 20.54, 12.57. HRMS (m/z): [M + H]
+
 calc. for 
C28H44N3O4, 486.3332; observed, 486.3317. 
 
 
 (S)-benzyl (1-diazo-5-methyl-2-oxohexan-3-yl)carbamate (43) 
 To a stirred solution of Z-L-leucine (1.02 g, 3.83 mmol) in anhydrous tetrahydrofuran (12 mL) 
under nitrogen at -78 °C was added anhydrous triethylamine (796 μL, 5.74 mmol) followed by isobutyl 
chloroformate (747 μL, 5.74 mmol). The reaction was stirred cold for 1 h and then warmed to room 
temperature for 1.5 h. The reaction was cooled to -78 °C before an ethereal solution of diazomethane (25 
mL, 8.1 mmol) was added in one portion and the reaction was then warmed to room temperature with 
stirring for 1 h. The reaction was evaporated to dryness, resulting in a yellow solid. The solid was taken 
up in ethyl acetate, washed twice with water, twice with a saturated solution of sodium bicarbonate, and 
once with brine. The organic phase was dried over sodium sulfate and concentrated by rotary evaporation. 
The product was purified by silica flash column chromatography (gradient of 0-6% EtOAc in CHCl3) to 
yield 43 as a yellow solid (951 mg, 86%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.34-7.27 (complex, 5H), 
5.77 (d, J = 8.5 Hz, 1H), 5.48 (s, 1H), 5.08 (dd, J1 = 12.5 Hz, J2 = 17.5 Hz, 2H), 4.25 (br s, 1H), 1.68 (m, 
1H), 1.55 (m, 1H), 1.46 (m, 1H), 0.93-0.84 (complex, 6H). 
13
C NMR (500 MHz, CDCl3) δ ppm 194.39, 
155.92, 136.05, 128.26, 127.91, 127.76, 66.68, 56.29, 53.53, 40.94, 24.45, 22.83, 21.50. HRMS (m/z): [M 
+ Na]
+
 calc. for C15H19N3O3Na, 312.1324; observed, 312.1322. 
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(S)-benzyl (1-chloro-5-methyl-2-oxohexan-3-yl)carbamate (44) 
 To a solution of 43 (951 mg, 3.29 mmol) in anhydrous tetrahydrofuran (8 mL) under nitrogen at 0 
°C was added 1 M HCl in diethyl ether (4.93 mL, 4.93 mmol) dropwise. The reaction was stirred at 0 °C 
for 30 min after complete addition. The solution was dried under reduced pressure to yield 44 as a yellow 
oil (951 mg). No further purification was made. 
1
H NMR (500 MHz, CDCl3) δ ppm 7.34-7.28 (complex, 
5H), 5.60 (d, J = 8.5 Hz, 1H), 5.07 (dd, J1 = 12 Hz, J2 = 15.5 Hz, 2H), 4.57 (m, 1H), 4.26 (dd, J1 = 16 Hz, 
J2 = 26.5 Hz, 2H), 1.69 (m, 1H), 1.57 (m, 1H), 1.42 (m, 1H), 0.96-0.86 (complex, 6H).
 13
C NMR (500 
MHz, CDCl3) δ ppm 201.86, 156.04, 135.87, 128.35, 128.05, 127.83, 66.95, 56.15, 46.53, 39.88, 24.58, 
22.99, 21.23. HRMS (m/z): [M + H]
+
 calc. for C15H21NO3Cl, 298.1210; observed, 298.1201. 
 
 
Benzyl ((2S,3S)-1-chloro-2-hydroxy-5-methylhexan-3-yl)carbamate (45) and benzyl ((2R,3S)-1-
chloro-2-hydroxy-5-methylhexan-3-yl)carbamate (46) 
 To a solution of 44 (951 mg, 3.19 mmol) in dichloromethane (7 mL) and methanol (4 mL) under 
nitrogen at 0 °C was added sodium borohydride (85 mg, 2.24 mmol). The reaction was stirred at 0 °C for 
1 h, and then quenched with slow addition of 2 M HCl (2 mL). The reaction was evaporated to dryness 
and the solid was taken up in ethyl acetate. The solution was washed twice with water followed by brine, 
dried over sodium sulfate, and concentrated by rotary evaporation. TLC analysis showed two 
diastereomers with the lower Rf compound being the (S,S)-isomer. Both diastereomers were purified by 
silica flash column chromatography (gradient of 0-5% EtOAc in DCM) to yield the (S,S)-isomer (45) as a 
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white solid (569 mg, 59%) and the (R,S)-isomer (46) as a white solid (62 mg, 6%) over two steps. 
Characterization of the (S,S)-isomer (45): 
1
H NMR (500 MHz, CDCl3) δ ppm 7.36-7.28 (complex, 5H), 
5.08 (m, 3H), 3.81 (m, 2H), 3.57 (dd, J1 = 4 Hz, J2 = 11.5 Hz, 1H), 3.50 (dd, J1 = 8 Hz, J2 = 11.5 Hz, 1H), 
3.27 (d, J = 4 Hz, 1H), 1.64 (m, 1H), 1.41 (m, 1H), 1.30 (m, 1H), 0.91 (t, J = 7 Hz, 6H).
 13
C NMR (500 
MHz, CDCl3) δ ppm 156.51, 136.12, 128.46, 128.13, 127.97, 74.45, 66.92, 51.99, 46.79, 38.35, 24.49, 
23.59, 21.33. HRMS (m/z): [M + H]
+
 calc. for C15H23NO3Cl, 300.1366; observed, 300.1374. 
Characterization of the (R,S)-isomer (46): 
1
H NMR (500 MHz, CDCl3) δ ppm 7.38-7.30 (complex, 5H), 
5.09 (s, 2H), 5.02 (d, J = 9.5 Hz, 1H), 3.83 (m, 1H), 3.76 (m, 1H), 3.62 (dd, J1 = 4 Hz, J2 = 11.5 Hz, 1H), 
3.49 (dd, J1 = 9 Hz, J2 = 11.5 Hz, 1H), 2.87 (d, J = 4.5 Hz, 1H), 1.61 (m, 2H), 1.35 (m, 1H), 0.93 (dd, J1 = 
3 Hz, J2 = 6 Hz, 6H). 
13
C NMR (500 MHz, CDCl3) δ ppm 156.64, 136.25, 128.53, 128.19, 128.00, 73.58, 
66.95, 51.02, 47.84, 41.55, 24.62, 22.99, 22.04. HRMS (m/z): [M + H]
+
 calc. for C15H23NO3Cl, 300.1366; 
observed, 300.1360. 
 
 
Benzyl ((S)-3-methyl-1-((S)-oxiran-2-yl)butyl)carbamate (47) 
 To a solution of 45 (569 mg, 1.90 mmol) in ethanol (15 mL) at 0 °C was added solid potassium 
hydroxide (117 mg, 2.09 mmol). The reaction was stirred cold for 15 min then warmed to room 
temperature and stirred for an additional 3 h. The reaction was evaporated to dryness and the solid was 
purified by silica flash column chromatography (gradient of 0-5% EtOAc in DCM) to yield 47 as a 
colorless oil (455 mg, 91%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.33-7.26 (complex, 5H), 5.21 (d, J = 
8.5 Hz, 1H), 5.06 (s, 2H), 3.57 (m, 1H), 2.82 (br s, 1H), 2.72 (s, 1H), 2.68 (m, 1H), 1.70 (m, 1H), 1.38 (t, 
J = 7 Hz, 2H), 0.90 (dd, J1 = 6.5 Hz, J2 = 12.5 Hz, 6H).
 13
C NMR (500 MHz, CDCl3) δ ppm 155.87, 
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136.21, 128.21, 127.82, 127.72, 66.39, 54.02, 50.56, 45.58, 40.39, 24.12, 23.04, 21.46. HRMS (m/z): [M 
+ H]
+
 calc. for C15H22NO3, 264.1600; observed, 264.1597. 
 
 
Benzyl ((2R,3S)-1-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-2-hydroxy-
5-methylhexan-3-yl)carbamate (48) 
 To a solution of 47 (455 mg, 1.73 mmol) in isopropyl alcohol (15 mL) was added (3S,4aS,8aS)-
N-(tert-butyl)decahydroisoquinoline-3-carboxamide (6, 494 mg, 2.07 mmol). The solution was heated to 
reflux and stirred. After 5 h, the reaction was cooled and dried to a solid. The product was purified by 
silica flash column chromatography (gradient of 0-4% MeOH in DCM) to yield 48 as a white solid (764 
mg, 88%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.33-7.27 (complex, 5H), 6.14 (s, 1H), 5.61 (d, J = 9 Hz, 
1H), 5.10 (d, J = 12 Hz, 1H), 5.04 (d, J = 12 Hz, 1H), 3.08 (m, 2H), 3.55 (s, 1H), 3.00 (dd, J1 = 2 Hz, J2 = 
12 Hz, 1H), 2.55 (m, 2H), 2.18 (m, 3H), 1.88 (q, J = 12 Hz, 1H), 1.70-1.17 (complex, 22H), 0.91 (d, J = 
6.5 Hz, 6H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.89, 156.91, 136.47, 128.26, 127.80, 72.77, 70.04, 
66.47, 64.05, 59.05, 58.85, 53.61, 50.72, 38.59, 35.61, 33.18, 30.55, 30.43, 28.57, 25.99, 25.80, 25.18, 
24.60, 23.54, 21.40, 20.61. HRMS (m/z): [M + H]
+
 calc. for C29H48N3O4, 502.3645; observed, 502.3637. 
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(3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3S)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-5-
methylhexyl)decahydroisoquinoline-3-carboxamide (10) 
 A solution of 48 (53 mg, 0.106 mmol) and 10% palladium on carbon (34 mg, 0.032 mmol) in 
methanol (6 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite 
and washed with excess methanol. The reaction was then dried to a solid and redissolved in THF (3 mL). 
3-hydroxy-2-methylbenzoic acid (18 mg, 0.117 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (22 mg, 0.117 mmol), and hydroxybenzotriazole hydrate (19 mg, 0.117 mmol) were added 
to the reaction and the solution was stirred at room temperature for 18 h. The reaction was taken up in 
ethyl acetate and washed once with saturated sodium bicarbonate and once with brine. The ethyl acetate 
fraction was dried over sodium sulfate, concentrated by rotary evaporation, and purified by silica flash 
column chromatography (gradient of 0-5% MeOH in DCM) to yield 10 as a white solid (39 mg, 73%). 
1
H 
NMR (500 MHz, CDCl3) δ ppm 7.40 (br s, 1H), 6.97 (t, J = 7.5 Hz, 1H), 6.87 (d, J = 7.5 Hz, 1H), 6.83 (d, 
J = 8 Hz, 1H), 6.62 (d, J = 8 Hz, 1H), 5.99 (s, 1H), 4.28 (m, 1H), 3.89 (m, 1H), 3.00 (dd, J1 = 2.5 Hz, J2 = 
12 Hz, 1H), 2.55 (dd, J1 = 6 Hz, J2 = 13 Hz, 1H), 2.50 (dd, J1 = 3.5 Hz, J2 = 11 Hz, 1H), 2.22 (m, 4H), 
1.91 (q, J = 11.5 Hz, 1H), 1.85-1.19 (complex, 25H), 0.97 (d, J = 6 Hz, 6H). 
13
C NMR (500 MHz, CDCl3) 
δ ppm 174.27, 171.55, 155.03, 137.79, 126.34, 122.54, 118.70, 116.75, 72.90, 70.24, 64.43, 59.46, 59.20, 
52.82, 51.04, 38.96, 35.86, 33.36, 30.70, 28.54, 26.11, 25.94, 25.31, 23.59, 21.50, 20.67, 12.54. HRMS 
(m/z): [M + H]
+
 calc. for C29H48N3O4, 502.3645; observed, 502.3635. 
 
 
(S)-benzyl (4-diazo-3-oxo-1-phenylbutan-2-yl)carbamate (49) 
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 To a stirred solution of Z-L-phenylalanine (971 mg, 3.25 mmol) in anhydrous tetrahydrofuran (12 
mL) under nitrogen at -78 °C was added anhydrous triethylamine (675 μL, 4.87 mmol) followed by 
isobutyl chloroformate (633 μL, 4.87 mmol). The reaction was stirred cold for 1 h and then warmed to 
room temperature for 1.5 h. The reaction was cooled to -78 °C before an ethereal solution of 
diazomethane (25 mL, 8.1 mmol) was added in one portion and the reaction was then warmed to room 
temperature with stirring for 1 h. The reaction was evaporated to dryness, resulting in a yellow solid. The 
solid was taken up in ethyl acetate, washed twice with water, twice with a saturated solution of sodium 
bicarbonate, and once with brine. The organic phase was dried over sodium sulfate and concentrated by 
rotary evaporation. The product was purified by silica flash column chromatography (gradient of 2-3% 
EtOAc in CHCl3) to yield 49 as a yellowish foam (642 mg, 61%). 
1
H NMR (500 MHz, CDCl3) δ ppm 
7.35-7.21 (complex, 8H), 7.16 (d, J = 7 Hz, 2H), 5.52 (d, J = 7.5 Hz, 1H), 5.22 (s, 1H), 5.06 (m, 2H) 4.47 
(d, J = 6.5 Hz, 1H), 3.07-2.98 (m, 2H). 
13
C NMR (500 MHz, CDCl3) δ ppm 192.73, 155.65, 136.06, 
135.97, 129.23, 128.57, 128.44, 128.12, 127.95, 126.97, 66.90, 58.77, 54.50, 38.29. HRMS (m/z): [M + 
H]
+
 calc. for C18H18N3O3, 324.1348; observed, 324.1355. 
 
 
(S)-benzyl (4-chloro-3-oxo-1-phenylbutan-2-yl)carbamate (50) 
 To a solution of 49 (642 mg, 1.99 mmol) in anhydrous tetrahydrofuran (8 mL) under nitrogen at 0 
°C was added 1 M HCl in diethyl ether (2.99 mL, 2.99 mmol) dropwise. The reaction was stirred at 0 °C 
for 30 min after complete addition. The solution was dried under reduced pressure to yield 50 as a white 
solid (717 mg). No further purification was made. 
1
H NMR (500 MHz, CDCl3) δ ppm 7.35-7.22 
(complex, 8H), 7.12 (d, J = 7 Hz, 2H), 5.56 (d, J = 7.5 Hz, 1H), 5.04 (dd, J1 = 12.5 Hz, J2 = 16 Hz, 2H), 
4.72 (dd, J1 = 7 Hz, J2 = 14.5 Hz, 1H), 4.15 (d, J = 16 Hz, 1H), 3.97 (d, J = 16.5 Hz, 1H), 3.08 (dd, J1 = 7 
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Hz, J2 = 14 Hz, 1H), 2.97 (dd, J1 = 7 Hz, J2 = 14 Hz, 1H). 
13
C NMR (500 MHz, CDCl3) δ ppm 200.90, 
155.72, 135.83, 135.26, 128.98, 128.79, 128.43, 128.16, 127.94, 127.24, 67.06, 58.65, 47.36, 37.35. 
HRMS (m/z): [M + H]
+
 calc. for C18H19NO3Cl, 332.1053; observed, 332.1052. 
 
 
Benzyl ((2S,3S)-4-chloro-3-hydroxy-1-phenylbutan-2-yl)carbamate (51) and benzyl ((2S,3R)-4-
chloro-3-hydroxy-1-phenylbutan-2-yl)carbamate (52) 
 To a solution of 50 (717 mg, 2.16 mmol) in dichloromethane (7 mL) and methanol (4 mL) under 
nitrogen at 0 °C was added sodium borohydride (57 mg, 1.51 mmol). The reaction was stirred at 0 °C for 
1 h, and then quenched with slow addition of 2 M HCl (2 mL). The reaction was evaporated to dryness 
and the solid was taken up in ethyl acetate. The solution was washed twice with water followed by brine, 
dried over sodium sulfate, and concentrated by rotary evaporation. TLC analysis showed two 
diastereomers with the lower Rf compound being the (S,S)-isomer. The (S,S)-isomer was recrystallized in 
hexanes/ethyl acetate. The crystals were collected and washed with cold 2:1 hexanes:ethyl acetate. The 
filtrate was collected, dried to a solid, and recrystallized again in the same manner. Both diastereomers 
were then separated further by silica flash column chromatography (gradient of 0-5% EtOAc in DCM) to 
yield the (S,S)-isomer (51) as a white solid (452 mg, 63%) and the (S,R)-isomer (52) as a white solid (115 
mg, 16%) over two steps. Characterization of the (S,S)-isomer (51): 
1
H NMR (500 MHz, CDCl3) δ ppm 
7.35-7.16 (complex, 10H), 5.02 (s, 2H), 4.92 (d, J = 9 Hz, 1H), 3.99 (m, 1H), 3.84 (m, 1H), 3.63 (dd, J1 = 
3.5 Hz, J2 = 11.5 Hz, 1H), 3.55 (dd, J1 = 7.5 Hz, J2 = 11 Hz, 1H), 3.12 (d, J = 4 Hz, 1H), 2.97 (dd, J1 = 
4.5 Hz, J2 = 14 Hz, 1H), 2.90 (dd, J1 = 8.5 Hz, J2 = 13.5 Hz, 1H). 
13
C NMR (500 MHz, CDCl3) δ ppm 
156.22, 137.04, 136.12, 129.37, 128.57, 128.49, 128.15, 127.92, 126.67, 73.16, 66.87, 54.60, 47.46, 
35.52. HRMS (m/z): [M + H]
+
 calc. for C18H21NO3Cl, 334.1210; observed, 334.1213. Characterization of 
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the (S,R)-isomer (52): 
1
H NMR (500 MHz, CDCl3) δ ppm 7.35-7.19 (complex, 10H), 5.32 (d, J = 9 Hz, 
1H), 5.05 (dd, J1 = 12.5 Hz, J2 = 16 Hz, 2H), 3.95 (dd, J1 = 8 Hz, J2 = 16 Hz, 1H), 3.73 (s, 1H), 3.49 (d, J 
= 6.5 Hz, 2H), 3.26 (s, 1H), 2.98-2.87 (complex, 2H). 
13
C NMR (500 MHz, CDCl3) δ ppm 156.49, 
137.44, 136.12, 129.20, 128.54, 128.47, 128.13, 127.92, 126.60, 71.13, 66.89, 54.23, 47.55, 38.42. 
HRMS (m/z): [M + H]
+
 calc. for C18H21NO3Cl, 334.1210; observed, 334.1207. 
 
 
Benzyl ((S)-1-((S)-oxiran-2-yl)-2-phenylethyl)carbamate (53) 
 To a solution of 51 (452 mg, 1.35 mmol) in ethanol (15 mL) and dichloromethane (5 mL) at 0 °C 
was added solid potassium hydroxide (83 mg, 1.49 mmol). The reaction was stirred cold for 15 min then 
warmed to room temperature and stirred for an additional 3 h. The reaction was evaporated to dryness and 
the solid was purified by silica flash column chromatography (gradient of 0-3% EtOAc in DCM) to yield 
53 as a white solid (361 mg, 90%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.32-7.14 (complex, 10H), 5.00 
(m, 3H), 3.76 (br s, 1H), 2.96-2.72 (complex, 5H). 
13
C NMR (500 MHz, CDCl3) δ ppm 155.71, 136.40, 
136.12, 129.17, 128.40, 128.30, 127.94, 127.80, 126.56, 66.52, 52.96, 46.46, 37.27. HRMS (m/z): [M + 
H]
+
 calc. for C18H20NO3, 298.1443; observed, 298.1447. 
 
 
Benzyl ((2S,3R)-4-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-3-hydroxy-
1-phenylbutan-2-yl)carbamate (54) 
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 To a solution of 53 (360 mg, 1.21 mmol) in isopropyl alcohol (10 mL) was added (3S,4aS,8aS)-
N-(tert-butyl)decahydroisoquinoline-3-carboxamide (6, 346 mg, 1.45 mmol). The solution was heated to 
reflux and stirred. After 5 h, the reaction was cooled and dried to a solid. The product was purified by 
silica flash column chromatography (gradient of 0-4% MeOH in DCM) to yield 54 as a white solid (606 
mg, 93%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.28-7.14 (complex, 10H), 6.19 (s, 1H), 5.74 (d, J = 8.5 
Hz, 1H), 4.99 (d, J = 12.5 Hz, 1H), 4.90 (d, J = 12.5 Hz, 1H), 3.99 (m, 3H), 2.95 (m, 3H), 2.66 (dd, J1 = 6 
Hz, J2 = 12.5 Hz, 1H), 2.57 (d, J = 9.5 Hz, 1H), 2.27 (dd, J1 = 5.5 Hz, J2 = 12.5 Hz, 1H), 2.19 (d, J = 10 
Hz, 1H), 1.94-1.15 (complex, 21H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.80, 156.50, 138.22, 136.38, 
129.07, 128.10, 127.57, 127.45, 125.98, 71.07, 70.07, 66.10, 58.94, 58.79, 55.90, 50.67, 35.55, 35.10, 
33.08, 30.47, 30.40, 28.43, 25.95, 25.59, 20.47. HRMS (m/z): [M + H]
+
 calc. for C32H46N3O4, 536.3488; 
observed, 536.3486. 
 
 
(3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3S)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-
phenylbutyl)decahydroisoquinoline-3-carboxamide (11) 
 A solution of 54 (37 mg, 0.069 mmol) and 10% palladium on carbon (22 mg, 0.021 mmol) in 
methanol (10 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite 
and washed with excess methanol. The reaction was then dried to a solid and redissolved in THF (3 mL). 
3-hydroxy-2-methylbenzoic acid (12 mg, 0.076 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (15 mg, 0.076 mmol), and hydroxybenzotriazole hydrate (12 mg, 0.076 mmol) were added 
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to the reaction and the solution was stirred at room temperature for 18 h. The reaction was taken up in 
ethyl acetate and washed once with saturated sodium bicarbonate and once with brine. The ethyl acetate 
fraction was dried over sodium sulfate, concentrated by rotary evaporation, and purified by silica flash 
column chromatography (gradient of 0-4% MeOH in DCM) to yield 11 as a white solid (21 mg, 57%). 
1
H 
NMR (500 MHz, CDCl3) δ ppm 7.29 (m, 4H), 7.22 (m, 1H), 6.86 (t, J = 7.5 Hz, 1H), 6.74 (d, J = 7.5 Hz, 
1H), 6.52 (m, 2H), 5.88 (s, 1H), 4.52 (m, 1H), 4.00 (m, 1H), 3.27 (dd, J1 = 11.5 Hz, J2 = 14.5 Hz, 1H), 
2.98 (m, 2H), 2.63 (dd, J1 = 7 Hz, J2 = 13 Hz, 1H), 2.54 (dd, J1 = 3 Hz, J2 = 11 Hz, 1H), 2.30 (dd, J1 = 6.5 
Hz, J2 = 13 Hz, 1H), 2.25 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 1.97 (m, 4H), 1.85 (qd, J1 = 3 Hz, J2 = 13.5 
Hz, 1H), 1.76-1.15 (complex, 21H). 
13
C NMR (500 MHz, CDCl3) δ ppm 174.07, 171.41, 154.69, 138.49, 
137.58, 129.26, 128.53, 126.47, 126.29, 122.41, 118.84, 116.66, 71.78, 70.41, 59.70, 59.07, 55.61, 51.13, 
35.97, 35.47, 33.43, 30.76, 28.52, 26.18, 25.86, 20.61, 12.22. HRMS (m/z): [M + H]
+
 calc. for 
C32H46N3O4, 536.3488; observed, 536.3487. 
 
 
(S)-benzyl (4-diazo-1-(1H-indol-3-yl)-3-oxobutan-2-yl)carbamate (55) 
 To a stirred solution of Z-L-tryptophan (1.01 g, 2.97 mmol) in anhydrous tetrahydrofuran (12 
mL) under nitrogen at -78 °C was added anhydrous triethylamine (618 μL, 4.46 mmol) followed by 
isobutyl chloroformate (580 μL, 4.46 mmol). The reaction was stirred cold for 1 h and then warmed to 
room temperature for 1.5 h. The reaction was cooled to -78 °C before an ethereal solution of 
diazomethane (25 mL, 8.1 mmol) was added in one portion and the reaction was then warmed to room 
temperature with stirring for 1 h. The reaction was evaporated to dryness, resulting in a yellow solid. The 
solid was taken up in ethyl acetate, washed twice with water, twice with a saturated solution of sodium 
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bicarbonate, and once with brine. The organic phase was dried over sodium sulfate and concentrated by 
rotary evaporation. The product was purified by silica flash column chromatography (gradient of 5-6% 
EtOAc in CHCl3) to yield 55 as a yellowish foam (916 mg, 85%). 
1
H NMR (500 MHz, CDCl3) δ ppm 
8.08 (s, 1H), 7.62 (d, J = 7.5 Hz, 1H), 7.38-7.28 (m, 6H), 7.20 (t, J = 7.5 Hz, 1H), 7.12 (t, J = 8 Hz, 1H), 
7.00 (s, 1H), 5.45 (s, 1H), 5.16-5.07 (m, 3H), 4.59 (s, 1H), 3.27 (dd, J1 = 5 Hz, J2 = 14 Hz, 1H), 3.19 (dd, 
J1 = 7.5 Hz, J2 = 14 Hz, 1H). 
13
C NMR (500 MHz, CDCl3) δ ppm 193.51, 155.81, 136.15, 128.53, 128.21, 
128.11, 127.39, 123.13, 123.04, 122.38, 119.88, 118.77, 111.23, 110.17, 67.01, 58.20, 54.45, 28.51. 
HRMS (m/z): [M + H]
+
 calc. for C20H19N4O3, 363.1457; observed, 363.1464. 
 
 
(S)-benzyl (4-chloro-1-(1H-indol-3-yl)-3-oxobutan-2-yl)carbamate (56) 
 To a solution of 55 (916 mg, 2.53 mmol) in anhydrous tetrahydrofuran (8 mL) under nitrogen at 0 
°C was added 1 M HCl in diethyl ether (3.80 mL, 3.80 mmol) dropwise. The reaction was stirred at 0 °C 
for 30 min after complete addition. The solution was dried under reduced pressure to yield 56 as a pink 
solid (886 mg). No further purification was made. 
1
H NMR (500 MHz, CDCl3) δ ppm 8.14 (s, 1H), 7.59 
(d, J = 8 Hz, 1H), 7.37-7.31 (complex, 6H), 7.22 (t, J = 7.5 Hz, 1H), 7.14 (t, J = 7.5 Hz, 1H), 6.95 (s, 1H), 
5.43 (d, J = 7Hz, 1H), 5.09 (m, 2H), 4.86 (dd, J1 = 7 Hz, J2 = 14 Hz, 1H), 4.09 (d, J = 16.5 Hz, 1H), 3.95 
(d, J = 16.5 Hz, 1H), 3.25 (m, 2H). 
13
C NMR (500 MHz, CDCl3) δ ppm 201.63, 155.85, 136.17, 135.92, 
128.56, 128.31, 128.15, 126.93, 122.95, 122.62, 120.08, 118.51, 111.42, 109.30, 67.22, 58.07, 47.70, 
27.80. HRMS (m/z): [M + H]
+
 calc. for C20H20N2O3Cl, 371.1162; observed, 371.1167. 
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Benzyl ((2S,3S)-4-chloro-3-hydroxy-1-(1H-indol-3-yl)butan-2-yl)carbamate (57) 
 To a solution of 56 (886 mg, 2.38 mmol) in dichloromethane (7 mL) and methanol (4 mL) under 
nitrogen at 0 °C was added sodium borohydride (67 mg, 1.77 mmol). The reaction was stirred at 0 °C for 
1 h, and then quenched with slow addition of 2 M HCl (2 mL). The reaction was evaporated to dryness 
and the solid was taken up in ethyl acetate. The solution was washed twice with water followed by brine, 
dried over sodium sulfate, and concentrated by rotary evaporation. TLC analysis showed two 
diastereomers with the lower Rf compound being the desired (S,S)-isomer. The product was purified by 
silica flash column chromatography (gradient of 0-2% MeOH in DCM) to yield 57 as a white solid (566 
mg, 60% over two steps). 
1
H NMR (500 MHz, CDCl3) δ ppm 10.78 (s, 1H), 7.51 (d, J = 8 Hz, 1H), 7.34-
7.25 (complex, 3H), 7.21 (d, J = 6.5 Hz, 2H), 7.16 (d, J = 9 Hz, 1H), 7.07 (d, J = 1.5 Hz, 1H), 7.04 (t, J = 
7 Hz, 1H), 6.93 (t, J = 7 Hz, 1H), 5.47 (d, J = 6.5 Hz, 1H), 4.92 (dd, J1 = 12.5 Hz, J2 = 20 Hz, 2H), 3.78-
3.68 (complex, 2H), 3.64 (m, 1H), 3.52 (dd, J1 = 7 Hz, J2 = 11 Hz, 1H), 3.08 (dd, J1 = 3 Hz, J2 = 14.5 Hz, 
1H), 2.76 (dd, J1 = 9 Hz, J2 = 14.5 Hz, 1H). 
13
C NMR (500 MHz, CDCl3) δ ppm 155.76, 137.25, 136.08, 
128.28, 127.68, 127.60, 127.36, 123.29, 120.69, 120.58, 118.37, 118.11, 111.22, 72.41, 64.95, 54.30, 
48.00, 25.18. HRMS (m/z): [M + H]
+
 calc. for C20H22N2O3Cl, 373.1319; observed, 373.1319. 
 
 
Benzyl ((S)-2-(1H-indol-3-yl)-1-((S)-oxiran-2-yl)ethyl)carbamate (58) 
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 To a solution of 57 (57 mg, 0.153 mmol) in ethanol (5 mL) and dichloromethane (5 mL) at 0 °C 
was added solid potassium hydroxide (10 mg, 0.168 mmol). The reaction was stirred cold for 15 min then 
warmed to room temperature and stirred for an additional 3 h. The reaction was evaporated to dryness and 
the solid was purified by silica flash column chromatography (gradient of 1-3% EtOAc in DCM) to yield 
58 as a white solid (45 mg, 87%). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.13 (s, 1H), 7.64 (d, J = 8 Hz, 1H), 
7.35-7.28 (complex, 6H), 7.20 (t, J = 8 Hz, 1H), 7.12 (t, J = 8 Hz, 1H), 7.01 (s, 1H), 5.04 (s, 2H), 4.84 (m, 
1H), 3.80 (br s, 1H), 3.11 (d, J = 5 Hz, 2H), 2.93 (br s, 1H), 2.79 (br s, 2H). 
13
C NMR (500 MHz, CDCl3) 
δ ppm 155.89, 136.22, 128.49, 128.13, 128.06, 122.96, 122.27, 119.76, 118.81, 111.17, 66.74, 53.13, 
52.68, 47.15, 27.00. HRMS (m/z): [M + H]
+
 calc. for C20H21N2O3, 337.1552; observed, 337.1562. 
 
 
Benzyl ((2S,3R)-4-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-3-hydroxy-
1-(1H-indol-3-yl)butan-2-yl)carbamate (59) 
 To a solution of 58 (41 mg, 0.122 mmol) in isopropyl alcohol (12 mL) was added (3S,4aS,8aS)-
N-(tert-butyl)decahydroisoquinoline-3-carboxamide (6, 35 mg, 0.146 mmol). The solution was heated to 
reflux and stirred. After 5 h, the reaction was cooled and dried to a solid. The product was purified by 
silica flash column chromatography (gradient of 0-6% MeOH in DCM) to yield 59 as a white solid (70 
mg, 100%). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.28 (s, 1H), 7.63 (d, J = 8 Hz, 1H), 7.38-7.21 (complex, 
6H), 7.16 (t, J = 7 Hz, 1H), 7.07 (t, J = 7.5 Hz, 1H), 7.01 (br s, 1H), 5.99 (s, 1H), 5.36 (d, J = 8 Hz, 1H), 
5.00 (dd, J1 = 12.5 Hz, J2 = 16 Hz, 2H), 4.10 (m, 1H), 3.89 (m, 1H), 3.58 (br s, 1H), 3.20 (dd, J1 = 9 Hz, 
J2 = 15 Hz, 1H), 3.01 (m, 2H), 2.69 (dd, J1 = 6 Hz, J2 = 13.5 Hz, 1H), 2.58 (dd, J1 = 2.5 Hz, J2 = 11 Hz, 
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1H), 2.31 (dd, J1 = 6 Hz, J2 = 13.5 Hz, 1H), 2.23 (d, J = 11 Hz, 1H), 1.97-1.18 (complex, 21H).
 13
C NMR 
(500 MHz, CDCl3) δ ppm 173.75, 156.86, 136.44, 136.25, 128.35, 128.01, 127.89, 127.81, 122.65, 
121.84, 119.27, 118.84, 111.73, 111.11, 71.02, 70.38, 66.53, 59.48, 58.98, 55.39, 50.87, 35.75, 33.25, 
30.67, 30.62, 28.54, 26.08, 25.87, 25.49, 20.69. HRMS (m/z): [M + H]
+
 calc. for C34H47N4O4, 575.3597; 
observed, 575.3589. 
 
 
(3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3S)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-(1H-indol-3-
yl)butyl)decahydroisoquinoline-3-carboxamide (12) 
 A solution of 59 (37 mg, 0.064 mmol) and 10% palladium on carbon (20 mg, 0.019 mmol) in 
methanol (6 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite 
and washed with excess methanol. The reaction was then dried to a solid and redissolved in THF (3 mL). 
3-hydroxy-2-methylbenzoic acid (11 mg, 0.070 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (13 mg, 0.070 mmol), and hydroxybenzotriazole hydrate (11 mg, 0.070 mmol) were added 
to the reaction and the solution was stirred at room temperature for 18 h. The reaction was taken up in 
ethyl acetate and washed once with saturated sodium bicarbonate and once with brine. The ethyl acetate 
fraction was dried over sodium sulfate, concentrated by rotary evaporation, and purified by silica flash 
column chromatography (gradient of 0-7% MeOH in DCM) to yield 12 as a white solid (22 mg, 59%). 
1
H 
NMR (500 MHz, CDCl3) δ ppm 8.29 (s, 1H), 7.66 (d, J = 8 Hz, 1H), 7.32 (d, J = 8.5 Hz, 1H), 7.16 (t, J = 
7.5 Hz, 1H), 7.08 (t, J = 7.5 Hz, 1H), 7.03 (s, 1H), 6.82 (t, J = 8 Hz, 1H), 6.73 (d, J = 8 Hz, 1H), 6.60 (d, J 
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= 8.5 Hz, 1H), 6.53 (d, J = 7.5 Hz, 1H), 5.92 (s, 1H), 4.62 (m, 1H), 4.04 (m, 2H), 3.44 (dd, J1 = 11 Hz, J2 
= 15.5 Hz, 1H), 3.08 (m, 2H), 2.69 (dd, J1 = 7.5 Hz, J2 = 13.5 Hz, 1H), 2.57 (dd, J1 = 2 Hz, J2 = 10.5 Hz, 
1H), 2.33 (dd, J1 = 6.5 Hz, J2 = 13 Hz, 1H), 2.27 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 2.03-1.12 (complex, 
25H). 
13
C NMR (500 MHz, CDCl3) δ ppm 174.00, 171.55, 154.53, 137.60, 136.33, 127.72, 126.39, 
122.33, 122.29, 122.00, 119.36, 119.15, 118.87, 116.69, 112.37, 111.17, 71.89, 70.51, 59.75, 59.06, 
55.02, 51.07, 35.96, 33.41, 30.85, 30.76, 28.47, 26.20, 26.01, 25.86, 25.35, 20.65, 12.17. HRMS (m/z): 
[M + H]
+
 calc. for C34H47N4O4, 575.3597; observed, 575.3600. 
 
 
(3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3R)-2-hydroxy-3-(3-hydroxybenzamido)-4-
(phenylthio)butyl)decahydroisoquinoline-3-carboxamide (13) 
 This reaction was performed according to the general EDC coupling procedure (0.039 mmol 3-
hydroxybenzoic acid for 48 h). Purification by flash column chromatography (gradient of 1-5% MeOH in 
DCM) yielded 13 as a white solid (11 mg, 54%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.58 (d, J = 8.5 Hz, 
1H), 7.39 (d, J = 8 Hz, 2H), 7.33 (d, J = 8 Hz, 1H), 7.29 (s, 1H), 7.26-7.20 (m, 3H), 7.17-7.13 (m, 2H), 
6.96 (dd, J1 = 2.5 Hz, J2 = 8 Hz, 1H), 5.61 (s, 1H), 4.43 (m, 1H), 4.12 (m, 1H), 3.78 (dd, J1 = 9 Hz, J2 = 
13.5 Hz, 1H), 3.40 (dd, J1 = 5.5 Hz, J2 = 14 Hz, 1H), 2.93 (d, J = 11 Hz, 1H), 2.58 (dd, J1 = 9 Hz, J2 = 
12.5 Hz, 1H), 2.45 (d, J = 9 Hz, 1H), 2.21 (dd, J1 = 4.5 Hz, J2 = 12.5 Hz, 1H), 2.17 (dd, J1 = 2.5 Hz, J2 = 
11.5 Hz, 1H), 2.01 (q, J = 12 Hz, 1H), 1.82-1.17 (complex, 11H), 1.12 (s, 9H). 
13
C NMR (500 MHz, 
CDCl3) δ ppm 174.23, 169.80, 156.44, 135.04, 130.14, 129.64, 129.04, 127.92, 126.36, 120.32, 119.13, 
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114.87, 70.77, 70.33, 59.53, 58.88, 55.48, 51.39, 36.05, 35.18, 33.73, 30.96, 30.93, 28.47, 26.33, 25.97, 
20.47. HRMS (m/z): [M + H]
+
 calc. for C31H44N3O4S, 554.3053; observed, 554.3047. 
 
 
(3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3R)-2-hydroxy-3-(2-methylbenzamido)-4-
(phenylthio)butyl)decahydroisoquinoline-3-carboxamide (14) 
 This reaction was performed according to the general EDC coupling procedure (0.048 mmol o-
toluic acid for 48 h). Purification by flash column chromatography (gradient of 1-3% MeOH in DCM) 
yielded 14 as a white solid (22 mg, 83%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.50 (d, J = 8 Hz, 1H), 7.44 
(dd, J1 = 1 Hz, J2 = 8 Hz, 2H), 7.30-7.23 (m, 3H), 7.21-7.15 (m, 3H), 5.47 (s, 1H), 4.49 (m, 1H), 3.83 (dd, 
J1 = 9.5 Hz, J2 = 14 Hz, 1H), 3.43 (dd, J1 = 5 Hz, J2 = 14 Hz, 1H), 2.92 (dd, J1 = 2 Hz, J2 = 12 Hz, 1H), 
2.56 (dd, J1 = 9.5 Hz, J2 = 13 Hz, 1H), 2.48 (s, 3H), 2.42 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 2.22-2.15 (m, 
2H), 2.98 (q, J = 11.5 Hz, 1H), 1.80-1.14 (complex, 11H), 1.02 (s, 9H). 
13
C NMR (500 MHz, CDCl3) δ 
ppm 173.96, 171.97, 136.93, 135.61, 135.36, 130.90, 130.17, 129.03, 128.01, 126.41, 125.66, 120.31, 
70.74, 70.41, 59.67, 58.71, 54.89, 51.18, 36.08, 35.52, 33.78, 30.99, 30.93, 28.33, 26.30, 26.01, 20.46, 
20.23. HRMS (m/z): [M + H]
+
 calc. for C32H46N3O3S, 552.3260; observed, 552.3254. 
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(3S,4aS,8aS)-2-((2R,3R)-3-benzamido-2-hydroxy-4-(phenylthio)butyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (15) 
 This reaction was performed according to the general EDC coupling procedure (0.042 mmol 
benzoic acid for 48 h). Purification by flash column chromatography (gradient of 1-3% MeOH in DCM) 
yielded 15 as a white solid (17 mg, 75%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.85 (d, J = 8 Hz, 2H), 7.66 
(d, J = 8 Hz, 1H), 7.46 (t, J = 8 Hz, 1H), 7.44-7.37 (m, 4H), 7.29-7.24 (m, 2H), 7.20-7.15 (m, 2H), 5.46 
(s, 1H), 4.48 (m, 1H), 4.13 (m, 1H), 3.88 (dd, J1 = 9.5 Hz, J2 = 14 Hz, 1H), 3.45 (dd, J1 = 5.5 Hz, J2 = 14 
Hz, 1H), 2.95 (d, J = 11.5 Hz, 1H), 2.58 (m, 1H), 2.41 (d, J = 11.5 Hz, 1H), 2.21-2.13 (m, 2H), 2.03 (q, J 
= 12.5 Hz, 1H), 1.83-1.15 (complex, 11H), 1.05 (s, 9H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.95, 
169.94, 135.45, 133.79, 131.64, 130.16, 129.04, 128.29, 128.06, 126.42, 70.91, 70.22, 59.53, 58.86, 
55.66, 51.24, 36.10, 35.52, 33.88, 31.06, 30.97, 28.42, 26.35, 26.04, 20.44. HRMS (m/z): [M + H]
+
 calc. 
for C31H44N3O3S, 538.3103; observed, 538.3108. 
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(3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3R)-2-hydroxy-4-(phenylthio)-3-
pivalamidobutyl)decahydroisoquinoline-3-carboxamide (16) 
 This reaction was performed according to the general EDC coupling procedure (0.049 mmol 
pivalic acid for 48 h). Purification by flash column chromatography (gradient of 1-4% MeOH in DCM) 
yielded 16 as a white solid (13.6 mg, 56%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.38 (d, J = 7.5 Hz, 2H), 
7.27 (t, J = 7.5 Hz, 2H), 7.18 (t, J = 7.5 Hz, 1H), 6.31 (d, J = 7.5 Hz, 1H), 5.73 (s, 1H), 4.16 (m, 1H), 3.97 
(br s, 1H), 3.91 (m, 1H), 3.52 (dd, J1 = 9 Hz, J2 = 14 Hz, 1H), 3.27 (dd, J1 = 4.5 Hz, J2 = 14 Hz, 1H), 2.92 
(dd, J1 = 2.5 Hz, J2 = 11.5 Hz, 1H), 2.61 (dd, J1 = 7 Hz, J2 = 13 Hz, 1H), 2.55 (dd, J1 = 3 Hz, J2 = 10.5 
Hz, 1H), 2.24-2.19 (m, 2H), 1.94 (q, J = 11.5 Hz, 1H), 1.80-1.17 (complex, 20H), 1.14 (s, 9H). 
13
C NMR 
(500 MHz, CDCl3) δ ppm 180.12, 173.80, 135.77, 129.85, 129.29, 126.59, 71.09, 70.61, 59.94, 58.70, 
53.56, 51.31, 39.05, 36.12, 34.71, 33.79, 31.33, 30.99, 29.11, 27.67, 26.38, 26.11, 20.88. HRMS (m/z): 
[M + H]
+
 calc. for C29H48N3O3S, 518.3416; observed, 518.3422. 
 
 
(3S,4aS,8aS)-2-((2R,3R)-3-(2-naphthamido)-2-hydroxy-4-(phenylthio)butyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (17) 
 This reaction was performed according to the general EDC coupling procedure (0.046 mmol 2-
naphthoic acid for 48 h). Purification by flash column chromatography (gradient of 1-3% MeOH in 
DCM) yielded 17 as a white solid (19 mg, 70%). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.35 (s, 1H), 7.92 (t, 
J = 9.5 Hz, 2H), 7.86-7.82 (m, 2H), 7.57-7.50 (m, 2H), 7.45 (d, J = 7.5 Hz, 2H), 7.29-7.7.24 (m, 2H), 
7.20-7.15 (m, 2H), 5.40 (s, 1H), 4.56 (m, 1H), 4.16 (m, 1H), 3.93 (dd, J1 = 9 Hz, J2 = 13.5 Hz, 1H), 3.49 
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(dd, J1 = 5.5 Hz, J2 = 14 Hz, 1H), 3.97 (dd, J1 = 2 Hz, J2 = 11.5 Hz, 1H), 2.61 (dd, J1 = 9.5 Hz, J2 = 13 
Hz, 1H), 2.41 (dd, J1 = 3.5 Hz, J2 = 12.5 Hz, 1H), 2.22-2.15 (m, 2H), 2.04 (q, J = 12.5 Hz, 1H), 1.85-1.17 
(complex, 11H), 0.93 (s, 9H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.96, 169.96, 135.80, 134.97, 
132.58, 131.02, 130.18, 129.20, 129.07, 128.64, 128.09, 127.92, 127.58, 126.45, 124.63, 121.21, 70.93, 
70.34, 59.60, 58.91, 55.90, 51.21, 36.14, 35.50, 33.93, 31.16, 31.00, 28.30, 26.38, 26.07, 20.46. HRMS 
(m/z): [M + H]
+
 calc. for C35H46N3O3S, 588.3260; observed, 588.3262. 
 
 
(3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3R)-3-(cyclohexanecarboxamido)-2-hydroxy-4-
(phenylthio)butyl)decahydroisoquinoline-3-carboxamide (18) 
 This reaction was performed according to the general EDC coupling procedure (0.056 mmol 
cyclohexanecarboxylic acid for 48 h). Purification by flash column chromatography (gradient of 1-3% 
MeOH in DCM) yielded 18 as a white solid (24 mg, 83%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.39 (d, J 
= 7.5 Hz, 2H), 7.27 (t, J = 7.5 Hz, 2H), 7.18 (t, J = 7.5 Hz, 1H), 6.66 (d, J = 8 Hz, 1H), 5.64 (s, 1H), 4.24 
(m, 1H), 4.00 (m, 1H), 3.57 (dd, J1 = 9 Hz, J2 = 13.5 Hz, 1H), 3.29 (dd, J1 = 5 Hz, J2 = 13.5 Hz, 1H), 2.92 
(dd, J1 = 2 Hz, J2 = 11.5 Hz, 1H), 2.57 (dd, J1 = 8.5 Hz, J2 = 13 Hz, 1H), 2.48 (dd, J1 = 2.5 Hz, J2 = 11 
Hz, 1H), 2.18-2.09 (m, 2H) 1.99 (q, J = 11.5 Hz, 1H), 1.86 (d, J = 12.5 Hz, 1H), 1.80-1.14 (complex, 
30H). 
13
C NMR (500 MHz, CDCl3) δ ppm 178.02, 173.94, 135.82, 129.75, 128.96, 126.25, 70.69, 70.11, 
59.55, 58.70, 53.96, 51.26, 45.23, 36.00, 34.99, 33.76, 31.08, 30.88, 29.88, 29.67, 28.83, 26.24, 25.93, 
25.79, 25.65, 25.52, 20.51. HRMS (m/z): [M + H]
+
 calc. for C31H50N3O3S, 544.3573; observed, 544.3562. 
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(3S,4aS,8aS)-2-((2R,3R)-3-(anthracene-9-carboxamido)-2-hydroxy-4-(phenylthio)butyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (19) 
 This reaction was performed according to the general EDC coupling procedure (0.048 mmol 9-
anthracenecarboxylic acid for 48 h). Purification by flash column chromatography (gradient of 1-3% 
MeOH in DCM) yielded 19 as a light yellow solid (19.6 mg, 67%). 
1
H NMR (500 MHz, CDCl3) δ ppm 
8.43 (s, 1H), 8.13 (br s, 1H), 7.96 (d, J = 7 Hz, 2H), 7.57 (d, J = 8.5 Hz, 1H), 7.52 (d, J = 7.5 Hz, 2H), 
7.46 (br s, 4H), 7.31 (t, J = 7.5 Hz, 2H), 7.20 (t, J = 7.5 Hz, 1H), 5.35 (s, 1H), 4.88 (m, 1H), 4.22 (m, 1H), 
3.83 (dd, J1 = 9.5 Hz, J2 = 13.5 Hz, 1H), 3.52 (dd, J1 = 4 Hz, J2 = 13.5 Hz, 1H), 2.97 (dd, J1 = 2 Hz, J2 = 
11.5 Hz, 1H), 2.68 (dd, J1 = 9 Hz, J2 = 13 Hz, 1H), 2.40 (dd, J1 = 3 Hz, J2 = 11 Hz, 1H), 2.30 (dd, J1 = 4.5 
Hz, J2 = 13 Hz, 1H), 2.19 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 1.88 (q, J = 11.5 Hz, 1H), 1.77-1.12 
(complex, 11H), 0.67 (s, 9H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.65, 171.22, 135.91, 131.70, 
131.13, 129.91, 129.05, 128.28, 128.12, 126.61, 126.35, 125.97, 125.35, 119.23, 70.81, 70.31, 59.73, 
58.35, 54.63, 50.92, 36.02, 35.36, 33.76, 31.05, 30.84, 28.01, 26.23, 26.04, 20.52. HRMS (m/z): [M + H]
+
 
calc. for C39H48N3O3S, 638.3416; observed, 638.3414. 
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(3S,4aS,8aS)-2-((2R,3S)-3-(2-naphthamido)-2-hydroxy-4-(1H-indol-3-yl)butyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (20) 
 A solution of 59 (30 mg, 0.052 mmol) and 10% palladium on carbon (17 mg, 0.016 mmol) in 
methanol (6 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite 
and washed with excess methanol. The reaction was then dried to a solid and redissolved in THF (3 mL). 
2-naphthoic acid (10 mg, 0.057 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(11 mg, 0.057 mmol), and hydroxybenzotriazole hydrate (9 mg, 0.057 mmol) were added to the reaction 
and the solution was stirred at room temperature for 18 h. The reaction was taken up in ethyl acetate and 
washed once with saturated sodium bicarbonate and once with brine. The ethyl acetate fraction was dried 
over sodium sulfate, concentrated by rotary evaporation, and purified by silica flash column 
chromatography (gradient of 0-5% MeOH in DCM) to yield 20 as a white solid (18 mg, 58%). 
1
H NMR 
(500 MHz, CDCl3) δ ppm 8.10 (br s, 1H), 8.03 (s, 1H), 7.80 (dd, J1 = 4.5 Hz, J2 = 8 Hz, 2H), 7.76 (d, J = 
9 Hz, 2H), 7.72 (dd, J1 = 2 Hz, J2 = 9 Hz, 1H), 7.51 (td, J1 = 1 Hz, J2 = 7 Hz, 1H), 7.47 (td, J1 = 1 Hz, J2 = 
7.5 Hz, 1H), 7.35 (m, 2H), 7.22 (td, J1 = 1 Hz, J2 = 8 Hz, 2H), 7.15 (t, J = 7 Hz, 1H), 5.92 (s, 1H), 4.71 
(m, 1H), 4.17 (m, 1H), 3.81 (dd, J1 = 10 Hz, J2 = 15 Hz, 1H), 3.14 (m, 2H), 2.78 (dd, J1 = 8 Hz, J2 = 13 
Hz, 1H), 2.57 (dd, J1 = 2 Hz, J2 = 11 Hz, 1H), 2.39 (dd, J1 = 6 Hz, J2 = 13 Hz, 1H), 2.30 (dd, J1 = 3 Hz, J2 
= 12 Hz, 1H), 2.11 (q, J = 12, 1H), 1.99 (qd, J1 = 3 Hz, J2 = 13 Hz, 1H), 1.79-1.65 (complex, 3H), 1.55-
1.20 (complex, 8H), 0.97 (s, 9H).
 13
C NMR (500 MHz, CDCl3) δ ppm 173.05, 169.23, 136.26, 134.77, 
132.51, 131.16, 129.03, 128.11, 128.07, 127.52, 127.48, 126.39, 124.23, 122.39, 122.36, 122.13, 119.60, 
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119.02, 112.89, 111.20, 71.37, 71.08, 60.11, 59.40, 56.38, 51.02, 36.09, 33.71, 30.90, 30.83, 28.31, 26.35, 
26.31, 26.10, 20.63. HRMS (m/z): [M + H]
+
 calc. for C37H47N4O3, 595.3648; observed, 595.3649. 
 
 
(3S,4aS,8aS)-2-((2R,3S)-3-(2-naphthamido)-2-hydroxy-4-phenylbutyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (21) 
 A solution of 54 (42 mg, 0.078 mmol) and 10% palladium on carbon (25 mg, 0.024 mmol) in 
methanol (15 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite 
and washed with excess methanol. The reaction was then dried to a solid and redissolved in THF (3 mL). 
2-naphthoic acid (15 mg, 0.086 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(16 mg, 0.086 mmol), and hydroxybenzotriazole hydrate (14 mg, 0.086 mmol) were added to the reaction 
and the solution was stirred at room temperature for 18 h. The reaction was taken up in ethyl acetate and 
washed once with saturated sodium bicarbonate and once with brine. The ethyl acetate fraction was dried 
over sodium sulfate, concentrated by rotary evaporation, and purified by silica flash column 
chromatography (gradient of 0-3% MeOH in DCM) to yield 21 as a white solid (25 mg, 58%). 
1
H NMR 
(500 MHz, CDCl3) δ ppm 8.14 (s, 1H), 7.85 (d, J = 8 Hz, 1H), 7.80 (m, 2H), 7.72 (dd, J1 = 1.5 Hz, J2 = 9 
Hz, 1H), 7.50 (m, 2H), 7.41 (m, 3H), 7.33 (t, J = 7.5 Hz, 2H), 7.21 (t, J = 7.5 Hz, 1H), 5.61 (s, 1H), 4.62 
(m, 1H), 4.49 (br s, 1H), 4.10 (m, 1H), 3.70 (dd, J1 = 11 Hz, J2 = 14 Hz, 1H), 3.02 (m, 2H), 2.67 (dd, J1 = 
9 Hz, J2 = 13 Hz, 1H), 2.47 (dd, J1 = 3 Hz, J2 = 11 Hz, 1H), 2.27 (dd, J1 = 5 Hz, J2 = 13 Hz, 1H), 2.21 (dd, 
J1 = 3 Hz, J2 = 11.5 Hz, 1H), 2.06 (q, J = 12 Hz, 1H), 1.89 (qd, J1 = 3.5 Hz, J2 = 13.5 Hz, 1H), 1.76-0.95 
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(complex, 19H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.91, 169.65, 139.15, 134.81, 132.52, 131.34, 
129.27, 129.01, 128.54, 128.29, 128.08, 127.55, 127.48, 126.40, 124.24, 71.63, 70.90, 59.50, 59.16, 
57.41, 51.04, 36.53, 36.15, 33.76, 30.97, 28.38, 26.34, 26.03, 20.52. HRMS (m/z): [M + H]
+
 calc. for 
C35H46N3O3, 556.3539; observed, 556.3536. 
 
 
(3S,4aS,8aS)-2-((2R,3S)-3-(2-naphthamido)-2-hydroxy-5-methylhexyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (22) 
 A solution of 48 (107 mg, 0.213 mmol) and 10% palladium on carbon (68 mg, 0.064 mmol) in 
methanol (6 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite 
and washed with excess methanol. The reaction was then dried to a solid and redissolved in THF (5 mL). 
2-naphthoic acid (40 mg, 0.234 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(45 mg, 0.234 mmol), and hydroxybenzotriazole hydrate (38 mg, 0.234 mmol) were added to the reaction 
and the solution was stirred at room temperature for 18 h. The reaction was taken up in ethyl acetate and 
washed once with saturated sodium bicarbonate and once with brine. The ethyl acetate fraction was dried 
over sodium sulfate, concentrated by rotary evaporation, and purified by silica flash column 
chromatography (gradient of 0-4% MeOH in DCM) to yield 22 as a white solid (75 mg, 67%). 
1
H NMR 
(500 MHz, CDCl3) δ ppm 8.41 (s, 1H), 7.93 (m, 2H), 7.84 (dd, J1 = 3 Hz, J2 = 8 Hz, 2H), 7.53 (m, 3H), 
5.81 (s, 1H), 4.46 (m, 1H), 3.97 (m, 1H), 3.00 (dd, J1 = 2 Hz, J2 = 11.5 Hz, 1H), 2.59 (dd, J1 = 8 Hz, J2 = 
12.5 Hz, 1H), 2.43 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 2.16 (m, 3H), 1.96 (q, J = 12 Hz, 1H), 1.82 (m, 2H), 
1.69 (m, 2H), 1.59 (d, J = 12.5 Hz, 1H), 1.51-0.96 (complex, 23H). 
13
C NMR (500 MHz, CDCl3) δ ppm 
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174.04, 169.38, 134.83, 132.58, 131.31, 129.04, 128.29, 128.06, 127.54, 127.45, 126.39, 124.40, 72.68, 
70.66, 59.31, 59.18, 54.11, 50.93, 39.86, 36.00, 33.60, 30.82, 30.75, 28.36, 26.24, 26.02, 25.52, 23.48, 
21.63, 20.48. HRMS (m/z): [M + H]
+
 calc. for C32H48N3O3, 522.3696; observed, 522.3700. 
 
 
(3S,4aS,8aS)-2-((S)-3-(2-naphthamido)-2-hydroxypropyl)-N-(tert-butyl)decahydroisoquinoline-3-
carboxamide (23) 
 A solution of 34 (50 mg, 0.112 mmol) and 10% palladium on carbon (36 mg, 0.034 mmol) in 
methanol (10 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite 
and washed with excess methanol. The reaction was then dried to a solid and redissolved in THF (3 mL). 
3-hydroxy-2-methylbenzoic acid (21 mg, 0.123 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (24 mg, 0.123 mmol), and hydroxybenzotriazole hydrate (20 mg, 0.123 mmol) were added 
to the reaction and the solution was stirred at room temperature for 18 h. The reaction was taken up in 
ethyl acetate and washed once with saturated sodium bicarbonate and once with brine. The ethyl acetate 
fraction was dried over sodium sulfate, concentrated by rotary evaporation, and purified by silica flash 
column chromatography (gradient of 0-3% MeOH in DCM) to yield 23 as a white solid (36 mg, 66%). 
1
H 
NMR (500 MHz, CDCl3) δ ppm 8.52 (s, 1H), 8.33 (t, J = 5.5 Hz, 1H), 8.04 (dd, J1 = 1.5 Hz, J2 = 8.5 Hz, 
1H), 7.93 (d, J = 8 Hz, 1H), 7.85 (m, 2H), 7.52 (m, 2H), 5.63 (s, 1H), 4.04 (m, 2H), 3.64 (dt, J1 = 4 Hz, J2 
= 14 Hz, 1H), 2.78 (dd, J1 = 2 Hz, J2 = 11.5 Hz, 1H), 2.52 (dd, J1 = 2.5 Hz, J2 = 11.5 Hz, 1H), 2.44 (dd, J1 
= 10 Hz, J2 = 12.5 Hz, 1H), 2.19 (m, 2H), 2.08 (q, J = 12 Hz, 1H), 1.85 (qd, J1 = 3.5 Hz, J2 = 13 Hz, 1H), 
1.73 (m, 1H), 1.63 (m, 1H), 1.56 (m, 1H), 1.48 (m, 2H), 1.39-1.05 (complex, 14H). 
13
C NMR (500 MHz, 
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CDCl3) δ ppm 174.06, 170.19, 134.83, 132.59, 131.16, 129.10, 128.43, 127.93, 127.55, 127.39, 126.30, 
124.54, 70.58, 69.19, 59.24, 57.71, 51.28, 43.70, 35.93, 33.69, 31.05, 30.97, 28.41, 26.21, 25.57, 20.22. 
HRMS (m/z): [M + H]
+
 calc. for C28H40N3O3, 466.3070; observed, 466.3065. 
 
 
(3S,4aS,8aS)-2-((R)-2-((S)-1-(2-naphthoyl)pyrrolidin-2-yl)-2-hydroxyethyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (24) 
 To a solution of 42 (30 mg, 0.085 mmol) in THF (3 mL) was added 2-naphthoic acid (16 mg, 
0.094 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (18 mg, 0.094 mmol), and 
hydroxybenzotriazole hydrate (15 mg, 0.094 mmol). The solution was stirred at room temperature for 16 
h. The reaction was taken up in ethyl acetate and washed once with saturated sodium bicarbonate and 
once with brine. The ethyl acetate fraction was dried over sodium sulfate, concentrated by rotary 
evaporation, and purified by silica flash column chromatography (gradient of 0-4% MeOH in DCM) to 
yield 24 as a white solid (33 mg, 68% over two steps). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.02 (s, 1H), 
7.87 (m, 3H), 7.61 (d, J = 8.5 Hz, 1H), 7.54 (m, 1H), 6.45 (s, 1H), 4.42 (t, J = 8 Hz, 1H), 4.25 (br s, 1H), 
3.58 (m, 2H), 3.47 (s, 2H), 3.33 (d, J = 12 Hz, 1H), 2.71 (dd, J1 = 3.5 Hz, J2 = 13 Hz, 1H), 2.65 (dd, J1 = 2 
Hz, J2 = 10.5 Hz, 1H), 2.26 (m, 2H), 2.13 (m, 1H), 2.03-1.20 (complex, 24H).
 13
C NMR (500 MHz, 
CDCl3) δ ppm 174.09, 171.38, 133.91, 133.72, 132.40, 128.54, 128.13, 127.72, 127.32, 127.27, 126.66, 
124.28, 71.56, 70.32, 62.82, 59.17, 58.87, 51.81, 50.58, 35.74, 32.95, 30.71, 30.59, 28.70, 26.61, 26.21, 
25.60, 25.27, 20.52. HRMS (m/z): [M + H]
+
 calc. for C31H44N3O3, 506.3383; observed, 506.3389. 
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Benzyl ((R)-1-((R)-oxiran-2-yl)-2-(phenylthio)ethyl)carbamate (61) 
 To a solution of 60 (439 mg, 1.33 mmol) in ethanol (25 mL) at 0 °C was added solid potassium 
hydroxide (82 mg, 1.47 mmol). The reaction was stirred cold for 15 min then warmed to room 
temperature and stirred for an additional 2 h. The reaction was evaporated to dryness and the solid was 
purified by silica flash column chromatography (gradient of 0-4% EtOAc in DCM) to yield 61 as a white 
solid (285 mg, 65%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.33 (m, 9H), 7.17 (t, J = 7 Hz, 1H), 5.06 (s, 
3H), 4.06 (d, J = 6.5 Hz, 1H), 3.23 (m, 2H), 3.07 (dd, J1 = 7.5 Hz, J2 = 13 Hz, 1H), 2.69 (t, J = 4 Hz, 1H), 
2.58 (s, 1H). 
13
C NMR (500 MHz, CDCl3) δ ppm 155.77, 136.08, 135.12, 129.42, 128.95, 128.38, 128.04, 
127.89, 126.38, 66.77, 51.81, 51.75, 49.44, 44.45, 36.63. HRMS (m/z): [M + H]
+
 calc. for C18H20NO3S, 
330.1164; observed, 330.1169. 
 
 
Benzyl ((2R,3S)-4-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-3-hydroxy-
1-(phenylthio)butan-2-yl)carbamate (62) 
 To a solution of 61 (285 mg, 0.865 mmol) in isopropyl alcohol (7 mL) was added (3S,4aS,8aS)-
N-(tert-butyl)decahydroisoquinoline-3-carboxamide (6, 248 mg, 1.04 mmol). The solution was heated to 
reflux and stirred for 5 h, then dried to a solid. The product was purified by silica flash column 
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chromatography (gradient of 0-4% MeOH in DCM) to yield 62 as a white solid (490 mg, 99%). 
1
H NMR 
(500 MHz, CDCl3) δ ppm 7.42 (d, J = 7.5 Hz, 2H), 7.32 (m, 7H), 7.16 (t, J = 7.5 Hz, 1H), 5.83 (s, 1H), 
5.35 (d, J = 9 Hz, 1H), 5.28 (s, 1H), 5.12 (d, J = 12.5 Hz, 1H), 5.00 (d, J = 12.5 Hz, 1H), 4.09 (dd, J1 = 2 
Hz, J2 = 11 Hz, 1H), 3.80 (s, 1H), 3.60 (m, 1H), 3.25 (dd, J1 = 5.5 Hz, J2 = 13.5 Hz, 1H), 3.10 (dd, J1 = 9 
Hz, J2 = 13.5 Hz, 1H), 2.79 (dd, J1 = 1.5 Hz, J2 = 11.5 Hz, 1H), 2.62 (dd, J1 = 3 Hz, J2 = 11 Hz, 1H), 2.56 
(dd, J1 = 11 Hz, J2 = 12.5 Hz, 1H), 2.19 (dd, J1 = 3 Hz, J2 = 12 Hz, 1H), 1.98 (dd, J1 = 3 Hz, J2 = 13 Hz, 
1H), 1.93 (q, J = 12 Hz, 1H), 1.74 (m, 3H), 1.61-1.19 (complex, 19H). 
13
C NMR (500 MHz, CDCl3) δ 
ppm 173.05, 156.06, 136.19, 135.82, 128.92, 128.66, 128.34, 127.95, 127.89, 125.88, 69.55, 66.67, 65.33, 
58.33, 58.01, 52.09, 50.88, 35.71, 35.56, 33.18, 30.82, 30.78, 28.51, 26.18, 25.32, 20.15. HRMS (m/z): 
[M + H]
+
 calc. for C32H46N3O4S, 568.3209; observed, 568.3196. 
 
 
(3S,4aS,8aS)-2-((2S,3R)-3-amino-2-hydroxy-4-(phenylthio)butyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (63) 
 A solution of 62 (113 mg, 0.119 mmol) in isopropyl alcohol (10 mL) was heated to reflux with 
stirring and 2 M NaOH (0.50 mL, 1.0 mmol) was added. The solution was refluxed for 16 h, then dried to 
a solid. The product was purified by silica flash column chromatography (gradient of 0-6% MeOH in 
DCM) to yield 63 as a white solid (53 mg, 61%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.35 (dd, J1 = 1 Hz, 
J2 = 8 Hz, 2H), 7.28 (t, J = 8 Hz, 2H), 7.19 (t, J = 7.5 Hz, 1H), 6.26 (s, 1H), 3.71 (dt, J1 = 3 Hz, J2 = 10.5 
Hz, 1H), 3.16 (dd, J1 = 4.5 Hz, J2 = 13.5 Hz, 1H), 2.89 (dd, J1 = 8.5 Hz, J2 = 13.5 Hz, 1H), 2.84 (dd, J1 = 
1.5 Hz, J2 = 11.5 Hz, 1H), 2.67 (m, 3H), 2.14 (dd, J1 = 3.5 Hz, J2 = 11.5 Hz, 1H), 2.00 (dd, J1 = 2.5 Hz, J2 
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= 12.5 Hz, 1H), 1.88 (q, J = 12.5 Hz, 1H), 1.77 (m, 3H), 1.63-1.20 (complex, 19H). 
13
C NMR (500 MHz, 
CDCl3) δ ppm 173.38, 135.59, 129.76, 129.00, 126.37, 69.94, 68.52, 59.35, 58.21, 52.89, 50.70, 39.63, 
35.79, 33.22, 30.92, 30.83, 28.59, 26.28, 25.49, 20.21. HRMS (m/z): [M + H]
+
 calc. for C24H40N3O2S, 
434.2841; observed, 434.2837. 
 
 
(3S,4aS,8aS)-2-((2S,3R)-3-(2-naphthamido)-2-hydroxy-4-(phenylthio)butyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (25) 
 To a solution of 63 (25 mg, 0.058 mmol) in THF (3 mL) was added 2-naphthoic acid (11 mg, 
0.063 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (12 mg, 0.063 mmol), and 
hydroxybenzotriazole hydrate (10 mg, 0.063 mmol). The solution was stirred at room temperature for 20 
h. The reaction was taken up in ethyl acetate and washed once with water, once with saturated sodium 
bicarbonate, and once with brine. The ethyl acetate fraction was dried over sodium sulfate, concentrated 
by rotary evaporation, and purified by silica flash column chromatography (gradient of 0-3% MeOH in 
DCM) to yield 25 as a white solid (33 mg, 97%). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.27 (s, 1H), 7.91 
(d, J = 7.5 Hz, 1H), 7.84 (m, 3H), 7.52 (m, 4H), 7.30 (t, J = 7.5 Hz, 2H), 7.15 (t, J = 7.5 Hz, 1H), 7.02 (d, 
J = 8.5 Hz, 1H), 5.45 (s, 1H), 4.38 (br s, 1H), 4.21 (dd, J1 = 2 Hz, J2 = 11 Hz, 1H), 4.13 (m, 1H), 3.47 (dd, 
J1 = 6 Hz, J2 = 14 Hz, 1H), 3.23 (dd, J1 = 9 Hz, J2 = 14 Hz, 1H), 2.84 (dd, J1 = 1.5 Hz, J2 = 11.5 Hz, 1H), 
2.61 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 2.51 (dd, J1 = 11 Hz, J2 = 12.5 Hz, 1H), 2.24 (dd, J1 = 3 Hz, J2 = 
11.5 Hz, 1H), 2.09 (dd, J1 = 3 Hz, J2 = 13 Hz, 1H), 2.01 (q, J = 13 Hz, 1H), 1.74 (m, 2H), 1.62-1.15 
(complex, 9H), 1.00 (s, 9H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.03, 167.05, 136.08, 134.77, 132.54, 
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131.08, 129.01, 128.61, 128.27, 127.61, 127.58, 127.56, 126.57, 125.84, 123.69, 69.26, 65.79, 58.33, 
58.05, 50.99, 50.94, 35.85, 35.34, 33.41, 31.07, 30.97, 28.37, 26.25, 25.35, 20.20. HRMS (m/z): [M + H]
+
 
calc. for C35H46N3O3S, 588.3260; observed, 588.3254. 
 
 
Methyl N-((benzyloxy)carbonyl)-S-phenyl-D-cysteinate (64) 
 To a stirred solution of triphenylphosphine (2.43 g, 9.25 mmol) in anhydrous tetrahydrofuran (20 
mL) under nitrogen at 0 °C was added diisopropyl azodicarboxylate (1.82 mL, 9.25 mmol) dropwise over 
15 min. The reaction was stirred cold for an additional 40 min before Z-D-serine methyl ester (1.95 g, 
7.71 mmol) in anhydrous tetrahydrofuran (20 mL) was added slowly over 15min. Immediately after 
addition, thiophenol (1.03 mL, 10.02 mmol) was added dropwise over 1 min. The reaction was warmed to 
room temperature and stirred for 18 h. Took up the reaction in ethyl acetate and washed once with water, 
once with sodium bicarbonate, and once with brine. The organic phase was dried over sodium sulfate and 
concentrated by rotary evaporation. The product was purified by silica flash column chromatography 
(gradient of 0-20% EtOAc in hexanes) to yield 64 as a colorless oil (699 mg, 26%). 
1
H NMR (500 MHz, 
CDCl3) δ ppm 7.32 (m, 9H), 7.20 (t, J = 7.5 Hz, 1H), 5.61 (d, J = 7.5 Hz, 1H), 5.07 (dd, J1 = 12 Hz, J2 = 
16 Hz, 2H), 4.63 (m, 1H), 3.53 (s, 3H), 3.40 (m, 2H). 
13
C NMR (500 MHz, CDCl3) δ ppm 170.59, 155.48, 
136.08, 134.42, 131.15, 128.99, 128.50, 128.17, 128.05, 127.12, 67.03, 53.61, 52.37, 37.07. HRMS (m/z): 
[M + H]
+
 calc. for C18H20NO4S, 346.1113; observed, 346.1120. 
 
130 
 
 
N-((benzyloxy)carbonyl)-S-phenyl-D-cysteine (65) 
  To a stirred solution of 64 (521 mg, 1.51 mmol) in acetonitrile (4 mL) was added 1M aq. sodium 
carbonate (8 mL). The reaction was stirred vigorously for 18 h, then heated to 50 °C and stirred for an 
additional 6 h. The pH of the reaction was adjusted to 1 with 6M HCl and extracted three times with ethyl 
acetate. The combined organic fraction was washed once with brine, dried over sodium sulfate, and 
concentrated by rotary evaporation. The product was purified by silica flash column chromatography 
(gradient of 2-10% MeOH in DCM) to yield 65 as an off-white solid (249 mg, 50%). 
1
H NMR (400 MHz, 
CDCl3) δ ppm 10.18 (br s, 1H), 7.30 (m, 10H), 5.72 (s, 1H), 5.00 (m, 2H), 4.53 (m, 1H), 3.42 (m, 2H). 
13
C NMR (400 MHz, CDCl3) δ ppm 175.03, 155.88, 135.98, 134.79, 130.46, 128.94, 128.54, 128.42, 
128.17, 128.02, 126.78, 67.06, 54.04, 36.47. HRMS (m/z): [M + Na]
+
 calc. for C17H17NO4NaS, 354.0776; 
observed, 354.0782. 
 
 
Benzyl (S)-(4-diazo-3-oxo-1-(phenylthio)butan-2-yl)carbamate (66) 
 To a stirred solution of 65 (334 mg, 1.01 mmol) in anhydrous tetrahydrofuran (4 mL) under 
nitrogen at -78 °C was added anhydrous triethylamine (210 μL, 1.51 mmol) followed by isobutyl 
chloroformate (196 μL, 1.51 mmol). The reaction was stirred cold for 1 h and then warmed to room 
temperature for 1.5 h. The reaction was cooled to -78 °C before an ethereal solution of diazomethane (10 
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mL, 3.24 mmol) was added in one portion and the reaction was then warmed to room temperature with 
stirring for 1 h. The reaction was evaporated to dryness, resulting in a yellow solid. The solid was taken 
up in ethyl acetate, washed twice with water, twice with a saturated solution of sodium bicarbonate, and 
once with brine. The organic phase was dried over sodium sulfate and concentrated by rotary evaporation. 
The product was purified by silica flash column chromatography (gradient of 10-40% EtOAc in hexanes) 
to yield 66 as a yellow oil (202 mg, 56%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.32 (m, 9H), 7.19 (t, J = 
7.5 Hz, 1H), 5.89 (d, J = 8 Hz, 1H), 5.47 (s, 1H), 5.08 (s, 2H), 4.39 (m, 1H), 3.30 (dd, J1 = 6 Hz, J2 = 14 
Hz, 1H), 3.23 (dd, J1 = 6 Hz, J2 = 14 Hz, 1H). 
13
C NMR (500 MHz, CDCl3) δ ppm 191.59, 155.62, 
135.89, 135.52, 130.05, 128.97, 128.37, 128.08, 127.92, 126.78, 69.74, 66.97, 56.92, 54.78, 35.93, 21.76. 
Ethyl acetate peaks are visible in the NMR. HRMS (m/z): [M + H]
+
 calc. for C18H18N3O3S, 356.1069; 
observed, 356.1070. 
 
 
(S)-benzyl (4-chloro-3-oxo-1-(phenylthio)butan-2-yl)carbamate (67) 
 To a solution of 66 (202 mg, 0.57 mmol) in anhydrous tetrahydrofuran (8 mL) under nitrogen at 0 
°C was added 1 M HCl in diethyl ether (0.85 mL, 0.85 mmol) dropwise. The reaction was stirred at 0 °C 
for 30 min after complete addition. The solution was dried under reduced pressure to yield 67 as an off-
white solid (189 mg). No further purification was made. 
1
H NMR (500 MHz, CDCl3) δ ppm 7.30 (m, 
10H), 5.75 (d, J = 7 Hz, 1H), 5.06 (s, 2H), 4.68 (q, J = 7 Hz, 1H), 4.18 (dd, J1 = 16.5 Hz, J2 = 26 Hz, 2H), 
3.39 (dd, J1 = 6 Hz, J2 = 14.5 Hz, 1H), 3.28 (dd, J1 = 6.5 Hz, J2 = 14.5 Hz, 1H). 
13
C NMR (500 MHz, 
CDCl3) δ ppm 199.60, 155.67, 135.74, 133.80, 130.65, 129.23, 128.49, 128.26, 128.02, 127.32, 67.26, 
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56.99, 46.98, 35.41, 21.84. HRMS (m/z): [M + H]
+
 calc. for C18H19NO3SCl, 364.0774; observed, 
364.0772. 
 
 
Benzyl ((2S,3R)-4-chloro-3-hydroxy-1-(phenylthio)butan-2-yl)carbamate (68) and benzyl ((2S,3S)-
4-chloro-3-hydroxy-1-(phenylthio)butan-2-yl)carbamate (69) 
 To a solution of 67 (202 mg, 0.57 mmol) in dichloromethane (7 mL) and methanol (4 mL) under 
nitrogen at 0 °C was added sodium borohydride (15 mg, 0.40 mmol). The reaction was stirred at 0 °C for 
1 h, and then quenched with slow addition of 2 M HCl (2 mL). The reaction was evaporated to dryness 
and the solid was taken up in ethyl acetate. The solution was washed twice with water followed by brine, 
dried over sodium sulfate, and concentrated by rotary evaporation. TLC analysis showed two 
diastereomers with the lower Rf compound being the (S,R)-isomer. Both diastereomers were purified by 
silica flash column chromatography (gradient of 0-4% EtOAc in DCM) to yield (S,R)-isomer (68) as a 
white solid (98 mg, 47%) and (S,S)-isomer (69) as a white solid (25 mg, 12%) over two steps. 
Characterization of the (S,R)-isomer (68): 
1
H NMR (500 MHz, CDCl3) δ ppm 7.30 (m, 10H), 5.19 (m, 
1H), 5.06 (m, 2H), 3.91 (m, 2H), 3.66 (dd, J1 = 3.5 Hz, J2 = 11.5 Hz, 1H), 3.59 (dd, J1 = 7 Hz, J2 = 11.5 
Hz, 1H), 3.28 (d, J = 4 Hz, 2H), 2.89 (s, 1H). 
13
C NMR (500 MHz, CDCl3) δ ppm 156.15, 136.03, 135.24, 
130.06, 129.13, 128.53, 128.25, 128.07, 126.78, 72.86, 67.13, 53.33, 47.39, 35.21. HRMS (m/z): [M + 
H]
+
 calc. for C18H21NO3SCl, 366.0931; observed, 366.0927. Characterization of the (S,S)-isomer (69): 
1
H 
NMR (500 MHz, CDCl3) δ ppm 7.41 (d, J = 7.5 Hz, 2H), 7.33 (m, 7H), 7.20 (t, J = 7.5 Hz, 1H), 5.28 (d, J 
= 9 Hz, 1H), 5.10 (m, 2H), 4.18 (m, 1H), 3.87 (q, J = 7.5 Hz, 1H), 3.53 (m, 2H), 3.26 (dd, J1 = 6 Hz, J2 = 
14 Hz, 1H), 3.11 (dd, J1 = 7.5 Hz, J2 = 14 Hz, 1H), 2.91 (d, J = 3.5 Hz, 1H). 
13
C NMR (500 MHz, CDCl3) 
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δ ppm 156.33, 136.07, 135.02, 129.51, 129.14, 128.57, 128.54, 128.26, 128.22, 128.12, 128.07, 126.56, 
70.84, 67.15, 66.98, 52.27, 47.40, 35.58. HRMS (m/z): [M + H]
+
 calc. for C18H21NO3SCl, 366.0931; 
observed, 366.0930. 
 
 
Benzyl ((S)-1-((S)-oxiran-2-yl)-2-(phenylthio)ethyl)carbamate (70) 
 To a solution of 69 (25 mg, 0.068 mmol) in ethanol (5 mL) at 0 °C was added solid potassium 
hydroxide (4 mg, 0.075 mmol). The reaction was stirred cold for 15 min then warmed to room 
temperature and stirred for an additional 2 h. The reaction was evaporated to dryness and the solid was 
purified by silica flash column chromatography (gradient of 1-4% EtOAc in DCM) to yield 70 as a white 
solid (10 mg, 45%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.42 (d, J = 7 Hz, 2H), 7.34 (m, 7H), 7.20 (t, J = 
7 Hz, 1H), 5.09 (s, 2H), 4.88 (d, J = 7 Hz, 1H), 4.11 (m, 1H), 3.29 (m, 2H), 3.11 (dd, J1 = 8 Hz, J2 = 13.5 
Hz, 1H), 2.75 (t, J = 4.5 Hz, 1H), 2.62 (s, 1H). 
13
C NMR (500 MHz, CDCl3) δ ppm 155.89, 136.16, 
135.20, 129.65, 129.13, 128.55, 128.22, 128.06, 126.60, 67.00, 51.77, 49.43, 44.52, 36.99. HRMS (m/z): 
[M + H]
+
 calc. for C18H20NO3S, 330.1164; observed, 330.1160. 
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(3S,4aS,8aS)-2-((2R,3S)-3-amino-2-hydroxy-4-(phenylthio)butyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (71) 
 To a solution of 70 (10 mg, 0.030 mmol) in isopropyl alcohol (5 mL) was added (3S,4aS,8aS)-N-
(tert-butyl)decahydroisoquinoline-3-carboxamide (6, 8 mg, 0.033 mmol). The solution was heated to 
reflux and stirred. After 5 h, 2 M NaOH (75 μL, 0.15 mmol) was added and the reaction was stirred at 
reflux for an additional 15 h. The reaction was diluted with toluene and extracted with 1 M HCl three 
times. The aqueous fractions were combined and washed with toluene twice. The aqueous phase was 
adjusted to pH 12 with 10 M NaOH and was extracted with toluene five times. The combined toluene 
fractions were washed with brine, dried over sodium sulfate, and concentrated to a solid by rotary 
evaporation. The product was purified by silica flash column chromatography (gradient of 1-9% MeOH 
in DCM) to yield 71 as a white solid (9 mg, 69%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.42 (d, J = 7.5 
Hz, 2H), 7.31 (t, J = 7.5 Hz, 2H), 7.21 (t, J = 7.5 Hz, 1H), 5.88 (s, 1H), 5.30 (s, 1H), 4.08 (m, 1H), 3.50 
(dd, J1 = 9 Hz, J2 = 14 Hz, 1H), 3.40 (m, 1H), 3.34 (dd, J1 = 6 Hz, J2 = 14 Hz, 1H), 2.60 (dd, J1 = 2.5 Hz, 
J2 = 11.5 Hz, 2H), 2.48 (m, 2H), 2.16 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 1.90 (q, J = 12 Hz, 1H), 1.76-0.62 
(complex, 22H). 
13
C NMR (500 MHz, CDCl3) δ ppm 174.82, 133.18, 130.09, 129.40, 127.04, 69.12, 
66.84, 58.20, 56.72, 52.43, 52.16, 35.44, 33.31, 30.96, 30.80, 29.70, 28.72, 26.09, 25.05, 20.08. HRMS 
(m/z): [M + H]
+
 calc. for C24H40N3O2S, 434.2841; observed, 434.2835. 
 
 
(3S,4aS,8aS)-2-((2R,3S)-3-(2-naphthamido)-2-hydroxy-4-(phenylthio)butyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (26) 
135 
 
 To a solution of 71 (9 mg, 0.021 mmol) in THF (3 mL) was added 2-naphthoic acid (4 mg, 0.023 
mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (4 mg, 0.023 mmol), and 
hydroxybenzotriazole hydrate (4 mg, 0.023 mmol). The solution was stirred at room temperature for 20 h. 
The reaction was taken up in ethyl acetate and washed once with water, once with saturated sodium 
bicarbonate, and once with brine. The ethyl acetate fraction was dried over sodium sulfate, concentrated 
by rotary evaporation, and purified by silica flash column chromatography (gradient of 0-3% MeOH in 
DCM) to yield 26 as a white solid (5 mg, 41%). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.39 (s, 1H), 7.92 (m, 
2H), 7.86 (m, 2H), 7.79 (m, 1H), 7.54 (m, 3H), 7.45 (d, J = 8 Hz, 2H), 7.27 (t, J = 7.5 Hz, 2H), 7.13 (t, J 
= 7.5 Hz, 1H), 5.77 (br s, 1H), 4.25 (m, 2H), 3.61 (dd, J1 = 6.5 Hz, J2 = 14 Hz, 1H), 3.46 (dd, J1 = 8 Hz, J2 
= 14 Hz, 1H), 2.83 (m, 1H), 2.60 (m, 2H), 2.29 (m, 3H), 2.09-0.81 (complex, 20H). 
13
C NMR (500 MHz, 
CDCl3) δ ppm 168.83, 135.96, 134.89, 132.58, 131.24, 129.09, 129.01, 128.73, 128.30, 128.16, 127.74, 
127.63, 126.54, 125.86, 125.86, 124.17, 70.56, 68.82, 59.81, 59.00, 55.97, 53.97, 53.09, 51.25, 35.74, 
33.68, 33.41, 30.70, 29.70, 28.42, 26.00, 25.44, 20.33. HRMS (m/z): [M + H]
+
 calc. for C35H46N3O3S, 
588.3260; observed, 588.3256. 
 
 
Benzyl ((S)-1-((R)-oxiran-2-yl)-2-(phenylthio)ethyl)carbamate (72) 
 To a solution of 68 (98 mg, 0.268 mmol) in ethanol (7 mL) at 0 °C was added solid potassium 
hydroxide (17 mg, 0.295 mmol). The reaction was stirred cold for 15 min then warmed to room 
temperature and stirred for an additional 2 h. The reaction was evaporated to dryness and the solid was 
purified by silica flash column chromatography (gradient of 1-4% EtOAc in DCM) to yield 72 as a white 
solid (71 mg, 80%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.34 (m, 7H), 7.26 (t, J = 8 Hz, 2H), 7.19 (t, J = 
7.5 Hz, 1H), 5.18 (br s, 1H), 5.07 (dd, J1 = 12 Hz, J2 = 16 Hz, 2H), 3.69 (m, 1H), 3.20 (d, J = 5.5 Hz, 2H), 
136 
 
2.98 (s, 1H), 2.75 (s, 2H). 
13
C NMR (500 MHz, CDCl3) δ ppm 155.74, 136.11, 135.07, 129.92, 129.09, 
128.49, 128.17, 128.05, 126.72, 66.95, 52.59, 52.20, 46.74, 35.99. HRMS (m/z): [M + H]
+
 calc. for 
C18H20NO3S, 330.1164; observed, 330.1166. 
 
 
(3S,4aS,8aS)-2-((2S,3S)-3-amino-2-hydroxy-4-(phenylthio)butyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (73) 
 To a solution of 72 (71 mg, 0.216 mmol) in isopropyl alcohol (15 mL) was added (3S,4aS,8aS)-
N-(tert-butyl)decahydroisoquinoline-3-carboxamide (6, 57 mg, 0.237 mmol). The solution was heated to 
reflux and stirred. After 5 h, 2 M NaOH (0.54 mL, 1.08 mmol) was added and the reaction was stirred at 
reflux for an additional 15 h. The reaction was diluted with toluene and extracted with 1 M HCl three 
times. The aqueous fractions were combined and washed with toluene twice. The aqueous phase was 
adjusted to pH 12 with 10 M NaOH and was extracted with toluene five times. The combined toluene 
fractions were washed with brine, dried over sodium sulfate, and concentrated to a solid by rotary 
evaporation. The product was purified by silica flash column chromatography (gradient of 0-8% MeOH 
in DCM) to yield 73 as a white solid (47 mg, 50%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.36 (dd, J1 = 1 
Hz, J2 = 8 Hz, 2H), 7.27 (t, J = 7.5 Hz, 2H), 7.19 (t, J = 7.5 Hz, 1H), 6.27 (s, 1H), 3.76 (m, 1H), 3.29 (dd, 
J1 = 3 Hz, J2 = 13.5 Hz, 1H), 2.91 (d, J = 12.5 Hz, 2H), 2.82 (br s, 2H), 2.81 (dd, J1 = 9.5 Hz, J2 = 13.5 
Hz, 1H), 2.70 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 2.59 (dd, J1 = 10 Hz, J2 = 12.5 Hz, 1H), 2.18 (dd, J1 = 1.5 
Hz, J2 = 12.5 Hz, 1H), 1.88 (q, J = 11.5 Hz, 1H), 1.75 (m, 3H), 1.63-1.15 (complex, 19H). 
13
C NMR (500 
MHz, CDCl3) δ ppm 173.34, 135.18, 129.71, 129.02, 126.40, 69.95, 69.18, 58.31, 58.05, 53.47, 50.90, 
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37.29, 35.75, 33.19, 30.89, 30.80, 28.59, 26.27, 25.45, 20.21. HRMS (m/z): [M + H]
+
 calc. for 
C24H40N3O2S, 434.2841; observed, 434.2841. 
 
 
(3S,4aS,8aS)-2-((2S,3S)-3-(2-naphthamido)-2-hydroxy-4-(phenylthio)butyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (27) 
 To a solution of 73 (47 mg, 0.108 mmol) in THF (5 mL) was added 2-naphthoic acid (21 mg, 
0.119 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (23 mg, 0.119 mmol), and 
hydroxybenzotriazole hydrate (19 mg, 0.119 mmol). The solution was stirred at room temperature for 20 
h. The reaction was taken up in ethyl acetate and washed once with water, once with saturated sodium 
bicarbonate, and once with brine. The ethyl acetate fraction was dried over sodium sulfate, concentrated 
by rotary evaporation, and purified by silica flash column chromatography (gradient of 0-3% MeOH in 
DCM) to yield 27 as a white solid (47 mg, 74%). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.15 (s, 1H), 7.84 
(m, 3H), 7.74 (dd, J1 = 1.5 Hz, J2 = 9 Hz, 1H), 7.54 (m, 2H), 7.40 (d, J = 7.5 Hz, 2H), 7.25 (t, J = 8 Hz, 
2H), 7.16 (t, J = 7.5 Hz, 1H), 6.89 (d, J = 8 Hz, 1H), 6.18 (s, 1H), 4.30 (m, 1H), 3.99 (m, 1H), 3.39 (dd, J1 
= 8 Hz, J2 = 14 Hz, 1H), 3.25 (dd, J1 = 4.5 Hz, J2 = 14 Hz, 1H), 2.80 (d, J = 10 Hz, 1H), 2.61 (m, 2H), 
2.14 (m, 2H), 1.91 (q, J = 12 Hz, 1H), 1.79-1.66 (complex, 3H), 1.57-1.13 (complex, 18H). 
13
C NMR 
(500 MHz, CDCl3) δ ppm 173.51, 167.67, 135.68, 134.76, 132.49, 131.17, 129.78, 129.13, 128.95, 
128.35, 127.68, 127.57, 126.68, 126.53, 123.63, 69.77, 69.17, 58.52, 58.34, 53.09, 50.98, 35.81, 34.37, 
33.27, 31.02, 30.86, 28.65, 26.23, 25.40, 20.17. HRMS (m/z): [M + H]
+
 calc. for C35H46N3O3S, 588.3260; 
observed, 588.3266. 
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(2R,3R)-3-(3-acetoxy-2-methylbenzamido)-1-((3S,4aS,8aS)-3-(tert-
butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-4-(phenylthio)butan-2-yl acetate (28) 
 To a stirred solution of 1 (75 mg, 0.132 mmol) in anhydrous tetrahydrofuran (3 mL) under 
nitrogen at room temperature was added anhydrous triethylamine (37 μL, 0.264 mmol) followed by acetic 
anhydride (125 μL, 1.32 mmol). The reaction was stirred at room temperature for 16 h. Ethyl acetate was 
added to the reaction. The crude material was washed once with saturated sodium bicarbonate and once 
with brine. The organic phase was dried over sodium sulfate and concentrated by rotary evaporation. The 
product was purified by silica flash column chromatography (gradient of 0-50% EtOAc in hexanes) to 
yield 28 as a white solid (41 mg, 48%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.44 (dd, J1 = 1 Hz, J2 = 7.5 
Hz, 2H), 7.39 (d, J = 9.5 Hz, 1H), 7.34 (dd, J1 = 1 Hz, J2 = 7.5 Hz, 1H), 7.28 (t, J = 7.5 Hz, 2H), 7.19 (m, 
2H), 7.04 (dd, J1 = 0.5 Hz, J2 = 8 Hz, 1H), 5.70 (s, 1H), 5.36 (m, 1H), 4.66 (m, 1H), 3.59 (dd, J1 = 9 Hz, 
J2 = 13.5 Hz, 1H), 3.44 (dd, J1 = 5.5 Hz, J2 = 13.5 Hz, 1H), 3.00 (dd, J1 = 2 Hz, J2 = 12 Hz, 1H), 2.64 (dd, 
J1 = 10 Hz, J2 = 12.5 Hz, 1H), 2.43 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 2.30 (s, 3H), 2.23 (s, 3H), 2.14 (m, 
2H), 2.03 (s, 3H), 1.97 (q, J = 12 Hz, 1H), 1.75-1.10 (complex, 20H). 
13
C NMR (500 MHz, CDCl3) δ ppm 
173.79, 170.22, 169.18, 168.95, 149.62, 138.74, 135.61, 129.87, 128.95, 128.50, 126.32, 124.85, 123.23, 
70.72, 70.69, 59.58, 55.92, 51.28, 50.62, 35.95, 35.61, 33.72, 30.97, 30.91, 28.36, 26.29, 25.82, 21.18, 
20.78, 20.35, 12.84. HRMS (m/z): [M + H]
+
 calc. for C36H50N3O6S, 652.3420; observed, 652.3414. 
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(2R,3R)-3-(2-naphthamido)-1-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-
yl)-4-(phenylthio)butan-2-yl acetate (29) 
 To a stirred solution of 17 (23.2 mg, 0.040 mmol) in anhydrous tetrahydrofuran (2 mL) under 
nitrogen at room temperature was added anhydrous triethylamine (10.9 μL, 0.079 mmol) followed by 
acetic anhydride (7.5 μL, 0.079 mmol). The reaction was stirred for 8 h, then additional acetic anhydride 
was added (15 μL, 0.16 mmol) and the reaction was stirred at room temperature for 12 h. Ethyl acetate 
was added to the reaction. The crude material was washed once with saturated sodium bicarbonate and 
once with brine. The organic phase was dried over sodium sulfate and concentrated by rotary evaporation. 
The product was purified by silica flash column chromatography (gradient of 1-3% MeOH in DCM) to 
yield 29 as a white solid (9.8 mg, 39%). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.33 (s, 1H), 7.92 (m, 2H), 
7.84 (m, 2H), 7.64 (d, J = 9.5 Hz, 1H), 7.52 (m, 2H), 7.45 (dd, J1 = 1 Hz, J2 = 7.5 Hz, 2H), 7.26 (t, J = 7.5 
Hz, 2H), 7.15 (t, J = 7.5 Hz, 1H), 5.73 (s, 1H), 5.45 (m, 1H), 4.77 (m, 1H), 3.62 (dd, J1 = 7.5 Hz, J2 = 
13.5 Hz, 1H), 3.51 (dd, J1 = 6 Hz, J2 = 14 Hz, 1H), 3.06 (dd, J1 = 2 Hz, J2 = 12 Hz, 1H), 2.78 (dd, J1 = 9.5 
Hz, J2 = 12.5 Hz, 1H), 2.47 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 2.21-2.16 (m, 2H), 2.07 (s, 3H), 2.02 (q, J = 
12 Hz, 1H), 1.83-1.13 (complex, 20H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.74, 170.49, 167.77, 
135.85, 132.60, 131.96, 129.80, 129.17, 128.99, 127.96, 127.56, 127.27, 126.29, 126.24, 124.45, 71.01, 
70.88, 59.69, 56.27, 51.39, 51.25, 36.00, 35.74, 33.85, 31.24, 30.95, 28.56, 26.33, 25.87, 21.27, 20.44. 
HRMS (m/z): [M + H]
+
 calc. for C37H48N3O4S, 630.3366; observed, 630.3361. 
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(3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3R)-2-hydroxy-3-(3-methoxy-2-methylbenzamido)-4-
(phenylthio)butyl)decahydroisoquinoline-3-carboxamide (74) 
 To a solution of 1 (41 mg, 0.074 mmol) in dry DMF (1 mL) under nitrogen was added potassium 
carbonate (20 mg, 0.15 mmol) and methyl iodide (9.1 μL). The solution was heated to 60 °C and stirred 
for 3 h. The reaction was cooled to room temperature and taken up in water. The aqueous phase was 
extracted three times with ethyl acetate. The combined organic phase was washed with water then brine, 
dried over sodium sulfate, and concentrated by rotary evaporation. The product was purified by silica 
flash column chromatography (gradient of 2-3% MeOH in DCM) to yield 74 as a white solid (22.3 mg, 
52%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.46 (d, J = 8 Hz, 2H), 7.30 (t, J = 8 Hz, 1H), 7.22 (t, J = 7.5 
Hz, 1H), 7.18 (t, J = 8 Hz, 2H), 7.10 (d, J = 7.5 Hz, 1H), 6.89 (d, J = 8 Hz, 1H), 5.51 (s, 1H), 4.44 (m, 
1H), 4.04 (m, 1H), 3.92 (br s, 1H), 3.84 (s, 3H), 3.78 (dd, J1 = 9 Hz, J2 = 13 Hz, 1H), 3.44 (dd, J1 = 5 Hz, 
J2 = 14 Hz, 1H), 2.94 (dd, J1 = 2.5 Hz, J2 = 12 Hz, 1H), 2.59 (dd, J1 = 9 Hz, J2 = 13 Hz, 1H), 2.46 (dd, J1 
= 2.5 Hz, J2 = 11 Hz, 1H), 2.32 (s, 3H), 2.26-2.19 (m, 2H), 2.00 (q, J = 12 Hz, 1H), 1.80-1.18 (complex, 
11H), 1.08 (s, 9H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.88, 171.79, 157.96, 137.24, 135.63, 130.10, 
129.01, 127.91, 126.39, 125.45, 119.77, 111.74, 70.62, 70.38, 59.68, 58.69, 55.68, 54.57, 51.15, 36.03, 
35.38, 33.71, 30.96, 30.89, 28.37, 26.26, 25.95, 20.48, 12.74. HRMS (m/z): [M + H]
+
 calc. for 
C33H48N3O4S, 582.3366; observed, 582.3361. 
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(3S,4aS,8aS)-2-((2R,3R)-3-(1-naphthamido)-2-hydroxy-4-(phenylthio)butyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (75) 
 This reaction was performed according to the general EDC coupling procedure (0.046 mmol 1-
naphthoic acid for 16 h). Purification by flash column chromatography (gradient of 1-3% MeOH in 
DCM) yielded 75 as a white solid (11.4 mg, 45%). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.45 (d, J = 8 Hz, 
1H), 7.90 (d, J = 8.5 Hz, 1H), 7.82 (d, J = 7.5 Hz, 1H), 7.77 (dd, J1 = 1 Hz, J2 = 7 Hz, 1H), 7.60 (br d, J = 
8.5 Hz), 7.54-7.43 (complex, 6H), 7.29 (t, J = 7.5 Hz, 2H), 7.20 (t, J = 7.5 Hz, 1H), 5.36 (s, 1H), 4.61 (m, 
1H), 4.14 (m, 1H), 3.93 (dd, J1 = 9.5 Hz, J2 = 13.5 Hz, 1H), 3.46 (dd, J1 = 5 Hz, J2 = 14 Hz, 1H), 2.94 
(dd, J1 = 2 Hz, J2 = 12 Hz, 1H), 2.59 (dd, J1 = 9.5 Hz, J2 = 13.5 Hz, 1H), 2.38 (dd, J1 = 3 Hz, J2 = 11 Hz, 
1H), 2.23 (dd, J1 = 4.5 Hz, J2 = 13 Hz, 1H), 2.17 (dd, J1 = 3 Hz, J2 = 12 Hz, 1H), 1.98 (q, J = 11.5 Hz, 
1H), 1.81-1.16 (complex, 11H), 0.78 (s, 9H). 
13
C NMR (500 MHz, CDCl3) δ ppm 174.12, 171.78, 135.78, 
133.95, 131.22, 130.92, 130.53, 129.30, 128.26, 127.29, 126.72, 126.63, 126.40, 126.26, 125.96, 124.91, 
71.01, 70.76, 59.93, 59.02, 55.44, 51.31, 36.35, 35.89, 34.03, 31.22, 31.19, 28.32, 26.56, 26.28, 20.69. 
HRMS (m/z): [M + H]
+
 calc. for C35H46N3O3S, 588.3260; observed, 588.3259. 
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(3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3R)-3-(2-cyclohexylacetamido)-2-hydroxy-4-
(phenylthio)butyl)decahydroisoquinoline-3-carboxamide (76) 
 This reaction was performed according to the general EDC coupling procedure (0.039 mmol 
cyclohexaneacetic acid for 16 h). Purification by flash column chromatography (gradient of 1-3% MeOH 
in DCM) yielded 76 as a white solid (13.5 mg, 65%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.38 (dd, J1 = 2 
Hz, J2 = 8 Hz, 2H), 7.27 (t, J = 8 Hz, 2H), 7.17 (t, J = 7.5 Hz, 1H), 6.80 (d, J = 8 Hz, 1H), 5.61 (s, 1H), 
4.27 (m, 1H), 4.03 (m, 1H), 3.54 (dd, J1 = 8.5 Hz, J2 = 13.5 Hz, 1H), 3.33 (dd, J1 = 6 Hz, J2 = 14 Hz, 1H), 
2.93 (dd, J1 = 2.5 Hz, J2 = 12 Hz, 1H), 2.57 (dd, J1 = 9 Hz, J2 = 12.5 Hz, 1H), 2.47 (dd, J1 = 2.5 Hz, J2 = 
11 Hz, 1H), 2.19-2.10 (m, 3H), 2.05-1.96 (m, 2H), 1.82-1.07 (complex, 29H), 0.98-0.88 (m, 2H). 
13
C 
NMR (500 MHz, CDCl3) δ ppm 174.38, 173.99, 135.82, 129.55, 128.97, 126.19, 70.69, 70.01, 59.57, 
58.79, 54.15, 51.32, 44.47, 36.00, 35.16, 34.88, 33.80, 33.04, 33.00, 31.10, 30.89, 28.91, 26.24, 26.04, 
25.93, 20.51. HRMS (m/z): [M + H]
+
 calc. for C32H52N3O3S, 558.3729; observed, 558.3740. 
 
(3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3R)-3-(cyclopentanecarboxamido)-2-hydroxy-4-
(phenylthio)butyl)decahydroisoquinoline-3-carboxamide (77) 
 This reaction was performed according to the general EDC coupling procedure (0.063 mmol 
cyclopentanecarboxylic acid for 48 h). Purification by flash column chromatography (gradient of 1-4% 
MeOH in DCM) yielded 77 as a white solid (17.3 mg, 54%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.39 (d, 
J = 7 Hz, 2H), 7.28 (t, J = 7.5 Hz, 2H), 7.18 (t, J = 7.5 Hz, 1H), 6.66 (d, J = 8.5 Hz, 1H), 5.63 (s, 1H), 
4.24 (m, 1H), 4.01 (m, 1H), 3.75 (br s, 1H), 3.55 (dd, J1 = 9 Hz, J2 = 13.5 Hz, 1H), 3.31 (dd, J1 = 5.5 Hz, 
J2 = 13.5 Hz, 1H), 2.92 (dd, J1 = 2 Hz, J2 = 11.5 Hz, 1H), 2.60-2.54 (m, 2H), 2.48 (dd, J1 = 3 Hz, J2 = 11 
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Hz, 1H), 2.20-2.15 (m, 2H), 1.99 (q, J = 11.5 Hz, 1H), 1.89 (m, 1H), 1.81-1.14 (complex, 27H). 
13
C NMR 
(500 MHz, CDCl3) δ ppm 178.44, 174.19, 136.02, 130.00, 129.23, 126.53, 70.97, 70.41, 59.83, 59.00, 
54.40, 51.50, 45.87, 36.25, 35.18, 33.99, 31.31, 31.13, 30.38, 29.04, 26.49, 26.17, 26.13, 20.76. HRMS 
(m/z): [M + H]
+
 calc. for C30H48N3O3S, 530.3416; observed, 530.3422. 
 
 
(3S,4aS,8aS)-2-((2R,3R)-3-([1,1'-biphenyl]-4-ylcarboxamido)-2-hydroxy-4-(phenylthio)butyl)-N-
(tert-butyl)decahydroisoquinoline-3-carboxamide (78) 
 This reaction was performed according to the general EDC coupling procedure (0.058 mmol 
biphenyl-4-carboxylic acid for 16 h). Purification by flash column chromatography (gradient of 0.5-3% 
MeOH in DCM) yielded 78 as a white solid (25.3 mg, 75%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.92 
(dd, J1 = 2 Hz, J2 = 7 Hz, 2H), 7.76 (d, J = 8.5 Hz, 1H), 7.61-7.58 (m, 4H), 7.47 (t, J = 8 Hz, 2H), 7.44 
(dd, J1 = 1 Hz, J2 = 7 Hz, 2H), 7.39 (t, J = 7.5 Hz, 1H), 7.28 (t, J = 7.5 Hz, 2H), 7.19 (t, J = 7.5 Hz, 1H), 
5.47 (s, 1H), 4.51 (m, 1H), 4.15 (m, 1H), 3.89 (dd, J1 = 4 Hz, J2 = 13.5 Hz, 1H), 3.46 (dd, J1 = 5 Hz, J2 = 
13.5 Hz, 1H), 2.95 (dd, J1 = 2 Hz, J2 = 12 Hz, 1H), 2.59 (dd, J1 = 10 Hz, J2 = 12.5 Hz, 1H), 2.41 (dd, J1 = 
3 Hz, J2 = 12 Hz, 1H), 2.19 (dd, J1 = 4 Hz, J2 = 12.5 Hz, 1H), 2.15 (dd, J1 = 3.5 Hz, J2 = 11.5 Hz, 1H), 
2.04 (q, J = 11.5 Hz, 1H), 1.84-1.15 (complex, 11H), 1.05 (s, 9H). 
13
C NMR (500 MHz, CDCl3) δ ppm 
173.99, 169.70, 144.43, 140.28, 135.50, 132.55, 130.16, 129.04, 128.88, 128.62, 127.88, 127.17, 126.96, 
126.42, 70.92, 70.23, 59.53, 58.93, 55.77, 51.26, 36.12, 35.55, 33.90, 31.11, 30.99, 28.44, 26.37, 26.06, 
20.45. HRMS (m/z): [M + H]
+
 calc. for C37H48N3O3S, 614.3416; observed, 614.3414. 
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(3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3R)-2-hydroxy-3-(2-nitrobenzamido)-4-
(phenylthio)butyl)decahydroisoquinoline-3-carboxamide (79) 
 This reaction was performed according to the general EDC coupling procedure (0.036 mmol 2-
nitrobenzoic acid for 16 h). Purification by flash column chromatography (gradient of 1-3% MeOH in 
DCM) yielded 79 as a white solid (15.8 mg, 80%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.96 (dd, J1 = 1 
Hz, J2 = 8 Hz, 1H), 7.92 (d, J = 9 Hz, 1H), 7.64 (td, J1 = 1 Hz, J2 = 7.5 Hz, 1H), 7.59 (dd, J1 = 1.5 Hz, J2 
= 7.5 Hz, 1H), 7.53 (m, 1H), 7.48 (dd, J1 = 1.5 Hz, J2 = 8.5 Hz, 2H), 7.30 (t, J = 7.5 Hz, 2H), 7.20 (tt, J1 = 
1.5 Hz, J2 = 7.5 Hz, 1H), 5.45 (s, 1H), 4.59 (m, 1H), 4.16 (m, 1H), 3.81 (dd, J1 = 9 Hz, J2 = 13.5 Hz, 1H), 
3.41 (dd, J1 = 10.5 Hz, J2 = 14 Hz, 1H), 2.95 (dd, J1 = 2 Hz, J2 = 12 Hz, 1H), 2.66 (dd, J1 = 9.5 Hz, J2 = 
13 Hz, 1H), 2.43 (dd, J1 = 2.5 Hz, J2 = 11.5 Hz, 1H), 2.29 (dd, J1 = 4.5 Hz, J2 = 13 Hz, 1H), 2.18 (dd, J1 = 
3.5 Hz, J2 = 11.5 Hz, 1H), 1.99 (q, J = 11.5 Hz, 1H), 1.79-1.12 (complex, 11H), 1.00 (s, 9H). 
13
C NMR 
(500 MHz, CDCl3) δ ppm 174.30, 167.86, 147.23, 135.64, 133.43, 133.23, 130.20, 129.97, 129.15, 
129.06, 126.36, 124.29, 70.62, 69.65, 59.64, 59.03, 55.13, 51.21, 36.10, 35.39, 33.90, 31.21, 30.97, 28.28, 
26.35, 26.00, 20.44. HRMS (m/z): [M + H]
+
 calc. for C31H43N4O5S, 583.2954; observed, 583.2951. 
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(3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3R)-2-hydroxy-3-(3-nitrobenzamido)-4-
(phenylthio)butyl)decahydroisoquinoline-3-carboxamide (80) 
 This reaction was performed according to the general EDC coupling procedure (0.065 mmol 3-
nitrobenzoic acid for 40 h). Purification by flash column chromatography (gradient of 1-3% MeOH in 
DCM) yielded 80 as a white solid (18.8 mg, 61%). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.72 (t, J = 2 Hz, 
1H), 8.32 (m, 1H), 8.21 (d, J = 8 Hz, 1H), 8.18 (d, 8.5 Hz, 1H), 7.58 (t, J = 8 Hz, 1H), 7.43 (dd, J1 = 1 Hz, 
J2 = 8 Hz, 2H), 7.28 (t, J = 7.5 Hz, 2H), 7.18 (t, J = 7.5 Hz, 1H), 5.41 (s, 1H), 4.56 (m, 1H), 4.18 (m, 1H), 
3.88 (dd, J1 = 9 Hz, J2 = 14 Hz, 1H), 3.63 (br s, 1H), 3.44 (dd, J1 = 5 Hz, J2 = 13.5 Hz, 1H), 2.93 (dd, J1 = 
2 Hz, J2 = 11.5 Hz, 1H), 2.54 (dd, J1 = 10 Hz, J2 = 12.5 Hz, 1H), 2.41 (dd, J1 = 2.5 Hz, J2 = 11.5 Hz, 1H), 
2.22-2.15 (m, 2H), 2.05 (q, J = 12 Hz, 1H), 1.81-1.15 (complex, 11H), 1.03 (s, 9H). 
13
C NMR (500 MHz, 
CDCl3) δ ppm 174.06, 167.38, 148.19, 135.80, 135.41, 134.03, 130.15, 129.32, 129.08, 126.51, 125.96, 
123.35, 70.80, 69.81, 59.66, 58.94, 56.27, 51.29, 36.14, 35.66, 34.01, 31.26, 30.98, 28.33, 26.38, 26.12, 
20.43. HRMS (m/z): [M + H]
+
 calc. for C31H43N4O5S, 583.2954; observed, 583.2951. 
 
 
(3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3R)-2-hydroxy-3-(4-nitrobenzamido)-4-
(phenylthio)butyl)decahydroisoquinoline-3-carboxamide (81) 
 This reaction was performed according to the general EDC coupling procedure (0.065 mmol 4-
nitrobenzoic acid for 40 h). Purification by flash column chromatography (gradient of 1-3% MeOH in 
DCM) yielded 81 as a white solid (19 mg, 53%). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.23 (dd, J1 = 2 Hz, 
J2 = 7 Hz, 2H), 8.15 (d, J = 8.5 Hz, 1H), 8.02 (dd, J1 = 2 Hz, J2 = 7 Hz, 2H), 7.43 (dd, J1 = 1.5 Hz, J2 = 8 
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Hz, 2H), 7.28 (t, J = 7.5 Hz, 2H), 7.20 (tt, J1 = 1.5 Hz, J2 = 7.5 Hz, 1H), 5.40 (s, 1H), 4.56 (m, 1H), 4.17 
(m, 1H), 3.92 (dd, J1 = 9 Hz, J2 = 13.5 Hz, 1H), 3.41 (dd, J1 = 10 Hz, J2 = 13.5 Hz, 1H), 2.93 (dd, J1 = 2 
Hz, J2 = 11.5 Hz, 1H), 2.53 (dd, J1 = 10 Hz, J2 = 12.5 Hz, 1H), 2.41 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 
2.21-2.14 (m, 2H), 2.40 (q, J = 11.5 Hz, 1H), 1.82-1.15 (complex, 11H), 1.04 (s, 9H). 
13
C NMR (500 
MHz, CDCl3) δ ppm 174.14, 167.77, 149.60, 139.65, 135.38, 130.13, 129.41, 129.09, 126.51, 123.34, 
70.80, 69.76, 59.60, 58.85, 56.39, 51.36, 36.12, 35.64, 34.00, 31.26, 30.98, 28.39, 26.38, 26.13, 20.41. 
HRMS (m/z): [M + H]
+
 calc. for C31H43N4O5S, 583.2954; observed, 583.2954. 
 
 
(3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3R)-3-(3,5-dinitrobenzamido)-2-hydroxy-4-
(phenylthio)butyl)decahydroisoquinoline-3-carboxamide (82) 
 This reaction was performed according to the general EDC coupling procedure (0.048 mmol 3,5-
dinitrobenzoic acid for 40 h). Purification by flash column chromatography (gradient of 1-3% MeOH in 
DCM) yielded 82 as a slightly yellow solid (15 mg, 52%). 
1
H NMR (400 MHz, CDCl3) δ ppm 9.13 (t, J = 
2 Hz, 1H), 9.07 (d, J = 2 Hz, 2H), 8.79 (d, J = 8.8 Hz, 1H), 7.45 (dd, J1 = 0.8 Hz, J2 = 8.4 Hz, 2H), 7.27 
(t, J = 8 Hz, 2H), 7.17 (t, J = 8 Hz, 1H), 5.36 (s, 1H), 4.61 (m, 1H), 4.24 (m, 1H), 3.86 (dd, J1 = 8.8 Hz, J2 
= 14 Hz, 1H),  3.42 (dd, J1 = 5.6 Hz, J2 = 14 Hz, 1H), 3.09 (br s, 1H), 2.93 (d, J = 10.4, 1H), 2.52 (dd, J1 
= 10 Hz, J2 = 12.8 Hz, 1H), 2.41 (dd, J1 = 2.4 Hz, J2 = 11.6 Hz, 1H), 2.23 (dd, J1 = 4 Hz, J2 = 12.8 Hz, 
1H), 2.18 (dd, J1 = 3.2 Hz, J2 = 11.6 Hz, 1H), 2.07 (q, J = 12.4 Hz, 1H), 1.81-1.14 (complex, 11H), 1.01 
(s, 9H).
 13
C NMR (500 MHz, CDCl3) δ ppm 174.14, 164.99, 148.29, 137.94, 135.24, 130.07, 129.13, 
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128.49, 126.59, 120.77, 70.72, 69.20, 59.80, 59.09, 56.93, 51.34, 36.10, 35.75, 34.05, 31.34, 30.94, 28.12, 
26.39, 26.17, 20.38. HRMS (m/z): [M + H]
+
 calc. for C31H42N5O7S, 628.2805; observed, 628.2807. 
 
 
 (3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3R)-3-(2-fluorobenzamido)-2-hydroxy-4-
(phenylthio)butyl)decahydroisoquinoline-3-carboxamide (83) 
 This reaction was performed according to the general EDC coupling procedure (0.046 mmol 2-
fluorobenzoic acid for 48 h). Purification by flash column chromatography (gradient of 1-3% MeOH in 
DCM) yielded 83 as a white solid (13.7 mg, 56%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.93 (dt, J1 = 2 
Hz, J2 = 8 Hz, 1H), 7.47-7.39 (m, 4H), 7.21 (t, J = 8 Hz, 2H), 7.19 (d, J = 1 Hz, 1H), 7.14-7.07 (m, 2H), 
5.66 (s, 1H), 4.42 (m, 1H), 4.08 (m, 1H), 3.57 (dd, J1 = 8 Hz, J2 = 14 Hz, 1H), 3.45 (dd, J1 = 5 Hz, J2 = 14 
Hz, 1H), 2.94 (dd, J1 = 2.5 Hz, J2 = 11.5 Hz, 1H), 2.62 (dd, J1 = 7.5 Hz, J2 = 13 Hz, 1H), 2.51 (dd, J1 = 3 
Hz, J2 = 11 Hz, 1H), 2.27 (dd, J1 = 5.5 Hz, J2 = 13 Hz, 1H), 2.23 (dd, J1 = 6.5 Hz, J2 = 12 Hz, 1H), 1.98 
(q, J = 13 Hz, 1H), 1.82-1.10 (complex, 20H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.62, 164.84, 
135.58, 133.32, 133.24, 131.82, 130.04, 128.95, 126.37, 124.70, 116.22, 116.02, 70.60, 70.38, 59.73, 
58.83, 54.50, 51.06, 35.98, 34.82, 33.56, 30.89, 30.81, 28.54, 26.19, 25.86, 20.59. 
19
F NMR (500 MHz, 
CDCl3) δ ppm -112.63. HRMS (m/z): [M + H]
+
 calc. for C31H43N3O3SF, 556.3009; observed, 556.3013. 
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(3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3R)-3-(3-fluorobenzamido)-2-hydroxy-4-
(phenylthio)butyl)decahydroisoquinoline-3-carboxamide (84) 
 This reaction was performed according to the general EDC coupling procedure (0.046 mmol 3-
fluorobenzoic acid for 48 h). Purification by flash column chromatography (gradient of 1-3% MeOH in 
DCM) yielded 84 as a white solid (23.4 mg, 96%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.82 (d, J = 8.5 
Hz, 1H), 7.65 (d, J = 7.5 Hz, 1H), 7.56 (m, 1H), 7.42 (d, J = 7.5 Hz, 2H), 7.37 (m, 1H), 7.27 (t, J = 7.5 
Hz, 2H), 7.18 (t, J = 7.5 Hz, 1H), 5.46 (s, 1H), 4.50 (m, 1H), 4.14 (m, 1H), 3.88 (dd, J1 = 9 Hz, J2 = 13.5 
Hz, 1H), 3.43 (dd, J1 = 5.5 Hz, J2 = 13.5 Hz, 1H), 2.94 (dd, J1 = 2 Hz, J2 = 12 Hz, 1H), 2.56 (dd, J1 = 9.5 
Hz, J2 = 12.5 Hz, 1H), 2.42 (dd, J1 = 2.5 Hz, J2 = 11.5 Hz, 1H), 2.20-2.14 (m, 2H), 2.04 (q, J = 11.5 Hz, 
1H), 1.82-1.15 (complex, 11H), 1.09 (s, 9H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.99, 168.55, 130.17, 
129.91, 129.85, 129.05, 126.47, 123.76, 118.61, 118.44, 115.33, 115.15, 70.86, 70.03, 59.59, 58.84, 
55.91, 51.33, 36.12, 35.55, 33.95, 31.16, 30.99, 28.43, 26.37, 26.07, 20.44. 
19
F NMR (500 MHz, CDCl3) 
δ ppm -112.95. HRMS (m/z): [M + H]+ calc. for C31H43N3O3SF, 556.3009; observed, 556.3013. 
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(3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3R)-3-(4-fluorobenzamido)-2-hydroxy-4-
(phenylthio)butyl)decahydroisoquinoline-3-carboxamide (85) 
 This reaction was performed according to the general EDC coupling procedure (0.053 mmol 4-
fluorobenzoic acid for 48 h). Purification by flash column chromatography (gradient of 1-3% MeOH in 
DCM) yielded 85 as a white solid (20.4 mg, 72%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.86 (dd, J1 = 5.5 
Hz, J2 = 8.5 Hz, 2H), 7.73 (d, J = 8.5 Hz, 1H) 7.42 (d, J = 8 Hz, 2H), 7.27 (t, J = 7.5 Hz, 2H), 7.18 (t, J = 
8 Hz, 1H), 7.06 (t, J = 7.5 Hz, 2H), 5.42 (s, 1H), 4.48 (m, 1H), 4.13 (m, 1H), 3.89 (dd, J1 = 9.5 Hz, J2 = 
14 Hz, 1H), 3.42 (dd, J1 = 5.5 Hz, J2 = 14 Hz, 1H), 2.94 (d, J = 12 Hz, 1H), 2.55 (dd, J1 = 10.5 Hz, J2 = 
12.5 Hz, 1H), 2.40 (dd, J1 = 2.5 Hz, J2 = 11 Hz, 1H), 2.19-2.13 (m, 2H), 2.04 (q, J = 12 Hz, 1H), 1.82-
1.16 (complex, 11H), 1.07 (s, 9H). 
13
C NMR (500 MHz, CDCl3) δ ppm 174.04, 168.96, 135.47, 130.59, 
130.52, 130.17, 129.05, 126.43, 115.31, 115.14, 70.95, 70.11, 59.53, 58.90, 56.02, 51.30, 36.13, 35.64, 
33.95, 31.14, 31.00, 28.41, 26.38, 26.10, 20.43. 
19
F NMR (500 MHz, CDCl3) δ ppm -108.75. HRMS 
(m/z): [M + H]
+
 calc. for C31H43N3O3SF, 556.3009; observed, 556.3004. 
 
 
(3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3R)-2-hydroxy-3-(isonicotinamido)-4-
(phenylthio)butyl)decahydroisoquinoline-3-carboxamide (86) 
 This reaction was performed according to the general EDC coupling procedure (0.080 mmol 
isonicotinic acid for 48 h). Purification by flash column chromatography (gradient of 1-5% MeOH in 
DCM) yielded 86 as a white solid (32 mg, 78%). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.68 (dd, J1 = 1 Hz, 
J2 = 4.5 Hz, 2H), 8.10 (d, J = 8.5 Hz, 1H), 7.71 (dd, J1 = 1 Hz, J2 = 4.5 Hz, 2H), 7.42 (d, J = 7.5 Hz, 2H), 
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7.28 (t, J = 7.5 Hz, 2H), 7.19 (t, J = 7.5 Hz, 1H), 5.51 (s, 1H), 4.55 (m, 1H), 4.17 (m, 1H), 3.87 (dd, J1 = 9 
Hz, J2 = 13.5 Hz, 1H), 3.70 (br s, 1H), 3.42 (dd, J1 = 5.5 Hz, J2 = 13.5 Hz, 1H), 2.93 (dd, J1 = 1.5 Hz, J2 = 
12 Hz, 1H), 2.54 (dd, J1 = 10 Hz, J2 = 9 Hz, 1H), 2.21-2.13 (m, 2H), 2.04 (q, J = 13 Hz, 1H), 1.82-1.15 
(complex, 11H), 1.08 (s, 9H). 
13
C NMR (500 MHz, CDCl3) δ ppm 174.11, 167.80, 150.19, 141.10, 
135.40, 130.05, 129.06, 126.46, 121.96, 70.72, 69.63, 59.53, 58.79, 55.94, 51.33, 36.07, 35.49, 33.94, 
31.19, 30.95, 28.40, 26.34, 26.06, 20.39. HRMS (m/z): [M + H]
+
 calc. for C30H43N4O3S, 539.3056; 
observed, 539.3060. 
 
 
(3S,4aS,8aS)-2-((2R,3R)-3-(3-amino-2-methylbenzamido)-2-hydroxy-4-(phenylthio)butyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (87) 
 This reaction was performed according to the general EDC coupling procedure (0.069 mmol 3-
amino-2-methylbenzoic acid for 48 h). Purification by flash column chromatography (gradient of 1-5% 
MeOH in DCM) yielded 87 as a white solid (24 mg, 65%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.43 (d, J 
= 7 Hz, 2H), 7.28 (t, J = 7.5 Hz, 2H), 7.19 (t, J = 7.5 Hz, 1H), 7.13 (d, J = 8.5 Hz, 1H), 7.01 (t, J = 7.5 
Hz, 1H), 6.92 (d, J = 7.5 Hz, 1H), 6.71 (t, J = 8 Hz, 1H), 5.55 (s, 1H), 4.45 (m, 1H), 4.05 (m, 1H), 3.75 
(dd, J1 = 9 Hz, J2 = 13.5 Hz, 1H), 3.66 (br s, 1H), 3.42 (dd, J1 = 5 Hz, J2 = 14 Hz, 1H), 2.93 (dd, J1 = 2.5 
Hz, J2 = 12 Hz, 1H), 2.57 (dd, J1 = 9 Hz, J2 = 13 Hz, 1H), 2.45 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 2.24-
2.17 (m, 3H), 1.97 (q, J = 11.5 Hz, 1H), 1.80-1.15 (complex, 11H), 1.09 (s, 9H). 
13
C NMR (500 MHz, 
CDCl3) δ ppm 173.88, 172.29, 145.26, 136.98, 135.63, 130.12, 129.01, 126.40, 120.51, 120.31, 118.13, 
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116.68, 70.65, 70.51, 59.68, 58.67, 54.49, 51.17, 36.04, 35.38, 33.70, 30.94, 30.89, 28.38, 26.26, 25.97, 
20.50, 13.88. HRMS (m/z): [M + H]
+
 calc. for C32H47N4O3S, 567.3369; observed, 567.3364. 
 
 
(3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3R)-2-hydroxy-4-(phenylthio)-3-(piperidine-2-
carboxamido)butyl)decahydroisoquinoline-3-carboxamide (88) 
 This reaction was performed according to the general EDC coupling procedure (0.061 mmol 
piperidine-2-carboxylic acid for 16 h). Purification by flash column chromatography (gradient of 3-10% 
MeOH in DCM) yielded 88 as a white solid (10.7 mg, 34%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.64 (d, 
J = 7.5 Hz, 1H), 7.39 (dd, J1 = 1 Hz, J2 = 8 Hz, 2H), 7.27 (t, J = 7.5 Hz, 2H), 7.17 (t, J = 7.5 Hz, 1H), 6.03 
(s, 1H), 4.11 (m, 1H), 3.99 (m, 1H), 3.43 (br s, 1H), 3.36 (dd, J1 = 9 Hz, J2 = 14 Hz, 1H), 3.27-3.23 (m, 
2H), 3.12 (d, J = 12.5 Hz, 1H), 2.99 (dd, J1 = 2 Hz, J2 = 12 Hz, 1H), 2.68-2.61 (m, 3H), 2.31-2.24 (m, 
2H), 2.00-1.91 (m, 4H), 1.82-1.15 (complex, 23H). 
13
C NMR (500 MHz, CDCl3) δ ppm 186.55, 173.50, 
136.25, 129.84, 129.21, 126.42, 70.57, 70.35, 60.08, 58.99, 53.94, 51.36, 45.55, 36.00, 34.09, 33.63, 
31.04, 30.92, 28.95, 26.35, 25.97, 24.91, 24.85, 23.75, 20.86, 11.06. HRMS (m/z): [M + H]
+
 calc. for 
C30H49N4O3S, 545.3525; observed, 545.3525. 
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(3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3S)-3-(2-chloro-4-nitrobenzamido)-2-hydroxy-5-
methylhexyl)decahydroisoquinoline-3-carboxamide (89) 
 A solution of 48 (527 mg, 1.05 mmol) and 10% palladium on carbon (335 mg, 0.315 mmol) in 
methanol (15 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite 
and washed with excess methanol. The reaction was then dried to a solid and redissolved in THF (10 mL). 
2-chloro-4-nitrobenzoic acid (234 mg, 1.16 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (222 mg, 1.16 mmol), and hydroxybenzotriazole hydrate (188 mg, 1.16 mmol) were added 
to the reaction and the solution was stirred at room temperature for 18 h. The reaction was taken up in 
ethyl acetate and washed once with saturated sodium bicarbonate and once with brine. The ethyl acetate 
fraction was dried over sodium sulfate, concentrated by rotary evaporation, and purified by silica flash 
column chromatography (gradient of 0-3% MeOH in DCM) to yield 89 as a yellow solid (99 mg, 17%). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.23 (d, J = 2.5 Hz, 1H), 8.12 (dd, J1 = 2 Hz, J2 = 8.5 Hz, 1H), 7.73 
(d, J = 8.5 Hz, 1H), 7.63 (d, J = 9 Hz, 1H), 5.76 (s, 1H), 4.21 (t, J = 10 Hz, 1H), 3.95 (t, J = 6 Hz, 1H), 
2.95 (d, J = 12 Hz, 1H), 2.53 (dd, J1 = 7.5 Hz, J2 = 13 Hz, 1H), 2.47 (d, J = 9 Hz, 1H), 2.24 (dd, J1 = 6 
Hz, J2 = 13 Hz, 1H), 2.19 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 2.01 (m, 1H), 1.90 (q, J = 12 Hz, 1H), 1.84-
0.85 (complex, 28H). 
13
C NMR (500 MHz, CDCl3) δ ppm 174.13, 166.02, 148.44, 141.76, 132.56, 
130.42, 125.09, 121.66, 71.78, 70.28, 59.34, 59.12, 53.66, 51.03, 39.52, 35.91, 33.60, 30.94, 30.75, 28.45, 
26.15, 26.04, 25.24, 23.53, 21.55, 20.51. HRMS (m/z): [M + H]
+
 calc. for C28H44N4O5Cl, 551.3000; 
observed, 351.3005. 
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(3S,4aS,8aS)-N-(tert-butyl)-2-((S)-3-(2-chloro-4-nitrobenzamido)-2-
hydroxypropyl)decahydroisoquinoline-3-carboxamide (90) 
 A solution of 34 (104 mg, 0.233 mmol) and 10% palladium on carbon (74 mg, 0.070 mmol) in 
methanol (15 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite 
and washed with excess methanol. The reaction was then dried to a solid and redissolved in THF (5 mL). 
2-chloro-4-nitrobenzoic acid (52 mg, 0.256 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (49 mg, 0.256 mmol), and hydroxybenzotriazole hydrate (42 mg, 0.256 mmol) were added 
to the reaction and the solution was stirred at room temperature for 18 h. The reaction was taken up in 
ethyl acetate and washed once with saturated sodium bicarbonate and once with brine. The ethyl acetate 
fraction was dried over sodium sulfate, concentrated by rotary evaporation, and purified by silica flash 
column chromatography (gradient of 0-3% MeOH in DCM) to yield 90 as a yellow solid (77 mg, 67%). 
Crystals were grown for x-ray crystallography from an ethyl acetate/pentane solution. 
1
H NMR (500 
MHz, CDCl3) δ ppm 8.41 (q, J = 4 Hz, 1H), 8.24 (d, J = 2 Hz, 1H), 8.13 (dd, J1 = 2 Hz, J2 = 8.5 Hz, 1H), 
7.76 (d, J = 8.5 Hz, 1H), 5.60 (s, 1H), 4.04 (m, 2H), 3.47 (dt, J1 = 4 Hz, J2 = 14 Hz, 1H), 3.35 (br, 1H), 
2.71 (dd, J1 = 2 Hz, J2 = 11.5 Hz, 1H), 2.49 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 2.36 (dd, J1 = 10 Hz, J2 = 
12.5 Hz, 1H), 2.22 (dd, J1 = 5 Hz, J2 = 12.5 Hz, 1H), 2.18 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 1.95 (q, J = 
12 Hz, 1H), 1.80-1.08 (complex, 20H). 
13
C NMR (500 MHz, CDCl3) δ ppm 174.16, 167.06, 148.39, 
142.00, 132.80, 130.18, 124.96, 121.56, 70.40, 68.29, 59.09, 57.54, 51.27, 43.27, 35.83, 33.55, 31.02, 
30.86, 28.39, 26.19, 25.52, 20.18. HRMS (m/z): [M + H]
+
 calc. for C24H36N4O5Cl, 495.2374; observed, 
495.2376. 
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(3S,4aS,8aS)-N-(tert-butyl)-2-((2S,3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-
(phenylthio)butyl)decahydroisoquinoline-3-carboxamide (91) 
 To a solution of 63 (25 mg, 0.058 mmol) in THF (3 mL) was added 3-hydroxy-2-methylbenzoic 
acid (10 mg, 0.063 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (12 mg, 0.063 
mmol), and hydroxybenzotriazole hydrate (10 mg, 0.063 mmol). The solution was stirred at room 
temperature for 20 h. The reaction was taken up in ethyl acetate and washed once with water, once with 
saturated sodium bicarbonate, and once with brine. The ethyl acetate fraction was dried over sodium 
sulfate, concentrated by rotary evaporation, and purified by silica flash column chromatography (gradient 
of 0-4% MeOH in DCM) to yield 91 as a white solid (22 mg, 67%). 
1
H NMR (500 MHz, CDCl3) δ ppm 
7.48 (d, J = 7.5 Hz, 2H), 7.29 (t, J = 7.5 Hz, 2H), 7.16 (t, J = 7.5 Hz, 1H), 7.13 (br s, 1H), 6.86 (m, 3H), 
6.43 (d, J = 9 Hz, 1H), 5.73 (s, 1H), 4.16 (d, J = 10 Hz, 1H), 4.03 (q, J = 8 Hz, 1H), 3.37 (dd, J1 = 6 Hz, 
J2 = 13.5 Hz, 1H), 3.20 (dd, J1 = 8.5 Hz, J2 = 13.5 Hz, 1H), 2.85 (d, J = 10 Hz, 1H), 2.63 (dd, J1 = 3 Hz, 
J2 = 11 Hz, 1H), 2.54 (dd, J1 = 11 Hz, J2 = 12.5 Hz, 1H), 2.22 (s, 3H), 2.20 (dd, J1 = 3 Hz, J2 = 12.5 Hz, 
1H), 2.07 (dd, J1 = 2.5 Hz, J2 = 12.5 Hz, 1H), 1.99 (q, J = 12.5 Hz, 1H), 1.88-1.18 (complex, 21H). 
13
C 
NMR (500 MHz, CDCl3) δ ppm173.65, 170.34, 154.87, 137.56, 135.92, 129.04, 128.82, 126.35, 125.99, 
122.24, 118.61, 116.64, 69.49, 66.15, 58.58, 58.04, 51.25, 50.93, 35.81, 35.43, 33.45, 31.14, 30.94, 28.61, 
26.24, 25.32, 20.24, 12.50. HRMS (m/z): [M + H]
+
 calc. for C32H45N3O4S, 568.3209; observed, 568.3212. 
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Benzyl ((S)-1-((R)-oxiran-2-yl)-2-phenylethyl)carbamate (92) 
 To a solution of 52 (115 mg, 0.35 mmol) in ethanol (5 mL) at 0 °C was added solid potassium 
hydroxide (21 mg, 0.38 mmol). The reaction was stirred cold for 15 min then warmed to room 
temperature and stirred for an additional 3 h. The reaction was evaporated to dryness and the solid was 
purified by silica flash column chromatography (gradient of 0-2.5% EtOAc in DCM) to yield 92 as a 
white solid (88 mg, 86%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.36-7.22 (complex, 10H), 5.05 (s, 2H), 
4.82 (d, J = 13.5 Hz, 1H), 4.18 (dd, J1 = 6.5 Hz, J2 = 14.5 Hz, 1H), 3.02-2.96 (m, 2H), 2.90 (dd, J1 = 8 Hz, 
J2 = 13.5 Hz, 1H), 2.67 (t, J = 4.5 Hz, 1H), 2.55 (br s, 1H). 
13
C NMR (500 MHz, CDCl3) δ ppm 155.91, 
136.97, 136.29, 129.31, 128.52, 128.46, 128.07, 127.89, 126.67, 66.69, 52.38, 51.00, 44.45, 39.60. 
HRMS (m/z): [M + H]
+
 calc. for C18H20NO3, 298.1443; observed, 298.1437. 
 
 
Benzyl ((2S,3S)-4-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-3-hydroxy-
1-phenylbutan-2-yl)carbamate (93) 
 To a solution of 92 (70 mg, 0.235 mmol) in isopropyl alcohol (7 mL) was added (3S,4aS,8aS)-N-
(tert-butyl)decahydroisoquinoline-3-carboxamide (6, 67 mg, 0.283 mmol). The solution was heated to 
reflux and stirred. After 5 h, the reaction was cooled and dried to a solid. The product was purified by 
silica flash column chromatography (gradient of 0-4% MeOH in DCM) to yield 93 as a white solid (110 
mg, 87%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.34-7.19 (complex, 10H), 5.80 (s, 1H), 5.28 (s, 1H), 5.19 
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(d, J = 9.5 Hz, 1H), 5.07 (d, J = 12.5 Hz, 1H), 4.90 (d, J = 12.5 Hz, 1H), 3.70 (m, 3H), 2.94 (m, 2H), 2.69 
(dd, J1 = 2 Hz, J2 = 11.5 Hz, 1H), 2.61 (m, 2H), 2.13 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 1.93 (m, 2H), 1.75 
(m, 3H), 1.58-1.18 (complex, 16H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.01, 156.12, 138.11, 136.43, 
129.36, 128.33, 127.86, 127.80, 126.28, 69.68, 66.42, 66.13, 58.49, 58.02, 54.17, 50.86, 39.36, 35.70, 
33.21, 30.82, 28.55, 26.21, 25.38, 20.19. HRMS (m/z): [M + H]
+
 calc. for C32H46N3O4, 536.3488; 
observed, 536.3485. 
 
 
(3S,4aS,8aS)-N-(tert-butyl)-2-((2S,3S)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-
phenylbutyl)decahydroisoquinoline-3-carboxamide (94) 
 A solution of 93 (51 mg, 0.095 mmol) and 10% palladium on carbon (30 mg, 0.029 mmol) in 
methanol (10 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite 
and washed with excess methanol. The reaction was then dried to a solid and redissolved in THF (5 mL). 
3-hydroxy-2-methylbenzoic acid (16 mg, 0.105 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (20 mg, 0.105 mmol), and hydroxybenzotriazole hydrate (17 mg, 0.105 mmol) were added 
to the reaction and the solution was stirred at room temperature for 18 h. The reaction was taken up in 
ethyl acetate and washed once with saturated sodium bicarbonate and once with brine. The ethyl acetate 
fraction was dried over sodium sulfate, concentrated by rotary evaporation, and purified by silica flash 
column chromatography (gradient of 0-4% MeOH in DCM) to yield 94 as a white solid (27 mg, 53%). 
1
H 
NMR (500 MHz, CDCl3) δ ppm 7.31-7.19 (complex, 8H), 6.84 (dd, J1 = 6 Hz, J2 = 7.5 Hz, 2H), 6.69 (dd, 
J1 = 2 Hz, J2 = 7.5 Hz, 1H), 6.28 (d, J = 9 Hz, 1H), 5.82 (s, 1H), 4.21 (q, J = 8 Hz, 1H), 3.82 (d, J = 10.5 
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Hz, 1H), 3.04 (m, 2H), 2.75 (d, J = 10 Hz, 1H), 2.62 (dd, J1 = 3 Hz, J2 = 11 Hz, 1H), 2.55 (dd, J1 = 11 Hz, 
J2 = 12 Hz, 1H), 2.15 (dd, J1 = 3 Hz, J2 = 11 Hz, 1H), 2.09 (dd, J1 = 2.5 Hz, J2 = 12.5 Hz, 1H), 2.00 (s, 
3H), 1.97 (m, 1H), 1.85 (m, 1H), 1.73 (m, 2H), 1.60-1.19 (complex, 16H).
 13
C NMR (500 MHz, CDCl3) δ 
ppm 173.78, 170.22, 154.90, 138.14, 137.80, 129.41, 128.41, 126.41, 126.23, 122.34, 118.41, 116.59, 
69.33, 67.47, 59.01, 58.14, 52.69, 51.19, 38.76, 35.80, 33.42, 31.17, 30.92, 28.62, 26.23, 25.32, 20.23, 
12.26. HRMS (m/z): [M + H]
+
 calc. for C32H46N3O4, 536.3488; observed, 536.3476. 
 
 
(3S,4aS,8aS)-2-((2S,3S)-3-(2-naphthamido)-2-hydroxy-4-phenylbutyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (95) 
 A solution of 93 (46 mg, 0.086 mmol) and 10% palladium on carbon (27 mg, 0.026 mmol) in 
methanol (15 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite 
and washed with excess methanol. The reaction was then dried to a solid and redissolved in THF (5 mL). 
2-naphthoic acid (16 mg, 0.095 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(18 mg, 0.095 mmol), and hydroxybenzotriazole hydrate (15 mg, 0.095 mmol) were added to the reaction 
and the solution was stirred at room temperature for 18 h. The reaction was taken up in ethyl acetate and 
washed once with saturated sodium bicarbonate and once with brine. The ethyl acetate fraction was dried 
over sodium sulfate, concentrated by rotary evaporation, and purified by silica flash column 
chromatography (gradient of 0-3% MeOH in DCM) to yield 95 as a white solid (37 mg, 77%). 
1
H NMR 
(500 MHz, CDCl3) δ ppm 8.23 (s, 1H), 7.89 (d, 7.5 Hz, 1H), 7.83 (m, 3H), 7.53 (m, 2H), 7.34 (d, J = 7 
Hz, 2H), 7.28 (t, J = 7.5 Hz, 2H), 7.19 (t, J = 7.5 Hz, 1H), 6.91 (d, J = 8.5 Hz, 1H), 5.56 (s, 1H), 4.34 (br 
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s, 1H), 4.24 (q, J = 8 Hz, 1H), 3.84 (d, J = 9 Hz, 1H), 3.14 (dd, J1 = 7 Hz, J2 = 13.5 Hz, 1H), 3.08 (dd, J1 
= 8 Hz, J2 = 14 Hz, 1H), 2.71 (d, J = 10.5 Hz, 1H), 2.58 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 2.53 (dd, J1 = 
11 Hz, J2 = 12.5 Hz, 1H), 2.15 (dd, J1 = 3 Hz, J2 = 11 Hz, 1H), 2.06 (dd, J1 = 2.5 Hz, J2 = 13 Hz, 1H), 
1.98 (q, J = 12 Hz, 1H), 1.85 (qd, J1 = 3 Hz, J2 = 13 Hz, 1H), 1.73 (m, 2H), 1.59-0.94 (complex, 17H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.12, 166.96, 138.33, 134.69, 132.54, 131.43, 129.43, 128.93, 
128.37, 128.21, 127.59, 127.45, 127.40, 126.51, 126.33, 123.69, 69.31, 66.67, 58.74, 58.11, 52.91, 50.90, 
39.08, 35.82, 33.38, 31.04, 30.93, 28.38, 26.23, 25.35, 20.19. HRMS (m/z): [M + H]
+
 calc. for 
C35H46N3O3, 556.3539; observed, 556.3538. 
 
 
(R)-benzyl (4-diazo-3-oxo-1-phenylbutan-2-yl)carbamate (96) 
 To a stirred solution of Z-D-phenylalanine (1.11 g, 3.70 mmol) in anhydrous tetrahydrofuran (12 
mL) under nitrogen at -78 °C was added anhydrous triethylamine (768 μL, 5.54 mmol) followed by 
isobutyl chloroformate (721 μL, 5.54 mmol). The reaction was stirred cold for 1 h and then warmed to 
room temperature for 1.5 h. The reaction was cooled to -78 °C before an ethereal solution of 
diazomethane (25 mL, 8.1 mmol) was added in one portion and the reaction was then warmed to room 
temperature with stirring for 1 h. The reaction was evaporated to dryness, resulting in a yellow solid. The 
solid was taken up in ethyl acetate, washed twice with water, twice with a saturated solution of sodium 
bicarbonate, and once with brine. The organic phase was dried over sodium sulfate and concentrated by 
rotary evaporation. The product was purified by silica flash column chromatography (gradient of 0-6% 
EtOAc in CHCl3) to yield 96 as a yellow solid (826 mg, 77%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.32-
7.18 (complex, 8H), 7.14 (d, J = 7 Hz, 2H), 5.70 (d, J = 7.5 Hz, 1H), 5.23 (s, 1H), 5.03 (dd, J1 = 12.5 Hz, 
J2 = 19 Hz, 2H), 4.47 (d, J = 5.5 Hz, 1H), 3.04 (dd, J1 = 7 Hz, J2 = 14 Hz, 1H), 2.95 (dd, J1 = 7 Hz, J2 = 
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14 Hz, 1H). 
13
C NMR (500 MHz, CDCl3) δ ppm 192.79, 155.61, 136.03, 129.09, 128.41, 128.29, 127.94, 
127.76, 126.78, 66.70, 58.74, 54.27, 38.03. HRMS (m/z): [M + H]
+
 calc. for C18H18N3O3, 324.1348; 
observed, 324.1354. 
 
 
(R)-benzyl (4-chloro-3-oxo-1-phenylbutan-2-yl)carbamate (97) 
 To a solution of 96 (826 mg, 2.86 mmol) in anhydrous tetrahydrofuran (8 mL) under nitrogen at 0 
°C was added 1 M HCl in diethyl ether (4.28 mL, 4.28 mmol) dropwise. The reaction was stirred at 0 °C 
for 30 min after complete addition. The solution was dried under reduced pressure to yield 97 as an off-
white solid (843 mg). No further purification was made. 
1
H NMR (500 MHz, CDCl3) δ ppm 7.34-7.21 
(complex, 8H), 7.11 (d, J = 7 Hz, 2H), 5.53 (d, J = 7.5 Hz, 1H), 5.03 (dd, J1 = 12 Hz, J2 = 17.5 Hz, 2H), 
4.72 (q, J = 7.5 Hz, 1H), 4.14 (d, J = 16.5 Hz, 1H), 3.97 (d, J = 16 Hz, 1H), 3.07 (dd, J1 = 6.5 Hz, J2 = 14 
Hz, 1H), 2.95 (dd, J1 = 7.5 Hz, J2 = 14 Hz, 1H). 
13
C NMR (500 MHz, CDCl3) δ ppm 200.90, 155.70, 
135.81, 135.26, 128.97, 128.76, 128.41, 128.15, 127.91, 127.22, 67.04, 58.65, 47.33, 37.31. HRMS (m/z): 
[M + H]
+
 calc. for C18H19NO3Cl, 332.1053; observed, 332.1060. 
 
 
Benzyl ((2R,3R)-4-chloro-3-hydroxy-1-phenylbutan-2-yl)carbamate (98) and benzyl ((2R,3S)-4-
chloro-3-hydroxy-1-phenylbutan-2-yl)carbamate (99) 
 To a solution of 97 (843 mg, 2.54 mmol) in dichloromethane (7 mL) and methanol (4 mL) under 
nitrogen at 0 °C was added sodium borohydride (67 mg, 1.78 mmol). The reaction was stirred at 0 °C for 
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1 h, and then quenched with slow addition of 2 M HCl (2 mL). The reaction was evaporated to dryness 
and the solid was taken up in ethyl acetate. The solution was washed twice with water followed by brine, 
dried over sodium sulfate, and concentrated by rotary evaporation. TLC analysis showed two 
diastereomers with the lower Rf compound being the (R,R)-isomer. The (R,R)-isomer was recrystallized 
in hexanes/ethyl acetate. The crystals were collected and washed with cold hexanes. The filtrate was 
collected and dried to a solid. Both diastereomers were then separated further by silica flash column 
chromatography (gradient of 0-6% EtOAc in DCM) to yield (R,R)-isomer (98) as a white solid (592 mg, 
70%) and (S,R)-isomer (99) as a white solid (124 mg, 15%) over two steps. Characterization of the (R,R)-
isomer (98): 
1
H NMR (500 MHz, CDCl3) δ ppm 7.37-7.21 (complex, 8H), 7.19 (d, J = 7 Hz, 2H), 5.04 (s, 
2H), 4.83 (d, J = 8.5 Hz, 1H), 3.99 (m, 1H), 3.85 (br s, 1H), 3.66 (dd, J1 = 4 Hz, J2 = 11.5 Hz, 1H), 3.58 
(dd, J1 = 7.5 Hz, J2 = 11.5 Hz, 1H), 2.96 (m, 3H). 
13
C NMR (500 MHz, CDCl3) δ ppm 156.24, 136.98, 
136.15, 129.42, 128.63, 128.53, 128.20, 127.98, 126.75, 73.19, 66.93, 54.65, 47.61, 35.62. HRMS (m/z): 
[M + H]
+
 calc. for C18H21NO3Cl, 334.1210; observed, 334.1217. Characterization of the (R,S)-isomer 
(99): 
1
H NMR (500 MHz, CDCl3) δ ppm 7.36-7.19 (complex, 10H), 5.26 (d, J = 9 Hz, 1H), 5.06 (dd, J1 = 
12.5 Hz, J2 = 14.5 Hz, 2H), 3.95 (q, J = 8 Hz, 1H), 3.74 (m, 1H), 3.50 (d, J = 6.5 Hz, 2H), 3.11 (d, J = 3.5 
Hz, 1H), 2.96 (dd, J1 = 7 Hz, J2 = 13.5 Hz, 1H), 2.90 (dd, J1 = 8 Hz, J2 = 13.5 Hz, 1H). 
13
C NMR (500 
MHz, CDCl3) δ ppm 156.51, 137.46, 136.18, 129.23, 128.59, 128.51, 128.16, 127.97, 126.65, 71.20, 
66.94, 54.29, 47.64, 38.47. HRMS (m/z): [M + H]
+
 calc. for C18H21NO3Cl, 334.1210; observed, 334.1208. 
 
 
Benzyl ((R)-1-((S)-oxiran-2-yl)-2-phenylethyl)carbamate (100) 
 To a solution of 99 (124 mg, 0.371 mmol) in ethanol (10 mL) at 0 °C was added solid potassium 
hydroxide (23 mg, 0.409 mmol). The reaction was stirred cold for 15 min then warmed to room 
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temperature and stirred for an additional 3 h. The reaction was evaporated to dryness and the solid was 
purified by silica flash column chromatography (gradient of 0-3% EtOAc in DCM) to yield 100 as a 
white solid (93 mg, 84%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.35-7.21 (complex, 10H), 5.05 (s, 2H), 
4.84 (d, J = 9 Hz, 1H), 4.17 (q, J = 7.5 Hz, 1H), 2.98 (m, 2H), 2.89 (dd, J1 = 7.5 Hz, J2 = 13 Hz, 1H), 2.66 
(t, J = 4.5 Hz, 1H), 2.54 (s, 1H).
 13
C NMR (500 MHz, CDCl3) δ ppm 155.90, 136.97, 136.28, 129.28, 
128.49, 128.43, 128.04, 127.86, 126.65, 66.66, 52.38, 51.01, 44.43, 39.56. HRMS (m/z): [M + H]
+
 calc. 
for C18H20NO3, 298.1443; observed, 298.1447. 
 
 
Benzyl ((2R,3R)-4-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-3-hydroxy-
1-phenylbutan-2-yl)carbamate (101) 
 To a solution of 100 (93 mg, 0.313 mmol) in isopropyl alcohol (7 mL) was added (3S,4aS,8aS)-
N-(tert-butyl)decahydroisoquinoline-3-carboxamide (6, 90 mg, 0.375 mmol). The solution was heated to 
reflux and stirred. After 5 h, the reaction was cooled and dried to a solid. The product was purified by 
silica flash column chromatography (gradient of 0-4% MeOH in DCM) to yield 101 as a white solid (140 
mg, 83%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.35-7.15 (complex, 10H), 5.93 (s, 1H), 5.69 (d, J = 9 Hz, 
1H), 5.08 (d, J = 12.5 Hz, 1H), 5.01 (d, J = 12 Hz, 1H), 3.90 (s, 1H), 3.75 (m, 2H), 3.01 (dd, J1 = 6 Hz, J2 
= 13 Hz, 1H), 2.92 (dd, J1 = 9 Hz, J2 = 13 Hz, 1H), 2.53 (m, 3H), 2.17 (dd, J1 = 7 Hz, J2 = 13 Hz, 1H), 
2.10 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 1.82 (q, J = 11.5 Hz, 1H), 1.68 (m, 3H), 1.50-1.16 (complex, 17H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.59, 156.69, 138.38, 136.41, 129.36, 128.35, 127.91, 127.88, 
126.21, 70.22, 67.81, 66.48, 59.30, 58.87, 54.57, 50.67, 38.00, 35.58, 33.01, 30.61, 30.50, 28.42, 25.94, 
25.52, 25.24, 20.51. HRMS (m/z): [M + H]
+
 calc. for C32H46N3O4, 536.3488; observed, 536.3489. 
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(3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-
phenylbutyl)decahydroisoquinoline-3-carboxamide (102) 
 A solution of 101 (45 mg, 0.084 mmol) and 10% palladium on carbon (27 mg, 0.025 mmol) in 
methanol (8 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite 
and washed with excess methanol. The reaction was then dried to a solid and redissolved in THF (3 mL). 
3-hydroxy-2-methylbenzoic acid (14 mg, 0.092 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (18 mg, 0.092 mmol), and hydroxybenzotriazole hydrate (15 mg, 0.092 mmol) were added 
to the reaction and the solution was stirred at room temperature for 18 h. The reaction was taken up in 
ethyl acetate and washed once with saturated sodium bicarbonate and once with brine. The ethyl acetate 
fraction was dried over sodium sulfate, concentrated by rotary evaporation, and purified by silica flash 
column chromatography (gradient of 0-4% MeOH in DCM) to yield 102 as a white solid (30 mg, 67%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.31-7.18 (complex, 5H), 6.94 (t, J = 7.5 Hz, 1H), 6.79 (m, 2H), 6.71 
(d, J = 7 Hz, 1H), 5.85 (s, 1H), 4.18 (q, J = 8 Hz, 1H), 3.82 (t, J = 7 Hz, 1H), 3.20 (dd, J1 = 8 Hz, J2 = 14 
Hz, 1H), 3.09 (dd, J1 = 8 Hz, J2 = 14 Hz, 1H), 2.70 (dd, J1 = 2 Hz, J2 = 11.5 Hz, 1H), 2.57 (dd, J1 = 3 Hz, 
J2 = 11 Hz, 1H), 2.45 (dd, J1 = 6.5 Hz, J2 = 13.5 Hz, 1H), 2.28 (m, 2H), 2.09 (s, 3H), 1.92 (q, J = 11.5 Hz, 
1H), 1.80 (qd, J1 = 3 Hz, J2 = 13 Hz, 1H), 1.68 (m, 2H), 1.57-1.14 (complex, 19H). 
13
C NMR (500 MHz, 
CDCl3) δ ppm 173.66, 171.38, 154.71, 138.41, 137.87, 129.38, 128.52, 126.43, 126.37, 122.27, 118.85, 
116.61, 70.21, 69.43, 60.40, 59.35, 54.25, 51.11, 37.48, 35.91, 33.20, 30.73, 30.65, 28.47, 26.08, 25.57, 
20.52, 12.41. HRMS (m/z): [M + H]
+
 calc. for C32H46N3O4, 536.3488; observed, 536.3486. 
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(3S,4aS,8aS)-2-((2R,3R)-3-(2-naphthamido)-2-hydroxy-4-phenylbutyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (103) 
 A solution of 102 (50 mg, 0.093 mmol) and 10% palladium on carbon (30 mg, 0.028 mmol) in 
methanol (8 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite 
and washed with excess methanol. The reaction was then dried to a solid and redissolved in THF (3 mL). 
2-naphthoic acid (18 mg, 0.102 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(20 mg, 0.102 mmol), and hydroxybenzotriazole hydrate (17 mg, 0.102 mmol) were added to the reaction 
and the solution was stirred at room temperature for 18 h. The reaction was taken up in ethyl acetate and 
washed once with saturated sodium bicarbonate and once with brine. The ethyl acetate fraction was dried 
over sodium sulfate, concentrated by rotary evaporation, and purified by silica flash column 
chromatography (gradient of 0-3% MeOH in DCM) to yield 103 as a white solid (41 mg, 79%). 
1
H NMR 
(500 MHz, CDCl3) δ ppm 8.36 (s, 1H), 7.88 (dd, J1 = 1.5 Hz, J2 = 8.5 Hz, 2H), 7.83 (m, 3H), 7.51 (m, 
2H), 7.34 (d, J = 7.5 Hz, 2H), 7.24 (t, J = 7.5 Hz, 2H), 7.15 (t, J = 7.5 Hz, 1H), 5.90 (br s, 1H), 4.31 (q, J 
= 8 Hz, 1H), 3.95 (t, J = 6 Hz, 1H), 3.28 (dd, J1 = 8 Hz, J2 = 13.5 Hz, 1H), 3.22 (dd, J1 = 7.5 Hz, J2 = 13.5 
Hz, 1H), 2.76 (d, J = 9.5 Hz, 1H), 2.61 (m, 2H), 2.27 (dd, J1 = 6 Hz, J2 = 12.5 Hz, 1H), 2.19 (dd, J1 = 3 
Hz, J2 = 11.5 Hz, 1H), 1.97 (q, J = 12 Hz, 1H), 1.69-1.00 (complex, 20H). 
13
C NMR (500 MHz, CDCl3) δ 
ppm 172.97, 168.67, 138.99, 134.76, 132.57, 131.62, 129.43, 128.99, 128.41, 128.10, 128.08, 127.57, 
127.47, 126.44, 126.24, 124.18, 70.71, 68.87, 59.99, 58.87, 55.45, 51.09, 36.27, 35.77, 33.40, 30.72, 
28.34, 26.04, 25.38, 20.22. HRMS (m/z): [M + H]
+
 calc. for C35H46N3O3, 556.3539; observed, 556.3546. 
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Benzyl ((R)-1-((R)-oxiran-2-yl)-2-phenylethyl)carbamate (104) 
 To a solution of 98 (592 mg, 1.77 mmol) in ethanol (20 mL) and dichloromethane (5 mL) at 0 °C 
was added solid potassium hydroxide (109 mg, 1.95 mmol). The reaction was stirred cold for 15 min then 
warmed to room temperature and stirred for an additional 3 h. The reaction was evaporated to dryness and 
the solid was purified by silica flash column chromatography (gradient of 0-5% EtOAc in DCM) to yield 
104 as a white solid (483 mg, 92%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.34-7.7.21 (complex, 8H), 7.18 
(d, J = 7 Hz, 2H), 5.02 (s, 2H), 4.82 (d, J = 7 Hz, 1H), 3.76 (br s, 1H), 2.97 (dd, J1 = 4.5 Hz, J2 = 14 Hz, 
1H), 2.92-2.83 (complex, 2H), 2.76 (s, 2H). 
13
C NMR (500 MHz, CDCl3) δ ppm 155.76, 136.35, 129.30, 
128.55, 128.43, 128.08, 127.94, 126.73, 66.69, 53.00, 46.70, 37.39. HRMS (m/z): [M + H]
+
 calc. for 
C18H20NO3, 298.1443; observed, 298.1448. 
 
 
Benzyl ((2R,3S)-4-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-3-hydroxy-
1-phenylbutan-2-yl)carbamate (105) 
 To a solution of 104 (483 mg, 1.62 mmol) in isopropyl alcohol (15 mL) was added (3S,4aS,8aS)-
N-(tert-butyl)decahydroisoquinoline-3-carboxamide (6, 465 mg, 1.95 mmol). The solution was heated to 
reflux and stirred. After 5 h, the reaction was cooled and dried to a solid. The product was purified by 
silica flash column chromatography (gradient of 0-4% MeOH in DCM) to yield 105 as a white solid (799 
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mg, 92%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.29-7.08 (complex, 10H), 6.90 (s, 1H), 5.88 (d, J = 8 Hz, 
1H), 4.99 (d, J = 12.4 Hz, 1H), 4.86 (d, J = 12.4 Hz, 1H), 4.39 (s, 1H), 3.87 (d, J = 6.4 Hz, 2H), 2.70 (m, 
5H), 2.05 (d, J = 11.6 Hz, 2H), 1.90-1.15 (complex, 21H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.83, 
156.10, 137.90, 136.26, 128.90, 127.97, 127.48, 127.40, 125.91, 69.50, 69.13, 65.95, 58.69, 57.91, 55.53, 
50.39, 35.38, 34.06, 32.89, 30.72, 30.55, 28.26, 28.17, 25.97, 25.02, 19.89. HRMS (m/z): [M + H]
+
 calc. 
for C32H46N3O4, 536.3488; observed, 536.3480. 
 
 
(3S,4aS,8aS)-N-(tert-butyl)-2-((2S,3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-
phenylbutyl)decahydroisoquinoline-3-carboxamide (106) 
 A solution of 105 (127 mg, 0.24 mmol) and 10% palladium on carbon (76 mg, 0.071 mmol) in 
methanol (15 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite 
and washed with excess methanol. The reaction was then dried to a solid and redissolved in THF (5 mL). 
3-hydroxy-2-methylbenzoic acid (40 mg, 0.264 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (51 mg, 0.264 mmol), and hydroxybenzotriazole hydrate (43 mg, 0.264 mmol) were added 
to the reaction and the solution was stirred at room temperature for 18 h. The reaction was taken up in 
ethyl acetate and washed once with saturated sodium bicarbonate and once with brine. The ethyl acetate 
fraction was dried over sodium sulfate, concentrated by rotary evaporation, and purified by silica flash 
column chromatography (gradient of 0-4% MeOH in DCM) to yield 106 as a white solid (83 mg, 65%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.26 (t, J = 8.5 Hz, 2H), 7.20 (d, J = 7 Hz, 2H), 6.82 (t, J = 8 Hz, 1H), 
6.75 (t, J = 7.5 Hz, 1H), 6.46 (s, 1H), 6.43 (d, J = 7.5 Hz, 1H), 6.19 (d, J = 9 Hz, 1H), 4.31 (m, 1H), 3.89 
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(d, J = 10 Hz, 1H), 2.93 (dd, J1 = 4.5 Hz, J2 = 14.5 Hz, 1H), 2.82 (m, 2H), 2.60 (dd, J1 = 2.5 Hz, J2 = 11 
Hz, 1H), 2.55 (t, J = 11 Hz, 1H), 2.13 (d, J = 12 Hz, 2H), 1.95-1.19 (complex, 26H). 
13
C NMR (500 MHz, 
CDCl3) δ ppm 174.10, 170.69, 155.07, 137.73, 137.60, 129.17, 128.49, 126.55, 126.17, 122.34, 117.96, 
116.46, 70.05, 69.42, 58.64, 58.21, 53.94, 51.12, 35.78, 34.86, 33.19, 30.91, 30.85, 28.60, 26.26, 25.34, 
20.20, 12.19. HRMS (m/z): [M + H]
+
 calc. for C32H46N3O4, 536.3488; observed, 536.3491. 
 
 
(3S,4aS,8aS)-2-((2S,3R)-3-(2-naphthamido)-2-hydroxy-4-phenylbutyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (107) 
 A solution of 105 (135 mg, 0.25 mmol) and 10% palladium on carbon (80 mg, 0.076 mmol) in 
methanol (15 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite 
and washed with excess methanol. The reaction was then dried to a solid and redissolved in THF (5 mL). 
2-naphthoic acid (47 mg, 0.275 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(53 mg, 0.275 mmol), and hydroxybenzotriazole hydrate (45 mg, 0.275 mmol) were added to the reaction 
and the solution was stirred at room temperature for 18 h. The reaction was taken up in ethyl acetate and 
washed once with saturated sodium bicarbonate and once with brine. The ethyl acetate fraction was dried 
over sodium sulfate, concentrated by rotary evaporation, and purified by silica flash column 
chromatography (gradient of 0-3% MeOH in DCM) to yield 107 as a white solid (102 mg, 73%). 
1
H 
NMR (500 MHz, CDCl3) δ ppm 8.05 (s, 1H), 7.78 (m, 3H), 7.64 (dd, J1 = 1 Hz, J2 = 8 Hz, 1H), 7.50 (m, 
2H), 7.27 (m, 4H), 7.20 (m, 1H), 6.79 (d, J = 8 Hz, 1H), 6.49 (s, 1H), 4.40 (m, 2H), 3.96 (d, J = 10 Hz, 
1H), 3.02 (dd, J1 = 9.5 Hz, J2 = 14 Hz, 1H), 2.96 (dd, J1 = 5 Hz, J2 = 14 Hz, 1H), 2.82 (d, J = 10.5 Hz, 
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1H), 2.66 (dd, J1 = 10.5 Hz, J2 = 12.5 Hz, 1H), 2.61 (dd, J1 = 3 Hz, J2 = 11 Hz, 1H), 2.16 (d, J = 11.5 Hz, 
1H), 2.10 (dd, J1 = 3 Hz, J2 = 12 Hz, 1H), 1.89 (q, J = 12 Hz, 1H), 1.78-1.12 (complex, 20H). 
13
C NMR 
(500 MHz, CDCl3) δ ppm 173.73, 168.14, 137.85, 134.63, 132.40, 131.39, 129.15, 128.82, 128.56, 
128.26, 127.61, 127.57, 127.52, 126.60, 123.53, 69.82, 58.63, 58.48, 54.98, 50.79, 35.82, 35.34, 33.24, 
31.06, 30.83, 28.59, 26.20, 25.38, 20.13. HRMS (m/z): [M + H]
+
 calc. for C35H46N3O3, 556.3539; 
observed, 556.3547. 
 
 
(R)-benzyl (1-diazo-5-methyl-2-oxohexan-3-yl)carbamate (108) 
 To a stirred solution of Z-D-leucine (923 mg, 3.48 mmol) in anhydrous tetrahydrofuran (12 mL) 
under nitrogen at -78 °C was added anhydrous triethylamine (723 μL, 5.22 mmol) followed by isobutyl 
chloroformate (679 μL, 5.22 mmol). The reaction was stirred cold for 1 h and then warmed to room 
temperature for 1.5 h. The reaction was cooled to -78 °C before an ethereal solution of diazomethane (25 
mL, 8.1 mmol) was added in one portion and the reaction was then warmed to room temperature with 
stirring for 1 h. The reaction was evaporated to dryness, resulting in a yellow solid. The solid was taken 
up in ethyl acetate, washed twice with water, twice with a saturated solution of sodium bicarbonate, and 
once with brine. The organic phase was dried over sodium sulfate and concentrated by rotary evaporation. 
The product was purified by silica flash column chromatography (gradient of 0-30% EtOAc in hexanes) 
to yield 108 as a yellow oil (898 mg, 89%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.28 (m, 5H), 6.01 (d, J = 
8 Hz, 1H), 5.52 (s, 1H), 5.07 (dd, J1 = 12 Hz, J2 = 20 Hz, 2H), 4.35 (m, 1H), 1.68 (m, 1H), 1.50 (m, 2H), 
0.91 (d, J = 6.5 Hz, 6H). 
13
C NMR (500 MHz, CDCl3) δ ppm 194.55, 155.85, 135.99, 128.09, 127.72, 
127.57, 66.45, 56.31, 53.28, 40.63, 24.30, 22.68, 21.29. HRMS (m/z): [M + H]
+
 calc. for C15H20N3O3, 
290.1505; observed, 290.1509. 
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(R)-benzyl (1-chloro-5-methyl-2-oxohexan-3-yl)carbamate (109) 
 To a solution of 108 (898 mg, 3.10 mmol) in anhydrous tetrahydrofuran (8 mL) under nitrogen at 
0 °C was added 1 M HCl in diethyl ether (4.66 mL, 4.66 mmol) dropwise. The reaction was stirred at 0 
°C for 30 min after complete addition. The solution was dried under reduced pressure to yield 109 as a 
yellow oil (945 mg). No further purification was made. 
1
H NMR (500 MHz, CDCl3) δ ppm 7.30 (m, 5H), 
5.72 (d, J = 8 Hz, 1H), 5.06 (dd, J1 = 12.5 Hz, J2 = 17 Hz, 2H), 4.55 (m, 1H), 4.26 (dd, J1 = 16 Hz, J2 = 34 
Hz, 2H), 1.67 (m, 1H), 1.56 (m, 1H), 1.42 (m, 1H), 0.92 (dd, J1 = 7 Hz, J2 = 12 Hz, 6H).
 13
C NMR (500 
MHz, CDCl3) δ ppm 201.78, 156.01, 135.83, 128.26, 127.94, 127.71, 66.84, 56.14, 46.48, 39.69, 24.48, 
22.89, 21.13. HRMS (m/z): [M + H]
+
 calc. for C15H21NO3Cl, 298.1210; observed, 298.1210. 
 
 
Benzyl ((2R,3R)-1-chloro-2-hydroxy-5-methylhexan-3-yl)carbamate (110) and benzyl ((2S,3R)-1-
chloro-2-hydroxy-5-methylhexan-3-yl)carbamate (111) 
 To a solution of 109 (945 mg, 3.10 mmol) in dichloromethane (7 mL) and methanol (4 mL) under 
nitrogen at 0 °C was added sodium borohydride (82 mg, 2.17 mmol). The reaction was stirred at 0 °C for 
1 h, and then quenched with slow addition of 2 M HCl (2 mL). The reaction was evaporated to dryness 
and the solid was taken up in ethyl acetate. The solution was washed twice with water followed by brine, 
dried over sodium sulfate, and concentrated by rotary evaporation. TLC analysis showed two 
diastereomers with the lower Rf compound being the (R,R)-isomer. Both diastereomers were purified by 
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silica flash column chromatography (gradient of 0-4% EtOAc in DCM) to yield the (R,R)-isomer (110) as 
a white solid (226 mg, 24%) and the (S,R)-isomer (111) as a white solid (37 mg, 4%) over two steps. 
Characterization of the (R,R)-isomer (110): 
1
H NMR (500 MHz, CDCl3) δ ppm 7.32 (m, 5H), 5.08 (s, 
2H), 5.03 (d, J = 8.5 Hz, 1H), 3.81 (m, 2H), 3.58 (dd, J1 = 3.5 Hz, J2 = 11 Hz, 1H), 3.51 (dd, J1 = 7.5 Hz, 
J2 = 11 Hz, 1H), 3.19 (d, J = 4 Hz, 1H), 1.64 (m, 1H), 1.42 (m, 1H), 1.31 (m, 1H), 0.91 (t, J = 12 Hz, 6H). 
13
C NMR (500 MHz, CDCl3) δ ppm 156.52, 136.15, 128.48, 128.15, 127.99, 74.48, 66.94, 52.05, 46.84, 
38.43, 24.52, 23.59, 21.35. HRMS (m/z): [M + H]
+
 calc. for C15H23NO3Cl, 300.1366; observed, 300.1368. 
Characterization of the (S,R)-isomer (111): 
1
H NMR (500 MHz, CDCl3) δ ppm 7.34 (m, 5H), 5.09 (s, 
2H), 4.99 (d, J = 9.5 Hz, 1H), 3.83 (m, 1H), 3.77 (m, 1H), 3.63 (dd, J1 = 4 Hz, J2 = 11 Hz, 1H), 3.50 (dd, 
J1 = 8.5 Hz, J2 = 11 Hz, 1H), 2.80 (d, J = 4 Hz, 1H), 1.61 (m, 2H), 1.36 (m, 1H), 0.93 (dd, J1 = 3 Hz, J2 = 
6.5 Hz, 6H).
 13
C NMR (500 MHz, CDCl3) δ ppm 156.64, 136.28, 128.54, 128.19, 128.02, 73.09, 66.96, 
51.05, 47.88, 41.59, 24.64, 23.00, 22.05. HRMS (m/z): [M + H]
+
 calc. for C15H23NO3Cl, 300.1366; 
observed, 300.1369. 
 
 
Benzyl ((R)-3-methyl-1-((S)-oxiran-2-yl)butyl)carbamate (112) 
 To a solution of 111 (37 mg, 0.123 mmol) in ethanol (5 mL) at 0 °C was added solid potassium 
hydroxide (8 mg, 0.136 mmol). The reaction was stirred cold for 15 min then warmed to room 
temperature and stirred for an additional 2 h. The reaction was evaporated to dryness and the solid was 
purified by silica flash column chromatography (gradient of 1-4% EtOAc in DCM) to yield 112 as a 
colorless oil (30 mg, 93%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.35 (m, 5H), 5.09 (dd, J1 = 12 Hz, J2 = 
20.5 Hz, 2H), 4.58 (d, J = 8 Hz, 1H), 4.04 (m, 1H), 3.00 (s, 1H), 2.72 (m, 1H), 2.57 (s, 1H), 1.73 (m, 1H), 
1.46 (m, 2H), 0.96 (s, 6H). 
13
C NMR (500 MHz, CDCl3) δ ppm 156.14, 136.38, 128.50, 128.12, 127.97, 
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66.76, 53.80, 47.91, 44.36, 42.29, 24.62, 23.05, 22.03. HRMS (m/z): [M + H]
+
 calc. for C15H22NO3, 
264.1600; observed, 264.1598. 
 
 
Benzyl ((2R,3R)-1-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-2-hydroxy-
5-methylhexan-3-yl)carbamate (113) 
 To a solution of 112 (30 mg, 0.114 mmol) in isopropyl alcohol (10 mL) was added (3S,4aS,8aS)-
N-(tert-butyl)decahydroisoquinoline-3-carboxamide (6, 30 mg, 0.125 mmol). The solution was heated to 
reflux and stirred. After 5 h, the reaction was cooled and dried to a solid. The product was purified by 
silica flash column chromatography (gradient of 0-4% MeOH in DCM) to yield 113 as a white solid (51 
mg, 89%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.32 (m, 5H), 5.89 (s, 1H), 5.35 (d, J = 9 Hz, 1H), 5.07 
(dd, J1 = 12.5 Hz, J2 = 22 Hz, 2H), 3.72 (t, J = 6 Hz, 1H), 3.63 (m, 1H), 3.36 (br s, 1H), 2.80 (dd, J1 = 2 
Hz, J2 = 12 Hz, 1H), 2.63 (dd, J1 = 2.5 Hz, J2 = 10 Hz, 1H), 2.56 (dd, J1 = 5.5 Hz, J2 = 13.5 Hz, 1H), 2.30 
(dd, J1 = 3 Hz, J2 = 12 Hz, 1H), 2.23 (dd, J1 = 8 Hz, J2 = 13.5 Hz, 1H), 1.93 (q, J = 12 Hz, 1H), 1.82-1.20 
(complex, 22H), 0.92 (t, J = 5.5 Hz, 6H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.29, 156.90, 136.62, 
128.41, 127.95, 127.91, 70.60, 69.79, 66.55, 59.83, 59.31, 51.52, 50.92, 41.25, 35.60, 33.22, 30.51, 30.45, 
28.63, 25.85, 24.76, 23.04, 22.22, 20.87. HRMS (m/z): [M + H]
+
 calc. for C29H48N3O4, 502.3645; 
observed, 502.3636. 
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(3S,4aS,8aS)-2-((2R,3R)-3-(2-naphthamido)-2-hydroxy-5-methylhexyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (114) 
 A solution of 113 (26 mg, 0.052 mmol) and 10% palladium on carbon (17 mg, 0.016 mmol) in 
methanol (5 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite 
and washed with excess methanol. The reaction was then dried to a solid and redissolved in THF (3 mL). 
2-naphthoic acid (10 mg, 0.057 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(11 mg, 0.057 mmol), and hydroxybenzotriazole hydrate (9 mg, 0.057 mmol) were added to the reaction 
and the solution was stirred at room temperature for 20 h. The reaction was taken up in ethyl acetate and 
washed once with water, once with saturated sodium bicarbonate, and once with brine. The ethyl acetate 
fraction was dried over sodium sulfate, concentrated by rotary evaporation, and purified by silica flash 
column chromatography (gradient of 0-3% MeOH in DCM) to yield 114 as an off-white solid (13 mg, 
48%). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.47 (s, 1H), 7.98 (dd, J1 = 1.5 Hz, J2 = 8.5 Hz, 1H), 7.93 (d, J 
= 8 Hz, 1H), 7.86 (t, J = 9 Hz, 2H), 7.77 (d, J = 7.5 Hz, 1H), 7.53 (m, 2H), 5.60 (s, 1H), 4.23 (m, 1H), 
3.88 (m, 1H), 2.76 (dd, J1 = 2 Hz, J2 = 11.5 Hz, 1H), 2.62 (dd, J1 = 8 Hz, J2 = 13 Hz, 1H), 2.54 (dd, J1 = 5 
Hz, J2 = 11 Hz, 1H), 2.20 (m, 2H), 1.96 (m, 2H), 1.78-0.92 (complex, 29H). 
13
C NMR (500 MHz, CDCl3) 
δ ppm 173.61, 168.32, 134.79, 132.67, 131.82, 129.02, 128.05, 127.59, 127.41, 126.43, 124.32, 70.63, 
70.38, 59.74, 58.91, 51.61, 51.18, 39.15, 35.82, 33.48, 30.89, 30.76, 28.55, 25.98, 25.58, 25.24, 23.25, 
22.29, 20.30. HRMS (m/z): [M + H]
+
 calc. for C32H48N3O3, 522.3696; observed, 522.3694. 
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Benzyl (R)-(4-diazo-1-(1H-indol-3-yl)-3-oxobutan-2-yl)carbamate (115) 
 To a stirred solution of Z-D-tryptophan (995 mg, 2.94 mmol) in anhydrous tetrahydrofuran (12 
mL) under nitrogen at -78 °C was added anhydrous triethylamine (611 μL, 4.41 mmol) followed by 
isobutyl chloroformate (574 μL, 4.41 mmol). The reaction was stirred cold for 1 h and then warmed to 
room temperature for 1.5 h. The reaction was cooled to -78 °C before an ethereal solution of 
diazomethane (25 mL, 8.1 mmol) was added in one portion and the reaction was then warmed to room 
temperature with stirring for 1 h. The reaction was evaporated to dryness, resulting in a yellow solid. The 
solid was taken up in ethyl acetate, washed twice with water, twice with a saturated solution of sodium 
bicarbonate, and once with brine. The organic phase was dried over sodium sulfate and concentrated by 
rotary evaporation. The product was purified by silica flash column chromatography (gradient of 0-40% 
EtOAc in hexanes) to yield 115 as a yellowish solid (950 mg, 89%). 
1
H NMR (500 MHz, CDCl3) δ ppm 
8.69 (s, 1H), 7.53 (d, J = 7.5 Hz, 1H), 7.24 (m, 6H), 7.12 (t, J = 7.5 Hz, 1H), 7.03 (t, J = 7.5 Hz, 1H), 6.81 
(s, 1H), 5.76 (d, J = 7.5 Hz, 1H), 5.02 (m, 3H), 4.51 (d, J = 5.5 Hz, 1H), 3.12 (d, J = 6.5 Hz, 2H). 
13
C 
NMR (500 MHz, CDCl3) δ ppm 193.93, 155.79, 135.99, 135.92, 128.24, 127.91, 127.73, 127.08, 123.13, 
121.80, 119.27, 118.26, 111.22, 109.33, 66.68, 58.16, 54.18, 27.94. Ethyl acetate peaks are visible in the 
NMR. HRMS (m/z): [M + H]
+
 calc. for C20H19N4O3, 363.1457; observed, 363.1455. 
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(R)-benzyl (4-chloro-1-(1H-indol-3-yl)-3-oxobutan-2-yl)carbamate (116) 
 To a solution of 115 (950 mg, 2.62 mmol) in anhydrous tetrahydrofuran (8 mL) under nitrogen at 
0 °C was added 1 M HCl in diethyl ether (3.93 mL, 3.93 mmol) dropwise. The reaction was stirred at 0 
°C for 30 min after complete addition. The solution was dried under reduced pressure to yield 116 as an 
orange solid (946 mg). No further purification was made. 
1
H NMR (500 MHz, CDCl3) δ ppm 8.14 (s, 
1H), 7.59 (d, J = 8 Hz, 1H), 7.33 (m, 6H), 7.22 (t, J = 7.5 Hz, 1H), 7.14 (t, J = 7.5 Hz, 1H), 6.95 (s, 1H), 
5.43 (d, J = 7 Hz, 1H), 5.09 (s, 2H), 4.85 (q, J = 7 Hz, 1H), 4.09 (d, J = 16 Hz, 1H), 3.95 (d, J = 16 Hz, 
1H), 3.24 (m, 2H). 
13
C NMR (500 MHz, CDCl3) δ ppm 201.62, 155.87, 136.19, 128.57, 128.31, 128.15, 
122.95, 122.62, 120.08, 118.51, 111.42, 109.31, 67.22, 58.08, 47.67, 27.80. HRMS (m/z): [M + H]
+
 calc. 
for C20H20N2O3Cl, 371.1162; observed, 371.1169. 
 
 
Benzyl ((2R,3R)-4-chloro-3-hydroxy-1-(1H-indol-3-yl)butan-2-yl)carbamate (117) and benzyl 
((2R,3S)-4-chloro-3-hydroxy-1-(1H-indol-3-yl)butan-2-yl)carbamate (118) 
 To a solution of 116 (946 mg, 2.62 mmol) in dichloromethane (7 mL) and methanol (4 mL) under 
nitrogen at 0 °C was added sodium borohydride (69 mg, 1.83 mmol). The reaction was stirred at 0 °C for 
1 h, and then quenched with slow addition of 2 M HCl (2 mL). The reaction was evaporated to dryness 
and the solid was taken up in ethyl acetate. The solution was washed twice with water followed by brine, 
dried over sodium sulfate, and concentrated by rotary evaporation. TLC analysis showed two 
diastereomers with the lower Rf compound being the (R,R)-isomer. Both diastereomers were purified by 
consecutive silica flash column chromatography (a gradient of 0-50% EtOAc in hexanes followed by a 
gradient of 1-8% EtOAc in DCM) to yield (R,R)-isomer (117) as a white solid (605 mg, 62%) and (R,S)-
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isomer (118) as a white solid (80 mg, 8%) over two steps. Characterization of the (R,R)-isomer (117): 
1
H 
NMR (500 MHz, (CD3)2SO) δ ppm 10.75 (s, 1H), 7.51 (d, J = 8 Hz, 1H), 7.30 (m, 3H), 7.21 (d, J = 7 Hz, 
2H), 7.14 (d, J = 8.5 Hz, 1H), 7.07 (d, J = 1.5 Hz, 1H), 7.04 (t, J = 7.5 Hz, 1H), 6.93 (t, J = 7.5 Hz, 1H), 
5.44 (d, J = 5.5 Hz, 1H), 4.92 (dd, J1 = 12.5 Hz, J2 = 19 Hz, 2H), 3.69 (m, 3H), 3.52 (dd, J1 = 7 Hz, J2 = 
11 Hz, 1H), 3.01 (dd, J1 = 3 Hz, J2 = 15 Hz, 1H), 2.76 (dd, J1 = 9 Hz, J2 = 15 Hz, 1H).
 13
C NMR (500 
MHz, (CD3)2SO) δ ppm 155.76, 137.25, 136.09, 128.29, 127.69, 127.60, 127.36, 123.29, 120.70, 118.37, 
118.11, 111.22, 110.98, 72.41, 64.95, 54.31, 47.99, 25.18. HRMS (m/z): [M + H]
+
 calc. for 
C20H22N2O3Cl, 373.1319; observed, 373.1313. Characterization of the (R,S)-isomer (118): 
1
H NMR (500 
MHz, CDCl3) δ ppm 8.06 (s, 1H), 7.69 (d, J = 8 Hz, 1H), 7.32 (m, 5H), 7.19 (t, J = 7.5 Hz, 1H), 7.11 (t, J 
= 7.5 Hz, 1H), 6.96 (d, J = 1 Hz, 1H), 5.32 (d, J = 9 Hz, 1H), 5.09 (s, 2H), 4.05 (q, J = 8 Hz, 1H), 3.80 
(m, 1H), 3.48 (m, 2H), 3.08 (m, 2H), 2.99 (d, J = 4 Hz, 1H). 
13
C NMR (500 MHz, CDCl3) δ ppm 156.66, 
136.22, 136.16, 128.54, 128.19, 128.04, 127.42, 122.77, 122.15, 119.61, 118.74, 111.55, 111.18, 71.15, 
66.94, 53.42, 47.91, 28.17. HRMS (m/z): [M + H]
+
 calc. for C20H22N2O3Cl, 373.1319; observed, 
373.1335. 
 
 
Benzyl ((R)-2-(1H-indol-3-yl)-1-((S)-oxiran-2-yl)ethyl)carbamate (119) 
 To a solution of 118 (80 mg, 0.215 mmol) in ethanol (7 mL) at 0 °C was added solid potassium 
hydroxide (13 mg, 0.236 mmol). The reaction was stirred cold for 15 min then warmed to room 
temperature and stirred for an additional 2 h. The reaction was evaporated to dryness and the solid was 
purified by silica flash column chromatography (gradient of 2-4% EtOAc in DCM) to yield 119 as a 
white solid (60 mg, 83%). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.09 (s, 1H), 7.69 (d, J = 7 Hz, 1H), 7.34 
(m, 6H), 7.20 (t, J = 7 Hz, 1H), 7.13 (m, 1H), 7.05 (s, 1H), 5.08 (s, 2H), 4.86 (d, J = 8 Hz, 1H), 4.29 (m, 
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1H), 3.09 (m, 4H), 2.66 (t, J = 4 Hz, 1H), 2.58 (s, 1H). Residual ethyl acetate is visible. 
13
C NMR (500 
MHz, CDCl3) δ ppm 156.12, 136.18, 128.51, 128.12, 127.99, 122.76, 122.15, 119.62, 118.83, 111.25, 
111.14, 66.76, 52.51, 50.17, 44.46, 29.35. HRMS (m/z): [M + H]
+
 calc. for C20H21N2O3, 337.1552; 
observed, 337.1547. 
 
 
benzyl ((2R,3R)-4-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-3-hydroxy-
1-(1H-indol-3-yl)butan-2-yl)carbamate (120) 
 To a solution of 119 (60 mg, 0.178 mmol) in isopropyl alcohol (10 mL) was added (3S,4aS,8aS)-
N-(tert-butyl)decahydroisoquinoline-3-carboxamide (6, 47 mg, 0.196 mmol). The solution was heated to 
reflux and stirred. After 6 h, the reaction was cooled and dried to a solid. The product was purified by 
silica flash column chromatography (gradient of 0-4% MeOH in DCM) to yield 120 as a white solid (88 
mg, 86%). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.29 (s, 1H), 7.76 (d, J = 8 Hz, 1H), 7.33 (m, 6H), 7.14 (t, 
J = 7.5 Hz, 1H), 7.08 (t, J = 7.5 Hz, 1H), 6.99 (s, 1H), 5.86 (s, 1H), 5.65 (d, J = 9 Hz, 1H), 5.10 (dd, J1 = 
12 Hz, J2 = 21 Hz, 2H), 3.89 (m, 1H), 3.82 (t, J = 7 Hz, 1H), 3.63 (br s, 1H), 3.16 (dd, J1 = 5.5 Hz, J2 = 
14.5 Hz, 1H), 3.07 (dd, J1 = 9 Hz, J2 = 14 Hz, 1H), 2.50 (m, 3H), 2.15 (dd, J1 = 7.5 Hz, J2 = 13 Hz, 1H), 
2.07 (dd, J1 = 3 Hz, J2 = 11 Hz, 1H), 1.79 (q, J = 12 Hz, 1H), 1.60 (m, 3H), 1.44-0.97 (complex, 19H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.60, 156.84, 136.49, 136.27, 128.43, 127.99, 127.59, 122.68, 
121.85, 119.36, 119.05, 112.23, 111.03, 70.20, 68.15, 66.59, 59.55, 59.11, 53.40, 50.65, 35.55, 33.01, 
30.59, 30.48, 28.31, 27.90, 25.92, 25.43, 20.62. HRMS (m/z): [M + H]
+
 calc. for C34H47N4O4, 575.3597; 
observed, 575.3589. 
176 
 
 
 
(3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3R)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-(1H-indol-3-
yl)butyl)decahydroisoquinoline-3-carboxamide (121) 
 A solution of 120 (34 mg, 0.059 mmol) and 10% palladium on carbon (19 mg, 0.018 mmol) in 
methanol (5 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite 
and washed with excess methanol. The reaction was then dried to a solid and redissolved in THF (3 mL). 
3-hydroxy-2-methylbenzoic acid (10 mg, 0.065 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (12 mg, 0.065 mmol), and hydroxybenzotriazole hydrate (11 mg, 0.065 mmol) were added 
to the reaction and the solution was stirred at room temperature for 20 h. The reaction was taken up in 
ethyl acetate and washed once with water, once with saturated sodium bicarbonate, and once with brine. 
The ethyl acetate fraction was dried over sodium sulfate, concentrated by rotary evaporation, and purified 
by silica flash column chromatography (gradient of 0-7% MeOH in DCM) to yield 121 as an off-white 
solid (21 mg, 62%). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.19 (s, 1H), 7.73 (d, J = 8 Hz, 1H), 7.34 (d, J = 
8 Hz, 1H), 7.17 (t, J = 8 Hz, 1H), 7.10 (t, J = 7.5 Hz, 1H), 7.06 (d, J = 1.5 Hz, 1H), 6.94 (t, J = 8 Hz, 1H), 
6.77 (m, 3H), 6.41 (br s, 1H), 5.75 (s, 1H), 4.28 (q, J = 7.5 Hz, 1H), 3.89 (t, J = 6.5 Hz, 1H), 3.38 (dd, J1 
= 7.5 Hz, J2 = 14.5 Hz, 1H), 3.19 (dd, J1 = 8 Hz, J2 = 14.5 Hz, 1H), 2.72 (dd, J1 = 2 Hz, J2 = 11.5 Hz, 1H), 
2.55 (dd, J1 = 3 Hz, J2 = 11 Hz, 1H), 2.46 (dd, J1 = 5.5 Hz, J2 = 13 Hz, 1H), 2.27 (m, 2H), 2.13 (s, 3H), 
1.88 (q, J = 11.5 Hz, 1H), 1.76-1.05 (complex, 21H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.66, 171.25, 
154.55, 138.07, 136.32, 127.62, 126.46, 122.73, 122.22, 121.96, 119.42, 119.15, 118.97, 116.60, 112.42, 
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111.08, 70.15, 69.81, 60.29, 59.51, 53.28, 50.96, 35.82, 33.17, 30.73, 30.59, 28.33, 27.26, 26.03, 25.68, 
20.60, 12.39. HRMS (m/z): [M + H]
+
 calc. for C34H47N4O4, 575.3597; observed, 575.3591. 
 
 
(3S,4aS,8aS)-2-((2R,3R)-3-(2-naphthamido)-2-hydroxy-4-(1H-indol-3-yl)butyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (122) 
 A solution of 120 (39 mg, 0.068 mmol) and 10% palladium on carbon (22 mg, 0.020 mmol) in 
methanol (5 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite 
and washed with excess methanol. The reaction was then dried to a solid and redissolved in THF (3 mL). 
2-naphthoic acid (13 mg, 0.075 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(14 mg, 0.075 mmol), and hydroxybenzotriazole hydrate (12 mg, 0.075 mmol) were added to the reaction 
and the solution was stirred at room temperature for 20 h. The reaction was taken up in ethyl acetate and 
washed once with water, once with saturated sodium bicarbonate, and once with brine. The ethyl acetate 
fraction was dried over sodium sulfate, concentrated by rotary evaporation, and purified by silica flash 
column chromatography (gradient of 0-5% MeOH in DCM) to yield 122 as an off-white solid (29 mg, 
72%). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.35 (s, 1H), 8.18 (s, 1H), 7.90 (dd, J1 = 1.5 Hz, J2 = 8.5 Hz, 
1H), 7.87 (d, J = 8 Hz, 1H), 7.82 (m, 4H), 7.51 (m, 2H), 7.33 (d, J = 8 Hz, 1H), 7.16 (t, J = 7.5 Hz, 1H), 
7.10 (m, 2H), 5.64 (s, 1H), 4.46 (q, J = 7.5 Hz, 1H), 3.99 (t, J = 6 Hz, 1H), 3.45 (dd, J1 = 7.5 Hz, J2 = 14 
Hz, 1H), 3.32 (dd, J1 = 7.5 Hz, J2 = 14 Hz, 1H), 2.60 (m, 2H), 2.48 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 2.21 
(dd, J1 = 6 Hz, J2 = 13 Hz, 1H), 2.08 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 1.85 (q, J = 11.5 Hz, 1H), 1.62-
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0.94 (complex, 21H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.63, 168.64, 136.29, 134.76, 132.59, 
131.75, 129.01, 128.09, 127.67, 127.57, 127.46, 126.46, 124.20, 122.72, 121.83, 119.31, 119.06, 122.89, 
111.06, 70.37, 69.49, 59.53, 58.86, 54.10, 50.95, 35.71, 33.30, 30.83, 30.70, 28.31, 26.12, 26.03, 25.51, 
20.28. HRMS (m/z): [M + H]
+
 calc. for C37H47N4O3, 595.3648; observed, 595.3655. 
 
 
Benzyl ((R)-2-(1H-indol-3-yl)-1-((R)-oxiran-2-yl)ethyl)carbamate (123) 
 To a solution of 117 (589 mg, 1.58 mmol) in ethanol (15 mL) and dichloromethane (5 mL) at 0 
°C was added solid potassium hydroxide (97 mg, 1.74 mmol). The reaction was stirred cold for 15 min 
then warmed to room temperature and stirred for an additional 3 h. The reaction was evaporated to 
dryness and the solid was purified by silica flash column chromatography (gradient of 2-5% EtOAc in 
DCM) to yield 123 as a white solid (470 mg, 88%). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.25 (s, 1H), 7.61 
(d, J = 8 Hz, 1H), 7.29 (m, 4H), 7.24 (m, 2H), 7.17 (t, J = 7.5 Hz, 1H), 7.09 (t, J = 7.5 Hz, 1H), 6.91 (s, 
1H), 5.02 (m, 2H), 4.93 (d, J = 6 Hz, 1H), 3.80 (m, 1H), 3.06 (d, J = 3.5 Hz, 2H), 2.90 (s, 1H), 2.74 (d, J 
= 12.5 Hz, 2H). 
13
C NMR (500 MHz, CDCl3) δ ppm 155.92, 136.17, 128.42, 128.06, 127.94, 127.63, 
122.98, 122.01, 119.58, 118.66, 111.17, 110.06, 66.68, 53.11, 52.59, 46.89, 26.94. HRMS (m/z): [M + 
H]
+
 calc. for C20H21N2O3, 337.1552; observed, 337.1547. 
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Benzyl ((2R,3S)-4-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-3-hydroxy-
1-(1H-indol-3-yl)butan-2-yl)carbamate (124) 
 To a solution of 123 (456 mg, 1.36 mmol) in isopropyl alcohol (10 mL) was added (3S,4aS,8aS)-
N-(tert-butyl)decahydroisoquinoline-3-carboxamide (6, 355 mg, 1.49 mmol). The solution was heated to 
reflux and stirred. After 6 h, the reaction was cooled and dried to a solid. The product was purified by 
silica flash column chromatography (gradient of 0-4% MeOH in DCM) to yield 124 as a white solid (691 
mg, 88%). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.95 (s, 1H), 7.56 (d, J = 8 Hz, 1H), 7.19 (m, 6H), 7.04 (t, 
J = 7.5 Hz, 1H), 6.90 (s, 1H), 6.73 (s, 1H), 5.45 (d, J = 8 Hz, 1H), 4.95 (m, 2H), 4.12 (s, 1H), 3.99 (m, 
1H), 3.83 (m, 1H), 2.95 (m, 2H), 2.63 (m, 3H), 2.03 (d, J = 12 Hz, 1H), 1.97 (d, J = 9 Hz, 1H), 1.84 (q, J 
= 12 Hz, 1H), 1.70 (m, 3H), 1.55-1.13 (complex, 18H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.99, 
156.60, 136.15, 128.18, 127.73, 127.61, 127.45, 122.68, 121.46, 118.87, 118.32, 111.20, 110.78, 69.42, 
69.23, 66.37, 58.49, 57.88, 54.92, 50.59, 35.51, 32.96, 30.83, 30.61, 28.36, 26.05, 25.30, 25.14, 20.00. 
HRMS (m/z): [M + H]
+
 calc. for C34H47N4O4, 575.3597; observed, 575.3588. 
 
 
(3S,4aS,8aS)-2-((2S,3R)-3-(2-naphthamido)-2-hydroxy-4-(1H-indol-3-yl)butyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (125) 
 A solution of 124 (126 mg, 0.219 mmol) and 10% palladium on carbon (70 mg, 0.066 mmol) in 
methanol (5 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite 
and washed with excess methanol. The reaction was then dried to a solid and redissolved in THF (3 mL). 
180 
 
2-naphthoic acid (41 mg, 0.241 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(46 mg, 0.241 mmol), and hydroxybenzotriazole hydrate (39 mg, 0.241 mmol) were added to the reaction 
and the solution was stirred at room temperature for 20 h. The reaction was taken up in ethyl acetate and 
washed once with water, once with saturated sodium bicarbonate, and once with brine. The ethyl acetate 
fraction was dried over sodium sulfate, concentrated by rotary evaporation, and purified by silica flash 
column chromatography (gradient of 0-5% MeOH in DCM) to yield 125 as an off-white solid (68 mg, 
52%). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.67 (s, 1H), 7.79 (s, 1H), 7.76 (d, J = 8.5 Hz, 1H), 7.72 (d, J = 
8.5 Hz, 1H), 7.66 (d, J = 8 Hz, 2H), 7.59 (dd, J1 = 1.5 Hz, J2 = 8.5 Hz, 1H), 7.50 (t, J = 7 Hz, 1H), 7.44 (t, 
J = 6.5 Hz, 1H), 7.38 (d, J = 8.5 Hz, 1H), 7.21 (t, J = 7.5 Hz, 1H), 7.14 (t, J = 7.5 Hz, 1H), 7.06 (d, J = 2 
Hz, 1H), 6.70 (d, J = 7.5 Hz, 1H), 6.55 (s, 1H), 4.46 (m, 1H), 3.95 (d, J = 10 Hz, 1H), 3.22 (dd, J1 = 9.5 
Hz, J2 = 15 Hz, 1H), 3.06 (dd, J1 = 5 Hz, J2 = 15 Hz, 1H), 2.76 (d, J = 10.5 Hz, 1H), 2.68 (dd, J1 = 10.5 
Hz, J2 = 13 Hz, 1H), 2.56 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 2.11 (d, J = 12 Hz, 1H), 1.93 (dd, J1 = 3 Hz, 
J2 = 11.5 Hz, 1H), 1.87 (q, J = 12 Hz, 1H), 1.76 (dq, J1 = 3 Hz, J2 = 13 Hz, 1H), 1.65 (m, 2H), 1.53-1.14 
(complex, 17H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.94, 168.50, 136.29, 134.61, 132.37, 131.23, 
128.89, 128.30, 127.83, 127.60, 127.56, 127.43, 126.60, 123.61, 122.68, 122.10, 119.59, 118.37, 111.49, 
111.25, 70.02, 69.85, 58.87, 58.26, 54.75, 50.83, 35.81, 33.19, 31.07, 30.83, 28.60, 26.26, 25.42, 25.19, 
20.17. HRMS (m/z): [M + H]
+
 calc. for C37H47N4O3, 595.3648; observed, 595.3636. 
 
 
(3S,4aS,8aS)-N-(tert-butyl)-2-(2-hydroxy-3-(3-hydroxy-2-
methylbenzamido)propyl)decahydroisoquinoline-3-carboxamide (126) 
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 A solution of 35 (32 mg, 0.072 mmol) and 10% palladium on carbon (23 mg, 0.022 mmol) in 
methanol (10 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite 
and washed with excess methanol. The reaction was then dried to a solid and redissolved in THF (3 mL). 
3-hydroxy-2-methylbenzoic acid (12 mg, 0.079 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (15 mg, 0.079 mmol), and hydroxybenzotriazole hydrate (12 mg, 0.079 mmol) were added 
to the reaction and the solution was stirred at room temperature for 18 h. The reaction was taken up in 
ethyl acetate and washed once with saturated sodium bicarbonate and once with brine. The ethyl acetate 
fraction was dried over sodium sulfate, concentrated by rotary evaporation, and purified by silica flash 
column chromatography (gradient of 0-4% MeOH in DCM) to yield 126 as a white solid (17 mg, 53%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.53 (br s, 1H), 6.95 (t, J = 8 Hz, 1H), 6.82 (d, J = 8 Hz, 1H), 6.47 (t, 
J = 6 Hz, 1H), 6.12 (s, 1H), 4.28 (br s, 1H), 3.91 (m, 1H), 3.63 (dq, J1 = 3 Hz, J2 = 6 Hz, 1H), 3.15 (m, 
1H), 2.85 (d, J = 10 Hz, 1H), 2.64 (dd, J1 = 3 Hz, J2 = 11 Hz, 1H), 2.43 (dd, J1 = 11 Hz, J2 = 12.5 Hz, 
1H), 2.20 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 2.11 (m, 4H), 1.95 (q, J = 12 Hz, 1H), 1.88-1.19 (complex, 
21H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.82, 170.96, 154.89, 137.81, 126.41, 122.31, 118.50, 
116.54, 69.58, 66.83, 59.01, 58.27, 51.15, 43.80, 35.82, 33.31, 30.96, 30.89, 28.62, 26.29, 25.44, 20.24, 
12.41. HRMS (m/z): [M + H]
+
 calc. for C25H40N3O4, 446.3019; observed, 446.3023. 
 
 
(3S,4aS,8aS)-2-(3-(2-naphthamido)-2-hydroxypropyl)-N-(tert-butyl)decahydroisoquinoline-3-
carboxamide (127) 
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 A solution of 35 (30 mg, 0.067 mmol) and 10% palladium on carbon (21 mg, 0.020 mmol) in 
methanol (10 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite 
and washed with excess methanol. The reaction was then dried to a solid and redissolved in THF (3 mL). 
2-naphthoic acid (13 mg, 0.074 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(14 mg, 0.074 mmol), and hydroxybenzotriazole hydrate (12 mg, 0.074 mmol) were added to the reaction 
and the solution was stirred at room temperature for 18 h. The reaction was taken up in ethyl acetate and 
washed once with saturated sodium bicarbonate and once with brine. The ethyl acetate fraction was dried 
over sodium sulfate, concentrated by rotary evaporation, and purified by silica flash column 
chromatography (gradient of 0-3% MeOH in DCM) to yield 127 as a white solid (28 mg, 90%). 
1
H NMR 
(500 MHz, CDCl3) δ ppm 8.33 (s, 1H), 7.87 (m, 4H), 7.54 (m, 2H), 7.09 (m, 1H), 5.99 (s, 1H), 3.98 (m, 
1H), 3.72 (ddd, J1 = 2.5 Hz, J2 = 6 Hz, J3, = 14Hz, 1H), 3.37 (dt, J1 = 6 Hz, J2 = 13.5 Hz, 1H), 2.85 (dd, J1 
= 2 Hz, J2 = 11.5 Hz, 1H), 2.63 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 2.51 (dd, J1 = 10.5 Hz, J2 = 13 Hz, 1H), 
2.20 (dd, J1 = 3 Hz, J2 = 12 Hz, 1H), 2.13 (dd, J1 = 2.5 Hz, J2 = 13 Hz, 1H), 1.95 (q, J = 11.5 Hz, 1H), 
1.87-1.18 (complex, 21H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.42, 167.96, 134.74, 132.58, 131.36, 
128.93, 128.31, 127.66, 127.57, 126.63, 123.70, 69.71, 66.63, 58.86, 58.31, 50.93, 43.67, 35.86, 33.32, 
31.00, 30.91, 28.56, 26.27, 25.47, 25.34, 20.22. HRMS (m/z): [M + H]
+
 calc. for C28H40N3O3, 466.3070; 
observed, 466.3063. 
 
 
(S)-benzyl 2-((R)-oxiran-2-yl)pyrrolidine-1-carboxylate (128) 
 To a solution of 39 (429 mg, 1.51 mmol) in ethanol (15 mL) at 0 °C was added solid potassium 
hydroxide (93 mg, 1.66 mmol). The reaction was stirred cold for 15 min then warmed to room 
temperature and stirred for an additional 3 h. The reaction was evaporated to dryness and the solid was 
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purified by silica flash column chromatography (gradient of 0.5-5.5% EtOAc in DCM) to yield 128 as a 
colorless oil (342 mg, 91%). 
1
H NMR (500 MHz, CDCl3, mixture of cis and trans isomers) δ ppm 7.38-
7.26 (complex, 10H), 5.19-5.08 (complex, 4H), 4.21 (br s, 1H), 4.10 (br s, 1H), 3.48-3.36 (complex, 4H), 
3.04 (br s, 1H), 2.99 (br s, 1H), 2.65 (br s, 1H), 2.59 (br s, 1H), 2.48 (br s, 1H), 2.43 (br s, 1H), 2.00-1.79 
(complex, 8H). 
13
C NMR (500 MHz, CDCl3, mixture of cis and trans isomers) δ ppm 155.03, 154.67, 
136.53, 136.47, 128.11, 127.95, 127.60, 127.45, 66.44, 56.04, 55.90, 53.56, 53.45, 46.89, 46.59, 44.00, 
43.92, 28.55, 28.04, 23.97, 23.19. HRMS (m/z): [M + H]
+
 calc. for C14H18NO3, 248.1287; observed, 
248.1295. 
 
 
(S)-benzyl 2-((S)-2-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-1-
hydroxyethyl)pyrrolidine-1-carboxylate (129) 
 To a solution of 128 (342 mg, 1.38 mmol) in isopropyl alcohol (15 mL) was added (3S,4aS,8aS)-
N-(tert-butyl)decahydroisoquinoline-3-carboxamide (6, 396 mg, 1.66 mmol). The solution was heated to 
reflux and stirred. After 5 h, the reaction was cooled and dried to a solid. The product was purified by 
silica flash column chromatography (gradient of 0-8% MeOH in DCM) to yield 129 as a white solid (622 
mg, 93%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.35-7.30 (complex, 6H), 7.00 (br s, 1H), 5.12 (m, 2H), 
4.53 (br s, 1H), 3.82-3.78 (m, 2H), 3.57 (m, 1H), 3.34 (m, 1H), 2.85 (d, J = 10.5 Hz, 1H), 2.62-2.50 
(complex, 3H), 2.12-1.16 (complex, 25H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.85, 157.18, 136.23, 
128.31, 127.88, 127.67, 71.02, 69.61, 67.12, 60.99, 59.66, 58.06, 50.32, 46.96, 35.74, 33.11, 30.90, 30.73, 
28.39, 27.85, 26.17, 25.30, 24.11, 20.09. HRMS (m/z): [M + H]
+
 calc. for C28H44N3O4, 486.3332; 
observed, 486.3343. 
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(3S,4aS,8aS)-N-(tert-butyl)-2-((S)-2-hydroxy-2-((S)-pyrrolidin-2-yl)ethyl)decahydroisoquinoline-3-
carboxamide (130) 
 A solution of 129 (622 mg, 1.28 mmol) and 10% palladium on carbon (405 mg, 0.38 mmol) in 
methanol (30 mL) was degassed with nitrogen for 30 min. The reaction was placed under 1 atm of 
hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was filtered through celite, 
washed with excess methanol, and dried to a solid. The solid was taken up in ethyl acetate and extracted 
with 1 M HCl three times. The aqueous fractions were combined, adjusted to pH 12 with 10 M NaOH, 
and extracted with ethyl acetate three times. The combined ethyl acetate fractions were washed with 
brine, dried over sodium sulfate, and concentrated by rotary evaporation to yield 130 as a white solid (435 
mg). The product was used without further purification. 
 
 
(3S,4aS,8aS)-N-(tert-butyl)-2-((S)-2-hydroxy-2-((S)-1-(3-hydroxy-2-methylbenzoyl)pyrrolidin-2-
yl)ethyl)decahydroisoquinoline-3-carboxamide (131) 
 To a solution of 130 (31 mg, 0.088 mmol) in THF (3 mL) was added 3-hydroxy-2-methylbenzoic 
acid (15 mg, 0.097 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (19 mg, 0.097 
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mmol), and hydroxybenzotriazole hydrate (16 mg, 0.097 mmol). The solution was stirred at room 
temperature for 16 h. The reaction was taken up in ethyl acetate and washed once with saturated sodium 
bicarbonate and once with brine. The ethyl acetate fraction was dried over sodium sulfate, concentrated 
by rotary evaporation, and purified by silica flash column chromatography (gradient of 0-7% MeOH in 
DCM) to yield 131 as a white solid (33 mg, 74% over two steps). 
1
H NMR (500 MHz, CDCl3) δ ppm 
7.96 (br s, 1H), 7.35 (br s, 1H), 7.03 (t, J = 8 Hz, 1H), 6.84 (d, J = 8 Hz, 1H), 6.70 (d, J = 7 Hz, 1H), 5.43 
(br s, 1H), 4.27 (dd, J1 = 8 Hz, J2 = 14 Hz, 1H), 3.88 (t, J = 9 Hz, 1H), 3.28 (m, 1H), 3.20 (m, 1H), 2.91 
(d, J = 10.5 Hz, 1H), 2.62 (m, 2H), 2.20-2.05 (complex, 6H), 1.90-1.17 (complex, 24H). 
13
C NMR (500 
MHz, CDCl3) δ ppm 174.69, 173.67, 155.37, 137.96, 126.97, 115.82, 72.32, 69.66, 61.10, 60.95, 58.54, 
50.77, 36.00, 33.25, 31.14, 30.91, 28.64, 28.44, 26.32, 25.60, 24.78, 20.26, 12.66. HRMS (m/z): [M + H]
+
 
calc. for C28H44N3O4, 486.3332; observed, 486.3335. 
 
 
(3S,4aS,8aS)-2-((S)-2-((S)-1-(2-naphthoyl)pyrrolidin-2-yl)-2-hydroxyethyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (132) 
 To a solution of 130 (33 mg, 0.094 mmol) in THF (3 mL) was added 2-naphthoic acid (18 mg, 
0.103 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (20 mg, 0.103 mmol), and 
hydroxybenzotriazole hydrate (17 mg, 0.103 mmol). The solution was stirred at room temperature for 16 
h. The reaction was taken up in ethyl acetate and washed once with saturated sodium bicarbonate and 
once with brine. The ethyl acetate fraction was dried over sodium sulfate, concentrated by rotary 
evaporation, and purified by silica flash column chromatography (gradient of 0-5% MeOH in DCM) to 
yield 132 as a white solid (44 mg, 90% over two steps). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.01 (s, 1H), 
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7.86 (m, 3H), 7.55 (m, 3H), 7.03 (br s, 1H), 5.00 (br s, 1H), 4.41 (q, J = 7.5 Hz, 1H), 3.97 (t, J = 8.5 Hz, 
1H), 3.58 (m, 1H), 2.92 (d, J = 11 Hz, 1H), 2.63 (m, 2H), 2.15 (m, 3H), 1.94-1.17 (complex, 24H).
 13
C 
NMR (500 MHz, CDCl3) δ ppm 174.06, 173.00, 133.93, 133.60, 132.45, 128.50, 128.15, 127.74, 127.29, 
126.70, 124.18, 72.23, 69.82, 60.96, 60.35, 58.46, 51.22, 50.55, 36.01, 33.32, 31.16, 30.93, 28.64, 28.12, 
26.33, 25.54, 25.26, 20.24. HRMS (m/z): [M + H]
+
 calc. for C31H44N3O3, 506.3383; observed, 506.3388. 
 
 
(3S,4aS,8aS)-N-(tert-butyl)-2-((S)-2-((S)-1-(2-chloro-4-nitrobenzoyl)pyrrolidin-2-yl)-2-
hydroxyethyl)decahydroisoquinoline-3-carboxamide (133) 
 To a solution of 130 (218 mg, 0.620 mmol) in THF (6 mL) was added 2-chloro-4-nitrobenzoic 
acid (138 mg, 0.682 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (131 mg, 
0.682 mmol), and hydroxybenzotriazole hydrate (111 mg, 0.682 mmol). The solution was stirred at room 
temperature for 18 h. The reaction was taken up in ethyl acetate and washed once with saturated sodium 
bicarbonate and once with brine. The ethyl acetate fraction was dried over sodium sulfate, concentrated 
by rotary evaporation, and purified by silica flash column chromatography (gradient of 0-5% MeOH in 
DCM) to yield 133 as a yellow solid (248 mg, 72% over two steps). Crystals were grown for x-ray 
crystallography from the layering of pentane on top of a dichloromethane solution.  
1
H NMR (500 MHz, 
CDCl3) δ ppm 8.31 (d, J = 2 Hz, 1H), 8.20 (dd, J1 = 2 Hz, J2 = 8.5 Hz, 1H), 7.54 (d, J = 8.5 Hz, 1H), 6.87 
(s, 1H), 5.31 (s, 1H), 4.36 (m, 1H), 3.99 (m, 1H), 3.24 (m, 2H), 2.91 (d, J = 11 Hz, 1H), 2.63 (m, 2H), 
2.18-1.13 (complex, 26H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.83, 172.95, 148.31, 142.45, 128.53, 
124.96, 122.35, 121.69, 69.81, 69.73, 60.88, 58.37, 57.98, 50.55, 50.51, 49.05, 35.84, 33.23, 31.07, 30.80, 
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28.56, 28.20, 26.20, 25.46, 24.53, 20.16. HRMS (m/z): [M + H]
+
 calc. for C27H40N4O5Cl, 535.2687; 
observed, 535.2692. 
 
 
(2S,3S)-3-(2-naphthamido)-1-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-
4-(phenylthio)butan-2-yl acetate (134) 
 To a stirred solution of 27 (44 mg, 0.075 mmol) in anhydrous tetrahydrofuran (3 mL) under 
nitrogen at room temperature was added anhydrous triethylamine (21 μL, 0.150 mmol) followed by acetic 
anhydride (14 μL, 0.150 mmol). The reaction was stirred for 3 h, then additional acetic anhydride was 
added (14 μL, 0.150 mmol) and the reaction was stirred at room temperature for 16 h. Ethyl acetate was 
added to the reaction. The crude material was washed once with water, once with saturated sodium 
bicarbonate, and once with brine. The organic phase was dried over sodium sulfate and concentrated by 
rotary evaporation. The product was purified by silica flash column chromatography (gradient of 0-3% 
MeOH in DCM) to yield 134 as a white solid (21 mg, 44%). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.24 (s, 
1H), 7.88 (d, J = 8 Hz, 1H), 7.85 (d, J = 8 Hz, 2H), 7.78 (dd, J1 = 1.5 Hz, J2 = 8.5 Hz, 1H), 7.53 (m, 2H), 
7.42 (d, J = 8 Hz, 2H), 7.26 (t, J = 8 Hz, 2H), 7.16 (t, J = 7.5 Hz, 1H), 6.23 (s, 1H), 5.52 (m, 1H), 4.58 
(m, 1H), 3.28 (dd, J1 = 6.5 Hz, J2 = 14 Hz, 1H), 3.23 (dd, J1 = 6 Hz, J2 = 14 Hz, 1H), 3.00 (dd, J1 = 2 Hz, 
J2 = 11 Hz, 1H), 2.91 (dd, J1 = 9 Hz, J2 = 13.5 Hz, 1H), 2.53 (dd, J1 = 3 Hz, J2 = 11 Hz, 1H), 2.25 (dd, J1 
= 3 Hz, J2 = 13 Hz, 1H), 2.13 (s, 3H), 2.01 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 1.81 (q, J = 11.5 Hz, 1H), 
1.69 (m, 1H), 1.55-1.04 (complex, 20H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.76, 170.33, 167.33, 
135.29, 134.74, 132.52, 131.59, 130.13, 129.17, 128.94, 128.25, 127.65, 127.55, 126.78, 126.58, 123.77, 
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70.76, 70.11, 58.12, 55.96, 51.24, 50.75, 35.55, 34.94, 33.16, 30.88, 30.63, 28.73, 26.08, 25.12, 21.28, 
20.15. HRMS (m/z): [M + H]
+
 calc. for C37H48N3O4S, 630.3366; observed, 630.3365. 
 
 
1-((benzyloxy)carbonyl)piperidine-2-carboxylic acid (135) 
 To a solution of piperidine-2-carboxylic acid (2.20 g, 17.0 mmol) in aqueous saturated sodium 
bicarbonate (55 mL) was added benzyl chloroformate (2.66 mL, 18.7 mmol) over 30 min. The solution 
was stirred at room temperature for 3 h before the pH was adjusted to 2 with sodium bisulfate. The 
solution was extracted with ethyl acetate three times. The combined organic extracts were washed once 
with brine, dried over sodium sulfate, and concentrated to a solid by rotary evaporation. The product was 
purified by silica flash column chromatography (gradient of 0-4% MeOH in DCM) to yield 135 as a 
colorless oil (2.58 g, 58%). 
1
H NMR (500 MHz, CDCl3, mixture of rotamers) δ ppm 7.32 (m, 5H), 5.30 
(s, 0.4H), 5.17 (m, 2H), 5.01 (d, J = 5 Hz, 0.6H), 4.90 (d, J = 5 Hz, 0.4H), 4.71 (s, 0.6H), 4.13 (d, J = 13 
Hz, 0.4H), 4.05 (d, J = 13 Hz, 0.6H), 3.08 (t, J = 12.5 Hz, 0.6H), 2.99 (t, J = 12.5 Hz, 0.4H), 2.28 (d, J = 
13.5 Hz, 0.6H), 2.23 (d, J = 13.5 Hz, 0.4H), 1.71 (m, 3H), 1.45 (m, 1H), 1.34 (m, 1H). 
13
C NMR (500 
MHz, CDCl3, mixture of rotamers) δ ppm 177.26, 177.19, 156.70, 155.94, 140.71, 136.45, 128.55, 
128.46, 128.00, 127.80, 127.67, 127.01, 67.50, 67.39, 65.36, 54.33, 54.13, 41.88, 41.73, 26.67, 26.52, 
24.61, 24.46, 20.67, 20.62. HRMS (m/z): [M + H]
+
 calc. for C14H18NO4, 264.1236; observed, 264.1233. 
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Benzyl 2-(tert-butylcarbamoyl)piperidine-1-carboxylate (136) 
 135 (551 mg, 2.09 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (441 
mg, 2.30 mmol), and hydroxybenzotriazole hydrate (373 mg, 2.30 mmol) were dried and placed under 
nitrogen. The solids were dissolved in dry THF (25 mL) and tert-butylamine (242 μL, 2.30 mmol) was 
added in one portion. The solution was stirred at room temperature for 20 h. The reaction was taken up in 
ethyl acetate and washed once with water, once with saturated sodium bicarbonate, and once with brine. 
The ethyl acetate fraction was dried over sodium sulfate, concentrated by rotary evaporation, and purified 
by silica flash column chromatography (gradient of 0-5% ethyl acetate in DCM) to yield 136 as a white 
solid (379 mg, 57%). 
1
H NMR (500 MHz, (CD3)2SO) δ ppm 7.32 (m, 5H), 5.80 (m, 1H), 5.18 (m, 2H), 
4.70 (s, 1H), 4.11 (m, 1H), 2.88 (br s, 1H), 2.28 (s, 1H), 1.50 (m, 5H), 1.29 (s, 9H). 
13
C NMR (500 MHz, 
CDCl3) δ ppm 169.57, 156.28, 136.27, 128.30, 127.89, 127.56, 67.20, 54.76, 50.81, 42.91, 28.41, 25.21, 
24.66, 20.09. HRMS (m/z): [M + H]
+
 calc. for C18H27N2O3, 319.2022; observed, 319.2028. 
 
 
N-(tert-butyl)piperidine-2-carboxamide (137) 
 A solution of 136 (379 mg, 1.19 mmol) and 10% palladium on carbon (380 mg, 0.36 mmol) in 
methanol (8 mL) and ethyl acetate (8 mL) was degassed with nitrogen for 30 min. The reaction was 
placed under 1 atm of hydrogen and was stirred vigorously for 2 h at room temperature. The reaction was 
filtered through celite, washed with excess methanol, and dried to a solid. The product was purified by 
silica flash column chromatography (gradient of 3-10% MeOH in DCM) to yield 137 as an off white solid 
(207 mg, 94%). 
1
H NMR (500 MHz, (CD3)2SO) δ ppm 7.16 (s, 1H), 3.42 (s, 2H), 2.97 (dd, J1 = 2 Hz, J2 = 
10 Hz, 1H), 2.89 (d, J = 13 Hz, 1H), 2.49 (m, 1H), 1.69 (m, 2H), 1.45 (m, 1H), 1.26 (m, 11H). 
13
C NMR 
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(500 MHz, (CD3)2SO) δ ppm 172.06, 59.38, 49.60, 44.78, 29.34, 28.38, 25.29, 23.62. HRMS (m/z): [M + 
H]
+
 calc. for C10H21N2O, 185.1654; observed, 185.1658. 
 
 
(S)-1-((2R,3R)-3-amino-2-hydroxy-4-(phenylthio)butyl)-N-(tert-butyl)piperidine-2-carboxamide 
(138) 
 To a solution of 5 (193 mg, 0.587 mmol) in isopropyl alcohol (10 mL) was added 137 (119 mg, 
0.646 mmol). The solution was heated to reflux and stirred. After 6 h, 2 M NaOH (1.47 mL, 2.93 mmol) 
was added and the reaction was stirred at reflux for an additional 18 h. The reaction was diluted with 
toluene (30 mL) and extracted with 1 M HCl (10 mL) three times. The aqueous fractions were combined 
and washed with toluene (15 mL) twice. The aqueous phase was adjusted to pH 11 with 10 M NaOH and 
was extracted with toluene (20 mL) four times. The combined toluene fractions were washed with brine 
(15 mL), dried over sodium sulfate, and concentrated to a solid by rotary evaporation. The product was 
purified by silica flash column chromatography (gradient of 1-8% MeOH in DCM) to yield 138 as a 
white solid (70 mg, 31%). No further purification was made. Which diastereomer was isolated was not 
determined. 
1
H NMR (500 MHz, CDCl3) δ ppm 7.36 (d, J = 7.5 Hz, 2H), 7.24 (t, J = 8 Hz, 2H), 7.19 (t, J 
= 7.5 Hz, 1H), 6.47 (s, 1H), 3.81 (m, 1H), 3.23 (dd, J1 = 3 Hz, J2 = 13 Hz, 1H), 3.12 (d, J = 11.5 Hz, 1H), 
2.88 (m, 2H), 2.80 (dd, J1 = 10 Hz, J2 = 13 Hz, 2H), 2.65 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 2.59 (dd, J1 = 
10.5 Hz, J2 = 13 Hz, 1H), 2.19 (dd, J1 = 2 Hz, J2 = 13 Hz, 1H), 1.97 (m, 2H), 1.73 (dt, J1 = 3 Hz, J2 = 13 
Hz, 1H), 1.63 (d, J = 11.5 Hz, 1H), 1.54-1.14 (complex, 13H). 
13
C NMR (500 MHz, CDCl3) δ ppm 
173.19, 135.23, 129.70, 128.99, 126.40, 69.43, 69.05, 58.67, 53.36, 52.33, 50.69, 37.16, 31.24, 28.52, 
25.15, 23.48. HRMS (m/z): [M + H]
+
 calc. for C20H34N3O2S, 380.2372; observed, 380.2370. 
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1-((2R,3R)-3-(2-naphthamido)-2-hydroxy-4-(phenylthio)butyl)-N-(tert-butyl)piperidine-2-
carboxamide (139) 
 To a solution of 138 (55 mg, 0.145 mmol) in THF (5 mL) was added 2-naphthoic acid (27 mg, 
0.159 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (30 mg, 0.159 mmol), and 
hydroxybenzotriazole hydrate (26 mg, 0.159 mmol). The solution was stirred at room temperature for 18 
h. The reaction was taken up in ethyl acetate and washed once with water, once with saturated sodium 
bicarbonate, and once with brine. The ethyl acetate fraction was dried over sodium sulfate, concentrated 
by rotary evaporation, and purified by silica flash column chromatography (gradient of 1-4% MeOH in 
DCM) to yield 139 as a white solid (62 mg, 80% over two steps). 
1
H NMR (500 MHz, CDCl3) δ ppm 
8.15 (s, 1H), 7.82 (m, 3H), 7.74 (d, J = 8.5 Hz, 1H), 7.52 (m, 2H), 7.39 (dd, J1 = 1 Hz, J2 = 8.5 Hz, 2H), 
7.24 (t, J = 7.5 Hz, 2H), 7.16 (t, J = 7.5 Hz, 1H), 7.04 (d, J = 7.5 Hz, 1H), 6.51 (s, 1H), 4.29 (m, 1H), 4.07 
(m, 1H), 3.36 (dd, J1 = 9 Hz, J2 = 14 Hz, 1H), 3.24 (dd, J1 = 4.5 Hz, J2 = 14 Hz, 1H), 3.05 (d, J = 11.5 Hz, 
1H), 2.62 (dd, J1 = 10.5 Hz, J2 = 13 Hz, 1H), 2.56 (dd, J1 = 3 Hz, J2 = 6 Hz, 1H), 2.17 (d, J = 14 Hz, 1H), 
1.89 (m, 2H), 1.68 (m, 1H), 1.59-1.13 (complex, 14H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.43, 
168.00, 135.47, 134.77, 132.45, 131.07, 129.90, 129.14, 128.92, 128.33, 127.68, 127.65, 126.67, 126.62, 
123.62, 69.30, 69.19, 59.27, 53.50, 52.41, 50.79, 34.38, 31.26, 28.56, 25.14, 23.51. HRMS (m/z): [M + 
H]
+
 calc. for C31H40N3O3S, 534.2790; observed, 534.2784. 
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(3S,4aS,8aS)-2-((2R,3R)-3-(4-benzoylbenzamido)-2-hydroxy-4-(phenylthio)butyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (140) 
 This reaction was performed according to the general EDC coupling procedure (0.050 mmol 4-
benzoylbenzoic acid for 40 hours). Purification by flash column chromatography (gradient of 1-3% 
MeOH in DCM) yielded 140 as a white solid (28.6 mg, 93%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.96 
(d, J = 8 Hz, 2H), 7.93 (d, J = 8.5 Hz, 1H), 7.80-7.78 (m, 4H), 7.61 (t, J = 7.5 Hz, 1H), 7.49 (t, J = 8 Hz, 
2H), 7.43 (dd, J1 = 1.5 Hz, J2 = 8 Hz, 2H), 7.28 (t, J = 7.5 Hz, 2H), 7.19 (t, J = 7.5 Hz, 1H), 5.49 (s, 1H), 
4.53 (m, 1H), 4.16 (m, 1H), 3.90 (dd, J1 = 9.5 Hz, J2 = 14 Hz, 1H), 3.44 (dd, J1 = 5 Hz, J2 = 13.5 Hz, 1H), 
2.94 (dd, J1 = 1.5 Hz, J2 = 11.5 Hz, 1H), 2.57 (dd, J1 = 10.5 Hz, J2 = 13 Hz, 1H), 2.42 (dd, J1 = 3 Hz, J2 = 
12 Hz, 1H), 2.19 (dd, J1 = 4 Hz, J2 = 12.5 Hz, 1H), 2.15 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 2.03 (q, J = 12 
Hz, 1H), 1.82-1.14 (complex, 11H), 1.07 (s, 9H). 
13
C NMR (500 MHz, CDCl3) δ ppm 195.99, 174.05, 
168.97, 140.10, 137.17, 137.05, 135.42, 132.82, 130.14, 130.06, 129.78, 129.05, 128.37, 128.06, 126.46, 
70.83, 70.03, 59.55, 58.87, 55.95, 51.29, 36.10, 35.57, 33.92, 31.15, 30.97, 28.47, 26.36, 26.07, 20.43. 
HRMS (m/z): [M + H]
+
 calc. for C38H48N3O4S, 642.3366; observed, 642.3362. 
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(3S,4aS,8aS)-N-(tert-butyl)-2-((2R,3R)-3-(3-ethynylbenzamido)-2-hydroxy-4-
(phenylthio)butyl)decahydroisoquinoline-3-carboxamide (141) 
 This reaction was performed according to the general EDC coupling procedure (0.065 mmol 3-
ethynylbenzoic acid for 40 hours). Purification by flash column chromatography (gradient of 1-3% 
MeOH in DCM) yielded 141 as a slightly yellow solid (21.8 mg, 66%). 
1
H NMR (400 MHz, CDCl3) δ 
ppm 7.97 (s, 1H), 7.84 (d, J = 7.5 Hz, 1H), 7.80 (d, J = 8.5 Hz, 1H), 7.58 (d, J = 8 Hz, 1H), 7.42 (dd, J1 = 
1 Hz, J2 = 8.5 Hz, 2H), 7.36 (t, J = 7.5 Hz, 1H), 7.27 (t, J = 7.5 Hz, 2H), 7.18 (t, J = 7.5 Hz, 1H), 5.46 (s, 
1H), 4.50 (m, 1H), 4.14 (m, 1H), 3.87 (dd, J1 = 9 Hz, J2 = 13.5 Hz, 1H), 3.45 (dd, J1 = 5 Hz, J2 = 13.5 Hz, 
1H), 2.96-2.88 (m, 2H), 2.55 (dd, J1 = 10 Hz, J2 = 13 Hz, 1H), 2.42 (dd, J1 = 2.5 Hz, J2 = 11.5 Hz, 1H), 
2.21-2.14 (m, 2H), 2.04 (q, J = 11.5 Hz, 1H), 1.83-1.15 (complex, 11H), 1.08 (s, 9H). 
13
C NMR (500 
MHz, CDCl3) δ ppm 173.96, 168.93, 135.40, 135.01, 134.08, 131.66, 130.17, 129.05, 128.49, 128.35, 
126.51, 122.44, 82.80, 77.97, 70.85, 70.14, 59.57, 58.84, 55.88, 51.31, 36.11, 35.51, 33.94, 31.15, 30.99, 
28.45, 26.37, 26.06, 20.44. HRMS (m/z): [M + H]
+
 calc. for C33H44N3O3S, 562.3103; observed, 562.3102. 
 
 
(R)-boc-4-oxo-norvaline (142) 
 (R)-Boc-4,5-dehydro-leucine dicyclohexylammonium salt (ChemImpex, 1.005 g, 2.45 mmol) 
was dissolved in DCM and cooled to -78°C. Ozone was bubbled through the reaction until a purplish-blue 
color persisted. Oxygen was flushed through the reaction until the solution was colorless. The reaction 
was warmed to room temperature, dimethyl sulfide (449 uL, 6.12 mmol) was added, and the reaction was 
stirred overnight (18 h). The solvent and excess dimethyl sulfide were removed by evaporation and the 
residue was purified by silica flash column chromatography (gradient of 0-3% MeOH in DCM with 0.1% 
acetic acid) to yield 142 as an amber oil (433 mg, 76%). 
1
H NMR (500 MHz, CDCl3) δ ppm 5.56 (d, J = 8 
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Hz, 1H), 4.46 (m, 1H), 3.13 (dd, J1 = 4 Hz, J2 = 18 Hz, 1H), 2.94 (dd, J1 = 3.5 Hz, J2 = 17.5 Hz, 1H), 2.67 
(d, J = 2 Hz, 3H), 1.40 (s, 9H). Residual acetic acid from the purification is visible at 2.14 ppm. 
13
C NMR 
(500 MHz, CDCl3) δ ppm 206.76, 174.47, 155.60, 80.00, 49.26, 45.19, 39.72, 28.17. HRMS (m/z): [M + 
Na]
+
 calc. for C10H17NO5Na, 254.1004; observed, 254.1008. 
 
 
(R)-boc-photo-leucine (143) 
 A three-necked flask containing 142 (449 mg, 1.94 mmol) was fitted with a dry ice condenser and 
cooled to -78°C. The flask was purged with dry nitrogen before gaseous ammonia (15 mL) was slowly 
condensed into the flask. The reaction was placed in an ice water bath and refluxed with stirring for 5 h. 
The reaction was then cooled to -78°C and a solution of hydroxylamine-O-sulfonic acid (253 mg, 2.23 
mmol) in anhydrous methanol (1.5 mL) was added over 15 min. The reaction was warmed to reflux for 
another 1 h. Anhydrous methanol (3 mL) was added and the reaction was warmed to room temperature. 
The ammonia was purged from the system with nitrogen and the reaction was stirred at room temperature 
overnight, which caused a white slurry to form. The slurry was filtered, the filter cake was washed with 
methanol, and triethylamine (270 uL, 1.94 mmol) was added to the combined filtrate and wash. The 
filtrate was concentrated to 8 mL and more triethylamine (270 uL, 1.94 mmol) was added. The solution 
was cooled to 0°C and titrated with a solution of iodine in methanol (0.1 M) until an orange color 
persisted. Solvent was removed by rotary evaporation and the residue was brought up in water. The pH 
was adjusted to 2 with 1 M HCl and solution was extracted three times with ethyl acetate. The combined 
organic fractions were washed with brine, dried over sodium sulfate, concentrated by rotary evaporation, 
and purified by silica flash column chromatography (gradient of 0-3% MeOH in DCM with 0.1% acetic 
acid). The product was taken up in ethyl acetate and washed twice with 0.5M HCl and once with brine to 
remove residual acetic acid. The organic layer was dried over sodium sulfate and concentrated by rotary 
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evaporation to yield 143 as an amber oil (240 mg, 51% yield). The product was determined to exist as a 
mixture of rotamers by 1D selective chemical-exchange NMR
60
. 
1
H NMR (500 MHz, CDCl3, mixture of 
rotamers) δ ppm 11.40 (br s, 1H), 6.76 (d, J = 6.5 Hz, 0.4H), 5.18 (d, J = 8 Hz, 0.6H), 4.39 (d, J = 5 Hz, 
0.6H), 4.12 (d, J = 4.5 Hz, 0.4H), 2.06 (dd, J1 = 4.5 Hz, J2 = 15 Hz, 0.6H), 1.88 (dd, J1 = 4 Hz, J2 = 15 
Hz, 0.4H), 1.71 (dd, J1 = 8.5 Hz, J2 = 14 Hz, 0.4H), 1.61 (dd, J1 = 9 Hz, J2 = 14.5 Hz, 0.6H), 1.48 (s, 9H), 
1.10 (s, 3H).
 13
C NMR (500 MHz, CDCl3, mixture of rotamers) δ ppm 175.95, 175.62, 156.71, 155.38, 
82.37, 80.56, 50.71, 50.10, 37.73, 37.55, 28.21, 23.69, 23.48, 19.91, 19.60. HRMS (m/z): [M + H]
+
 calc. 
for C10H18N3O4, 244.1297; observed, 244.1303. 
 
 
Tert-butyl (R)-(4-diazo-1-(3-methyl-3H-diazirin-3-yl)-3-oxobutan-2-yl)carbamate (144) 
 To a stirred solution of 143 (415 mg, 1.71 mmol) in anhydrous tetrahydrofuran (10 mL) under 
nitrogen at -78 °C was added anhydrous triethylamine (355 μL, 2.56 mmol) followed by isobutyl 
chloroformate (333 μL, 2.56 mmol). The reaction was stirred cold for 1 hour and then warmed to room 
temperature for 1.5 h. The reaction was cooled to -78 °C before an ethereal solution of diazomethane (25 
mL, 8.1 mmol) was added in one portion and the reaction was then warmed to room temperature with 
stirring for 1 hour. The reaction was evaporated to dryness, resulting in a yellow solid. The solid was 
taken up in ethyl acetate, washed twice with water, twice with a saturated solution of sodium bicarbonate, 
and once with brine. The organic phase was dried over sodium sulfate and concentrated by rotary 
evaporation. The product was purified by silica flash column chromatography (gradient of 0-30% EtOAc 
in hexanes) to yield 144 as a yellowish solid (273 mg, 60%). 
1
H NMR (500 MHz, CDCl3) δ ppm 5.61 (s, 
1H), 5.23 (d, J = 8 Hz, 1H), 4.17 (m, 1H), 2.03 (dd, J1 = 5 Hz, J2 = 15 Hz, 1H), 1.47 (s, 9H), 1.44 (m, 
1H), 1.08 (s, 3H). 
13
C NMR (500 MHz, CDCl3) δ ppm 192.86, 155.04, 80.33, 54.08, 53.69, 37.00, 28.20, 
23.65, 19.76. HRMS (m/z): [M + Na]
+
 calc. for C11H17N5O3Na, 290.1229; observed, 290.1223. 
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Tert-butyl (R)-(4-chloro-1-(3-methyl-3H-diazirin-3-yl)-3-oxobutan-2-yl)carbamate (145) 
 To a solution of 144 (273 mg, 1.02 mmol) in anhydrous tetrahydrofuran under nitrogen at 0 °C 
was added 1 M HCl in diethyl ether (1.53 mL, 1.53 mmol) dropwise. The reaction was stirred at 0 °C for 
30 min after complete addition. The solution was dried under reduced pressure to yield 145 as a white 
solid (278 mg). No further purification was made. 
1
H NMR (500 MHz, CDCl3) δ ppm 5.13 (d, J = 7.5 Hz, 
1H), 4.39 (m, 1H), 4.30 (s, 2H), 2.13 (dd, J1 = 5 Hz, J2 = 15 Hz, 1H), 1.49 (m, 1H), 1.47 (s, 9H), 1.09 
(3H). 
13
C NMR (500 MHz, CDCl3) δ ppm 200.58, 155.17, 80.90, 53.67, 46.42, 36.01, 28.22, 23.55, 
19.81. HRMS (m/z): [M + H]
+
 calc. for C11H19N3O3Cl, 276.1115; observed, 276.1117. 
 
 
Tert-butyl ((2R,3R)-4-chloro-3-hydroxy-1-(3-methyl-3H-diazirin-3-yl)butan-2-yl)carbamate (146) 
 To a solution of 145 (278 mg, 1.01 mmol) in dichloromethane (5 mL) and methanol (3 mL) under 
nitrogen at 0 °C was added sodium borohydride (27 mg, 0.714 mmol). The reaction was stirred at 0 °C for 
1 h, and then quenched with slow addition of 2 M HCl (2 mL). The reaction was evaporated to dryness 
and the solid was taken up in ethyl acetate. The solution was washed twice with water followed by brine, 
dried over sodium sulfate, and concentrated by rotary evaporation. TLC analysis showed two 
diastereomers with the lower Rf compound being the (R,R) product. Both diastereomers were purified by 
silica flash column chromatography (gradient of 0-6% EtOAc in DCM) to yield 146 as a white solid (183 
mg, 65%) over two steps. 
1
H NMR (500 MHz, CDCl3) δ ppm 4.78 (d, J = 9 Hz, 1H), 3.80 (br s, 1H), 3.67 
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(m, 1H), 3.60 (dd, J1 = 4 Hz, J2 = 11.5 Hz, 1H), 3.51 (dd, J1 = 8 Hz, J2 = 11 Hz, 1H), 3.15 (d, J = 4 Hz, 
1H), 1.92 (dd, J1 = 3 Hz, J2 = 15 Hz, 1H), 1.48 (s, 9H), 1.33 (dd, J1 = 11 Hz, J2 = 15 Hz, 1H), 1.07 (s, 
3H). 
13
C NMR (500 MHz, CDCl3) δ ppm 155.76, 80.33, 73.89, 49.97, 46.89, 34.81, 28.32, 24.10, 19.77. 
HRMS (m/z): [M + H]
+
 calc. for C11H21N3O3Cl, 278.1271; observed, 278.1278. 
 
 
Tert-butyl ((R)-2-(3-methyl-3H-diazirin-3-yl)-1-((R)-oxiran-2-yl)ethyl)carbamate (147) 
 To a solution of 146 (183 mg, 0.659 mmol) in ethanol (10 mL) at 0 °C was added solid potassium 
hydroxide (41 mg, 0.725 mmol). The reaction was stirred cold for 15 min then warmed to room 
temperature and stirred for an additional 2 h. The reaction was evaporated to dryness and the solid was 
purified by silica flash column chromatography (gradient of 1-4% EtOAc in DCM) to yield 147 as a 
white solid (147 mg, 92%). 
1
H NMR (500 MHz, CDCl3) δ ppm 4.72 (br s, 1H), 3.51 (br s, 1H), 2.89 (s, 
1H), 2.79 (t, J = 4 Hz, 1H), 2.72 (s, 1H), 1.78 (dd, J1 = 2.5 Hz, J2 = 14.5 Hz, 1H), 1.47 (s, 9H), 1.35 (m, 
1H), 1.07 (s, 3H). 
13
C NMR (500 MHz, CDCl3) δ ppm 155.07, 79.79, 53.40, 48.89, 46.30, 36.58, 28.25, 
23.75, 19.60. HRMS (m/z): [M + H]
+
 calc. for C11H20N3O3, 242.1505; observed, 242.1508. 
 
 
Tert-butyl ((2R,3S)-4-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-3-
hydroxy-1-(3-methyl-3H-diazirin-3-yl)butan-2-yl)carbamate (148) 
 To a solution of 147 (62 mg, 0.257 mmol) in isopropyl alcohol (7 mL) was added (3S,4aS,8aS)-
N-(tert-butyl)decahydroisoquinoline-3-carboxamide (6, 67 mg, 0.283 mmol). The solution was heated to 
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reflux and stirred. After 6 h, the reaction was cooled and dried to a solid. The product was purified by 
silica flash column chromatography (gradient of 0-6% MeOH in DCM) to yield 148 as a white solid (91 
mg, 74%). 
1
H NMR (500 MHz, CDCl3) δ ppm 6.21 (s, 1H), 4.87 (d, J = 9 Hz, 1H), 3.77 (d, J = 10 Hz, 
1H), 3.59 (br, 2H), 2.83 (d, J = 11 Hz, 1H), 2.62 (dd, J1 = 3 Hz, J2 = 11 Hz, 1H), 2.38 (dd, J1 = 11 Hz, J2 
= 12.5 Hz, 1H), 2.15 (dd, J1 = 3.5 Hz, J2 = 11.5 Hz, 1H), 1.99 (d, J = 13 Hz, 1H), 1.87 (q, J = 12 Hz, 1H), 
1.82-1.20 (complex, 31H), 1.05 (s, 3H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.40, 155.68, 79.68, 
69.85, 69.61, 58.39, 58.22, 50.80, 50.34, 35.79, 34.79, 33.25, 30.96, 30.82, 28.60, 28.37, 26.24, 25.46, 
24.16, 20.19, 19.68. HRMS (m/z): [M + H]
+
 calc. for C25H46N5O4, 480.3550; observed, 480.3551. 
 
 
(3S,4aS,8aS)-2-((2S,3R)-3-(2-naphthamido)-2-hydroxy-4-(3-methyl-3H-diazirin-3-yl)butyl)-N-(tert-
butyl)decahydroisoquinoline-3-carboxamide (149) 
 A solution of trifluoroacetic acid and dichloromethane (1:1, 6 mL) was used to dissolve 148 (46 
mg, 0.096 mmol). The reaction was stirred at room temperature for 1 h then dried to a solid. The residue 
was taken up in water and the pH adjusted to 10 with 10 M NaOH. The aqueous phase was extracted 
three times with ethyl acetate. The ethyl acetate fractions were combined and washed once with 10 M 
NaOH and once with brine.  The ethyl acetate was dried over sodium sulfate and dried to a solid. The 
solid was taken up in tetrahydrofuran (5 mL), 2-naphthoic acid (18 mg, 0.103 mmol), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (20 mg, 0.103 mmol), and hydroxybenzotriazole 
hydrate (17 mg, 0.103 mmol) were added, and the solution was stirred at room temperature for 18 h. The 
reaction was taken up in ethyl acetate and washed once with saturated sodium bicarbonate and once with 
brine. The ethyl acetate fraction was dried over sodium sulfate, concentrated by rotary evaporation, and 
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purified by silica flash column chromatography (gradient of 10-60% EtOAc in hexanes) to yield 149 as a 
white solid (22 mg, 44%). 
1
H NMR (500 MHz, CDCl3) δ ppm 8.40 (s, 1H), 7.95-7.87 (complex, 4H), 
7.56 (m, 2H), 6.84 (d, J = 9 Hz, 1H), 6.06 (s, 1H), 4.27 (m, 1H), 3.96 (br, 1H), 3.90 (dt, J1 = 2.5 Hz, J2 = 
10.5 Hz, 1H), 2.82 (dd, J1 = 1.5 Hz, J2 = 11.5 Hz, 1H), 2.62 (dd, J1 = 3.5 Hz, J2 = 11.5 Hz, 1H), 2.43 (dd, 
J1 = 10.5 Hz, J2 = 13 Hz, 1H), 2.16 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 2.10 (dd, J1 = 2.5 Hz, J2 = 13 Hz, 
1H), 1.90 (q, J = 11.5 Hz, 1H), 1.83 (dd, J1 = 3.5 Hz, J2 = 10.5 Hz, 1H), 1.78-1.12 (complex, 21H), 1.09 
(s, 3H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.50, 167.73, 134.82, 132.62, 131.50, 129.01, 128.49, 
127.76, 127.72, 127.70, 126.73, 123.69, 69.91, 69.80, 58.49, 58.25, 51.00, 49.90, 35.82, 34.37, 33.27, 
31.02, 30.86, 28.64, 26.21, 25.39, 24.46, 20.14, 19.55. HRMS (m/z): [M + H]
+
 calc. for C31H44N5O3, 
534.3444; observed, 534.3450. 
 
 
(3S,4aS,8aS)-N-(tert-butyl)-2-((2S,3R)-3-(3-ethynylbenzamido)-2-hydroxy-4-(3-methyl-3H-diazirin-
3-yl)butyl)decahydroisoquinoline-3-carboxamide (150) 
 A solution of 47.5% trifluoroacetic acid, 47.5% dichloromethane, and 5% thioanisole (5 mL) was 
cooled to 0°C and used to dissolve 148 (47 mg, 0.098 mmol). The reaction was stirred cold for 30 min 
then dried to a solid. The residue was taken up in water and the pH adjusted to 10 with 10 M NaOH. The 
aqueous phase was extracted three times with ethyl acetate. The ethyl acetate fractions were combined, 
washed once with brine, dried over sodium sulfate, and dried to a solid. The solid was taken up in 
tetrahydrofuran (5 mL), 3-ethynylbenzoic acid (16 mg, 0.108 mmol), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (21 mg, 0.108 mmol), and hydroxybenzotriazole 
hydrate (18 mg, 0.108 mmol) were added, and the solution was stirred at room temperature for 18 h. The 
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reaction was taken up in ethyl acetate and washed once with saturated sodium bicarbonate and once with 
brine. The ethyl acetate fraction was dried over sodium sulfate, concentrated by rotary evaporation, and 
purified by silica flash column chromatography (gradient of 10-80% EtOAc in hexanes) to yield 150 as a 
white solid (24 mg, 48%). 
1
H NMR (500 MHz, CDCl3) δ ppm 7.98 (t, J = 1.5 Hz, 1H), 7.86 (dt, J1 = 1.5 
Hz, J2 = 8 Hz, 1H), 7.62 (dt, J1 = 1.5 Hz, J2 = 8 Hz, 1H), 7.42 (t, J = 8 Hz, 1H), 6.71 (d, J = 9 Hz, 1H), 
5.97 (s, 1H), 4.21 (m, 1H), 3.85 (dt, J1 = 3 Hz, J2 = 10 Hz, 1H), 3.13 (s, 1H), 2.84 (dd, J1 = 2 Hz, J2 = 11.5 
Hz, 1H), 2.63 (dd, J1 = 3.5 Hz, J2 = 11.5 Hz, 1H), 2.40 (dd, J1 = 10.5 Hz, J2 = 13 Hz, 1H), 2.18 (dd, J1 = 3 
Hz, J2 = 11.5 Hz, 1H), 2.10 (dd, J1 = 2 Hz, J2 = 13 Hz, 1H), 1.91 (q, J = 11.5 Hz, 1H), 1.82-1.14 
(complex, 23H), 1.07 (s, 3H). 
13
C NMR (500 MHz, CDCl3) δ ppm 173.43, 166.66, 134.99, 134.72, 
130.80, 128.70, 127.55, 122.73, 82.67, 78.24, 69.95, 69.66, 58.56, 58.10, 51.05, 49.76, 35.84, 34.29, 
33.31, 31.03, 30.88, 28.66, 26.23, 25.42, 24.36, 20.19, 19.54. HRMS (m/z): [M + H]
+
 calc. for 
C29H42N5O3, 508.3288; observed, 508.3304. 
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Chapter 3: Targeting aldehydes and ketones for reactivity based natural product discovery 
 I am grateful to Jonathan Tietz for helping to set up NMR experiments and advice on analyzing the data. 
3.1 Introduction 
 Natural products have historically been a valuable source of medically important drugs and drug 
leads or have served as inspirations for synthetic approaches.
1-3
 While novel natural products are still 
being discovered at a rapid pace, quickly filtering out known structures has become increasingly 
challenging.
4, 5
 This is especially true for traditional activity-based screening which selects for abundantly 
produced products and often results in rediscovery of compounds commonly produced by many species, 
such as streptomycin in antibiotic screening.
6
 Many natural products are easily missed by traditional 
screening due to production at very low levels (if at all) under laboratory conditions and but can be 
extremely interesting as tools to understand biological systems or as starting points for drug 
development.
3, 7, 8
 A number of inventive methods to facilitate natural product discovery that circumvent 
the issues surrounding activity-based screening have been advanced, including new cultivation 
techniques, bioinformatics guided discovery, activation of silent gene clusters, and chemoselective 
enrichment.
5, 9-12
 Similar to chemoselective enrichment, another strategy for the rapid identification of 
select natural products is to target a specific, reactive chemical handle that is generally not present on 
other cellular components. A recent example of this approach successfully targeted the α,β-unsaturated 
carbonyls present in dehydrated amino acid-containing natural products with a thiol nucleophile, resulting 
in the discovery of a novel thiopeptide.
13
 We aimed to expand the scope of this approach to additional 
reactive handles as well as introduce a method for the facile identification of labeled products based on a 
unique isotopic signature. 
 While not exceedingly common, aldehydes and ketones can be found on various natural products, 
especially those produced by polyketide synthases (PKS).
14
 For example, the ketone in erythromycin is 
formed due to the absence of a ketoreductase domain in the third module of the PKS and a similar 
strategy is commonly utilized in other PKS systems.
14, 15
 One method for the installation of aldehydes is 
through the oxidation of hydroxyl groups by cytochrome P450 type enzymes, as with the PKS products 
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tylosin and rosamicin.
16, 17
 Due to their rarity in most biological systems, aldehydes have previously been 
used for bioconjugation
18, 19
 with numerous examples of labeling on oligonucleotides
20, 21
 and 
glycoproteins.
22, 23
 These bioconjugations are typically carried out with aminooxy or hydrazine groups to 
afford oxime or hydrazone linkages respectively.
18
 Although oxime formation is sluggish for many 
substrates at neutral pH, sufficient reaction progress for detection of labeling can be achieved for 
aldehydes and more electrophilic ketones under mild conditions within a few hours.
24, 25
 We therefore 
reasoned that the aminooxy group could likewise be utilized in a probe for the discovery of aldehyde, and 
possibly ketone, containing natural products. 
 A major hurdle of natural product discovery that we sought to overcome with this strategy is the 
often extremely low quantities produced by most biosynthetic gene clusters under laboratory conditions.
3
 
Coupled with a complicated metabolic background, labeling events could be easily overlooked for low 
abundance compounds. We believed that the introduction of a unique isotopic signature to our probe 
would help ameliorate this issue by providing a distinct peak distribution for detection with mass 
spectrometry (MS). This concept was recently expounded by Bertozzi and coworkers, who found that a 
dibromide motif provides a unique and readily detectable pattern by MS.
26
 The naturally occurring 1:1 
ratio of Br
79
 to Br
81
 results in a symmetrical triplet with major peaks at M, M+2, and M+4. Based on this 
distribution, Bertozzi and coworkers developed a mass pattern prediction program, IsoStamp,
26
 which was 
successfully utilized for glycoproteome profiling.
27, 28
 By including a dibromide motif on an aldehyde 
reactive probe, we hoped to facilitate the discovery of low abundance natural products through reactivity 
based screening tied to facilitated peak detection, especially in the context of a complicated metabolic 
background (Figure 3.1). 
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Figure 3.1. Reaction scheme for labeling aldehydes and ketones with a dibrominated aminooxy probe. 
Labeled compounds will show a mass shift accompanied by a distinctive isotopic distribution by mass 
spectrometry, allowing facile identification of peaks of interest. Diagrams representing the mass shift and 
isotopic distribution upon labeling are shown beneath the reaction. 
 
3.2 Probe design and validation 
 Probe 2 was designed with an aminooxy warhead for the specific labeling of aldehyde and ketone 
chemical handles. While oxime formation can require hours or even days to reach completion at room 
temperature and neutral pH, complete labeling of the natural product is unnecessary for detection. We 
thus believed that 2 would be sufficient for labeling target natural products in 1 to 2 hours under mild 
conditions,
24
 while providing a highly stable oxime linkage.
29
 Probe 2 is also easily synthesized from 
readily available starting materials, requiring only a standard amide bond formation by EDC coupling 
followed by an acid deprotection (Scheme 3.1). A dibromide tag was included on 2 to provide a unique 
isotopic signature to aid in detection of labeled peaks by MS analysis (Figure 3.1). We believed that this 
signature would prove useful in situations where numerous extraneous signals from background 
metabolites resulted in overlapping peaks. The signature was also expected to be beneficial for low 
abundance compounds and for compounds that do not ionize well by MS. Finally, the distinctive isotopic 
distribution simplifies spectral analysis by providing an easily recognizable pattern that can be detected 
without comparison to a spectrum of the unreacted sample. Detection of labeled peaks could also be 
automated with software such as the IsoStamp program developed by Bertozzi and coworkers,
26
 but we 
found visual analysis of the resultant spectra to be extremely rapid and sufficient for our purposes. 
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Scheme 3.1. Synthesis of dibromo aminooxy probe 2
a
 
a
(a) 3-hydroxy-2-methylbenzoic acid, EDC, HOBt, THF (63%). (b) 4 M HCl in dioxane (55%). 
 
 With probe 2 in hand, we sought to establish a simple labeling and detection procedure and to 
validate the reactivity of the probe towards known aldehyde and ketone containing natural products. We 
selected a small panel of commercially available compounds with aldehydes and ketones in different 
chemical environments for this purpose. As oxime formation on aldehydes is much more rapid than on 
many ketones,
25
 we first tested labeling on streptomycin. Streptomycin is an aminoglycoside antibiotic 
produced by a number of Actinomycetes, including Streptomyces griseus, that contains an aldehyde group 
installed enzymatically in the penultimate step of its biosynthesis (Figure 3.2A).
30
 Reactions were 
performed with streptomycin and probe 2 in water for 2 hours at room temperature. The reaction mixture 
was then subjected to matrix assisted laser desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF-MS) analysis along with an unreacted standard. Near complete conversion of the peak 
corresponding to streptomycin (m/z 582.3 Da) to a peak with the unique isotopic distribution of a 
dibromide tag corresponding to labeled streptomycin (m/z 902.2 Da) was observed (Figure 3.2B). To 
confirm that probe 2 would also effectively label aldehydes in the context of a bacterial extract, the 
streptomycin producer Steptomyces griseus WC-3480 was grown on solid media and several colonies 
were used for a cell-surface extraction with water. As with commercial streptomycin, efficient labeling 
was readily observed (Figure 3.3). The labeling reaction was also successful with a range of organic 
solvents, including methanol, butanol, acetonitrile, ethyl acetate, and chloroform, indicating that the 
labeling reaction could be performed on extracts directly without the need to remove or dilute the 
extraction solvent. However, acetone and other aldehyde/ketone containing solvents cannot be used as the 
presence of the carbonyl rapidly quenches the probe. 
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Figure 3.2. Labeling of commercial streptomycin. (A) Structure of streptomycin. (B) MALDI-TOF MS 
spectra of streptomycin either unreacted (top) or labeled with aminooxy probe 2 (bottom). The labeled 
streptomycin peak is shown magnified to display the unique dibromide isotopic pattern. 
 
 
 
Figure 3.3. Labeling of streptomycin from S. griseus. MALDI-TOF MS spectra of extract from S. griseus 
WC3480 either unreacted (top) or labeled with aminooxy probe 2 (bottom). The labeled streptomycin 
peak is shown magnified to display the unique dibromide isotopic pattern. 
 
As aryl aldehydes are known to form oximes more slowly than alkyl aldehydes,
25
 the labeling 
reaction was also performed on anisaldehyde (Figure 3.4A). Although the unreacted compound was too 
small for detection with the MALDI-TOF-MS instrument employed in this study, a peak with a 
dibromine isotopic distribution was observed at the expected mass of the labeled product (m/z 456.9 Da) 
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(Figure 3.4B). In addition to confirming that probe 2 is effective at labeling aryl aldehydes, this result also 
supports the utility of this labeling strategy for the detection of very small molecules that are below the 
mass range of detection. Without the presence of the dibromide tag, the appearance of peaks at low m/z 
ratios in labeling reactions would be difficult to interpret due to the lack of detection of the unreacted 
natural product. 
 
Figure 3.4. Labeling of anisaldehyde. (A) Structure of anisaldehyde. (B) MALDI-TOF MS spectra of 
anisaldehyde either unreacted (top) or labeled with aminooxy probe 2 (bottom). Unlabeled anisaldehyde 
is below the mass to charge ratio cut-off of the MALDI-TOF MS instrument used and is thus not shown. 
The labeled anisaldehyde peak is shown magnified to display the unique dibromide isotopic pattern. 
 
 The labeling reaction was next tested on ketone-containing natural products to determine if the 
reaction would proceed rapidly enough to be of use in labeling this reactive handle. The macrolide 
antibiotic erythromycin, which contains a ketone in the macrocyclic ring (Figure 3.5A), was tested first in 
the labeling reaction. Surprisingly, no detectable labeling was observed under the mild reaction conditions 
employed, even when the reaction was allowed to proceed for multiple days (Figure 3.5B). This result 
was unexpected given that alkyl ketones with similar neighboring groups are known to react efficiently 
with hydrazine reagents.
25
 It is possible that erythromycin adopts a structure in solution that occludes the 
ketone and prevents oxime formation. If this were the case, other alkyl ketones would potentially be more 
susceptible to nucleophilic attack. The ketone containing natural products daunomycin and FK506 were 
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thus also tested and were found to efficiently label (Figure 3.6 and Figure 3.7). These data indicate that 
the exact chemical context of the ketone functionality is important in determining whether detectable 
labeling will be observed. 
 
Figure 3.5. Labeling of erythromycin. (A) Structure of erythromycin. (B) MALDI-TOF MS spectra of 
erythromycin either unreacted (top) or reacted with aminooxy probe 2 (bottom). No labeling of 
erythromycin was observed. 
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Figure 3.6. Labeling of commercial daunomycin (daunorubicin). (A) Structure of daunomycin. (B) 
Possible structure of an ionization-induced degradation product of daunomycin generated during MALDI 
ionization. Fully intact daunomycin produces a very weak or no signal by MALDI-TOF MS or ESI-MS. 
(C) MALDI-TOF MS spectra of daunomycin either unreacted (top) or labeled with aminooxy probe 2 
(bottom). The labeled peak of the ionization-induced degradation product is shown magnified to display 
the unique dibromide isotopic pattern. 
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Figure 3.7. Labeling of commercial FK506 (tacrolimus). (A) Structure of FK506. (B) MALDI-TOF MS 
spectra of FK506 either unreacted (top) or labeled with aminooxy probe 2 (bottom). The labeled FK506 
peak is close to the baseline and is shown magnified to display the unique dibromide isotopic pattern. 
 
3.3 Screening of the NCI NP collection 
 Due in part to the results during probe validation on ketones, the National Cancer Institute’s 
Natural Product (NCI NP) collection of 117 compounds was screening with probe 2. The collection 
contains a large number of diverse ketones in the context of natural products, providing an ideal set of test 
cases to further elucidate the specificity of this method. Further, many of the compounds in the collection 
contain additional functionality, including other potential electrophiles. This set of compounds thus 
provides an indirect screen of functional groups that may display off-target reactivity with the probe. 
 The reactions were run under standardized conditions in methanol at room temperature and were 
analyzed by MALDI-TOF-MS in positive mode. A peak corresponding to the natural product was 
observed for 83 of 117 compounds; the remainder either did not ionize effectively or appeared to be 
degraded (either due to instability of the compounds in storage or due to ionization induced 
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fragmentation). Of the compounds that did not effectively ionize, most were small, hydrophobic, and 
devoid of functionality that might easily ionize. These compounds also tended to lack any functionality 
that could reasonably be expected to react with a strong nucleophile such as an aminooxy group and thus 
their exclusion from the screening data is likely not significant. 
 The collection contained two compounds with aldehyde groups. One was severely degraded but 
labeling was observed for the other. Both of the two methyl ketones and both of the two α-keto-carbonyl 
containing compounds labeled as well, although one of the methyl ketones was daunomycin which had 
been previously tested independently of the NCI NP collection (Figure 3.8). The remaining ketones in the 
collection can be separated into three groups, each of which had one or two compounds label: saturated 
aliphatic (2/5), unsaturated aliphatic (2/13), and aryl (1/7) ketones (Figure 3.8 and Figure 3.9). These 
compounds did not display robust labeling, with the labeled peak having an ion intensity less than 5% of 
the unlabeled ion. The lone exception to this trend was virginiamycin S1, which interestingly showed near 
complete labeling (Figure 3.10). The differences between compounds that labeled and those that did not 
were often minute, indicating that subtle differences in the chemical context of the natural product can 
sufficiently adjust the reactivity of the ketone and dictate labeling. 
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Figure 3.8. Structures of NCI NP collection compounds that displayed observable labeling with probe 2. 
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Figure 3.9. Structures of NCI NP collection compounds that did not labeling with probe 2. 
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Figure 3.10. Labeling of commercial virginiamycin S1. (A) Structure of virginiamycin S1. (B) MALDI-
TOF MS spectra of virginiamycin S1 either unreacted (top) or labeled with aminooxy probe 2 (bottom). 
The labeled virginiamycin S1 [M+H]
+
 peak is shown magnified to display the unique dibromide isotopic 
pattern. 
 
Compounds containing other potential electrophiles, including other carbonyls, epoxides, 
chloroalkanes, and nitriles, displayed no reactivity towards the probe. None of the glycoside-containing 
natural products (6 compounds) labeled, although the sugars in all of these cases were non-reducing. 
Given that the utility of oxime bioconjugation in oligonucleotide research stems from the ability of 
aminooxy warheads to label the open form of deoxyribose at abasic sites,
21
 natural products containing 
reducing sugars may label. Interesting, 1 of 8 non-glycosidic acetals labeled, although the reason for this 
is unclear (Figure 3.8). A caveat to the analysis of any unlabeled compounds in this screen is that the NCI 
collection used may contain degraded compounds. Thus, a lack of labeling may not be due to a lack of 
reactivity, but rather from the degradation of the functional group of interest. 
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3.4 Screening of bacterial extracts 
 A previously generated extract collection that was created for Doroghazi et al.
10
 was obtained for 
screening by oxime labeling. The collection contains extracts from 334 strains of Actinomycetes grown 
on solid media. Extracts from an additional 14 strains of Actinomycetes that were collected prior to 
obtaining the larger collection were also screened. From these 348 extracts, 36 hits were initially 
identified. Eleven of the strains containing hits were selected for verification based on their availability, 
of which six were confirmed to contain compounds that were labeled with probe 2. The original extracts 
from the strains in which hits were not replicated had been in long term storage and may not have been 
stable over that time, perhaps forming ketones or aldehydes from the degradation of extracted glycans.  
 One of the hit strains contained two compounds that underwent complete labeling (m/z 582.3 and 
744.3). The species was identified as Streptomyces bikiniensis subsp. bikiniensis ISP-5582 and an 
analysis of the strain quickly revealed it to be a known producer of streptomycin and 
mannosidostreptomycin (Figure 3.11). High resolution masses matched the hit masses to these known 
antibiotics and thus these hits were considered as further validation for the screening method. Another hit 
found in Streptomyces albulus B-3066 (m/z 606.3 Da) was then chosen for follow up as a high resolution 
mass did not correspond to any known structures in the natural product database Dictionary of Natural 
Products and due to the ease of growing the organism on a large scale (Figure 3.12A). The hit was found 
to be an analog of the natural product antipain, which we have named antipain-cit (Figure 3.12B). 
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Figure 3.11. Labeling of streptomycin and mannosidostreptomycin (streptomycin B) in an extract from S. 
bikiniensis subsp. bikiniensis ISP-5582. (A) Structure of streptomycin (3). (B) Structure of 
mannosidostreptomycin (4). (C) MALDI-TOF MS spectra of S. bikiniensis extract either unreacted (top) 
or labeled with aminooxy probe 2 (bottom). 
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Figure 3.12. Labeling antipain-cit in S. albulus B3066. (A) MALDI-TOF MS spectra of partially purified 
bacterial extract either unreacted (top) or labeled with aminooxy probe 2 (bottom). The labeled peak is 
shown magnified to display the unique dibromide isotopic pattern. (B) Proposed structure of antipain-cit. 
(C) Structure of antipain. 
 
3.5 Isolation and structural determination of antipain-cit 
 Despite numerous efforts to purify antipain-cit by MPLC, HPLC, and ion exchange 
chromatography, conditions that did not cause excessive smearing of the compound were not identified. 
This was exacerbated by a weak chromophore, resulting in no defined peak in the UV trace during HPLC 
purification. Therefore, extract from S. albulus B3066 was labeled after desalting with a solid phase 
extraction column. The chromophore present on probe 2 provided a distinct signature in the UV trace and 
it quickly became apparent that antipain-cit was actually a collection of two major and two minor isomers 
(Figure 3.13A). One of the major isomers (antipain-cit-2) was purified in sufficient quantities to allow 
structural characterization (Figure 3.13B). 
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Figure 3.13. HPLC traces of labeled antipain-cit. (A) HPLC trace showing the 220 nm absorbance of 
partially purified, labeled antipain-cit. The peaks corresponding to the isomers of labeled antipain-cit are 
highlighted in red. (B) HPLC trace showing the 220 nm absorbance of purified antipain-cit for quality 
control. The two small peaks eluting before 5 min are part of the void and appear in blank runs. 
 
 The mass spectrum of the labeled product displayed an [M + H]
+
 ion of m/z 926.2156 while an 
analysis of the collision induced dissociation (CID) spectrum only suggested the presence of a 
phenylalanine residue (Figure 3.14). NMR spectroscopy was then used to establish that the structure was 
highly similar to the known natural product antipain, with the high resolution mass suggesting the 
substitution of one of the arginine residues for a citrulline (Figure 3.12B, C). Connectivity was 
determined by 
1
H-
1
H COSY, 
1
H-
1
H TOCSY, 
1
H-
1
H NOESY, 
 1
H-
13
C HSQC, and 
1
H-
13
C HMBC (Table 
3.1, Figure 3.15, and Figure 3.16). However, the location of the citrulline residue could not be 
conclusively determined due to the absence of cross peaks for the protons on the guanidine and urea 
groups of the arginine and citrulline respectively. Additional experiments will be required to conclusively 
determine the location of each residue. 
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Figure 3.14. High resolution Fourier transform mass spectrometry (FT-MS) analysis of antipain-cit (A) 
and labeled antipain-cit (B). CID spectrum of m/z 606 Da with monoisotopic masses given. *The loss of  
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Figure 3.14. (cont.) 
phenylalanine corresponds to the complete amino acid rather than the loss of 147 Da usually seen in 
peptide fragmentation. This is due to the urea connection between the phenylalanine and the remainder of 
the natural product. 
 
Position 
1H δ, ppm (J) 13C δ, ppm COSY TOCSY HMBC NOESY 
A 8.18 d (3.0 Hz) 119.42 B B B - 
B 7.16 d (3.0 Hz) 128.70 A A, C A - 
C 8.16 d (3.0 Hz) - - B - - 
D - 168.30 - - - - 
E 4.56 s 72.71 - - D - 
F 7.57 d (5.25 Hz) 152.50 G G, H, I, Ja, Jb, L G, H G 
G 4.47 q (6.75 Hz) 48.68 F, H F, H, I, Ja, Jb, L F, M F, H 
H 1.79 m 28.38 G, I F, G, I, Ja, Jb, L F, G, J G 
I 1.59 m 24.68 H, Ja, Jb F, G, H, Ja, Jb, L J J 
J a: 3.12 m 40.40 I, Jb F, G, H, I, Jb, L H, I, K I 
 
b: 3.17 m 
 
I, Ja F, G, H, I, Ja, L H, I, K I 
K - 157.24 - - - - 
L 8.12 m - - F, G, H, I, Ja, Jb - - 
M - 172.06 - - - - 
N 4.06 d (6.0 Hz) 59.27 O O, P, Q, R M, O, P, Q, S L, O, R 
O 2.11 dq (6.75, 13.7 Hz) 29.84 N, P, Q N, P, Q, R N, P, Q N, P, Q 
P 0.87 d (6.75 Hz) 17.11 O N, O, Q, R N, O, Q O 
Q 0.91 d (6.75 Hz) 18.44 O N, O, P, R N, O, P O 
R 7.58 m - - N, O, P, Q - N 
S - 174.40 - - - - 
T 4.03 dd (5.25, 8.25 Hz) 54.55 Ua, Ub Ua, Ub, V, W, X, Z S Ua, Z 
U a: 1.76 m 28.99 T, Ub, V T, Ub, V, W, X, Z - T 
 
b: 1.52 m 
 
T, Ua, V T, Ub, V, W, X, Z - - 
V 1.51 m 26.07 Ua, Ub, W T, Ua, Ub, W, X, Z W W 
W 3.10 m 38.97 V T, Ua, Ub, V, X, Z V, Y V 
X 6.21 m - - T, Ua, Ub, V, W, Z - - 
Y - 160.95 - - - - 
Z 6.57 d (6.75 Hz) - - 
T, Ua, Ub, V, W, 
X - T, A' 
A' 6.00 d (5.25 Hz) - - B', D'a, D'b - Z 
B' 4.30 m 56.87 D'a, D'b A', D'a, D'b C', D' D'a, D'b 
C' - 177.96 - - - - 
D' a: 3.13 m 38.30 B', D'b A', B', D'b B', E', F' B', D'b, F' 
 
b: 2.94 dd (7.5, 13.5 Hz) 
 
B', D'a A', B', D'a B', E', F' B', D'a, F' 
 
Table 3.1. NMR assignments for labeled antipain-cit. 
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E’ - 138.36 - - - - 
F' 7.23 m 129.15 G' G', H' D', E', G', H' D'a, D'b 
G' 7.22 m 127.82 F', H' F', H' H' - 
H' 7.14 m 125.86 G' G', F' - - 
 
Table 3.1. (cont.) 
Abbreviations: s, singlet; d, doublet; q, quartet; m, multiplet 
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Figure 3.15. NMR assignments for labeled antipain-cit. (A) Labeling scheme for NMR peak assignments. 
(B) 
1H peak assignments (δ ppm). (C) 13C peak assignments (δ ppm). (D) Though-molecular correlations  
from 
1
H-
13
C HMBC connectivity. (E) Though-molecular correlations from 
1
H-
1
H COSY/TOCSY 
connectivity. (F) Though-space correlations from 
1
H-
1
H NOESY connectivity. 
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Figure 3.16. NMR spectra for labeled antipain-cit. (A) 
1
H NMR in CD3OD. (B) 
1
H-
1
H COSY in CD3OD. 
(C) 
1
H-
1
H TOCSY in CD3OD. (D) 
1
H-
1
H TOCSY in CD3OH. (E) 
1
H-
13
C HSQC in CD3OD. (F) 
1
H-
13
C 
HMBC in CD3OD. (G) 
1
H-
1
H NOESY in CD3OH. 
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Figure 3.16. (cont.) 
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Figure 3.16. (cont.) 
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Figure 3.16. (cont.) 
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Figure 3.16. (cont.) 
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Figure 3.16. (cont.) 
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Figure 3.16. (cont.) 
 
 Antipain is a natural product produced by several species of Actinomycetes including 
Streptomyces yokosukanensis and Streptomyces michiganensis.
31
 The compound was found to possess 
inhibitory activity against serine and cysteine proteases and has been used commercially.
31
 One other 
analog of antipain (antipain Y) was recently described that contains a tyrosine in place of the 
phenylalanine residue.
32
 Antipain is known to exist as a mixture of the D- and L-arginal, with the 
aldehyde primarily tied up in either a cyclic hemiaminal forming from the ε-nitrogen or in a hydrate.33 As 
two stereoisomers result from formation of the cyclic hemiaminal, antipain thus exists as a complex 
mixture of eight isoforms: four cyclic hemiaminals, two hydrates, and two unhydrated aldehydes.
33
 This 
complexity as well as continuing conversion between the various isoforms is likely the cause of the 
difficulties encountered during purification with reverse phase liquid chromatography. The presence of 
both D- and L-arginal also likely accounts for two of the detected isomers in the labeled product, while 
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the other two isomers may arise from racemization of a second amino acid. Purification of unlabeled 
antipain-cit is ongoing and will allow for biological assays, although it is expected that it will also 
function as a protease inhibitor. The biosynthetic origin of antipain is currently unknown but we hope 
analysis of the genome after sequencing is completed will illuminate a gene cluster with the capacity to 
produce this modified tetrapeptide. 
3.6 Summary and outlook 
 In this study, we have developed a new tool for reactivity based screening for natural product 
discovery based on oxime formation. Probe 2 selectively labels aldehydes and certain ketones under 
extremely mild conditions, and the method utilizes commonly available laboratory equipment. Although 
many ketones do not label to an observable extent under the reaction conditions used here, more 
aggressive reaction conditions or previously reported catalysts
34, 35
 could be employed to widen the scope 
of the reaction. However, utilizing conditions with significantly highly reactivity may cause problems 
with labeling other cellular components, such as sugars. Aldehydes are not generally found on primary 
metabolites so hits from screening with mild conditions have a high probability of being natural products 
of interest. The lack of off-target reactivity also allows large excesses of probe to be used without the 
need for accurate stoichiometric calculations. The dibromide tag on probe 2 allows for rapid analysis of 
mass spectra for labeled products. The unique isotopic distribution aids in determining true labeling 
events in noisy spectra and for products that are produced in small quantities or that do not ionize well. 
 The use of oxime ligations in natural product discovery was validated by labeling several 
aldehyde or ketone containing natural products, including streptomycin, daunomycin, and virginiamycin 
S1. Screening of a collection of 348 bacterial extracts led to the discovery of a new natural product, 
antipain-cit, as well as the dereplication of streptomycin and mannosidostreptomycin. Labeling of 
antipain-cit with probe 2 facilitated the isolation of a single isomer for structural elucidation. The 
structure of antipain-cit was determined through high resolution MS and NMR spectroscopy. Biological 
activity testing will be performed once unlabeled material is isolated, although it is likely that antipain-cit 
also acts as a serine and cysteine protease inhibitor. Sequencing of the genome of S. albulus B3066 is 
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ongoing and identification of the gene cluster responsible for the production of antipain-cit will hopefully 
provide insight into how the aldehyde and urea linkage moieties are installed, as these are both fairly 
uncommon and understudied groups in natural products. 
3.7 Experimental 
3.7.1 Materials 
All chemicals were purchased from Sigma-Aldrich, VWR, or Fisher Scientific and used without 
further purification unless otherwise specified. 
3.7.2 Synthesis 
1
H and 
13
C NMR spectra were collected on Varian Inova 500 MHz spectrometers. All 
1
H and 
13
C 
spectra were referenced to the solvent peaks. High-resolution mass spectrometry (HRMS) data were 
obtained on a Micromass Q-TOF Ultima tandem quadrupole mass-spectrometer at the University of 
Illinois at Urbana-Champaign Mass Spectrometry Laboratory. 
 
Tert-butyl (2-((3,5-dibromo-2-hydroxyphenyl)amino)-2-oxoethoxy)carbamate (1) 
 To a solution of (Boc-aminooxy)acetic acid (200 mg, 1.05 mmol) in dry tetrahydrofuran (10 mL) 
was added 2-amino-4,6-dibromophenol (294 mg, 1.10 mmol), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (220 mg, 1.15 mmol), and hydroxybenzo-triazole 
hydrate (186 mg, 1.15 mmol). The solution was stirred at room temperature for 18 h. The reaction was 
then taken up in ethyl acetate and washed twice with saturated sodium bicarbonate and once with brine. 
The ethyl acetate fraction was dried over sodium sulfate and concentrated by rotary evaporation. The 
product was purified by silica flash column chromatography (gradient of 0-25% ethyl acetate in hexanes) 
to yield 1 as an orange solid (292 mg, 63%). 
1
H NMR (500 MHz, CDCl3) δ ppm 10.66 (br, 1H), 9.64 (br, 
1H), 7.92 (s, 1H), 7.52 (d, J = 2.5 Hz, 1H), 7.43 (d, J = 2 Hz, 1H), 4.52 (s, 2H), 1.52 (s, 9H). 
13
C NMR 
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(500 MHz, CDCl3) δ ppm 169.49, 158.67, 145.26, 132.43, 127.16, 124.61, 114.28, 111.52, 84.51, 76.28, 
28.08. HRMS (m/z): [M + Na]
+
 calc. for C13H16N2O5Br2Na, 460.9324; observed, 460.9320. 
 
2-(aminooxy)-N-(3,5-dibromo-2-hydroxyphenyl)acetamide (2) 
 The boc protected probe 1 (122 mg, 0.277 mmol) was dissolved in 4 M HCl in dioxane (3 mL) 
and stirred at room temperature for 3 h. The reaction was taken up in ethyl acetate and washed twice with 
saturated sodium bicarbonate and once with brine. The ethyl acetate fraction was dried over sodium 
sulfate and concentrated by rotary evaporation. The product was purified by silica flash column 
chromatography (gradient of 0-5% methanol in dichloromethane) to yield 2 as a white solid (52 mg, 
55%). 
1
H NMR (500 MHz, (CD3)2SO) δ ppm 8.02 (d, J = 2 Hz, 1H), 7.51 (d, J = 2.5 Hz, 1H), 4.18 (s, 
2H). 
13
C NMR (500 MHz, (CD3)2SO) δ ppm 169.83, 144.49, 129.60, 129.35, 123.62, 112.33, 110.91, 
74.31. HRMS (m/z): [M - H]
-
 calc. for C8H7N2O3Br2, 336.8823; observed, 336.8816. 
3.7.3 Test labeling reactions 
Labeling reactions for streptomycin, daunomycin, 4-anisaldehyde, and FK-506 were prepared in 
water, methanol, or ethanol with a final concentration of 1 µM aldehyde or ketone and 1 mM probe 2 
from 10x stocks (in water or ethanol). The choice of reaction solvent did not significantly affect labeling. 
The reactions were run at room temperature for 3 h with occasional manual shaking. The reactions were 
analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF 
MS) in reflector positive mode using α-cyano-4-hydroxycinnamic acid (CHCA) as a matrix. 
3.7.4 Screening of the NCI NP collection 
The Natural Products Set III, consisting of a select set of 117 natural products, was obtained from 
the National Cancer Institute’s Developmental Therapeutics Program. The compound set was 
reconstituted by the addition of 18 µL of DMSO to give a final stock of 20 µL at 10 mM for each 
compound. The compounds were further diluted to 1 mM with DMSO before use in screening. The screen 
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was performed by the addition of 3 µL of the 1 mM natural product stock solutions to 24 µL methanol 
followed by the addition of 3 µL of a 10 mM stock of 2 in methanol. The reactions were sealed and 
incubated at room temperature without stirring for 24 h. The reactions were analyzed by MALDI-TOF 
MS in reflector positive mode using α-cyano-4-hydroxycinnamic acid (CHCA) as a matrix. Matrix 
suppression was disabled and the detection range was set from the minimum allowed (200 Da) to 2000 
Da. 
3.7.5 Verification of streptomycin labeling in S. griseus and S. bikiniensis extract 
Frozen stocks of S. griseus WC-3480 and S. bikiniensis ISP5582 were streaked out on agar plates 
of ATCC172 media (10 g/L glucose, 20 g/L soluble starch, 5 g/L yeast extract, 5 g/L N-Z amine type A 
(Sigma C0626), 1 g/L reagent grade calcium carbonate, pH 7.3) and grown at 30 °C for 10 d. Several 
colonies were then scrapped from the surface of the agar and suspended in 60% acetonitrile in water. The 
suspension was vortexed vigorously before use in labeling reactions. Reactions were set up with 9 µL of 
extract and 1 µL of a 10 mM solution of 2 in methanol or just methanol as a control. The reactions were 
incubated at room temperature overnight. The reactions were analyzed by MALDI-TOF MS in reflector 
positive mode using α-cyano-4-hydroxycinnamic acid (CHCA) as a matrix. 
3.7.6 Growth and extraction for extracts collected in this study 
Seed cultures of actinobacteria (5 mL) were grown in ATCC172 media at 30 °C on a tube roller 
for 4-7 d. A 1 mL portion of the seed cultures were used to inoculate 15 cm agar plates (60 mL media per 
plate) of ATCC172 (with 15 g/L agar), ISP4 (10 g/L soluble starch, 1 g/L potassium phosphate dibasic, 1 
g/L magnesium sulfate heptahydrate, 1 g/L sodium chloride, 2 g/L ammonium sulfate, 2 g/L calcium 
carbonate, 1 mg/L iron sulfate heptahydrate, 1 mg/L zinc sulfate heptahydrate, 1 mg/L manganese 
chloride tetrahydrate, 15 g/L agar, pH 7.2), or MS (10 g/L mannitol, 10 g/L soy flour (Kinako, Wel-Pac), 
10 g/L malt extract, 15 g/L agar). Agar plates were grown at 30 °C for 10 days. Bacteria and the top layer 
of agar were scrapped off the plate and extracted with methanol overnight. Solid material was removed by 
centrifugation at 20,000 x g for 30 min followed by careful removal of the liquid extract and 
concentration under reduced pressure. 
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3.7.7 Bacterial extract screening 
A previously described collection of extracts from actinobacteria
10
 combined with the extracts 
from above was screened using the aminooxy probe 2. The previously collected extracts had been 
partially purified on Oasis HLB extraction columns (Waters) and were dissolved in 50% acetonitrile in 
water. Labeling reactions were set up with 9 µL of extract solution and 1 µL of 2 from a 10 mM stock in 
ethanol in 0.2 mL tubes. The reactions were run for at least 3 h at room temperature with occasional 
manual shaking. Each reaction was submitted to MALDI-TOF MS in reflector positive mode using 
CHCA as a matrix. Spectra were analyzed manually for peaks displaying an isotope pattern consistent 
with the presence of two bromine atoms. Initial hits were verified by a follow up screen using the same 
conditions as above but with the commercially available 1-[(aminooxy)methyl]-4-chlorobenzene 
hydrochloride (Santa Cruz Biotechnology). 
3.7.8 Purification of antipain-cit from S. albulus B3066 
A frozen stock of S. albulus B3066 was streaked out on agar plates of ATCC172 media (10 g/L 
glucose, 20 g/L soluble starch, 5 g/L yeast extract, 5 g/L N-Z amine type A (Sigma C0626), 1 g/L reagent 
grade calcium carbonate, pH 7.3) and grown at 30 °C for 4 d. The plates were used to inoculate liquid 
cultures of ATCC172 media. The liquid cultures were grown at 30 °C for 7 days before they were used to 
inoculate 600 mL x 6 half sheet cake pans of solid ATCC172 media. The cake pans were incubated at 30 
°C for 10 d before harvesting. To harvest, the agar was frozen at -20 °C, warmed to room temperature, 
and squeezed to collect the liquid. The agar was then washed with 50% methanol in water and this wash 
was combined with the agar squeeze. The methanol was removed by evaporation and the remaining 
aqueous material was loaded onto a HyperSep C18 SPE 10 g column (Thermo Scientific). The column 
was washed with 200 mL water before product was eluted with 10-100% acetonitrile in water. Fractions 
containing antipain-cit were combined and dried to a solid. The material was taken up in 8 mL water and 
2 mL methanol and 10 mg of probe 2 was added. The reaction was stirred for 2 d at room temperature and 
was then adsorbed onto celite 545 and solid loaded onto an 86 g C18 reversed-phase column with a 
CombiFlash Rf 200 (Teledyne Isco). Chromatography was performed with a flow rate of 60 mL/min 
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using a gradient of 10-100% acetonitrile in water. Fractions containing antipain-cit were pooled and dried 
to a solid. The solid was resuspended in water and loaded onto a 250 mm x 10 mm inner diameter, 5 µm 
particle size Betasil C18 reversed-phase LC column (Thermo Scientific). Chromatography was performed 
with a flow rate of 4 mL/min using water with 10 mM ammonium bicarbonate (solvent A) and 
acetonitrile (solvent B) with a gradient of: 5 min of 17% B, 20 min ramp from 17% to 27% B, 5 min ramp 
from 27% to 95% B. Fractions containing the second isomer to elute were pooled and concentrated. 
Purity of the isolated labeled antipain-cit was evaluated by HPLC with a 250 mm x 4.6 mm inner 
diameter, 5 µm particle size Betasil C18 reversed-phase LC column (Thermo Scientific) using the same 
conditions as above but with a 1 mL/min flow rate. Isolated yield was approximately 2 mg for a single 
major isomer. 
3.7.9 FT-MS/MS analysis of antipain-cit 
Partially purified antipain-cit and labeled antipain-cit were dissolved in water. Samples were 
directly infused using an Advion Nanomate 100 into a ThermoFisher Scientific LTQ-FT hybrid linear ion 
trap, operating at 11T (calibrated weekly). The FT-MS was operated using the following parameters: 
minimum target signal counts, 5,000; resolution, 100,000; isolation width (MS/MS), 5 m/z; normalized 
collision energy (MS/MS), 35; activation q value (MS/MS), 0.4; activation time (MS/MS), 30 ms. Data 
analysis was conducted using the Qualbrowser application of Xcalibur software (Thermo-Fisher 
Scientific). 
3.7.10 NMR of labeled antipain-cit 
NMR spectra were collected on a Varian NMR System 750 MHz narrow bore magnet 
spectrometer (VNS750NB employing a 5 mm Varian 
1
H[
13
C/
15
N] PFG X, Y, Z probe) The spectrometer 
was operated at 750 MHz for 1 H detection and 188 MHz for indirect 13C detection. Carbon resonances 
were assigned only via indirect detection (HSQC and HMBC experiments). Resonances were referenced 
internally to the CD3OH solvent peak (3.30 ppm). Default Varian pulse sequences were employed for 
1
H, 
gCOSY, zTOCSY, dpfgse-TOCSY, HSQCAD, HMBCAD, and dpfgse-NOESY experiments. Samples 
were prepared by dissolving approximately 2 mg of labeled antipain-cit (HPLC-purified and lyophilized) 
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in CD3OD or CD3OH. CD3OD or CD3OH were obtained from Sigma. Samples were held at 25 °C during 
acquisition. 
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Appendix A: Review of molecular diagnostics for bacterial infections 
This chapter is taken in part from Maxson and Mitchell
1
 and is reproduced with permission from 
Tetrahedron. 
 
A.1 The need for advanced diagnostics 
 Rapid diagnostic tests to determine an infecting organism and its resistance profile are crucial as 
treatment with inappropriate antibiotics not only promotes resistance but also destroys a patient’s 
microbiome. This is especially true for narrow-spectrum antibiotics for which it is imperative to know 
which organism is causing the infection or treatment will be a complete failure. In some cases, the 
manifestation of disease is indicative of a specific pathogen, such as an erythema migrans rash with Lyme 
disease, and any future narrow-spectrum antibiotic could likely be prescribed before further testing. 
Similarly, around 80% of UTI cases are caused by E. coli
2
 and, since they are generally non-life 
threatening, could be initially treated with an E. coli-specific antibiotic until diagnostic testing indicates a 
different pathogen is present. Narrow-spectrum antibiotics could also be used for prophylaxis, targeting 
the pathogens most often responsible for complications following surgeries or implants. However, most 
diseases can be caused by a multitude of different pathogens and thus the need for rapid and accurate 
diagnosis inherently goes hand in hand with the use of narrow-spectrum antibiotics. 
 Traditional culture-based diagnostic methods combined with Gram staining can take 1-2 days to 
identify a pathogen, or even longer for slow growing organisms.
3-5
 Subsequent determination of resistance 
by phenotypic methods (Kirby-Bauer testing, microbroth dilutions, Etests) then requires up to an 
additional day before results are available.
6, 7
 During this time frame, patients are typically treated 
empirically with broad-spectrum agents that may or may not be de-escalated when appropriate after 
testing is complete. After this delay, the advantage of treating with a narrow-spectrum antibiotic may be 
lost, with the microbiome already perturbed and potentially problematic organisms on the rise. The 
sensitivity and specificity of some gold standards leaves something to be desired as well, with blood 
culture failing to detect pathogens up to 50% of the time after empiric treatment has started
8, 9
 and sputum 
samples often resulting in the growth of multiple species in culture.
3
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 To sufficiently improve upon traditional methods such that narrow-spectrum antibiotics can be 
readily employed, several important requirements must be met (Table A.1). Specifically focusing on 
diagnostics for narrow-spectrum antibiotic use, the most important criteria are the time to result and the 
accuracy and sensitivity of the test, especially with regards to the ability to rule out polymicrobial 
infections. Ideally, a point-of-care diagnostic test would be rapid enough to provide a result in time for the 
initial treatment decision. For outpatient care, this would ideally occur during the visit. For inpatients, 
especially those in critical condition, getting results as soon as possible is essential.
10, 11
 Reducing delays 
in appropriate antibiotic treatment for critical conditions such as sepsis has been repeatedly shown to have 
a major impact on patient survival.
11-13
 Fulfilling this speed requirement will likely mean development of 
devices that are portable or can be set up in hospital clinical microbiology labs, as sending samples to a 
third party would cause a significant delay. 
 The other central requirements of high accuracy and sensitivity for diagnostic tests are 
particularly important for pathogen-specific antibiotics. Misidentification or the failure to detect a 
pathogen would lead to an incorrect treatment strategy with potentially dire consequences.
11
 Identification 
of polymicrobial infections would also be crucial to prevent treatment failure due to a second, untreated 
pathogen.
14, 15
 Many newer diagnostic methods are designed around technologies that simply do not work 
well when multiple species are present in the sample.
16, 17
 False negatives with rarer pathogens resulting 
from molecular diagnostics that only test for the most common causes of infection is an additional 
concern, although this certainly applies to treatment with any antibiotic regardless of spectrum. Thus, 
tests that can incorporate the detection of the largest number of potential pathogens while maintaining a 
high degree of specificity and sensitivity are warranted. 
 Beyond speed and accuracy, several other factors should be considered when comparing new 
diagnostic technologies.
5
 Tests that can incorporate rapid resistance determination have a significant 
advantage in utility, especially if high levels of resistance are known to exist for the narrow-spectrum 
antibiotic that could be employed. From a financial standpoint, expensive instrumentation may be 
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prohibitive for smaller institutions while a high cost per sample may discourage routine use, particularly if 
the test is not readily accepted for reimbursement by insurers. Another consideration is the amount of 
hands on time required to perform the test.  A test that only takes an hour to complete but requires the 
attention of a technician the entire time for a single sample may not be feasible. More sample 
manipulation also leads to more opportunities for contamination, leading to inaccurate results. Finally, 
tests that provide quantification may be useful for the differentiation of colonizing and infectious 
organisms although the benefit of this has been called into question.
18
 
 While improved diagnostics are discussed here in terms of their ability to aid in narrow-spectrum 
antibiotic use, it is important to keep in mind that there are other advantages to improved diagnostics such 
as tracking outbreaks and epidemics, monitoring resistance, and discontinuing isolation of patients falsely 
suspected of having highly infectious diseases. We will first review the two main areas of advancement in 
diagnostics, nucleic acid- and MS-based methods. Many of the techniques from these two methods have 
been extensively tested and have already begun to enter the clinic. We will then briefly touch on emerging 
technologies that have the potential to significantly improve diagnostic methods in the future. 
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Table A.1. Summary of molecular diagnostic techniques. 
Technique 
Turnaround 
time 
Number of species 
possible per assay 
Resistance 
detection 
Approximate 
Instrumentation cost 
PNA-FISH 
< 1 h after 
blood culture 
1 No < $1,000 
NanoString 8 h 
Undeveloped, > 800 
targets possible 
Yes > $100,000 
Microring resonators 
(RNA hybridization) 
< 1 h 
Undeveloped, 
multiplexing possible 
Yes ~ $100,000 
PCR from culture 1 - 3 h > 50 for commercial assay Yes 
$20,000 - 50,000 
(for real time) 
PCR from blood 6 - 12 h 
> 300 for commercial 
assay 
Currently no $20,000 - 50,000 
PCR HRMA 3 h after culture All No $20,000 - 50,000 
WGS > 24 h All Yes > $100,000 
MALDI-MS 
< 15 min after 
culture 
All In development > $100,000 
PCR ESI-MS 5 h after culture All Yes > $100,000 
Rapid antigen 
testing 
< 30 min 1 No N/A 
Microring resonators 
(Direct pathogen 
detection) 
< 1 h 
Undeveloped, 
multiplexing possible 
No ~ $100,000 
T2MR 3 h 
Undeveloped, 
multiplexing possible 
Yes Undeveloped 
IC 3D 4 h 
Undeveloped, 
multiplexing possible 
No Undeveloped 
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A.2 Nucleic acid-based technologies 
New molecular biology techniques developed over the last few decades were quickly seized upon 
by the diagnostics field for novel strategies for pathogen identification. Nucleic acid-based technologies 
(NATs) utilize bacterial DNA or RNA to rapidly pinpoint the infecting pathogen either through 
hybridization leading directly to a signal or through the amplification of DNA. Both strategies have been 
extensively developed with commercial tests available that offer significant improvements over 
traditional culture-based methods. 
A.2.1 Non-amplification NATs 
 The field of non-amplification based NATs is primarily focused on peptide nucleic acid (PNA) 
fluorescence in situ hybridization (FISH) techniques. PNA-FISH based tests were among the first new 
molecular diagnostics to receive FDA clearance and have been available for clinical use since the early 
2000s.
19
 The tests report the presence of the target bacteria via a fluorescent signal generated upon 
hybridization of a short PNA probe (<25 bases) to bacterial RNA or DNA.
20
 Due to its high cellular 
abundance and sequence differences between organisms in the variable regions, ribosomal RNA (rRNA) 
is often used as the target for PNA probes.
21
 The use of PNA probes instead of DNA minimizes 
electrostatic repulsion, allowing for rapid and tight binding.
22
 Short PNA probes are also able to cross the 
cell membrane, removing any need for a lysis step and reducing hands on time.
23
 Extremely rapid 
commercial kits are available that can provide results in under an hour (e.g. QuickFISH, AdvanDx)
24
 and 
it has been demonstrated that PNA-FISH can provide excellent accuracy in a clinical setting.
25, 26
 
However, PNA-FISH methods require a high bacterial count for detection and have thus far only been 
designed for use on positive blood cultures, resulting in a 1-2 day delay from when a patient sample is 
collected to when the test can be performed.
19
 While this is a significant improvement on identification of 
pathogens by subculturing from a positive blood culture, the sensitivity of the method would need to be 
dramatically improved to allow the direct testing of patient samples required for a truly rapid result. 
Additionally, since rRNA is targeted, the presence of resistance markers is not analyzed at all with current 
methods and an amplification step would likely be required to detect the relatively low abundance of 
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RNA from resistance genes. Like most NAT methods, PNA-FISH requires a specific probe or set of 
probes for each target organism. This results in an increasing cost per sample as additional probes for 
other pathogens are included, although the initial instrumentation costs are minimal.
19
 As PNA-FISH does 
not multiplex (simultaneously measure multiple analytes in a single assay) effectively and will miss the 
presence of any pathogens not specifically targeted, it is not ideally suited for diagnosis prior to narrow-
spectrum antibiotic use. 
 Several other promising hybridization techniques have also been proposed for bacterial detection 
and identification, although these have not been nearly as extensively validated as PNA-FISH. One such 
technology is NanoString, an RNA detection method that is commercially available with the nCounter 
system.
27
 NanoString allows for bacterial detection through the use of capture and reporter probes specific 
to targeted RNA sequences, with the reporter probe containing sets of colored indicators that are read 
through microscopy.
27, 28
 The technique has been shown to be effective for bacterial, viral, and fungal 
pathogen detection with the use of several probe pairs per species.
28, 29
 Up to 800 probes can be 
multiplexed in a single reaction, allowing a large number of species to be targeted at once.
27
 However, the 
upfront cost of the instrumentation is in the hundreds of thousands of dollars and the technique requires a 
long hybridization time (>12 h),
27
 although a recent report shortened this significantly, allowing the entire 
technique to be performed in around 8 h.
30
 
 An emerging technique for RNA detection via hybridization is the use of microring resonators. 
Microring resonators detect changes in the local refractive index upon binding of target molecules.
31
 By 
functionalizing the rings with DNA capture probes designed for species specificity, bacterial detection 
based on target RNA molecules can be achieved in <1 h after RNA isolation.
32-34
 Microring resonators 
can be inexpensively manufactured with many rings on a single, small chip, allowing for highly 
multiplexed detection of a large number of targets.
32
 Both microring resonators and NanoString allow for 
a degree of quantification,
27, 33
 which, unlike PNA-FISH, provides the advantage of possible resistance 
determination by examining transcriptome changes during antibiotic treatment in susceptible organisms.
28
 
Despite the ease of multiplexing these two technologies, untargeted organisms will still be missed, 
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resulting in rarer pathogens evading detection. Additionally, both methods have only been tested with 
relatively high bacterial counts so the limits of detection may not be sufficient for direct analysis of 
certain patient samples like blood. 
A.2.2 Amplification NATs 
 In contrast to the hybridization-based techniques, many other NATs rely on DNA amplification to 
generate a readout, commonly through gel electrophoresis or an increasing fluorescent signal. While some 
tests target rRNA (directly as complementary DNA (cDNA) or as the gene) similar to the PNA-FISH 
based tests, amplification allows lower abundance, species-specific genes to be used.
35
 This opens the 
possibility of determining the antibiotic susceptibility of pathogens through the detection of common 
resistance-conferring genes.
36
 The earliest amplification based tests were introduced in the mid-1990s for 
the specific detection of M. tuberculosis,
37
 and a number of tests capable of identifying a wide range of 
pathogens and resistance markers have since been released.
35-38
 The advent of real-time PCR allowed for 
further improvements to amplification based technologies, eliminating the need for post-amplification 
analysis through techniques like gel electrophoresis and allowing for quantitative results.
39
 An early 
example of a commercial real-time PCR device is the Cepheid Xpert MRSA/SA test, which can identify 
the presence of S. aureus and the mecA gene for methicillin resistance in an hour from a positive blood 
culture.
40
 Real-time PCR systems with multiplexing to allow the detection of multiple pathogens have 
also been developed, such as the SeptiFast system for the identification of the 25 most common pathogens 
responsible for blood stream infections.
41
 
 There are several important considerations when discussing amplification based techniques, 
which have been discussed in several comprehensive reviews.
35, 36, 42
 One issue is the amount of sample 
handling required to prepare DNA and set up reactions. The possibility of contamination is relatively high 
during this time so significant effort has gone into the development of automated, cartridge based systems 
for DNA extraction and preparation.
42
 Generally, free DNA is not removed prior to lysis of bacterial cells 
so many amplification-based tests will report on the presence of dead cells and DNA from recent 
infections.
36
 This can be advantageous in some cases, especially if a patient sample is collected after 
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antibiotic treatment has already begun, but can also lead to false positives as the presence of small 
amounts of bacterial DNA in samples like blood is not always indicative of infection.
43
 Another 
consideration concerning resistance profiling is that only known resistance genes can be targeted, so the 
reliability of susceptibility determination through these methods may be questionable for some pathogens. 
Financially, real-time PCR instruments require a moderate initial investment and highly multiplexed tests 
for the detection of numerous pathogens can carry a significant cost per sample. Finally, as with direct 
hybridization techniques, only specifically targeted pathogens can be detected. 
 A method to circumvent the need to target specific primers to each species is to use broad range 
PCR. This approach relies on amplification of common genes such as the 16S RNA with primers that 
bind in conserved regions, similar to 16S typing for bacterial identification. Rapid species determination 
can then be performed with high-resolution melt analysis (HRMA) by comparing the melting curves of a 
set of amplification products to an existing database.
44, 45
 Sequence differences between species lead to 
slight changes in the melting temperature for each amplification product and have been used to 
differentiate clinically relevant pathogens.
16
 The accuracy of the technique is inherently limited by the 
quality of the reference database and a large number of known clinical isolates will need to analyzed and 
recorded to ensure sufficient species coverage for comparison. Strain variants with polymorphisms in the 
amplified gene regions could pose a problem however, and polymicrobial samples are impossible to 
analyze with HRMA, severely limiting its applicability.
46
 Other detection methods for broad range PCR 
exist, including sequencing and electrospray ionization (ESI)-MS (discussed in section 3.3.2). 
 Moving a step beyond sequencing with broad range PCR, whole genome sequencing (WGS) with 
next-generation sequencing (NGS) methods has the potential to supplant traditional clinical microbiology 
as the gold standard in identifying the causative agent(s) of infectious disease.
5, 47
 After sequencing, the 
infective species can be identified with the highest degree of confidence by alignment to a reference 
genome (if available) or by multilocus sequence typing (MLST) if a member of the same species has not 
yet been sequenced.
5, 48
 In addition to species identification, WGS provides information on the presence 
of resistance markers and virulence factors and is an unparalleled tool for differentiating strains for 
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epidemiological purposes.
5, 49
 A number of platforms for NGS have been developed utilizing different 
chemistry, including 454, Illumina, Ion Torrent, and PacBio, among others.
50, 51
 Currently, WGS is too 
slow and expensive for routine pathogen identification, but may be a viable option in the near future if the 
rapid advancement in sequencing technology over the past decades continues.
5
 Pathogen identification 
directly from patient samples using a metagenomics approach removes the >24 h delay required for DNA 
extraction from culture,
52, 53
 while improvements in NGS have already drastically reduced the time and 
price required for sequencing (a single bacterial genome with sufficient depth coverage can now be 
obtained in less than a day for $200 by academic core facilities, with cost-savings truly becoming 
significant when many bacteria are sequenced).
5, 47, 54
 With continued advances in NGS and automated 
data analysis software,
52
 it appears that WGS is posed to replace all other NAT diagnostics. 
 While amplification techniques have proven to be accurate enough to be used with narrow-
spectrum antibiotics, the time currently required for amplification is of concern. Many commercial tests 
are designed to work with the high bacterial counts available after initial culture and can give a result in 
as little as an hour,
40, 55
 but the delay from culture time is significant. Testing directly from patient 
samples suffers from low starting bacterial counts and the presence of substances inhibitory to 
amplification, such as heme in blood.
39
 The presence of vast excesses of host DNA can also be 
problematic in PCR assays.
39, 56
 Several tests have been developed that overcome these issues and can be 
used directly on blood samples but they require much longer amplification times of 6-12 h.
35
 This is still 
an improvement over waiting for cultures to grow however and can likely be further improved through 
methods of isolating bacteria or high quality bacterial DNA from patient samples, as discussed in section 
3.2.3. No resistance determination is available in the tests currently marketed for use on blood but could 
presumably be included for known resistance genes in the future. 
A.2.3 Bacterial isolation from patient samples 
 While some clinical sample types such as urine from UTIs can contain high bacterial counts 
(>10
5
 colony forming units (CFU)/mL),
57
 many samples have far fewer bacteria present. Blood in 
particular can have as little as 1-10 CFU/mL of an invading pathogen in adult sepsis patients.
58
 Therefore, 
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methods for isolating high quality bacterial DNA from samples that often contain large amounts of human 
DNA can improve the reliability of NAT methods. The simplest way to achieve this is through the 
coupling of standard DNA purification systems with the selective removal of human DNA. One approach 
is to gently lyse human cells while leaving bacterial cells intact, followed by enzymatic or chemical 
degradation of human DNA. After washing, bacterial cells are lysed through a more vigorous method and 
the DNA is isolated.
59, 60
 Another approach involves exploiting the differences between bacterial and 
human DNA, specifically in methylation of cytidylate-phosphate-deoxyguanylate (CpG) motifs by human 
CpG-binding protein. Unmethylated prokaryotic CpG motifs are selectively bound with an immobilized 
protein, allowing human DNA to be washed away to give an affinity purification of the bacterial DNA.
59, 
61
 
 An alternative strategy for the isolation of bacteria or bacterial DNA from patient samples 
involves the use of microfluidics technologies. Patient samples can be passed through devices that contain 
bacterial capture materials, including antibodies,
62-64
 synthetic ligands,
65
 or even human opsonin.
66
 After 
capture, human cells and other sample components are readily washed away before release of bacterial 
DNA via cell lysis.
63
 A different microfluidics based approach that does not rely on specific bacterial 
capture but rather on the intrinsic physical properties of the bacterial cells was recently reported.
30
 The 
method utilizes inertial lift forces to separate bacteria from blood cells based on size differences. This 
type of method also has the advantage of collecting intact cells, which could then potentially be used in 
non-DNA based detection methods such as MALDI. 
A.3 Mass spectrometry-based technologies 
The advent of so called “soft” ionization methods that are capable of ionizing large biomolecules 
without significant fragmentation has made the development of MS-based methods appealing for 
pathogen identification. These methods are based on the detection of sets of genus- or species-specific 
biomolecules, typically proteins or nucleic acids.
17, 67
 The collected spectra are compared to a database 
assembled from known isolates to identify the species present, similar to PCR HRMA. Although MS 
methods require a large initial investment with the purchase of instrumentation, they have the advantage 
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of extremely low per-sample costs and very fast turnaround times. In contrast to NATs, MS-based 
methods do not require specific probes for each species of interest and can thus theoretically identify any 
species in a sample without any prior knowledge if robust databases are available. Two different general 
approaches to MS-based identification have been developed thus far, matrix-assisted laser 
desorption/ionization (MALDI)-MS and PCR ESI-MS, although MALDI-based techniques have been 
more extensively investigated. 
A.3.1 MALDI-MS 
 MALDI-MS functions through desorption and ionization of sample molecules after laser 
irradiation with the assistance of matrix compounds followed by analyte detection, typically in a time of 
flight (TOF) analyzer. The application of MALDI-TOF-MS to clinical microbiology has been extensively 
reviewed.
17, 68, 69
 Differences in bacterial proteomes are commonly used for species identification with 
MALDI-TOF-MS, although other biomolecules can also be detected. Generally, the focus is on ribosomal 
proteins as they are abundantly expressed throughout all stages of growth.
17
 Since no prior knowledge of 
the organism in a sample is needed, fungi can also be identified without additional testing assuming a 
reference database including the organisms of interest is available.
68
 While samples can be analyzed 
directly using whole cells, a protein extraction step improves signal intensity and reproducibility and is 
required for some organisms.
68
 Sample preparation and analysis with MALDI-TOF-MS is extremely 
rapid, generally taking less than 15 minutes. With a sufficiently extensive database, the presence of any 
pathogen in a sample can be accurately detected.
70
 Several MALDI-TOF-MS instruments designed for 
microorganism detection are available, including the Bruker BioTyper and the Shimadzu Axima 
Assurance system.
71
 
 However, there are several important limitations in the application of MALDI-TOF-MS for 
diagnostics that still need to be overcome. Currently, MALDI-TOF-MS for bacterial identification 
generally requires a high CFU count and thus is often not feasible directly on patient samples.
17, 69
 
Samples are usually analyzed after culture, which adds a significant amount of time to obtain results. 
However, several studies have reported success when analyzing urine
72-75
 and cerebral spinal fluid
76
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samples directly. Bacteria could potentially be concentrated from patient samples as well using 
microfluidics technologies as described in section 3.2.3 to help circumvent the lack of sensitivity. Another 
issue facing the widespread implementation of MALDI-TOF-MS as a clinical tool is the often poor 
reproducibility between labs, as different sample preparation techniques and instrument types can cause 
substantial variation in analyte detection,
77, 78
 although standardization between labs (perhaps through the 
Clinical and Laboratory Standards Institute or a similar organization) will improve this. The detection of 
antibiotic resistance is difficult with MALDI-TOF-MS but strategies to accomplish this have been 
advanced,
79
 including the detection of methylation on rRNA
80
 and reaction monitoring of β-lactam 
hydrolysis.
81
 Differentiation between highly similar species and deconvolution of polymicrobial samples 
also pose significant challenges. Despite these problems, MALDI-TOF-MS has been successfully 
validated as a highly accurate method for pathogen identification in numerous clinical samples and 
several commercial platforms are currently available.
17, 70, 71
 MALDI-TOF-MS systems have been adopted 
in many advanced clinical labs and reductions in size and cost of the instruments will enable smaller labs 
to utilize this technology as well. If improvements in analyzing patient samples directly can be made, the 
ability to identify any pathogen in the available databases makes MALDI-TOF-MS a promising 
possibility for diagnosis prior to narrow-spectrum antibiotic use. 
A.3.2 PCR ESI-MS 
 ESI is another MS ionization method whereby a high voltage is used to disperse a sample into an 
aerosol containing charged droplets.
82
 It has been used as a general detection method for bacterial 
identification after PCR amplification with broad range primers, similar to PCR HRMA.
46
 The amplified 
DNA is analyzed by ESI-MS and species identification is achieved by comparing the experimental mass 
to charge (m/z) ratio of the PCR products to the expected m/z ratio based on the gene sequence.
36, 83, 84
 
Like with MALDI-MS based methods, a robust database is required, but databases for ESI-MS can be 
built from existing sequencing information in addition to clinical isolates.
36
 This can ease the 
identification of strain variants and results that do not have an exact match in the database can have the 
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nearest neighbor identified by a BLAST-like search algorithm.
36
 As with PCR HRMA and MALDI-MS, 
no prior knowledge of the sample species is required before testing. 
 However, the requirement of an amplification step introduces many of the issues described in 
section 3.2.2 for amplification based NAT techniques, such as sample processing and the time needed for 
amplification. The ESI-MS step itself is very rapid however and can be set up to run in an automated 
fashion. Several sets of primers for different gene regions are used to mitigate the risk posed by genotypic 
strain variants, although it is still possible that a divergent strain could be misidentified.
84, 85
 Resistance 
determination can be performed in a manner similar to other amplification based methods by including 
primers for specific resistance-conferring genes at the cost of increased complexity and number of 
reactions that must be run on each sample.
85
 PCR ESI-MS also has the advantage of working well with 
mixtures of organisms, with the identification of both species and the relative ratios of abundance usually 
determined.
85, 86
 As with MALDI-MS instruments, ESI-MS instruments tend to be large and expensive, 
but improvements in miniaturized ESI-MS units
87
 and in amplification technologies offer the potential for 
PCR ESI-MS to be a rapid point-of-care diagnostic. The Iridica system from Abbott Molecular is 
currently on the market and is specifically designed for pathogen identification directly from patient 
samples although it is not yet available in the United States.
88
 
A.4 Alternative detection and identification technologies 
 Outside of NAT and MS-based methods, there are a number of other promising technologies that 
could be utilized for bacterial detection and identification prior to narrow-spectrum antibiotic use. One 
established method for diagnosis is rapid antigen testing, which relies on a visible readout for antibody-
antigen binding. Rapid antigen testing has been used for years for S. pyogenes and provides results in ~15 
min at the point-of-care, compared to 1-2 d for traditional culture on blood agar plates.
89-91
 However, 
antigen testing in its current form only exists for a few select pathogens, likely due in part to the limited 
scope of such tests. It is thus generally used where clinical signs point to a certain type of infection, as 
with pharyngitis. Rapid antigen testing could be extended to additional pathogens (e.g. E. coli for UTIs) 
or potentially even multiplexed to allow broader identification. 
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 The remaining techniques discussed in this section are relatively new and have not undergone the 
extensive testing with patient samples that most of the previous methods have, but they offer some 
promising possibilities for future development. Microring resonators were discussed in section 3.2.1 as an 
emerging technology for bacterial identification by hybridization of RNA but they could also be used for 
the direct detection of pathogens with species-specific antibody functionalized rings. This concept has 
been demonstrated for detection of intact bacterial cells
32
 and virus particles.
92
 Microring resonators 
designed around this concept rather than RNA detection would eliminate the need for an RNA isolation 
step and could be extremely rapid, but would require highly specific antibody generation for each 
pathogen of interest. 
 Another method that is being applied to pathogen detection and identification is T2 magnetic 
resonance (T2MR)-based biosensing. T2MR measures the transverse relaxation time of the nuclear 
magnetic resonance signal of water and is sensitive to changes in the microenvironments in aqueous 
solutions.
93
 Recently, DNA functionalized nanoparticles that cluster upon binding of target nucleic acids 
were reported, resulting in easily detected T2 relaxation rate changes.
94
 In combination with a specially 
designed, portable T2MR instrument that is compatible with standard PCR tubes, detection of Candida 
species at concentrations <5 CFU/mL in blood directly from patient samples was reported.
94, 95
 Although 
an amplification step is required, results could be obtained in <3 h, which is less than half the time 
required for real-time PCR based methods. The method is also currently in development for bacterial 
detection by T2 Biosystems. Although the ability of T2MR to determine resistance profiles has not been 
discussed in the literature, it would theoretically be possible by functionalizing additional nanoparticles 
with DNA oligomers targeting known resistance genes. 
 The final technology we will discuss is integrated comprehensive droplet digital detection (IC 
3D).
96
 IC 3D provides a readout for highly sensitive bacterial detection through single fluorescent 
particles suspended in picoliter droplets. The fluorescent droplets are produced by mixing a DNAzyme 
sensor solution and the sample solution with lysis buffer in a microfluidic channel that encapsulates them 
into the droplets. The DNAzymes are activated by specific target bacterial molecules, which results in the 
256 
 
cleavage of a nucleic acid substrate to release a fluorophore from its associated quencher. The fluorophore 
is then detected by a recently developed 3D particle counter.
97
 The entire process takes around 4 h for 
bacterial identification and is sensitive enough to detect <10 CFU/mL while also providing quantitative 
results directly from blood samples. While this method has many promising advantages, it will need to be 
developed into a multiplexed system for multiple species detection and suffers from the requirement for a 
specific DNAzyme for each species. 
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Appendix B: Further publications with minor contributions 
B.1 Identification of the minimal cytolytic unit for streptolysin S and an expansion of the toxin 
family 
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This chapter was reproduced from Molloy et al.
1
 and is reproduced with permission from BMC 
Microbiology. 
 
I aided in the in vitro reconstitution of cytolysin production and in testing the lytic activity of SLS 
truncation mutants. 
 
Abstract  
Background 
Streptolysin S (SLS) is a cytolytic virulence factor produced by the human pathogen 
Streptococcus pyogenes and other Streptococcus species. Related “SLS-like” toxins have been 
characterized in select strains of Clostridium and Listeria, with homologous clusters bioinformatically 
identified in a variety of other species. SLS is a member of the thiazole/oxazole-modified microcin 
(TOMM) family of natural products. The structure of SLS has yet to be deciphered and many questions 
remain regarding its structure-activity relationships. 
Results 
In this work, we assessed the hemolytic activity of a series of C-terminally truncated SLS 
peptides expressed in SLS-deficient S. pyogenes. Our data indicate that while the N-terminal poly-
heterocyclizable (NPH) region of SLS substantially contributes to its bioactivity, the variable C-terminal 
region of the toxin is largely dispensable. Through genome mining we identified additional SLS-like 
clusters in diverse Firmicutes, Spirochaetes and Actinobacteria. Among the Spirochaete clusters, 
naturally truncated SLS-like precursors were found in the genomes of three Lyme disease-causing 
Borrelia burgdorferi sensu lato (Bbsl) strains. Although unable to restore hemolysis in SLS-deficient S. 
pyogenes, a Bbsl SLS-like precursor peptide was converted to a cytolysin using purified SLS biosynthetic 
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enzymes. A PCR-based screen demonstrated that SLS-like clusters are substantially more prevalent in 
Bbsl than inferred from publicly available genome sequences. 
Conclusions 
The mutagenesis data described herein allowed us to define the minimal cytolytic unit of SLS as 
the NPH region. Interestingly, this region is found in all characterized TOMM cytolysins, as well as the 
novel putative TOMM cytolysins we discovered. We propose that this conserved region represents the 
defining feature of the SLS-like TOMM family. We demonstrate the cytolytic potential of a Bbsl SLS-like 
precursor peptide, which is of similar length to the SLS minimal cytolytic unit, when modified with 
purified SLS biosynthetic enzymes. As such, we speculate that some Borrelia have the potential to 
produce a TOMM cytolysin, although the biological significance of this finding remains to be determined. 
In addition to providing new insight into the structure-activity relationships of SLS, this study greatly 
expands the cytolysin group of TOMMs. 
Background  
Streptococcus pyogenes (Group A Streptococcus) commonly causes mild diseases such as 
pharyngitis and impetigo, and in rare cases, invasive infections such as necrotizing fasciitis and 
streptococcal toxic shock syndrome.
2
 While the characteristic β-hemolytic phenotype of S. pyogenes 
grown on blood agar has long been known,
3
 more than four decades passed before the responsible 
hemolytic/cytolytic factor,
4
 streptolysin S (SLS), was identified.
5
 The eventual discovery of the SLS 
biosynthetic gene cluster
6
 prompted investigations that subsequently designated SLS a member of the 
thiazole/oxazole-modified microcin (TOMM) group of natural products.
7-9
 TOMMs are a class of 
functionally and structurally diverse ribosomal peptides that are posttranslationally modified to contain 
the eponymous thiazole and (methyl)oxazole heterocycles derived from select cysteine, serine, and 
threonine residues.
9
 The SLS biosynthetic operon (Figure B.1A) encodes a precursor peptide, SagA 
(Figure B.1B), and three heterocycle-forming proteins, SagBCD.
6, 8
 Similar to other characterized 
ribosomal natural products, the SagA N-terminal leader peptide contains residues recognized by the 
modifying enzymes, while the C-terminal core peptide undergoes heterocyclization
8, 10, 11
 (Figure B.1B & 
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C). The suspected protease, SagE, is believed to remove the leader peptide,
12, 13
 permitting the export of 
mature and bioactive SLS via a dedicated ABC transporter, SagGHI (Figure B.1A). 
 
Figure B.1. Gene cluster organization and precursor peptide sequences of SLS-like cytolysins, and post-
translational modification scheme. (A) Lettering corresponds to the SLS operon “sag” genes. The 
proposed function of each gene is color-coded according to the legend. A representative is shown, as in 
some cases, organization varies among strains and/or not all strains of a species possess the cluster. (B) 
Heterocyclizable residues (Cys, Ser, Thr) are shown in blue. The predicted leader cleavage sites are 
indicated with carets. 
abioactivity of “Clostridiolysin S” shown from C. sporogenes18 and upon 
heterologous expression in S. pyogenes ΔsagA8 bbioactivity of “listeriolysin S” shown from native 
producers,
19, 20
 but neither the precursor peptide nor core peptide fused to SagA leader were cytolytic 
upon heterologous expression in S. pyogenes ΔsagA8. cbioactivity of putative cytolysin not yet shown 
from a native producer, but core peptide fused to SagA leader cytolytic upon heterologous expression in 
S. pyogenes ΔsagA8. (C) Azole heterocycles are installed on a TOMM precursor peptide by the successive 
action of a cyclodehydratase (C and D proteins) and dehydrogenase (B protein). X = S or O; R = H or 
CH3. 
 
SLS is the founding member of a group of homologous TOMM cytolysins that have been 
characterized in other Streptococcus species (Figure B.2A), including invasive human isolates of the β-
hemolytic Group C and Group G streptococci, which belong to S. dysgalactiae subsp. equisimilis.
14
 SLS 
variants are also produced by the animal pathogens S. iniae
15
 and S. equi.
16
 More recently, S. anginosus, a 
human commensal organism and emerging opportunistic pathogen, has been shown to produce twin SLS 
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homologs.
17
 Notably, SLS-like toxins are not limited to Streptococcus, being produced by other 
Firmicutes including select strains of Clostridium
18
 and Listeria
19-21
 (Figure B.1A & B). 
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Figure B.2. Alignment of experimentally validated streptococcal SLS variants and SLS structure-activity 
relationships. (A) Alignment using Clustal Omega
50
 reveals that the SLS core region possesses a highly 
conserved N-terminus containing 9–10 contiguous heterocylizable residues (underlined), while the C-
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terminus is variable in terms of both identity of residues and length. This phylogenetic data is deposited in 
the Dryad Digital Repository, doi:10.5061/dryad.d4863. The putative leader peptide cleavage sites are 
shown as carets. Residues of SagA from S. pyogenes are numbered. C-terminal residues where alanine 
substitutions were previously installed and that are specifically referred to in the article are marked in red 
(see panel B). (B) Summary of cytolytic activity of SagA core peptide mutants measured by expression in 
S. pyogenes ΔsagA. Activity on blood agar equal to complementation with wild-type SagA is designated 
as +++, 30–70 % activity is ++, less than 30 % activity is +, and non-detectable activity is –. C-terminal 
mutations specifically referred to in the article are marked in red. Mutants were expressed from pDCerm 
under control of a constitutive promoter
7
 or from pAD under control of the native sagA promoter.
23 
 
Despite intense study, the precise mechanism of SLS toxicity towards mammalian cells remains 
incompletely understood.
22
 SLS has also thus far been recalcitrant to structural elucidation owing to its 
poor physicochemical properties, although an extensive mass spectral analysis detected two oxazole 
moieties at positions S46 and S48 of SLS modified with purified biosynthetic enzymes
18
 (Figure B.3A). 
Previous mutagenesis studies indicate that residues spanning the entire SLS core peptide are required for 
S. pyogenes hemolysis
8, 23
 (Figure B.2B). This contrasts with the highly conserved N-terminal poly-
heterocyclizable (NPH) region and variable C-terminus of SLS natural variants (Figure B.2A). Here, we 
sought to reconcile these discrepancies by probing the contribution of the C-terminus to SLS bioactivity. 
We demonstrate that severely C-terminally truncated SLS peptides expressed in a sagA deletion mutant of 
S. pyogenes M1 5448 (S. pyogenes ΔsagA) retain hemolytic activity and posit that the NPH region found 
in all TOMM cytolysins is the defining feature of the family (Figure B.3A, underlined portion). Using 
bioinformatics, we identified a set of SagA homologs containing the NPH region in TOMM biosynthetic 
clusters in additional Firmicutes, as well as the Actinobacteria and Spirochaete phyla. We demonstrate 
that a naturally truncated precursor peptide encoded by a member of Borrelia burgdorferi sensu lato 
(Bbsl) species group can be matured into a cytolysin using purified SLS biosynthetic enzymes. Notably, 
several Bbsl cause Lyme disease, the most commonly reported tick-borne illness in the Northern 
hemisphere,
24, 25
 and our PCR-based screen revealed that genes encoding SLS-like precursors are 
prevalent in diverse Bbsl isolates. While our preliminary findings are intriguing, it remains to be seen if 
these putative cytolytic TOMMs are produced by Borrelia, and if so, whether they function to enhance 
virulence. Together, our results identify the minimal cytoytic determinant of SLS and indicate that there 
are potentially considerably more producers of related cytolysins than currently appreciated.  
271 
 
 
Figure B.3. Assessment of the hemolytic activity of truncated SLS precursor peptides expressed in S. 
pyogenes ΔsagA. (A) Residues of the SagA core peptide are numbered. Potentially modified residues of 
SLS are blue, while those known to be heterocyclized when SagA is modified with purified SagBCD are 
purple. The predicted leader cleavage site is indicated with a caret. The positions of stop codons 
introduced in SagA are marked with asterisks (yields truncation mutants listed in panel B). The minimal 
unit required for hemolytic activity of SLS in S. pyogenes ΔsagA (SagA24-34) is underlined (see panel B).  
(B) The labels correspond to the SagA truncation mutants described in panel A. A representative colony 
on blood agar of GAS M1 ΔsagA expressing each precursor from pDCerm is shown. The colony labeled 
“Empty” was a negative control containing pDCerm vector.  
Results and Discussion 
Expression of truncated SLS precursors in S. pyogenes ∆sagA reveals the importance of N-terminal 
heterocyclizable region for hemolytic activity 
An alignment of experimentally validated SLS core peptides revealed a highly conserved N-
terminal region, containing 9-10 contiguous heterocyclizable residues, while the C-terminus is 
considerably more variable in terms of both identity of residues and length (Figure B.2A). Since only the 
NPH region of the core peptide is apparently under strict evolutionary pressure, we postulated that the C-
terminal region might be less important for SLS function. Indeed, heterologous expression data support 
this, as peptides with divergent C-termini were able to restore the β-hemolytic phenotype in S. pyogenes 
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∆sagA8 (Figure B.1B). To test our hypothesis, we installed premature stop codons in sagA (Figure B.3A) 
and expressed the resultant C-terminally truncated SLS derivatives in S. pyogenes ΔsagA. Unfortunately, 
the ring-state of processed SagA cannot be readily determined, even with advanced spectroscopic 
methods.
7, 18
 We thus relied on a simple phenotypic assay, i.e. β-hemolysis on blood agar, to 
simultaneously evaluate successful production and export of SLS variants.  
Consistent with the divergence of the core peptides (Figure B.2A), SLS retained significant 
activity upon C-terminal truncation. In fact, S. pyogenes ΔsagA expressing SLS derivatives missing up to 
17 residues (SagA
1-36) showed comparable levels of β-hemolysis on blood agar to that complimented with 
full-length SagA (Figure B.3B). Hemolytic activity substantially decreased with additional truncation to 
yield SagA
1-35 
and SagA
1-34
, with activity being undetectable in the case of SagA
1-33
 (Figure B.3B). These 
findings allowed us to define SagA
1-34
 as the minimal unit required for hemolytic activity of SLS 
expressed by S. pyogenes. Interestingly, this segment encompasses the entirety of the conserved NPH 
region (Figure B.2A), as well as just two additional residues (Figure B.3A). Based on the predicted leader 
peptide cleavage site,
23
 this indicates that only 11 core residues are required for detectable bioactivity of 
SLS expressed by S. pyogenes. 
 The retention of activity by such drastically C-terminally truncated SLS derivatives expressed in 
S. pyogenes ΔsagA stands in contrast to alanine substitution studies that implicated several of the 
“missing” residues in SLS activity by both expression in S. pyogenes ΔsagA and by modification using 
purified enzymes (Figure B.2B).
8, 23
 While a K53A mutation eliminated SLS hemolytic activity from S. 
pyogenes,
23
 our truncation series demonstrated that its removal is not detrimental to activity (Figure 
B.3B). Our results are consistent with the existence of natural SLS variants that lack a terminal lysine 
(Figure B.2A). Moreover, known SLS-like toxins encoded by non-Streptoccocus species also lack 
terminal lysines (Figure B.1B). Even more striking is our observation that peptides that lack S39 retain 
cytolytic activity (Figure B.3B). S39 was identified as a critical residue because S. pyogenes ΔsagA 
expressing SagA-S39A was devoid of cytolytic activity and avirulent in a mouse infection model
8
 (Figure 
B.2B). As before, this position is not conserved in the SLS family (Figure B.2A) or in SLS-like toxins 
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encoded by non-Streptoccocus species (Figure B.1B). Finally, many of our mutants that lack the 
unconserved residues S46 and S48 are hemolytic to levels indistinguishable from WT. Previous 
mutagenesis suggested that these positions contribute to the hemolytic properties of SLS both in S. 
pyogenes and when modified with purified enzymes.
8
 S46 and S48 have also been shown to be cyclized 
when SLS is modified with its cognate purified biosynthetic enzymes,
18
 although it is not known if this 
holds true for native SLS. Thus, many positions that were previously implicated in SLS activity by point 
mutation are not conserved across the SLS family and were herein found to be dispensable. In the absence 
of a complete structure for SLS or detailed mechanism of action, it is unclear why mutation of a residue 
can be more detrimental than removal, but it is possible that the “alanine-substituted” toxins adopt an 
unproductive topology that is incapable of lysing cells. 
Bioinformatics-guided discovery of novel TOMM cytolysins 
Given that the number of bioinformatically identifiable TOMM biosynthetic clusters more than 
quadrupled since 2011,
9, 26
 we sought to determine if naturally truncated precursor peptides are present in 
any novel SLS-like clusters. Our genome mining effort revealed TOMM clusters encoding SagB, -C and 
–D homologs in the vicinity of SagA homologs in Firmicutes genera not previously known to possess 
such clusters (i.e. Bacillus, Lactobacillus, Enterococcus, Exiguobacterium, Oenococcus and 
Virgibacillus) (Figure B.4 & Table B.1). Interestingly, a number of Actinobacteria (Mobiluncus and 
Propionibacterium) and Spirochaetes (Borrelia, Brachyspira) encoded SLS-like clusters (Figure B.4A & 
Table B.1). The Brachyspira TOMM clusters were independently noted in a recent publication.
27
 We 
hypothesized that the newly-annotated SLS-like precursors (Figure B.4B) represent novel TOMM 
cytolysins since the sequence of a TOMM precursor dictates the function of the natural product after 
posttranslational modification.
7, 9
  Moreover, while the novel SagA-like precursor peptides were of 
variable length, all contained the aforementioned NPH region. Our identification of these putative SLS-
like cytolysins greatly expands the TOMM cytolysin family (Figure B.5 & Table B.2) and suggests that 
the TOMM cytolysins are not confined to Firmicutes. 
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Figure B.4. Gene cluster organization and precursor peptide sequences of predicted SLS-like TOMM 
biosynthetic gene clusters. (A) One example is given for each genus with strain abbreviations as per Table 
B.1A. Lettering corresponds to the SLS operon “sag” genes. The proposed function of each gene is color-
coded according to the legend. In the case of Lactococcus and Catelliglobosispora (included in Fig. 
B.1.5), the protein sequences are not associated with a genome in GenBank, making it difficult to confirm 
all surrounding genes; thus, a representative cluster organization was not given. Those clusters identified 
in Borrelia are depicted in Fig. B.1.6 and Fig. B.1.7. (B) Potentially modified residues are shown in blue. 
The predicted leader cleavage sites are indicated with a caret. 
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Table B.1. Accession numbers and expectation values of BCD proteins from representative SLS-like 
TOMM clusters. (A) Strains used for the similarity analysis and the corresponding abbreviations 
(continued in panels B and C). (B) GenBank accession numbers (ncbi.nlm.nih.gov) of the B, C and D 
proteins used for the analysis. (C) BLAST e-values for the designated proteins upon comparison with the 
B. valaisiana VS116 homolog. E-values were determined using BLAST-P with standard settings and 
limiting the searched organisms to include only the strains in panel A, except B. valaisiana VS116. 
 
276 
 
 
Figure B.5. Phylogenetic analysis of the TOMM cytolysin family. A maximum-likelihood tree based on 
the D protein (listed in Table B.2) for the majority of known and putative producers of cytolytic TOMMs 
(as of December 2014). This phylogenetic data is deposited in the Dryad Digital Repository, 
doi:10.5061/dryad.d4863. Clades are color-coded based on the originating genus for each SLS-like toxin, 
as represented in the legend. The relevant phyla are given in parentheses. 
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Table B.2. List of accession identifiers for D proteins of putative TOMM cytolysin clusters. The genus, 
species, strain, and GenBank accession identifiers are given for all D proteins used in the phylogenetic 
analysis (Fig. B.1.5), with inherent duplications from GenBank RefSeq annotations deleted. 
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Table B.2 (cont.) 
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Table B.2 (cont.) 
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Of particular interest were the three potential SLS-like TOMM biosynthetic clusters we 
discovered among the 23 published Bbsl genomes (Figure B.6A; hereafter referred to as “Bor TOMM 
clusters”), namely in B. afzelii PKo [GenBank: CP002947],28 B. valaisiana VS116 [GenBank: 
CP001442],
29
 and B. spielmanii A14S [GenBank: CP001465]
29
 (Figure B.6A). The novel Bbsl-encoded 
precursor peptides consisted of SagA homologs that were of similar length to our “minimal cytolytic unit” 
for SLS (Figure B.6B). We preliminarily classified the putative Bbsl SLS-like products as TOMM 
cytolysins based on sequence similarity to SLS, with support from a maximum likelihood tree of a subset 
of the TOMM family based on the associated D proteins (Figure B.6C). Thus, we assigned names to the 
homologous genes within the clusters following the SLS nomenclature, with borA encoding the precursor 
peptide (refers collectively to bafzA from B. afzelii PKo, bvalA from B. valaisiana VS116, and bspiA 
from B. spielmanii; Figure B.6B), borB encoding the dehydrogenase and borC/D encoding the 
cyclodehydratase and so forth. 
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Figure B.6. Gene cluster organization and precursor peptide sequences of SLS and Bor TOMM, and 
phylogenetic analysis of the TOMM family. (A) Lettering corresponds to the SLS operon “sag” genes. 
The proposed function of each gene is color-coded according to the legend. (B) BorA refers collectively 
to BafzA from B. afzelii PKo, BvalA from B. valaisiana VS116, and BspiA from B. spielmanii A14S. 
Potentially modified residues are shown in blue. The predicted leader cleavage sites are indicated with a 
caret. The minimal core length required for hemolytic activity of SLS in S. pyogenes ΔsagA (SagA24-34) is 
underlined. (C) A maximum-likelihood tree of a representative sample of TOMMs based on the D protein 
from each cluster. This phylogenetic data is depostied in the Dryad Digital Repository, 
doi:10.5061/dryad.d4863. Clades are color-coded based on the predicted class of TOMM natural product. 
NHLP, nitrile hydratase leader peptide; NHLP-Burk, NHLP from Burkholderia; PZN, plantazolicin; 
Balh, uncharacterized TOMM from Bacillus sp. Al Hakam; McB, microcin B from 
Gammaproteobacteria. SLS, streptolysin S; Bor TOMM, putative SLS-like cytolysin from Bbsl. 
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SLS-like TOMM biosynthetic genes are widely distributed among Bbsl 
We noted that the Bor TOMM clusters identified in B. afzelii PKo, B. valaisiana VS116 and B. 
spielmanii A14S were present on lp28-8 plasmids (Figure B.7). These plasmids exhibit 7-9% nucleotide 
sequence divergence from each other, which is consistent with that observed on the chromosome and 
other linear plasmids in these species.
30
 Moreover, the G+C content of the cluster is 25-26% in all three 
species, which is typical for Bbsl plasmids. It thus appears that the Bor TOMM cluster did not arrive into 
the genus recently by horizontal transfer, but has likely been present for a long time, diverging in parallel 
with the chromosome approximately when the three species diverged. 
 
Figure B.7. Open reading frame (ORF) diagrams for Borrelia lp28-8 plasmids. Four published Bbsl 
genomes harbor plasmids in the lp28-8 compatibility group.
51
 As is typical for Bbsl linear plasmids,
52
 the 
lp28-8 plasmids are mosaically related; gray areas between maps denote regions of sequence similarity. 
Lp28-8 from B. burgdorferi 94a lacks the Bor TOMM biosynthetic cluster so is not further discussed. The 
ORFs of the Bor TOMM clusters of B. spielmanii A14S, B. valaisiana VS116 and B. afzelii PKo are 
color-coded as in Fig. B.1.1A; white arrows are hypothetical or have functions unrelated to the Bor 
TOMM biosynthetic cluster. The numbers above an ORF give the Pfam designation. Names of the ORFs 
known from type strain B. burgdorferi B31 are labeled “b31_” and are shown below the maps. Each lp28-
8 carries a truncated vls cassette region, which allows alteration of the antigenic properties of VlsE outer 
surface proteins, a key pathogenic strategy. An “X” over an ORF indicates a pseudogene. In VS116, the 
ABC transporter gene has a substantial deletion and may be nonfunctional, suggesting that a different 
transporter performs export or that VS116 does not produce the Bor TOMM. 
 
We hypothesized that the three Bor TOMM clusters identified in Bbsl genomes is an 
underestimation of the true prevalence given that Bbsl are prone to losing plasmids when cultured in 
vitro.
31, 32
 In order to estimate the distribution of Bor TOMM clusters in Bbsl, we performed a PCR screen 
for the associated biosynthetic genes in 140 genomic DNA samples from tick or human patient isolates 
(Table B.3). Seven Bbsl species were represented, originating from North America and 13 countries in 
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Europe and Asia. Because of the similarity among the VS116, PKo, and A14S Bor TOMM cluster 
sequences, primers specific to bvalB, -C and -D were used to detect borB, -C and -D in the isolates 
(Figure B.8 & Table B.4). 
        Presence of gene  
Bbsl* species Strain Geographic Origin Biological Source P# borB borC borD Source 
B. burgdorferi 
sensu stricto  
(pathogen, 
North 
America and 
Western 
Europe) 
B297   New York  Skin  4 - - - IS 
B331  New York (Westchester 
County) 
Skin (EM) 5 - - - IS 
B356  New York (Westchester 
County) 
Skin (EM) 3 - - - IS 
B376  New York (Westchester 
County) 
Skin (EM) 4 - - - IS 
B379  New York Skin (EM) 5 - - - IS 
B418   New York (Westchester 
County) 
Skin (EM) 2 - - - IS 
B477  New York  Skin (EM) 2 - - - IS 
B500  New York (Westchester 
County) 
Skin (EM) 2 - - - IS 
B515  New York (Westchester 
County) 
Skin (EM) 4 - - - IS 
BL206  New York (Westchester 
County) 
Blood (LD) 4 - - - IS 
BL268  New York Blood 3 - - - IS  
IPT2 France (Alsace) I. ricinus (M) Unknown - - - IP 
IPT19 France (Alsace) I. ricinus (M) Unknown - - - IP 
IPT23 France (Alsace) I. ricinus (F) Unknown - - - IP 
IPT39 France (Alsace) I. ricinus (M) Unknown - - - IP 
IPT58 France (Alsace) I. ricinus (F) Unknown - - - IP 
IPT69 France (Alsace) I. ricinus (N) Unknown - - - IP 
IPT135 France (Auvergne) I. ricinus (F) Unknown - - - IP 
IPT137 France (Alsace) I. ricinus (F) Unknown - - - IP 
IPT190 France (Normandie) I. ricinus (M) Unknown - - - IP 
IPT191 France (Normandie) I. ricinus (F) Unknown - - - IP 
IPT193 France (Normandie) I. ricinus (M) Unknown - - - IP 
PAli  Germany (Regensburg) Vitreous body 1 - - - VF 
PDri Germany (Munich) Skin (EM & 
arthritis) 
2 - - - VF 
B. garnii 
(pathogen, 
Eurasia)  
IPT28 France (Alsace) I. ricinus (M) Unknown - - - IP 
IPT114 France (Alsace) I. ricinus (M) Unknown - - - IP 
IPT130 France (Alsace) I. ricinus (M) Unknown - - - IP 
IPT139 France (Alsace) I. ricinus (F) Unknown - - - IP 
IPT140 France (Alsace) I. ricinus (M) Unknown - - - IP 
IPT156 France (Auvergne) I. ricinus (M) Unknown - - - IP 
IPT157 France (Limousin) I. ricinus (F) Unknown - + - IP 
IPT158 France (Limousin) I. ricinus (M) Unknown - - - IP 
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IPT165 France (Auvergne) I. ricinus (M) Unknown - - - IP 
IPT167 France (Limousin) I. ricinus (F) Unknown - - - IP 
IPT168 France (Limousin) I. ricinus (M) Unknown - - - IP 
IPT169 France (Auvergne) I. ricinus (F) Unknown - + - IP 
IPT171 France (Auvergne) I. ricinus (F) Unknown - - - IP 
IPT172 France (Auvergne) I. ricinus (F) Unknown - - - IP 
IPT178 France (Auvergne) I. ricinus (F) Unknown - - - IP 
PBes  Germany (Minden) CSF (NB) 5 - + - VF 
PBol Germany (Nurnberg) CSF (NB) 3 - - - VF 
PBr Germany (Günzburg) CSF (NB) 7 - - - VF 
PBu Germany (Ulm) Skin (EM) 4 - + - VF 
PFr  Germany (Munich) CSF (NB) 6 - - - VF 
PHei  Germany (Göttingen) CSF (NB) 6 - - - VF 
PKi  Germany (Tübingen) CSF (NB) 11 - - - VF 
PLa  Germany (Koblenz) CSF (NB) 5 - - - VF 
PRef Germany (Günzburg) CSF (NB) 11 - + - VF 
PWudII Germany (Munich) Skin (EM) 5 - - - VF 
20047 France I. ricinus 3 - - - SC from 
RM 
B. afzelii  
(pathogen, 
Eurasia) 
ACA-1a Sweden Skin (ACA) <10 + + + SC from 
SB 
ACA-1a Sweden  Skin (ACA) 3 + + + SC from 
IS 
ACA-1a Sweden Skin (ACA) 4 - - - SC from 
IS 
B023 Germany Skin (EM) <10 - - - SC from 
UM 
DK26 Denmark Skin (EM) <10 - - - SC from 
RM 
EMC1 Sweden Skin (EM) 3 - - + SC from 
RM 
HT10 Japan I. persulcatus <10 + + + SC from 
RM 
IBS11 France (Alsace) Skin (EM) Unknown - - - IP 
IBS12 France (Alsace) Skin (EM) Unknown + + - IP 
IBS13 France (Alsace) Skin (ACA) Unknown - + - IP 
IPT109 France (Alsace) I. ricinus (F) Unknown - + - IP 
IPT110 France (Alsace) I. ricinus (F) Unknown + + - IP 
IPT118 France (Auvergne) I. ricinus (F) Unknown - - - IP 
IPT122 France (Auvergne) I. ricinus (F) Unknown + + - IP 
IPT138 France (Alsace) I. ricinus (F) Unknown + + - IP 
IPT142 France (Alsace) I. ricinus (M) Unknown - + - IP 
IPT152 France (Limousin) I. ricinus (M) Unknown - + - IP 
IPT154 France (Limousin) I. ricinus (F) Unknown - + - IP 
IPT164 France (Auvergne) I. ricinus (M) Unknown + + - IP 
IPT179 France (Auvergne) I. ricinus (M) Unknown + + - IP 
Isau1  Germany (Munich) I. ricinus  4 + + + VF 
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J1 
("IPF") 
Japan I. persulcatus <10 - + - SC from 
RM 
PBas  Germany (Munich) Skin (borrelial 
lymphocytoma) 
2 + + + VF 
PBec  Germany (Hamburg) Skin (ACA) 3 + + - VF 
PBil  Germany (Minden) Skin (EM) 4 + + - VF 
PBo  Germany (Munich) CSF (NB) 3 + + + VF 
PBog  Germany 
(Berchtesgarden) 
Skin (EM) 6 + + + VF 
PEbe  Germany (Altötting) Skin (EM) 2 + + + VF 
PFiII  Germany (Munich) Skin (ACA) 6 - + - VF 
PFuk Germany (Munich) Skin (ACA) 3 + + + VF 
PHak  Germany (Munich) Skin (EM) 3 + + + VF 
PHes  Germany (Bad Homburg) Skin (ACA) 4 + + - VF 
PKap Germany (Tübingen) Skin (ACA)  2 + + + VF 
PKob Germany Skin, EM 7 - - - SC from 
RM 
PKob Germany (Munich) Skin (EM) 10 + + + VF 
PKr  Germany (Munich) CSF (NB) 2 + + + VF 
PObf  Germany (Bad 
Mertengheim) 
Skin 1 - - + VF 
PWe  Germany (Munich) Skin (ACA) 2 - - - VF 
R-IP3  Russia I. persulcatus  <10 + + + SC from 
PR 
R-IP21 
("IP21") 
Russia I. persulcatus  <10 - + + SC from 
RM 
TDe  Germany (unknown) I. ricinus  7 + + - VF 
T10  Germany (Munich) I. ricinus  <10 + + - VF 
UM01 Sweden Skin (EM) <10 - + + SC from 
RM 
UO1 Sweden Skin (EM) <10 - - - SC from 
RM 
VS461 Switzerland I. ricinus <10 - - - SC from 
RM 
61BV3  Germany (Berlin) I. ricinus  <10 + + - AS 
97B3  Germany (Berlin) I. ricinus  <10 - - + AS 
B. spielmanii 
(rare 
pathogen, 
Eurasia)   
Anzic Slovenia Skin (EM) Unknown - - - FS 
A14S The Netherlands Skin Low + + + AvD 
Isau2  Germany (Munich) I. ricinus 2 - - - VF 
PHap  Germany (Munich) Skin (EM) 2 + + + VF 
PMai  Germany (Munich) Skin (EM) 7 + + + VF 
PMEW  Germany (Munich) Skin (EM) 5 + + + VF 
PSigII Germany (Munich) Skin (ACA) 7 + + + VF 
B. bavariensis 
(rare 
pathogen, 
Eurasia)   
PBaeI Germany (Munich) Skin (EM) Low - - - GM from 
VF1 
PBi Germany (Ingolstadt) CSF (NB) 5 - - - VF 
PBN Germany (Munich) CSF Low - - - GM from 
VF 
PFin Germany (Munich) CSF (NB) 8 - - - VF 
PFlk  Germany (Munich)  CSF (EM & NB) Low - - - GM from 
VF 
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PHoe Germany (Munich) CSF (NB) Low - - - GM from 
VF 
PNi Germany (Halle) Skin (EM) 6 - - - VF 
POb Germany (Munich) Skin (EM) Low - - - GM from 
VF 
PRab Austria (Villach) Hand joint 
synovia  
Low - - - GM from 
VF 
PRof Germany (Munich) Skin (ACA) 3 - - - VF 
PScf Germany (Munich) CSF (NB) Low - - - GM from 
VF 
PTrob  Slovenia Skin Low - - - FS 
B. valaisiana  
(probable 
pathogen, 
Eurasia)   
IPT29 France (Meuse) I. ricinus (N) Unknown - + - IP 
IPT31 France (Meuse) I. ricinus (F) Unknown - + - IP 
IPT33 France (Meuse) I. ricinus (N) Unknown - + - IP 
IPT47 France (Alsace) I. ricinus (F) Unknown - + - IP 
IPT85 France (Alsace) I. ricinus (M) Unknown - + - IP 
IPT102 France (Auvergne) I. ricinus (F) Unknown - + - IP 
IPT111 France (Alsace) I. ricinus (F) Unknown - + - IP 
IPT121 France (Alsace) I. ricinus (F) Unknown - + - IP 
IPT144 France (Limousin) I. ricinus (F) Unknown + + + IP 
IPT163 France (Auvergne) I. ricinus (F) Unknown - + - IP 
IPT174 France (Auvergne) I. ricinus (F) Unknown - + - IP 
IPT177 France (Limousin) I. ricinus (F) Unknown + + + IP 
IPT184 France (Limousin) I. ricinus (M) Unknown - - - IP 
IPT186 France (Limousin) I. ricinus (F) Unknown - + - IP 
IPT187 France (Limousin) I. ricinus (F) Unknown - - - IP 
IPT188 France (Normandie) I. ricinus (M) Unknown - + - IP 
VS116 Switzerland I. ricinus 11 + + + SC from 
RM 
10MT Korea I. nipponensis  <10 - - - SC from 
RM 
61104B
T 
UK (Bath) I. ricinus  0 (not 
cultured) 
- - - GM 
61214B
T 
UK (Bath) I. ricinus  0 (not 
cultured) 
- - - GM 
61306L UK (Bath) I. ricinus 0 (not 
cultured) 
- - - GM 
B. lusitaniae  
(probable 
pathogen, 
Eurasia)   
Poti B2  Portugal I. ricinus  7 - + + IP 
Poti B3  Portugal I. ricinus  5 - + + IP 
 
Table B.3. PCR screen for Bor TOMM biosynthetic genes. These results provide more detail on those 
given in Table B.5. Strains marked in gray have published genomes. P# indicates number of passages 
where known. Male (M), female (F) or nymph (N) is indicated for tick isolates where known. In the case 
of human isolates, CSF indicates isolation from cerebrospinal fluid. Disease presentation is given where 
known: EM, erythema migrans; LD, Lyme disease; NB, neuroborreliosis; ACA, acrodermatitis chronica 
atrophicans. Source abbreviations: IP, Institute Pasteur; VF, Volker Fingerle; IS, Ira Schwartz; SC, 
Sherwood Casjens; RM, Richard Marconi; AS, Arno Schönberg; GM: Gabriele Margos; SB, Sven 
Bergstrom; PR, Patricia Rosa; UM, Ulrike Munderloh; FS, Franc Strle; AvD, Alje van Dam. LGL 
Bayern, Germany. *Bbsl species group currently contains 21 confirmed and proposed species, including 
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human pathogens, suspected pathogens and non-pathogenic species.
53-55
 
a
The reported B. afzelii ACA-1 
genome sequence does not contain Bor TOMM genes;
28
 however, we detected borBCD in two of three 
ACA-1 strains of differing passage numbers. Presumably lp28-8 was present in the original ACA-1 
isolate but was lost prior to the sequencing of its genome. This hypothesis is supported by a report of the 
sequence of ACA-1 vls cassette region, also missing from the published ACA-1 genome, indicating the 
presence of the lp28-8 in their culture.
56
 
b
BorBCD were not detected in passage 7 of a PKo strain that at 
passage 6 had its genome sequenced.
28
 In contrast, borBCD were detected in another isolate of PKo at 
passage 10, again highlighting the well-known heterogeneous nature of Bbsl upon cultivation. 
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Figure B.8. Nucleotide alignments of Bor TOMM biosynthetic genes. BorB (A), borC (B) and borD (C) 
from Borrelia afzelii PKo (Bafz), B. spielmanii A14S (Bspi), and B. valaisiana VS116 (Bval) were 
aligned using ClustalW. This phylogenetic data is deposited in the Dryad Digital Repository, 
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doi:10.5061/dryad.d4863. Sites where PCR screening primers annealed are underlined. The primers used 
to detect borB/C/D (Table B.5 and Table B.3) were based on bvalB/C/D from B. valaisiana VS116 (Table 
B.4). The number of mismatches per primer when compared to the two other sequenced examples of the 
gene is indicated in parentheses for each. 
 
Primer Name Sequence (5’ → 3’) Description 
PCR Screening 
BvalA-fwd ATGTTTATTAGAAATAAACATTTT
TTGACTAGC 
Forward primer to amplify borA based on bvalA 
BvalA-rev TTATAGACTAAAGCTGCAACTACA
AGTGC 
Reverse primer to amplify borA based on bvalA 
BvalB-fwd ATGGTAAAAAATGATAATGAAAG
TTCTGAAGT 
Forward primer to amplify borB based on bvalB 
BvalB-rev TTAGACATTCCCTAAAATAGCAGC
TG 
Reverse primer to amplify borB based on bvalB  
BvalC-fwd ATGAATAATGGTTTGTATTATTTT
TCAGATAATGTAAG 
Forward primer to amplify borC based on bvalC  
BvalC-rev TTAATTAGAATTAGAAATTAATGT
TGAAACAAGCTTT 
Reverse primer to amplify borC based on bvalC  
BvalD-fwd GTGATTAACTATTATCCTTATTCT
AGTAAGCTTTATAGA 
Forward primer to amplify borD based on bvalD  
BvalD-rev CTAAGGTATTGGGTGTGGGTAATA
TTC 
Reverse primer to amplify borD based on bvalD  
pDCerm Constructs 
BvalA-5'XbaI AAATCTAGAATGTTTATTAGAAAT
AAACATTTTTTGAC 
Forward primer to subclone bvalA from 
pIDTSMART construct  
BvalA-3'BamHI AAAGGATCCTTATAGACTAAAGCT
GCAACTACAAGTG 
Reverse primer to subclone bvalA from 
pIDTSMART construct 
SagA-BvalA-
5'XbaI 
AAATCTAGAATGTTAAAATTTACT
TCAAATATTTTAGCTAC 
Forward primer to subclone sagA-bvalA from 
pIDTSMART construct  
SagA-BvalA-
3'BamHI 
AAAGGATCCTTATAGACTAAAGCT
GCAACTACAAGTGCAAC 
Reverse primer to subclone sagA-bvalA from 
pIDTSMART construct  
sagA
1-50
For GAAGTTATACGtaAGGTAAATAAG
GATCCTGATCTTCAGAA 
Forward primer for incorporation of stop codon 
at position corresponding to P51 in sagA  
sagA
1-50
Rev CCTTATTTACCTtaCGTATAACTTC
CGCTACCACCTTGAGA 
Reverse primer for incorporation of stop codon 
at position corresponding to P51 in sagA  
sagA
1-44
For ATTCTCAAGGTtaaAGCGGAAGTTA
TACGCCAGGTAAATAA 
Forward primer for incorporation of stop codon 
at position corresponding to G45 in sagA  
sagA
1-44
Rev TAACTTCCGCTttaACCTTGAGAATT
ACCACTTCCAGTAGC 
Reverse primer for incorporation of stop codon 
at position corresponding to G45 in sagA  
sagA
1-42
For GTGGTAATTCTtAAGGTGGTAGCG
GAAGTTATACGCCAGGT 
Forward primer for incorporation of stop codon 
at position corresponding to Q43 in sagA  
sagA
1-42
Rev CCGCTACCACCTTaAGAATTACCA
CTTCCAGTAGCAATTGA 
Reverse primer for incorporation of stop codon 
at position corresponding to Q43 in sagA  
sagA
1-40
For CTGGAAGTGGTtAaTCTCAAGGTG
GTAGCGGAAGTTATACG 
Forward primer for incorporation of stop codon 
at position corresponding to N41 in sagA  
sagA
1-40
Rev CCACCTTGAGAtTaACCACTTCCAG
TAGCAATTGAGAAGCA 
Reverse primer for incorporation of stop codon 
at position corresponding to N41 in sagA  
sagA
1-38
For TTGCTACTGGAtaaGGTAATTCTCA
AGGTGGTAGCGGAAGT 
Forward primer for incorporation of stop codon 
at position corresponding to S39 in sagA  
sagA
1-38
Rev TGAGAATTACCttaTCCAGTAGCAA
TTGAGAAGCAACAAGT 
Reverse primer for incorporation of stop codon 
at position corresponding to S39 in sagA  
294 
 
sagA
1-37
For CAATTGCTACTtaAAGTGGTAATTC
TCAAGGTGGTAGCGGA 
Forward primer for incorporation of stop codon 
at position corresponding to G38 in sagA 
sagA
1-37
Rev GAATTACCACTTtaAGTAGCAATTG
AGAAGCAACAAGTAGT 
Reverse primer for incorporation of stop codon 
at position corresponding to G38 in sagA  
sagA
1-36
For TCTCAATTGCTtaaGGAAGTGGTAA
TTCTCAAGGTGGTAGC 
Forward primer for incorporation of stop codon 
at position corresponding to T37 in sagA  
sagA
1-36
Rev TTACCACTTCCttaAGCAATTGAGA
AGCAACAAGTAGTACA 
Reverse primer for incorporation of stop codon 
at position corresponding to T37 in sagA  
sagA
1-35
For GCTTCTCAATTtaaACTGGAAGTGG
TAATTCTCAAGGTGGT 
Forward primer for incorporation of stop codon 
at position corresponding to A36 in sagA  
sagA
1-35
Rev CCACTTCCAGTttaAATTGAGAAGC
AACAAGTAGTACAGCA 
Reverse primer for incorporation of stop codon 
at position corresponding to A36 in sagA  
sagA
1-34
For GTTGCTTCTCAtaaGCTACTGGAAG
TGGTAATTCTCAAGGT 
Forward primer for incorporation of stop codon 
at position corresponding to I35 in sagA  
sagA
1-34
Rev CTTCCAGTAGCttaTGAGAAGCAAC
AAGTAGTACAGCAGCA 
Reverse primer for incorporation of stop codon 
at position corresponding to I35 in sagA  
sagA
1-33
For CTTGTTGCTTCtaaATTGCTACTGGA
AGTGGTAATTCTCAA 
Forward primer for incorporation of stop codon 
at position corresponding to S34 in sagA  
sagA
1-33
Rev CCAGTAGCAATttaGAAGCAACAAG
TAGTACAGCAGCAACA 
Reverse primer for incorporation of stop codon 
at position corresponding to S34 in sagA  
sagA-
bvalA+A_For 
GCTTTAGTCTAgctTAAGGATCCTG
ATCTTCAGAACTTAAG 
Forward primer for appending alanine codon 
after position corresponding to L36 in sagA-
bvalA  
sagA-
bvalA+A_Rev 
CAGGATCCTTAagcTAGACTAAAGC
TGCAACTACAAGTGCA 
Reverse primer for appending alanine codon 
after position corresponding to L36 in sagA-
bvalA 
sagA-bvalA-
S27CFor 
GCTGCTGTTGTtgcTGCACTTGTAG
TTGCAGCTTTAGTCTA 
Forward primer for substitution with cysteine 
codon at position corresponding to S27 in sagA-
bvalA 
sagA-bvalA-
S27CRev 
CTACAAGTGCAgcaACAACAGCAG
CCTCCAGGAGCAACTTG 
Reverse primer for substitution with cysteine 
codon at position corresponding to S27 in sagA-
bvalA 
pDC_SeqMCS_F GGGAGGAAATAAAGCGCTAGG Forward primer for verification of site-directed 
mutants of sagA by DNA sequencing  
S. pyogenes M1 ΔsagA Transformant Confirmation 
pDC_SeqMCS_F GGGAGGAAATAAAGCGCTAGG Forward primer to detect pDCerm containing 
gene of interest 
pDCerm_PCR_R ACAAGTAACCAGTGACTGCCG Reverse primer to detect pDCerm containing 
gene of interest 
SagB_F ATGTCATTTTTTACAAAGGAACAA Forward primer to detect sagB gene 
SagB_R ATTGACGATGACTTCTTCG Reverse primer to detect sagB gene 
spy1258F AAAGACCGCCTTAACCACCT Forward primer to detect gene unique to S. 
pyogenes (Liu et al., 2005)  
spy1258R TGGCAAGGTAAACTTCTAAAGCA Reverse primer to detect gene unique to S. 
pyogenes (Liu et al., 2005) 
pET28b-MBP Constructs 
BvalA-5'BamHI AAAAGGATCCATGTTTATTAGAAA
TAAAC 
Forward primer to subclone bvalA from 
pIDTSMART construct  
BvalA-3'NotI AAAAGCGGCCGCTTATAGACTAA
AGCTGC 
Reverse primer to subclone bvalA from 
pIDTSMART construct  
SagA-BvalA-
5'BamHI 
AAAAGGATCCATGTTAAAATTTAC
TTCAAA 
Forward primer to subclone sagA-bvalA from 
pIDTSMART construct  
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SagA-BvalA-
3'NotI 
AAAAGCGGCCGCTTATAGACTAA
AGCTGCAAC 
Reverse primer to subclone sagA-bvalA from 
pIDTSMART construct  
sagA
1-35
For GCTTCTCAATTtaaACTGGAAGTGG
TAATTCTCAAGGTGGT 
Forward primer for incorporation of stop codon 
at position corresponding to A36 in sagA  
sagA
1-35
Rev CCACTTCCAGTttaAATTGAGAAGC
AACAAGTAGTACAGCA 
Reverse primer for incorporation of stop codon 
at position corresponding to A36 in sagA  
 
Table B.4. Primers used in this study. In all cases, bvalA/B/C/D or BvalA/B/C/D refers to the relevant 
TOMM genes or proteins from B. valaisiana VS116. Restriction endonuclease recognition sites are 
underlined. Lower-case letters indicate bases targeted for mutagenesis. 
 
Our results reveal that Bor TOMM biosynthetic genes are present in select B. afzelii, B. 
spielmanii, B. valaisiana, B. lusitaniae, and B. garinii isolates (Table B.3, summarized in Table B.5). In 
line with the well-known plasmid instability of Borrelia plasmids, we observed cases of passage-
dependent amplification of Bor TOMM genes (Table B.3). While all three biosynthetic genes could be 
amplified from some of the aformentioned strains, there were many instances where only one or two 
biosynthetic genes were detected (Table B.3 & Table B.5). Overall, borC was successfully amplified 
more frequently than borB or borD, likely due to higher conservation at the extreme 5’ and 3’ ends where 
the primers were designed to anneal (Table B.4). Since mutational inactivation of nonessential genes is 
quite common on Bbsl linear plasmids, another possibility is that some target genes are too divergent to 
detect with the primers employed.
33
 
  PCR Positive 
Bbsl species No. of strains screened borB borC borD All 
Bbss 24 0 0 0 0 
B. garinii 26 0 5 0 0 
B. afzelii 47 26 34 19 14 
B. spielmanii 7 5 5 5 5 
B. bavariensis 13 0 0 0 0 
B. valaisiana 21 3 15 3 3 
B. lusitaniae 2 0 2 2 0 
 
Table B.5. The Bor TOMM biosynthetic cluster is present among diverse Bbsl isolates. Positive PCR hits 
for Bor TOMM biosynthetic genes in Bbsl isolates. Strains originated in Europe and Asia, except 11 
Borrelia burgdorferi sensu stricto (Bbss) from North America. “All” indicates the number of isolates 
testing positive for genes encoding all three putative heterocycle forming enzymes, BorBCD. More 
details are provided in Table B.3. 
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In contrast, Bor TOMM genes were absent from all B. burgdorferi sensu stricto (Bbss) and B. 
bavariensis isolates screened (Table B.3 & Table B.5), suggesting that they do not possess a Bor TOMM 
cluster, or again, that the target genes are too divergent to detect. The fact that the Bor TOMM is not 
present in the 13 Bbss published genomes
34
 suggests that the former is likely true for this species. 
Notably, Bbss has been reported to produce a number of hemolytic factors.
35, 36
 
Mapping the distribution of a subset of the Bor TOMM cluster data onto a maximum likelihood 
tree, which was generated from a multilocus sequence typing (MLST) analysis, further supports our 
hypothesis that the Bor TOMM cluster has long been present in Borrelia (Figure B.9). The combined 
effects of a non-exhaustive PCR screen with non-degenerate primers and the unavoidable plasmid loss 
upon cultivation means that data reported here represent the minimum distribution and prevalence of the 
Bor TOMM cluster in Bbsl. However, these data demonstrate that the newly-identified Bor TOMM 
cluster is underrepresented in available genome sequences. 
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Figure B.9. Maximum likelihood tree of Bbsl strains used in the Bor TOMM PCR screen. The tree shows 
the relationships of a number of Borrelia strains, including a subset of the Bbsl strains included in our 
PCR screen. This phylogenetic data is deposited in the Dryad Digital Repository, 
doi:10.5061/dryad.d4863. A plus sign (+) next to the strain designation indicates that gene(s) from the 
Bor TOMM biosynthetic cluster (borB/borC/borD) was/were detected (Table B.3). WGS: whole genome 
sequence. 
 
The SLS-like peptides from Borrelia are potential cytolysins 
Given that cytolytic TOMM production has been implicated in the virulence of some pathogens,
8, 
19, 23
 coupled with the prevelance of SLS-like TOMM clusters in Bbsl, we decided to study the cytolytic 
potential of one of the naturally C-terminally truncated SLS-like peptides from Bbsl. In light of the 
complexity of Borrelia cultivation requirements, the aformentioned tendency to lose plasmids when 
cultured and inefficient genetic tools,
37, 38
 we opted to take a reductionist approach and assess the cytolytic 
potential of BvalA by heterologous expression in S. pyogenes ΔsagA. Importantly, there is precedent for 
this approach, e.g. the SLS-like precursor from C. sporogenes (Figure B.1B) successfully complemented 
S. pyogenes ΔsagA8 and was later confirmed to function as a cytolysin in the context of its native producer 
18
. BvalA bears ~70% amino acid similarity to SagA (Figure B.10A) and the SagBCD proteins are ~50% 
similar to their BvalBCD equivalents. However, no hemolytic activity was observed upon heterologous 
expression of the non-cognate substrate BvalA in S. pyogenes ΔsagA (Figure B.10B). 
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Figure B.10. Hemolytic activity of SLS-like peptides expressed in S. pyogenes ΔsagA and modified by 
purified SagBCD enzymes. (A) Residues of the SagA and SagA-BvalA precursors are numbered. The 
motifs known to be important for binding SagC
8
 are shown in red for the SagA leader. Partial binding 
motifs also shown in red for the BvalA leader. Potentially modified residues are blue except C32, the 
position of a previously generated alanine substitution that abolished cytolytic activity of SagA, which is 
marked in purple. The predicted leader cleavage sites are indicated with a caret. The position of a stop 
codon introduced in SagA to yield the SagA
1-35
 (BvalA mimic) is marked with an asterisk. SagA-BvalA-
S27C and SagA-BvalA+A point mutants are represented by italicized letters adjacent to the SagA-BvalA 
precursor sequence. The precursor peptide labels continue in panel B & C.  (B) A representative colony 
on blood agar of S. pyogenes ΔsagA expressing each precursor peptide from pDCerm is shown. The 
colony labeled “Empty” was a negative control containing pDCerm vector. (C) Where appropriate, bars 
are labeled with + or – indicating presence or absence, respectively, of MBP-SagBCD in the reaction 
using the indicated MBP-tagged precursor peptide. Triton X-100, positive control for 100% lysis; PBS, 
negative control for background hemolysis. Error is reported as the standard deviation of the mean (n = 
3). * indicates P < 0.01 for each synthetase reaction versus the relevant unreacted precursor. P < 0.01 for 
all lytic samples versus all negative controls, i.e. SagA-C32A reaction, enzymes alone, PBS. 
 
 Substrate binding during TOMM biosynthesis occurs via recognition of key motifs within N-
terminal leader region of the precursor peptide by the C-protein component of the synthetase.
8, 26
 
Although partial binding motifs appear to be present in the BorA leader peptides (Figure B.10A), we 
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cannot rule out the possibility that BvalA was not bound by the S. pyogenes biosynthetic machinery 
during heterologous expression. In light of this, we generated a chimeric construct encoding the cognate 
SagA leader peptide fused to the non-cognate BvalA core peptide (SagA-BvalA; Figure B.10A). Such a 
strategy has been exploited to replace highly divergent leader peptides with the SagA leader to allow 
native interaction with the heterocycle-forming synthetase.
8
 In this way, hemolytic activity was 
demonstrated for the SLS-like core from S. aureus (Figure B.1B) upon expression in S. pyogenes ΔsagA.8 
However, SagA-BvalA was not hemolytic under identical conditions (Figure B.10B). Co-expression of 
rare streptococcal tRNAs
39
 also failed to yield hemolysis from BvalA or SagA-BvalA, suggesting that 
their inactivity was not due to codon-usage bias during heterologous expression.  
Returning to the native SagA precursor peptide, we noted a dramatic decrease in activity for 
SagA
1-35
 (which could be considered a BvalA mimic; Figure B.10A), compared to SagA
1-36
 (Figure 
B.3B). In case the hemolytic activity of SagA-BvalA was just below the limit of detection of this assay, 
we appended an alanine to the C-terminus of SagA-BvalA (SagA-BvalA+A is akin to SagA
1-36
); however, 
hemolysis was again not observed (Figure B.10B). While the SagA core begins with a stretch of five 
contiguous cysteine residues, there is a serine residue at the fourth position of the comparable region of 
BvalA (Figure B.10A). We thus created SagA-BvalA-S27C, which partly rescued activity (Figure 
B.10B), causing hemolysis only directly beneath the colony compared to the zone of clearing observed in 
strains with high hemolytic activity. Synthetase reactions with reconstituted TOMM biosynthetic 
enzymes have established that cysteine is cyclized more rapidly than serine and threonine and several 
TOMM synthetases are known to be selective for cysteine.
40, 41
 We speculate that replacing serine with 
cysteine partly ameliorates a bottleneck for SagBCD in processing an unnatural substrate.  
 The lack of activity from BvalA-derived substrates upon expression in S. pyogenes ΔsagA 
prompted us to assess cytolytic potential using purified SagBCD enzymes. Previously, SLS-like 
cytolysins with no detectable activity when expressed in S. pyogenes ΔsagA were converted to cytolysins 
by this approach.
8
 Numerous factors contribute to this, but perhaps most importantly, high concentrations 
of reactants can be employed to increase the heterocyclization yield on non-optimal substrates. 
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Additionally, this cell-free system obviates the need for export/proteolysis machinery to generate lytic 
entities.
7, 8
 Attempts to obtain sufficiently pure, full-length and active recombinant BvalBCD were 
unsuccessful; however, after treatment with the SagBCD homologs (Table B.1C), BvalA and SagA-
BvalA were both converted into cytolysins with activity comparable to SagA and SagA
1-36
 (Figure 
B.10C). Omission of either the peptide substrate or SagBCD resulted in no lysis, similar to the non-lytic 
C32A mutant of SagA.
8
 These data indicated that the BvalA precursor peptide has the potential to be 
converted into a cytolysin under certain conditions.  
The majority of non-cognate and mutant precursor peptides that become cytolytic upon treatment 
with purified SagBCD were also lytic when constitutively expressed in S. pyogenes ΔsagA.8 However, 
there is precedent for the failure of bona fide SLS-like precursors to restore hemolysis in S. pyogenes 
ΔsagA, e.g. as was the case with listeriolysin S (Figure B.1B).8, 19 The contrasting results for BvalA and 
SagA-BvalA (Figure B.10B & C) are reminiscent of the chimeric L. monocytogenes substrate, SagA-
LlsA, which was inactive in S. pyogenes ΔsagA but was transformed into a cytolysin by purified 
SagBCD.
8
 These results underscore the strict requirements for efficient enzymatic processing and toxin 
export in S. pyogenes. Nevertheless, the ability of purified SagBCD to convert BvalA into a cytolysin, 
coupled with the retention of activity by truncated SagA peptides upon functional expression, suggests 
that the short SagA homologs found in Bbsl may function as cytolysins in the context of their native 
producers. However, whether this activity is the primary function of the Bor TOMM (if produced) 
requires additional study.   
Conclusions  
The results of our SagA truncation series indicate that, of the 30 predicted to comprise the core 
peptide, the first 11 residues (SagA
24-34
) are sufficient for detectable hemolytic activity of SLS when 
expressed in S. pyogenes ΔsagA. Thus, our data indicates that the C-terminus of SagA is largely 
dispensable and points to the NPH region as central to SLS functionality, consistent with the conservation 
of this motif in natural SLS variants as well as the greater TOMM cytolysin family. Similar regions 
consisting of contiguous heterocyclizable residues exist in the newly-described SLS-like precursors 
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encoded in multiple genera within Firmicutes, Spirochaetes and Actinobacteria. Although the ability of 
BvalA and SagA
1-35
 to be matured into cytolysins by purified SagBCD suggests that the “minimal 
cytolytic unit” may be a general feature of TOMM cytolysins, additional study will be required to 
determine if this holds true for all family members, especially those with longer stretches of 
heterocyclizable residues (e.g. listeriolysin S). In order to comprehend our observation that much of the 
hemolytic activity of SLS can be attributed to a mere 11 residues, a complete chemical structure of SLS 
and greater molecular insight into the interaction of SLS with the cellular membrane will be required.  
Our identification of novel SLS-like biosynthetic clusters greatly expands the TOMM cytolysin 
family. Of particular interest is our discovery that many pathogenic Bbsl harbor the genetic capacity to 
produce naturally truncated SLS-like toxins. Although confirmation is needed, the most probable function 
for the SLS-like biosynthetic clusters in Bbsl is to generate a cytolytic factor, akin to the virulence-
enhancing SLS of S. pyogenes.  Thus, the hypothetical “borreliolysin S” toxin we identify herein warrants 
further investigation as it would represent, to the best of our knowledge, the first posttranslationally 
modified natural product from any Spirochaete.  
In summary, this work provides evidence that the core NPH motif represents the defining feature 
of the SLS-like TOMM family, as well as providing a foundation for studies of the potential utilization of 
cytolytic TOMMs by the diverse organisms described herein. 
Experimental 
Bacterial culture conditions 
Strains and plasmids used in this study are listed in Table B.6, except Bbsl strains which are listed 
in Table B.3. S. pyogenes were grown at 37 
o
C in Todd–Hewitt broth or agar plates, or on plates of 5% 
sheep blood in tryptic soy agar (Hardy Diagnostics) when determining hemolytic activity by functional 
expression. For antibiotic selection, 5 μg ml-1 erythromycin was used. E. coli strains were grown at 37 oC 
with aeration in Luria–Bertani (LB) broth or on LB agar plates; antibiotic selection utilized 500 μg ml-1 
erythromycin and 50 μg ml-1 kanamycin where relevant. 
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Strain/Plasmid Relevant characteristics/Uses References 
Strains 
Escherichia coli DH5α Plasmid construction/maintenance Lab stock 
Escherichia coli 
BL21(DE3)-RIPL 
Protein overexpression for purification Lab stock 
Streptococcus pyogenes 
(GAS) M1  
Group A Streptococcus  Lab stock 
Streptococcus pyogenes 
(GAS) M1 ΔsagA 
Group A Streptococcus; sagA allelic exchange mutant of S. pyogenes 
M1 
[21] 
Plasmids 
pDCerm-empty Empty GAS expression vector; Erm
R
 [21] 
pDCerm-sagA Constitutive expression of SagA wild-type precursor peptide; 
compliments GAS M1 ΔsagA 
[21] 
pDCerm-sagA
1-50
 Constitutive expression of SagA
1-50
 truncation This study 
pDCerm-sagA
1-44
 Constitutive expression of SagA
1-44
 truncation This study 
pDCerm-sagA
1-42
 Constitutive expression of SagA
1-42
 truncation This study 
pDCerm-sagA
1-40
 Constitutive expression of SagA
1-40
 truncation This study 
pDCerm-sagA
1-38
 Constitutive expression of SagA
1-38
 truncation This study 
pDCerm-sagA
1-37
 Constitutive expression of SagA
1-37
 truncation This study 
pDCerm-sagA
1-36
 Constitutive expression of SagA
1-36
 truncation This study 
pDCerm-sagA
1-35
 Constitutive expression of SagA
1-35
 truncation as BvalA mimic This study 
pDCerm-sagA
1-34
 Constitutive expression of SagA
1-34
 truncation This study 
pDCerm-sagA
1-33
 Constitutive expression of SagA
1-33
 truncation This study 
pDCerm-bvalA Constitutive expression of BvalA wild-type precursor peptide This study 
pDCerm-sagA-bvalA Constitutive expression of SagA
1-23
 fused to BvalA
25-37
 to yield chimeric 
precursor peptide consisting of SagA leader with BvalA core 
This study 
pDCerm-sagA-bvalA+A 
 
Constitutive expression of SagA-BvalA chimera with alanine residue 
appended after terminal leucine residue 
This study 
pDCerm-sagA-bvalA-
S27C 
Constitutive expression of SagA-BvalA chimera with S27C substitution This study 
pET28b-MBP Empty E. coli vector for high heterologous expression of proteins; Kan
R
 [6] 
pET28b-MBP-sagA Overexpression of SagA plus N-terminal MBP tag [6] 
pET28b-MBP-sagA
1-35
 Overexpression of SagA
1-35
 truncation as BvalA mimic plus N-terminal 
MBP tag 
This study  
pET28b-MBP-bvalA Overexpression of BvalA plus N-terminal MBP tag This study 
pET28b-MBP-sagA-
bvalA 
Overexpression of SagA
1-23
 fused to BvalA
25-37
 to yield chimeric 
precursor peptide consisting of SagA leader with BvalA core plus N-
terminal MBP tag 
This study 
pET28b-MBP-sagA-
C32A 
Overexpression of SagA precursor peptide with C32A substitution plus 
N-terminal MBP tag 
[7] 
pET28b-MBP-sagB Overexpression of SagB dehydrogenase plus N-terminal MBP tag [6] 
pET28b-MBP-sagC Overexpression of SagC component of cyclodehydratase plus N-
terminal MBP tag 
[6] 
pET28b-MBP-sagD Overexpression of SagD component of cyclodehydratase plus N-
terminal MBP tag 
[6] 
 
Table B.6. Strains and plasmids used in this study. In all cases, bvalA/BvalA refers to the TOMM 
gene/peptide from B. valaisiana VS116. The sequences of the relevant precursor peptides are shown in 
Figure B.3A & Figure B.10A. 
  
304 
 
Genome mining for novel SLS-like clusters 
The majority of TOMM clusters encode a precursor peptide adjacent to SagB, -C and -D 
homologs,
9, 11
 enabling their bioinformatic detection. Thus, novel SLS-like clusters were identified by 
BLAST-P of known SLS-like D proteins (SagD and homologs from C. botulinum, S. aureus, L. 
monocytogenes) as the query sequence. After identification of BvalD, BmurD, LactD, and EnduD, these 
sequences were used as a query sequence to find other homologs, with a BLAST e-value of 1e-30 as a 
cutoff. Subsequently, homologs of other sag genes were identified in the local genomic region of a single 
representative cluster from each genus. Manual searches were performed in the intergenic regions of the 
representative clusters for short, unannotated genes encoding recognizable TOMM precursors, which are 
usually overlooked by gene-identification algorithms. Because of inherent duplications in RefSeq, only a 
single representative sequence was used from organisms with no strain information. Genome clusters with 
low e-values were annotated manually for precursor peptides and genomic regions that resembled known 
cytolysins.  
Maximum likelihood phylogenetic analysis 
The D proteins of a diverse set of putative TOMM cytolysin producers were analyzed because it 
known that the B and C proteins can sometimes be omitted from TOMM biosynthetic gene 
clusters, whereas D proteins are always present.
11
 Further, the B and C proteins are homologous to non-
TOMM dehydrogenases and the E1-ubiquitin activating family of enzymes, and thus are prone to 
bioinformatic false-positivies. Thus, a D protein alignment was created using the standard parameters of 
ClustalW
42
 and then a maximum likelihood tree was made using the standard parameters of Molecular 
Evolutionary Genetics Analysis (MEGA).
43
 MLST phylogenetic analysis was generated in MEGA 5.1 
using concatenated sequences of eight chromosomally-located housekeeping genes (clpA, clpX, nifS, 
pepX, pyrG, recG, rplB, and uvrA)
44
 using the maximum likelihood method with 1,000 bootstrap repeats, 
the GTR model, uniform rates among sites and nearest-neighbor-interchange. 
PCR screen for Bor TOMM biosynthetic genes 
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Genomic DNA of cultured Bbsl isolates was purified using either a Qiagen DNeasy blood and 
tissue kit or a High Pure PCR Template Preparation Kit (Roche Diagnostics).
45, 46
 Total DNA from field-
collected questing ticks was extracted using alkaline hydrolysis 
47
. Genomic DNA from each Bbsl isolate 
was tested for the presence of borB, -C, and -D by Taq PCR with primers specific to VS116 (Table B.4). 
Amplification of a product of appropriate length as determined by agarose gel electrophoresis was 
considered a positive hit. Sanger sequencing confirmed the identity of PCR amplicons from each species. 
Primers that effectively amplified Bbsl 16S rRNA gene sequences were used to verify that sufficient 
DNA was present in all samples.  
Preparation of plasmids for S. pyogenes transformation  
The chemically synthesized genes (IDT) encoding BvalA and SagA-BvalA were subcloned into 
pDCerm as previously described.
8
 Stop codons were introduced by site-directed mutagenesis. Mutant 
candidates were miniprepped and verified by DNA sequencing using pDCerm_SeqMCS_F Primers are 
listed in Table B.4. In order to obtain sufficient plasmid DNA for transformation of S. pyogenes ΔsagA, 
each pDCerm construct was maxiprepped using an E.Z.N.A. Plasmid Maxi Kit (Omega Bio-tek). 
S. pyogenes transformation 
S. pyogenes ΔsagA23 was rendered electrocompetent using a modified version of a previously 
published method.
48
 Briefly, S. pyogenes ΔsagA was grown to an OD600 of 0.35 in 50 ml Todd–Hewitt 
broth with 0.6% (w/v) glycine. Cells were washed three times with cold 0.625 M sucrose (pH 4) and 
resuspended in 300 μl of the same buffer with 20% (v/v) glycerol. 50 μl cells were equilibrated with ~1 
μg of plasmid DNA on ice for 30 min and electroporated at 1.65 kV with a BioRad Micropulser. 
Immediately, cells were added to 250 μl Todd–Hewitt broth with 0.25 M sucrose and recovered for 2 h at 
37 °C, before plating. The S. pyogenes-nature of transformants
49
 and presence of pDCerm were verified 
by PCR (Table B.4). 
Reaction of SLS-like peptides with purified SagBCD  
All proteins were expressed with maltose-binding protein (MBP) fused to the N-terminus. SagA, 
SagA-C32A,
8
 SagB, SagC and SagD were prepared as previously described.
7
 The genes encoding BvalA 
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and SagA-BvalA were subcloned into pET28b-MBP as previously described.
7
 Site-directed mutagenesis 
was performed to yield pET28b-MBP-SagA
1-35
 (Table B.4). Precursor peptides were expressed from E. 
coli BL21(DE3)-RIPL (Strategene) for 1 h at 30 °C after induction with 1 mM IPTG at OD600 of 0.6. 
Following standard lysis procedures, each protein was purified by amylose affinity chromatography.
7
 
MBP-SagB, -C and -D (10 μM each) were combined with the relevant MBP-tagged precursor peptide (40 
μM) and allowed to react in synthetase buffer as previously described.7 The products of the synthetase 
reactions were applied to washed erythrocytes and lysis assessed as previously described.
7
 Hemoglobin 
absorbance was measured at 410 nm on a Tecan Infinite
®
 200 PRO plate reader. Values were normalized 
to a Triton X-100 positive control. Phosphate buffered saline (PBS) served as a negative control. 
References 
1. Molloy, E. M., Casjens, S. R., Cox, C. L., Maxson, T., Ethridge, N. A., Margos, G., Fingerle, V., 
and Mitchell, D. A. (2015) Identification of the minimal cytolytic unit for streptolysin S and an 
expansion of the toxin family, BMC Microbiol. 15, 141. 
 
2. Cunningham, M. W. (2000) Pathogenesis of group A streptococcal infections, Clin. Microbiol. 
Rev. 13, 470-511. 
 
3. Marmorek, A. (1895 ) Le streptocoque et le sérum antistreptococcique, Ann. Inst. Pasteur, 593–
620. 
 
4. Todd, E. W. (1938) The differentiation of two distinct serologic varieties of streptolysin, 
streptolysin O and streptolysin S., J. Pathol. Bacteriol., 423–445. 
 
5. Molloy, E. M., Cotter, P. D., Hill, C., Mitchell, D. A., and Ross, R. P. (2011) Streptolysin S-like 
virulence factors: the continuing sagA, Nat. Rev. Microbiol. 9, 670-681. 
 
6. Nizet, V., Beall, B., Bast, D. J., Datta, V., Kilburn, L., Low, D. E., and De Azavedo, J. C. (2000) 
Genetic locus for streptolysin S production by group A streptococcus, Infect. Immun. 68, 4245-
4254. 
 
7. Lee, S. W., Mitchell, D. A., Markley, A. L., Hensler, M. E., Gonzalez, D., Wohlrab, A., 
Dorrestein, P. C., Nizet, V., and Dixon, J. E. (2008) Discovery of a widely distributed toxin 
biosynthetic gene cluster, Proc. Natl. Acad. Sci. U. S. A. 105, 5879-5884. 
 
8. Mitchell, D. A., Lee, S. W., Pence, M. A., Markley, A. L., Limm, J. D., Nizet, V., and Dixon, J. 
E. (2009) Structural and functional dissection of the heterocyclic peptide cytotoxin streptolysin S, 
J. Biol. Chem. 284, 13004-13012. 
 
9. Melby, J. O., Nard, N. J., and Mitchell, D. A. (2011) Thiazole/oxazole-modified microcins: 
complex natural products from ribosomal templates, Curr. Opin. Chem. Biol. 15, 369-378. 
 
307 
 
10. Oman, T. J., and van der Donk, W. A. (2010) Follow the leader: the use of leader peptides to 
guide natural product biosynthesis, Nat. Chem. Biol. 6, 9-18. 
 
11. Arnison, P. G., Bibb, M. J., Bierbaum, G., Bowers, A. A., Bugni, T. S., Bulaj, G., Camarero, J. 
A., Campopiano, D. J., Challis, G. L., Clardy, J., Cotter, P. D., Craik, D. J., Dawson, M., 
Dittmann, E., Donadio, S., Dorrestein, P. C., Entian, K. D., Fischbach, M. A., Garavelli, J. S., 
Goransson, U., Gruber, C. W., Haft, D. H., Hemscheidt, T. K., Hertweck, C., Hill, C., Horswill, 
A. R., Jaspars, M., Kelly, W. L., Klinman, J. P., Kuipers, O. P., Link, A. J., Liu, W., Marahiel, M. 
A., Mitchell, D. A., Moll, G. N., Moore, B. S., Muller, R., Nair, S. K., Nes, I. F., Norris, G. E., 
Olivera, B. M., Onaka, H., Patchett, M. L., Piel, J., Reaney, M. J., Rebuffat, S., Ross, R. P., Sahl, 
H. G., Schmidt, E. W., Selsted, M. E., Severinov, K., Shen, B., Sivonen, K., Smith, L., Stein, T., 
Sussmuth, R. D., Tagg, J. R., Tang, G. L., Truman, A. W., Vederas, J. C., Walsh, C. T., Walton, 
J. D., Wenzel, S. C., Willey, J. M., and van der Donk, W. A. (2013) Ribosomally synthesized and 
post-translationally modified peptide natural products: overview and recommendations for a 
universal nomenclature, Nat. Prod. Rep. 30, 108-160. 
 
12. Pei, J., Mitchell, D. A., Dixon, J. E., and Grishin, N. V. (2011) Expansion of type II CAAX 
proteases reveals evolutionary origin of gamma-secretase subunit APH-1, J. Mol. Biol. 410, 18-
26. 
 
13. Maxson, T., Deane, C. D., Molloy, E. M., Cox, C. L., Markley, A. L., Lee, S. W., and Mitchell, 
D. A. (2015) HIV Protease Inhibitors Block Streptolysin S Production, ACS Chem. Biol. 
 
14. Humar, D., Datta, V., Bast, D. J., Beall, B., De Azavedo, J. C., and Nizet, V. (2002) Streptolysin 
S and necrotising infections produced by group G streptococcus, Lancet 359, 124-129. 
 
15. Fuller, J. D., Camus, A. C., Duncan, C. L., Nizet, V., Bast, D. J., Thune, R. L., Low, D. E., and 
De Azavedo, J. C. (2002) Identification of a streptolysin S-associated gene cluster and its role in 
the pathogenesis of Streptococcus iniae disease, Infect. Immun. 70, 5730-5739. 
 
16. Flanagan, J., Collin, N., Timoney, J., Mitchell, T., Mumford, J. A., and Chanter, N. (1998) 
Characterization of the haemolytic activity of Streptococcus equi, Microb. Pathog. 24, 211-221. 
 
17. Tabata, A., Nakano, K., Ohkura, K., Tomoyasu, T., Kikuchi, K., Whiley, R. A., and Nagamune, 
H. (2013) Novel twin streptolysin S-like peptides encoded in the sag operon homologue of beta-
hemolytic Streptococcus anginosus, J. Bacteriol. 195, 1090-1099. 
 
18. Gonzalez, D. J., Lee, S. W., Hensler, M. E., Markley, A. L., Dahesh, S., Mitchell, D. A., 
Bandeira, N., Nizet, V., Dixon, J. E., and Dorrestein, P. C. (2010) Clostridiolysin S, a post-
translationally modified biotoxin from Clostridium botulinum, J. Biol. Chem. 285, 28220-28228. 
 
19. Cotter, P. D., Draper, L. A., Lawton, E. M., Daly, K. M., Groeger, D. S., Casey, P. G., Ross, R. 
P., and Hill, C. (2008) Listeriolysin S, a novel peptide haemolysin associated with a subset of 
lineage I Listeria monocytogenes, PLoS Pathog. 4, e1000144. 
 
20. Clayton, E. M., Daly, K. M., Guinane, C. M., Hill, C., Cotter, P. D., and Ross, P. R. (2014) 
Atypical Listeria innocua strains possess an intact LIPI-3, BMC Microbiol. 14, 58. 
 
21. Clayton, E. M., Hill, C., Cotter, P. D., and Ross, R. P. (2011) Real-time PCR assay to 
differentiate Listeriolysin S-positive and -negative strains of Listeria monocytogenes, Appl. 
Environ. Microbiol. 77, 163-171. 
308 
 
 
22. Carr, A., Sledjeski, D. D., Podbielski, A., Boyle, M. D., and Kreikemeyer, B. (2001) Similarities 
between complement-mediated and streptolysin S-mediated hemolysis, J. Biol. Chem. 276, 
41790-41796. 
 
23. Datta, V., Myskowski, S. M., Kwinn, L. A., Chiem, D. N., Varki, N., Kansal, R. G., Kotb, M., 
and Nizet, V. (2005) Mutational analysis of the group A streptococcal operon encoding 
streptolysin S and its virulence role in invasive infection, Mol. Microbiol. 56, 681-695. 
 
24. Radolf, J. D., Caimano, M. J., Stevenson, B., and Hu, L. T. (2012) Of ticks, mice and men: 
understanding the dual-host lifestyle of Lyme disease spirochaetes, Nat. Rev. Microbiol. 10, 87-
99. 
 
25. Stanek, G., Wormser, G. P., Gray, J., and Strle, F. (2012) Lyme borreliosis, Lancet 379, 461-473. 
 
26. Dunbar, K. L., Chekan, J. R., Cox, C. L., Burkhart, B. J., Nair, S. K., and Mitchell, D. A. (2014) 
Discovery of a new ATP-binding motif involved in peptidic azoline biosynthesis, Nat. Chem. 
Biol. 10, 823-829. 
 
27. Letzel, A. C., Pidot, S. J., and Hertweck, C. (2014) Genome mining for ribosomally synthesized 
and post-translationally modified peptides (RiPPs) in anaerobic bacteria, BMC Genomics 15, 983. 
 
28. Casjens, S. R., Mongodin, E. F., Qiu, W. G., Dunn, J. J., Luft, B. J., Fraser-Liggett, C. M., and 
Schutzer, S. E. (2011) Whole-genome sequences of two Borrelia afzelii and two Borrelia garinii 
Lyme disease agent isolates, J. Bacteriol. 193, 6995-6996. 
 
29. Schutzer, S. E., Fraser-Liggett, C. M., Qiu, W. G., Kraiczy, P., Mongodin, E. F., Dunn, J. J., Luft, 
B. J., and Casjens, S. R. (2012) Whole-genome sequences of Borrelia bissettii, Borrelia 
valaisiana, and Borrelia spielmanii, J. Bacteriol. 194, 545-546. 
 
30. Mongodin, E. F., Casjens, S. R., Bruno, J. F., Xu, Y., Drabek, E. F., Riley, D. R., Cantarel, B. L., 
Pagan, P. E., Hernandez, Y. A., Vargas, L. C., Dunn, J. J., Schutzer, S. E., Fraser, C. M., Qiu, W. 
G., and Luft, B. J. (2013) Inter- and intra-specific pan-genomes of Borrelia burgdorferi sensu 
lato: genome stability and adaptive radiation, BMC Genomics 14, 693. 
 
31. Biskup, U. G., Strle, F., and Ruzic-Sabljic, E. (2011) Loss of plasmids of Borrelia burgdorferi 
sensu lato during prolonged in vitro cultivation, Plasmid 66, 1-6. 
 
32. Stewart, P. E., Byram, R., Grimm, D., Tilly, K., and Rosa, P. A. (2005) The plasmids of Borrelia 
burgdorferi: essential genetic elements of a pathogen, Plasmid 53, 1-13. 
 
33. Casjens, S. (2001) Borrelia genomes, In The spirochetes: molecular and cellular biology (Saier, 
M., and Garcia-Lara, G., Ed.), pp 75-85, Horizon Scientific Press, Norfolk UK. 
 
34. Schutzer, S. E., Fraser-Liggett, C. M., Casjens, S. R., Qiu, W. G., Dunn, J. J., Mongodin, E. F., 
and Luft, B. J. (2011) Whole-genome sequences of thirteen isolates of Borrelia burgdorferi, J. 
Bacteriol. 193, 1018-1020. 
 
35. Williams, L. R., and Austin, F. E. (1992) Hemolytic activity of Borrelia burgdorferi, Infect. 
Immun. 60, 3224-3230. 
 
309 
 
36. Shaw, D. K., Hyde, J. A., and Skare, J. T. (2012) The BB0646 protein demonstrates lipase and 
haemolytic activity associated with Borrelia burgdorferi, the aetiological agent of Lyme disease, 
Mol. Microbiol. 83, 319-334. 
 
37. Hyde, J. A., Weening, E. H., and Skare, J. T. (2011) Genetic transformation of Borrelia 
burgdorferi, Current Protocols Microbiology Chapter 12, Unit 12C 14. 
 
38. Chaconas, G., and Norris, S. J. (2013) Peaceful coexistence amongst Borrelia plasmids: getting 
by with a little help from their friends?, Plasmid 70, 161-167. 
 
39. Lee, S. F., Li, Y. J., and Halperin, S. A. (2009) Overcoming codon-usage bias in heterologous 
protein expression in Streptococcus gordonii, Microbiology 155, 3581-3588. 
 
40. Melby, J. O., Dunbar, K. L., Trinh, N. Q., and Mitchell, D. A. (2012) Selectivity, directionality, 
and promiscuity in peptide processing from a Bacillus sp. Al Hakam cyclodehydratase, J. Am. 
Chem. Soc. 134, 5309-5316. 
 
41. Belshaw, P. J., Roy, R. S., Kelleher, N. L., and Walsh, C. T. (1998) Kinetics and regioselectivity 
of peptide-to-heterocycle conversions by microcin B17 synthetase, Chem. Biol. 5, 373-384. 
 
42. Larkin, M. A., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P. A., McWilliam, H., 
Valentin, F., Wallace, I. M., Wilm, A., Lopez, R., Thompson, J. D., Gibson, T. J., and Higgins, 
D. G. (2007) Clustal W and Clustal X version 2.0, Bioinformatics 23, 2947-2948. 
 
43. Tamura, K., Peterson, D., Peterson, N., Stecher, G., Nei, M., and Kumar, S. (2011) MEGA5: 
molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and 
maximum parsimony methods, Mol. Biol. Evol. 28, 2731-2739. 
 
44. Margos, G., Vollmer, S. A., Cornet, M., Garnier, M., Fingerle, V., Wilske, B., Bormane, A., 
Vitorino, L., Collares-Pereira, M., Drancourt, M., and Kurtenbach, K. (2009) A new Borrelia 
species defined by multilocus sequence analysis of housekeeping genes, Appl. Environ. 
Microbiol. 75, 5410-5416. 
 
45. Margos, G., Gatewood, A. G., Aanensen, D. M., Hanincova, K., Terekhova, D., Vollmer, S. A., 
Cornet, M., Piesman, J., Donaghy, M., Bormane, A., Hurn, M. A., Feil, E. J., Fish, D., Casjens, 
S., Wormser, G. P., Schwartz, I., and Kurtenbach, K. (2008) MLST of housekeeping genes 
captures geographic population structure and suggests a European origin of Borrelia burgdorferi, 
Proc. Natl. Acad. Sci. U. S. A. 105, 8730-8735. 
 
46. Schulte-Spechtel, U., Fingerle, V., Goettner, G., Rogge, S., and Wilske, B. (2006) Molecular 
analysis of decorin-binding protein A (DbpA) reveals five major groups among European 
Borrelia burgdorferi sensu lato strains with impact for the development of serological assays and 
indicates lateral gene transfer of the dbpA gene, Int. J. Med. Microbiol. 296 Suppl 40, 250-266. 
 
47. Vollmer, S. A., Bormane, A., Dinnis, R. E., Seelig, F., Dobson, A. D., Aanensen, D. M., James, 
M. C., Donaghy, M., Randolph, S. E., Feil, E. J., Kurtenbach, K., and Margos, G. (2011) Host 
migration impacts on the phylogeography of Lyme Borreliosis spirochaete species in Europe, 
Environ. Microbiol. 13, 184-192. 
 
48. Framson, P. E., Nittayajarn, A., Merry, J., Youngman, P., and Rubens, C. E. (1997) New genetic 
techniques for group B streptococci: high-efficiency transformation, maintenance of temperature-
310 
 
sensitive pWV01 plasmids, and mutagenesis with Tn917, Appl. Environ. Microbiol. 63, 3539-
3547. 
 
49. Liu, D., Hollingshead, S., Swiatlo, E., Lawrence, M. L., and Austin, F. W. (2005) Rapid 
identification of Streptococcus pyogenes with PCR primers from a putative transcriptional 
regulator gene, Res. Microbiol. 156, 564-567. 
 
50. Sievers, F., Wilm, A., Dineen, D., Gibson, T. J., Karplus, K., Li, W., Lopez, R., McWilliam, H., 
Remmert, M., Soding, J., Thompson, J. D., and Higgins, D. G. (2011) Fast, scalable generation of 
high-quality protein multiple sequence alignments using Clustal Omega, Mol. Syst. Biol. 7, 539. 
 
51. Casjens, S. R., Mongodin, E. F., Qiu, W. G., Luft, B. J., Schutzer, S. E., Gilcrease, E. B., Huang, 
W. M., Vujadinovic, M., Aron, J. K., Vargas, L. C., Freeman, S., Radune, D., Weidman, J. F., 
Dimitrov, G. I., Khouri, H. M., Sosa, J. E., Halpin, R. A., Dunn, J. J., and Fraser, C. M. (2012) 
Genome stability of Lyme disease spirochetes: comparative genomics of Borrelia burgdorferi 
plasmids, PLoS One 7, e33280. 
 
52. Casjens, S., Eggers, C., and Schwartz, I. (2010) Borrelia genomics: chromosome, plasmids, 
baceriophages and genetic variation., In Borrelia: Molecular biology, host interaction and 
pathogenesis (Samuels, S., and Radolf, J., Ed.), pp 27-52, Horizon Scientific Press, Norwich. 
 
53. Casjens, S. R., Fraser-Liggett, C. M., Mongodin, E. F., Qiu, W. G., Dunn, J. J., Luft, B. J., and 
Schutzer, S. E. (2011) Whole genome sequence of an unusual Borrelia burgdorferi sensu lato 
isolate, J. Bacteriol. 193, 1489-1490. 
 
54. Margos, G., Vollmer, S. A., Ogden, N. H., and Fish, D. (2011) Population genetics, taxonomy, 
phylogeny and evolution of Borrelia burgdorferi sensu lato, Infect. Genet. Evol. 11, 1545-1563. 
 
55. Ivanova, L. B., Tomova, A., Gonzalez-Acuna, D., Murua, R., Moreno, C. X., Hernandez, C., 
Cabello, J., Cabello, C., Daniels, T. J., Godfrey, H. P., and Cabello, F. C. (2014) Borrelia 
chilensis, a new member of the Borrelia burgdorferi sensu lato complex that extends the range of 
this genospecies in the Southern Hemisphere, Environ. Microbiol. 16, 1069-1080. 
 
56. Wang, D., Botkin, D. J., and Norris, S. J. (2003) Characterization of the vls antigenic variation 
loci of the Lyme disease spirochaetes Borrelia garinii Ip90 and Borrelia afzelii ACAI, Mol. 
Microbiol. 47, 1407-1417. 
  
311 
 
B.2 Plantazolicin is an ultra-narrow spectrum antibiotic that targets the Bacillus anthracis 
membrane 
Katie J. Molohon, Patricia M. Blair, Seongjin Park, James R. Doroghazi,
 
Tucker Maxson, Jeremy 
R. Hershfield, Kristen M. Flatt, Nathan E. Schroeder, Taekjip Ha, and Douglas A. Mitchell 
 
This chapter was reproduced from Molohon et al., currently in review at ACS Infectious Diseases. 
 
I generated genetic deletions in Bacillus anthracis. 
 
Abstract 
Plantazolicin (PZN) is a ribosomally synthesized and post-translationally modified natural 
product from Bacillus amyloliquefaciens FZB42 and Bacillus pumilus. Extensive tailoring to twelve of 
the fourteen amino acid residues in the mature natural product endows PZN with not only a rigid, 
polyheterocyclic structure, but also antibacterial activity. Here we report on the remarkably 
discriminatory activity of PZN toward Bacillus anthracis, which rivals a previously-described gamma (γ) 
phage lysis assay in distinguishing B. anthracis from other members of the Bacillus cereus group. We 
evaluate the underlying cause of this selective activity by measuring the RNA expression profile of PZN-
treated B. anthracis, which revealed significant upregulation of genes within the cell envelope stress 
response. PZN depolarizes the B. anthracis membrane like other cell envelope-acting compounds but 
uniquely localizes to distinct foci within the envelope. Selection and whole-genome sequencing of PZN-
resistant mutants of B. anthracis implicate a relationship between the action of PZN and cardiolipin (CL) 
within the membrane. Exogenous CL increases the potency of PZN in wild type B. anthracis and 
promotes the incorporation of fluorescently tagged PZN in the cell envelope. We propose that PZN 
localizes to and exacerbates structurally compromised regions of the bacterial membrane, which 
ultimately results in cell lysis.  
Introduction 
The current practice of employing broad-spectrum antibiotics to treat bacterial infections 
contributes to the rise of antibiotic resistance.
1
 As a countermeasure, species-selective and narrow-
spectrum antibacterial compounds are garnering increased attention in the medical community for their 
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potential as therapeutics and diagnostics.
2, 3
 Plantazolicin (PZN) is a polyheterocyclic, linear compound of 
the ribosomally synthesized and post-translationally modified peptide (RiPP) natural product family with 
narrow-spectrum antibiotic activity (Figure S1).
4
 More specifically, PZN is a member of the 
thiazole/oxazole-modified microcins (TOMMs), a recently grouped and rapidly expanding RiPP class 
with ~1,500 identified gene clusters.
5, 6
 Previously, PZN was described as an antibiotic compound that 
inhibits Gram-positive organisms closely related to its producing organism, Bacillus amyloliquefaciens 
FZB42.
4
 In 2011, by screening a small panel of microorganisms, we described PZN as having potent 
activity towards Bacillus anthracis, but not other Gram-positive pathogens.
7
 Several additional PZN-like 
gene clusters have been identified in six distinct bacterial genera (from three phyla) through genome 
mining, but experimental data on antibiotic specificity has so far been limited to PZN.
4, 7
 Although PZN 
has been the subject of total synthesis,
8, 9
 heterologous expression,
10
 and enzymological studies,
11-13
 
insight into the mode of action (MOA) of PZN has not been reported in the seven years since the 
discovery of its biosynthetic gene cluster.
14
 
B. anthracis, the causative agent of anthrax and a category A priority pathogen, is a Gram-
positive bacterium and is a member of the B. cereus sensu lato group, which includes B. cereus, B. 
anthracis, B. thuringiensis, and B. mycoides.
15
 Microbiologists have debated whether these organisms 
should be considered as one species, given that some strains share greater than 99% DNA sequence 
identity. Despite being grouped with other Bacillus species, B. anthracis harbors a number of features that 
set it apart from other members of the B. cereus group. Fully virulent B. anthracis contains two conserved 
plasmids, pXO1 and pXO2, which harbor the genes responsible for producing the anthrax toxin and poly-
D-glutamic acid capsule, respectively. However, homologous plasmids are also found in certain B. cereus 
strains.
16
 Beyond characteristic plasmid content, B. anthracis, unlike other members of the B. cereus 
group, harbors a nonsense mutation in plcR (phospholipase C regulator), rendering B. anthracis non-
motile and non-hemolytic.
16
 Nonetheless, differentiation of B. anthracis from other nonpathogenic B. 
cereus species is necessary due to concerns in the agricultural and public health communities regarding 
bioterrorism. 
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Other defining features of B. anthracis that may facilitate species selectivity are exterior to the 
cell wall. B. anthracis displays a two-dimensional protein lattice called the surface layer (S-layer). 
Decorated with surface-associated proteins in a csaB (cell surface attachment)-dependent manner,
17
 the S-
layer is non-covalently attached to the secondary cell wall polysaccharide (SCWP),
18
 which is covalently 
tethered to the peptidoglycan. The B. anthracis SCWP is structurally unique
19
 and serves as the binding 
site for gamma (γ) phage20, 21 and previously described B. anthracis typing antibodies.22 γ phage produce a 
peptidoglycan hydrolase, PlyG, which specifically recognizes the terminal galactoses of the B. anthracis 
SCWP and subsequently hydrolyzes the cell wall.
20
 Similarly, typing methods using monoclonal 
antibodies to the SCWP also exploit differences in the terminal sugar unit. However, there exist atypical 
B. anthracis strains that would constitute false-negatives in any diagnostic assay based on these 
methods.
22, 23
 Wip1, another B. anthracis-specific phage, is even more selective than γ phage, yet certain 
B. cereus strains remain sensitive.
24
 Thus, the species specificity of PZN is intriguing not just from a 
MOA standpoint, but also as a means to distinguish B. anthracis from other B. cereus sensu lato 
members. 
Here we describe PZN as a remarkably selective small molecule antibiotic towards B. anthracis. 
The intriguing specificity was first examined by gene expression profiling, which yielded an expression 
signature distinct from broader spectrum antibiotics. We have identified and characterized a set of 
resistant mutants and evaluated their role in PZN resistance, which led to us to further investigate the 
bacterial membrane as the probable target of PZN. Using fluorescence-based approaches, we confirmed 
that PZN localizes to the cell envelope and rapidly causes membrane depolarization. Taken together with 
the observation that PZN interacts synergistically with the negatively charged phospholipid, cardiolipin 
(CL), we propose that PZN localizes to and aggravates transient weaknesses present in the B. anthracis 
cell membrane.  
Results and Discussion 
B. anthracis, the causative agent of anthrax, can often be mistaken for other members of the B. 
cereus group. As a bacterium associated with bioterrorism, there is an increasing need for accurate and 
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rapid identification of this dangerously pathogenic strain. We therefore set out to characterize and 
understand the selectivity of PZN.  
Defining the species selectivity of PZN 
PZN was originally described as a Gram-positive antibiotic, inhibiting the growth of B. subtilis, 
B. cereus, and B. megaterium.
4
 It is important to note, however, that the spot on lawn assay employed to 
reach this conclusion used an exorbitant amount of purified PZN (1 mg per spot). Using a microbroth 
dilution assay, the activity of PZN was later revealed to be considerably more selective, in that 
antibacterial activity was only detected toward B. anthracis upon screening a small panel of human 
pathogens.
7
 We continued to establish this unusually narrow-spectrum of activity by screening a larger 
panel of strains with varying degrees of genetic similarity (Table S1). PZN was found to be selective for 
vegetative B. anthracis, including fully virulent biosafety level 3 strains, with minimum inhibitory 
concentrations (MICs) between 1-16 μg/mL (0.75-12 µM). Endospores, the dormant phase of the B. 
anthracis life cycle, were resistant to PZN until germination was initiated (Table S2). By microbroth 
dilution, B. subtilis and B. cereus were not susceptible to PZN at concentrations up to 64 μg/mL, which is 
in contrast to the previously reported spot on lawn assay.
4
  
To further investigate the selectivity of PZN towards B. anthracis, we conducted a head-to-head 
comparison using the γ phage assay. Prior to modern genomic methods, γ phage sensitivity and other 
phenotype testing were popular methods for identifying B. anthracis.
23
 Notwithstanding the reported 96% 
positive accuracy, non-B. anthracis strains that are sensitive to γ phage and true B. anthracis strains that 
are insensitive have been reported.
23, 25, 26
 We obtained a panel of atypical B. cereus strains that are 
sensitive to γ phage and tested them for PZN susceptibility (Table B.7). B. cereus strains that generated a 
false positive in the γ phage assay were not susceptible to PZN.24, 26, 27 
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Table B.7. γ phage sensitivity and PZN susceptibility of Bacillus strains 
Strain γ Phage Sensitivity
a
 PZN MIC
b
 Source
c
 
B. anthracis Sterne 7702 +++ 1 USDA 
B. anthracis Sterne 34F2 A0517-1
d
 +++ 2 BEI 
B. cereus 2002013145 +++ >64 CDC
e
 
B. cereus 2002013146 +++ >64 CDC 
B. cereus 2002013100 ++ >64 CDC 
B. cereus 2000031002 +++ >64 CDC 
B. cereus ATCC 4342 + >64 ATCC 
B. cereus ATCC 7064 + >64 ATCC 
B. cereus CDC 32805 + >64 Ref 25 
B. cereus G9241 - 8 BEI 
B. megaterium 899 - 32 BGSC 
B. mycoides 96/3308 - >64 BGSC 
 
a 
Plus signs indicate the level of phage sensitivity, with +++ representing the most sensitive  
b 
MIC (minimum inhibitory concentration) as determined by microbroth dilution, units in μg/mL 
c 
Abbreviations: USDA, United States Department of Agriculture; BEI, Biodefense and Emerging 
Infections Research Resources Repository; CDC, United States Centers for Disease Control and 
Prevention; ATCC, American Type Culture Collection; BGSC, Bacillus Genetic Stock Center 
d 
LLNL A0517 was obtained from BEI as a mixture of two colony types. A0517_1 was confirmed to be 
devoid of pXO1 by PCR (Figure S2) 
e 
Strains identified by multilocus sequence typing analysis
25
 
 
In an attempt to further define the attributes giving rise to the species selectivity of PZN, we 
procured various bacterial strains that address key differences between B. anthracis and B. cereus. plcR, 
encoding the phospholipase C regulator, is nonfunctional in B. anthracis but is intact in B. cereus.
16
 
Deletion of plcR in B. cereus did not increase its susceptibility to PZN (Table S1). Additionally, sortase-
deficient strains of B. anthracis, which lack the ability to anchor various proteins to the cell wall, remain 
susceptible to PZN.
28
 Similarly, PZN activity was not dependent on the presence or composition of the B. 
anthracis S-layer, as strains deficient in S-layer assembly or decoration, namely those harboring 
mutations in csaB, sap, and eag, are equally susceptible to PZN.
17
 We further confirmed that 
susceptibility to PZN is plasmid-independent given that the susceptibility of a plasmid-deficient strain, B. 
anthracis LLNL A0517-1. (Table S1; Figure S2). Wip1 phage and antibody typing have also been used to 
discriminate B. cereus sensu lato strains, but also have known exceptions to their specificity for B. 
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anthracis.
22, 24
 We obtained a “false-positive for B. anthracis” strain for each marker: B. cereus 
CDC32805 for Wip1 and B. cereus ATCC 7064 for antibody typing. We again observed no measurable 
PZN susceptibility for either strain (Table S1).  
After extensive susceptibility testing, the only notable exception to the B. anthracis selectivity of 
PZN was B. cereus G9241 (MIC of 8 µg/mL). B. cereus G9241 encodes the genes for an anthrax-like 
toxin on its pBCXO1 plasmid, which is named for its homology to the B. anthracis pXO1 plasmid.
29
 As 
B. cereus G9241 is encapsulated and toxigenic, it causes an anthrax-like disease but is undetectable in the 
γ phage assay.25 From a pathogen detection perspective, the action of PZN towards G9241 could be 
considered fortuitous if it were to be further developed as a diagnostic test. Together, these data not only 
highlight the species discrimination of PZN but also rule out plcR-related effects, sortase-mediated 
proteins, the SCWP, the S-layer, and plasmid-borne entities as targets of PZN.  
The spectrum of PZN activity calls into question whether bacteria are the naturally intended 
target. The canonical PZN-producing strain, B. amyloliquefaciens FZB42, has been described to have 
antifungal and nematicidal activity and is a prolific producer of other natural products.
30
 Liu et al. 
assigned a nematicidal activity to PZN, derived from experiments showing that PZN-deficient FZB42 
strains exhibit reduced nematicidal activity against Caenorhabditis elegans.
31
 Since these experiments 
employed crude cellular extracts, we evaluated purified PZN in a similar manner, embedding the 
compound in agar (slow killing assay) or providing PZN in a liquid suspension (liquid fast killing assay). 
PZN was found to be no more toxic to C. elegans than a vehicle control and is clearly not nematicidal in 
its own right (Figure S3). Purified PZN was also not responsible for the antifungal activity of the native 
producer, leaving the ecological function of PZN unknown (Table S1). 
After observing the specificity of PZN under one growth medium condition (Luria-Bertani broth, 
LB), we re-assessed specificity against a smaller but representative panel of strains in two additional 
growth media (Mueller-Hinton and brain-heart infusion broths, Table S3). All tested strains of B. 
anthracis remained equally susceptible, but unexpectedly, some Staphylococcus aureus strains were 
susceptible to PZN under alternative growth media (MICs from 8 – 32 µg/mL). Only S. aureus showed 
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media-dependent susceptibility to PZN; all other tested strains remained non-susceptible to PZN. The 
broadened spectrum of PZN activity in rich media convolutes the search for PZN’s precise MOA.  
Assessing potential macromolecules as the target of PZN 
In an attempt to identify the molecular target(s) of PZN, two biotinylated PZN probes were 
prepared for affinity purification, a standard technique for identifying targets of bioactive small 
molecules.
32 First, an N-terminally biotinylated PZN was prepared from desmethylPZN, which is a 
biosynthetic intermediate obtainable by fermentation of an expression strain missing the PZN N-
methyltransferase (Figure S1; Figure S4).7 Unfortunately, N-biotinylated PZN was devoid of antibiotic 
activity at the concentrations tested; however, C-terminally biotinylated PZN retained bioactivity, albeit 
with a 16-fold reduction in potency (Figure S1; Figure S5). For this reason, C-terminally labeled PZN-
biotin was chosen for affinity-based target identification. Despite numerous attempts, we were unable to 
identify interactions unique to PZN-biotin compared to the control (data not shown). A photoaffinity 
tagged derivative of PZN was then prepared on the notion that PZN-biotin may weakly interact with its 
target, (Figure S1, Figure S6). To minimally perturb potential interactions, a minimalist, bifunctional 
analog containing a diazirine and alkyne was employed to enable crosslinking prior to biotinylation and 
enrichment.
33
 Again, no binding partners were identified by either mass spectrometry or western blot.  
Because affinity purification-based strategies to identify small molecule targets is most successful 
when the interaction is proteinaceous and of high-affinity,
34
 we next considered the possibility that PZN 
interacted with a non-protein macromolecule. We used radiolabeled precursors of the cell wall, fatty 
acids, and RNA (as well as protein), to assay for their biosynthesis in the presence of PZN. Similar to the 
nisin-like lanthipeptide Pep5, PZN extensively disrupted macromolecular biosynthesis (Figure S7).
35
 
Interestingly, PZN did not affect cell wall biosynthesis compared to the vancomycin control. 
The gene expression signature of PZN 
Sub-lethal antibiotic treatment stimulates rapid transcriptional responses in bacteria  and the 
induced/repressed genes may be indicative of MOA.
36
 We thus performed RNA-Seq to evaluate the 
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transcriptional response of B. anthracis following exposure to 0.25 µg/mL (0.25 × MIC) PZN for 10 
min.
37
 A total of 74 genes were differentially regulated, including 63 upregulated and 11 downregulated 
genes, with an adjusted false discovery rate (q-value) of 0.01 (Figure B.11; Table S4). The expression of a 
subset of these genes was validated by qRT-PCR (Tables S5-S6). Fourteen of the upregulated genes were 
transporter subunits, a common stress response upon antibiotic treatment.
38
 Conversely, PZN treatment 
led to the downregulation of genes associated with L-lactate metabolism, for which the implications 
remain unclear. 
 
Figure B.11. B. anthracis gene expression profile when treated with PZN. A volcano plot represents the 
set of differentially regulated genes in response to treatment with 0.25 × MIC of PZN. Red (upregulated) 
and green (downregulated) points are genes with significantly altered expression in response to PZN 
treatment, while black genes did not meet the q--value (< 0.01) threshold. Genes where the q-value = 0 
were given a value of 1 × 10-105. Abbreviations: # – hypothetical, * – transporter, ^ – transcriptional 
regulator, bdbD – B. subtilis hypothetical homolog, lldP-1 – L-lactate permease, ldh2/3 – L-lactate 
dehydrogenase, cydA-2 – cytochrome d ubiquinol oxidase, mmgD – citrate synthase 3, hutHIU – histidine 
utilization genes, gerN – germination protein, kamA – L-lysine 2,3-aminomutase, § – remaining 
upregulated genes. All differentially expressed genes are summarized in Table S4. 
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The most highly upregulated B. anthracis genes upon PZN treatment were bas1344 and bas1345, 
which encode a hypothetical protein and a predicted member of the PspA/IM30 family, respectively 
(Table S5). These genes are homologous to the B. subtilis genes liaI and liaH (lipid II cycle interfering 
antibiotics), which are involved in the cell envelope stress response. Induction of these genes upon 
antibiotic treatment is well documented in B. subtilis, specifically to antibiotics interacting with lipid II in 
some capacity (e.g., nisin, vancomycin, and bacitracin).
39
 Induction of lia is also seen upon treatment of 
B. subtilis with daptomycin, despite the lack of direct interaction between daptomycin and lipid II.
40
 PZN 
treatment also results in massive upregulation of bas5200 and bas5201, which are homologous to a B. 
subtilis thermosensor two-component system that regulates the lipid desaturase, desRK.
41
 To our 
knowledge, PZN is the first compound known to alter the expression of desRK, further suggestive of a 
unique MOA.  
Recently, we reported on the synthesis of a PZN derivative, Me2-Arg-Az5 (Figure S1).
13
  
Chemically, Me2-Arg-Az5 represents the N-terminal half of PZN, but the activity spectrum of Me2-Arg-
Az5 is broader and includes other Bacillus species as well as S. aureus (Table S7). Additionally, 
mutations conferring PZN resistance did not confer resistance to other antibiotics or to Me2-Arg-Az5. To 
investigate their differing spectra of activity, we recorded the gene expression profile of B. anthracis 
treated with Me2-Arg-Az5 under otherwise identical conditions (0.25 × MIC, 10 min) by RNA-Seq. The 
two compounds shared a minor portion of their expression profiles, but each profile was largely 
independent (Figure S8; Tables S8-S9). For example, sub-lethal Me2-Arg-Az5 treatment also induced the 
desRK two-component system, but expression of liaIH remained unchanged. Additionally, Me2-Arg-Az5 
failed to induce B. anthracis lysis, in contrast to PZN (Figure S9). A possible explanation for the 
observed differences between PZN and Me2-Arg-Az5 is that the C-terminal portion of the molecule is 
responsible for the species selectivity of the mature molecule and the N-terminal portion harbors the 
antibiotic activity, although this remains to be more extensively investigated. The expression profiles of 
PZN and Me2-Arg-Az5, together with strain susceptibility, suggest that PZN and Me2-Arg-Az5 pursue 
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independent, but possibly related, targets. Thus, while Me2-Arg-Az5 is not useful as a mimic for the full-
length natural product, it may represent a way to broaden the spectrum of PZN activity. 
PZN depolarizes the B. anthracis membrane 
We examined the activity of PZN towards B. anthracis in the presence of the membrane 
disrupting agents nisin and daptomycin. Based on the resulting isobolograms, both compounds elicited 
strong synergistic activity with PZN (Figure B.12).
42
 Both nisin and daptomycin disrupt membrane 
potential in Gram-positive organisms,
43, 44
 and their synergism with PZN suggests that PZN might also 
depolarize the B. anthracis membrane. Thus, DiOC2(3) (3,3’-diethyloxacarbocyanine iodide) was used to 
measure the membrane potential of PZN-treated B. anthracis cells. As expected, PZN treatment, at both 
inhibitory and sub-inhibitory concentrations, correlated with a decrease in membrane potential, 
suggesting that PZN exerts its action by disrupting the integrity of the cell membrane (Figure B.12). 
 
Figure B.12. PZN synergizes with cell envelope-acting antibiotics and depolarizes the B. anthracis 
membrane. (A) Isobolograms of the minimum inhibitory concentrations (μg/mL) of PZN with nisin (top) 
and daptomycin (bottom). Interactions taking place below the dotted line represent synergistic behavior. 
(B) Detection of membrane potential in B. anthracis. Red/green ratios were calculated using mean 
fluorescence intensities of cells treated for 30 min at RT with 0.1 μM DiOC2(3) and the vehicle of DMSO 
(negative control), 0.1 μM DiOC2(3) and 5.0 μM CCCP (positive control), 0.1 μM DiOC2(3) and 0.5 μM 
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PZN, and 0.1 μM DiOC2(3) and 1.0 μM PZN. Data were normalized to the positive control sample of 
DiOC2(3) and vehicle (DMSO). Error is given as standard deviation with n = 3. P-values are given 
relative to the DMSO control with * indicating < 0.0005 and ** indicating < 0.0001. Abbreviations: Dap, 
daptomycin; DiOC2(3), 3,3’- diethyloxacarbocyanine iodide; CCCP, carbonyl cyanide m-chlorophenyl 
hydrazone. 
 
Subcellular Localization of PZN 
With mounting evidence that PZN targets the cell membrane, we aimed to determine the subcellular 
localization of PZN by confocal microscopy. Antibiotics derivatized with fluorescent probes have 
previously been used to shed light on their MOAs.
45, 46
 Localization of PZN was established by employing 
a Cy5-labeled PZN derivative (PZN-Cy5) (Figs. S1, S10) that retained much of its anti-B. anthracis 
activity (MIC of 4 µg/mL, 2 μM). PZN-Cy5 localized to distinct ~200 nm wide foci in B. anthracis 
Sterne (Figure B.13a). To confirm that PZN-Cy5 behaved in a matter identical to unlabeled PZN, we 
carried out a competition assay where and excess of PZN was applied to B. anthracis Sterne followed by 
addition of PZN-Cy5. Due to the extensive cell lysis elicited by PZN, we employed a later-described 
spontaneously PZN-resistant Sterne mutant (PR06) for this competition assay. Just as in B. anthracis 
Sterne, PZN-Cy5 localized to distinct foci in B. anthracis PR06 (Figure B.13b). PZN-Cy5 failed to label 
strain PR06 when an excess of unlabeled PZN was administered first, demonstrating that PZN and the 
PZN-Cy5 probe identically interact with B. anthracis (Figure B.13c). Due to the photoswitching 
properties of Cy5, we were able to further investigate PZN-Cy5 localization using stochastic optical 
reconstruction microscopy (STORM, Figure B.14).
47
 Using this super-resolution imaging technique, B. 
anthracis Sterne cells were again confirmed to accumulate PZN-Cy5 at the foci described above. These 
foci were clearly localized to the surface of the cells, further implicating a component of the cell envelope 
as the target of PZN (Figure S11, Videos S1-S2). B. anthracis cells contain 16 ± 2 foci per cell, each with 
a diameter of 181 ± 7 nm, as determined by analysis of 14 cells treated with PZN-Cy5 (Figure S11). 
Notably, the labeling pattern of PZN-Cy5 is different from BODIPY-vancomycin, which has been shown 
to localize to bacterial septa at the site of peptidoglycan synthesis.
48
 If PZN were acting on the cell wall, 
sites of active PG synthesis or the entire cell wall would be labeled with PZN-Cy5. The non-septal, 
punctate labeling of PZN-Cy5 suggests that the target of PZN is neither nascent nor existing 
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peptidoglycan, which is congruent with the observation that PZN did not block cell wall biosynthesis 
(Figure S7).  
 
 
Figure B.13. PZN-Cy5 localizes to distinct foci on B. anthracis. (A) Representative fluorescence 
microscopy images are shown for the Cy5, DIC, and merged channels of B. anthracis Sterne treated with 
0.1 μM PZN-Cy5 (0.05 × MIC) for 30 min. Competition experiments in a PZN-resistant B. anthracis 
strain (PR06, vide infra) show (B) robust labeling with 0.05 μM PZN-Cy5 in the absence of unlabeled 
PZN and (C) significantly decreased labeling when cells are pretreated with 1 μM PZN (0.016 × MIC, 
resistant strain PR06) for 20 min. Scale bars, 2 μm. 
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Figure B.14. STORM images of PZN-Cy5 labeled B. anthracis. (A) 3-D super-resolution images of 12 
representative B. anthracis treated with PZN-Cy5. (B) Two representative cells rotated about the z-axis 
show distinct, non--septal localization of PZN-Cy5. Green, blue, and yellow circles mark three individual 
foci in each rotated view. Scale bars, 1 μm. 
 
Isolation and characterization of PZN-resistant mutants 
An orthogonal strategy for obtaining antibiotic MOA information involves the selection and 
mapping of resistance-conferring polymorphisms.
49
 The mutated gene(s) can either be involved directly in 
the MOA of the antibiotic or in a target-unrelated mechanism of immunity. We isolated PZN-resistant B. 
anthracis by growing the Sterne strain on agar plates containing PZN at 4 × MIC. The resistance 
frequency was determined to be 2.3 × 10
-7
, and the resulting mutants exhibited MICs that were ≥32 
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μg/mL. Genomic DNA was isolated and sequenced for six independently-selected PZN-resistant strains 
(PR01 through PR06) and the parent Sterne strain. Comparison of PR01 through PR06 to the parent 
revealed that all six polymorphisms were confined to a 50-nucleotide section of a single gene, bas4114, 
which is annotated as an AcrR transcriptional repressor (Table S10).
50
 This particular AcrR protein is 
predicted to contain a single transmembrane domain near the C-terminus (Figure S12), which is precisely 
where the PZN-resistance conferring mutations were found, all resulting in premature stop codons. 
Directly downstream of bas4114 are two EmrE-type efflux pumps, encoded by bas4115-4116. We 
hypothesized that as an AcrR transcriptional repressor, BAS4114 would negatively regulate bas4115-
4116, and mutations near the C-terminus of BAS4114 would result in regulator dysfunction and 
derepression of the efflux pumps. This in turn would increase resistance to PZN. Therefore, RNA-Seq 
was employed to compare the mRNA expression profiles of PR06 to the parent Sterne strain. This 
analysis revealed a significant upregulation of bas4114-4117 (Table S11). PR06 and the Sterne parent 
were equally susceptible to Me2-Arg-Az5 (Table S7), again underscoring differences between PZN and 
Me2-Arg-Az5. The susceptibility of PR06 to a panel of mechanistically-diverse antibiotics, including 
daptomycin, was also assessed (Table S12). The PZN resistance-conferring mutation did not alter the 
susceptibility towards any tested antibiotic. 
Mutation of bas4114 is clearly the favored route for generating PZN-resistance in B. anthracis, as 
shown by the occurrence of multiple independent mutations within the same gene. In order to subvert this 
resistance mechanism, and to obtain more insightful information about PZN MOA, we deleted bas4114-
4117 from the parental strain by homologous recombination (Figure S13). B. anthracis Sterne Δbas4114-
4117 thus became the new parental strain for isolating second-generation PZN-resistant mutants, as the 
removal of bas4114-4117 rendered the strain resensitized to PZN at wild type levels (1 μg/mL). This 
time, two routes were pursued for obtaining PZN-resistant strains. First, we selected spontaneous PZN-
resistant mutants by challenging with 4 × MIC. Isolation of the spontaneous mutants resulted in a 
mutation frequency an order of magnitude lower than before (1.3 × 10
-8
). Two independently-selected 
resistant strains (PR07 and PR08) were subjected to whole-genome sequencing, revealing single point 
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mutations within ftsE (Table B.8). FtsE is an ATP-binding protein that associates with its cognate 
permease FtsX, which together comprise an ABC transporter that functions during cell wall elongation 
and septum formation.
51
 
 
Table B.8. PZN-resistant mutants of B. anthracis Sterne Δbas4114-4117 
Strain Mutation Gene 
Amino Acid 
Consequence 
MIC
a
 
PR07 bas5034 A425G cell division ABC transporter, FtsE G142E 8 
PR08 bas5034 G270T cell division ABC transporter, FtsE F90L 32 
PR09-1 bas1659 G190C 
CitB RR
b
/luxR family transcriptional 
regulator 
V64L 
16 
PR09-4 bas1659 G190C 
CitB RR
b
/luxR family transcriptional 
regulator 
V64L 
>64 
 
bas1662 A638G ABC transporter permease H213R 
 
PR10-4 bas1659 C248T 
CitB RR
b
/luxR family transcriptional 
regulator 
T83M 
64 
 
bas1663 C1127T ABC transporter permease A376V 
 
 
bas1842 A43G petrobactin biosynthesis asbE S15G 
 
 
a MIC as determined by microbroth dilution, measured in μg/mL 
b 
Response regulator 
 
In a second strategy to obtain PZN-resistant mutants, we cultured B. anthracis Sterne Δbas4114-4117 in 
the presence of a sub-lethal concentration of PZN. The concentration of PZN was gradually increased 
with the number of passages.
52
 We isolated genomic DNA from a 1
st
 passage strain (PR09-1, MIC 16 
μg/mL) in addition to two independent 4th passage strains (PR09-4, PR10-4, MICs ≥64 μg/mL) for whole 
genome sequencing. PR09-1 contained a point mutation in bas1659, which is annotated as a CitB-like 
response regulator (Table B.8). Downstream of bas1659 are genes encoding a predicted histidine kinase 
(bas1660), ABC transporter subunits (bas1661-1663), and a cardiolipin (CL) synthase gene (bas1664). 
PR09-4 is a descendent of PR09-1, and as such, PR09-4 contained the same bas1659 mutation as PR09-1 
in addition to another point mutation in bas1662 (the permease domain of a locally-encoded ABC 
transporter). PR10-4 contained a similar mutation series (bas1663, a second permease gene for what is 
presumably a trimeric ABC transporter) but had an additional mutation in bas1842, which is implicated in 
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petrobactin biosynthesis.
53
 However, deletion of the petrobactin biosynthetic gene cluster did not decrease 
susceptibility to PZN (Table S1). 
Cardiolipin increases sensitivity to PZN 
We hypothesized that the regulatory- and transport-related mutations upstream of the gene 
encoding CL synthase could alter CL concentrations and thus, CL may be playing a role in PZN’s 
activity. We first examined the effect of exogenous CL on the interaction of PZN with the B. anthracis 
cell membrane. B. anthracis cells were treated with PZN-Cy5 (1 nM) in the presence and absence of 
exogenous CL (up to 100 µg/mL). Cell-associated PZN was then quantified by flow cytometry. The 
extent of PZN-Cy5 binding to B. anthracis was significantly increased when cells were co-treated with 
CL (Figure B.15). This result is in contrast to that with daptomycin, which acts on the bacterial membrane 
but exhibits an antagonistic relationship with CL in Enterococci.
54, 55
 As predicted, co-administration of 
CL did not increase the labeling efficiency of daptomycin-Cy5 on B. anthracis cells (Figs. S1, 5, S14).
54
 
Congruent with these data was the observation that CL potentiated the killing activity of PZN towards B. 
anthracis without being cytotoxic at the concentrations investigated here. Indeed, the strongly synergistic 
behavior with CL enhanced the potency of PZN upwards of 16-fold while CL alone had no antibiotic 
activity at the concentrations tested (Figure B.15). 
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Figure B.15. Cardiolipin increases PZN-Cy5 interaction with bacterial cells. (A) Mean fluorescence 
intensities of B. anthracis cell populations treated with daptomycin-Cy5 or PZN-Cy5 in the presence or 
absence of exogenous CL were determined by flow cytometry and normalized to cells treated only with 
the Cy5-labeled compound and vehicle. Error is reported as standard deviation with n = 3. The PZN-Cy5 
p-values are given relative to the 0 μg/mL control with * indicating <0.01 and ** indicating <0.001. The 
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p-values for daptomycin-Cy5 were both >0.01. (B) Isobologram of the minimum inhibitory 
concentrations (μg/mL) of PZN and CL. Interactions taking place below the dotted line represent 
synergistic behavior. 
 
The proportion of CL in cell membranes has been reported to increase during growth in high 
osmolarity medium, especially for B. subtilis.
56
 We thus tested whether increasing the osmolarity of the B. 
subtilis medium (and thus the CL content) would induce susceptibility to PZN. When grown in standard 
LB supplemented with an additional 1.5 M NaCl (final 1.67 M NaCl), PZN was weakly growth-
suppressive towards B. subtilis (Table B.9). By measuring CL from total lipid extractions, CL levels did 
increase compared to standard growth in LB (Table B.9). However, exogenous cardiolipin alone does not 
induce PZN susceptibility in B. subtilis (data not shown). Unfortunately, members of B. cereus sensu lato, 
including B. anthracis, are not tolerant of high osmolarity media.
57
 Therefore, induced susceptibility to 
PZN under high osmolarity conditions could not be evaluated for these strains. 
 
Table B.9. Effect of B. anthracis Sterne mutations and B. subtilis growth conditions on PZN 
susceptibility and cardiolipin content of bacterial membranes 
 
Strain MIC (µg/mL) % CL
a 
B. anthracis Sterne 7702 1 4.6 ± 0.1 
B. anthracis Sterne 7702 Δbas4114-4117 1 3.6 ± 0.5 
B. anthracis PR09-4 >64 6.1 ± 2.5 
B. anthracis PR10-4 64 24.2 ± 1.6* 
B. subtilis 168 >128 27.5 ± 2.7 
B. subtilis 168
b 
32 37.0 ± 6.1 
 
a
 Error is given as standard deviation with n = 3. P-values were compared to either a parental strain 
(Δbas4114-4117 for PR10-4) or the same strain grown in a normal osmolarity medium with * indicating 
<0.0001 
b
 Luria-Bertani broth supplemented with 1.5 M NaCl  
 
Cell survival in conditions of increased osmolarity is dependent on membrane fluctuations with 
an increase in unsaturated fatty acid composition.
56
 Increased CL levels are characteristic of osmotic 
stress in B. subtilis, Escherichia coli, and Lactococcus lactis, among others.
56
 Furthermore, excess CL 
within the membrane results in increased fluidity and lipid bilayer deformation.
58
 Regulation of the lipid 
desaturase, Des, influences the composition of phospholipids within the membrane.
59
 We predict that 
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PZN induces stress in the cell membrane and induces the des two-component system, potentially affecting 
membrane fluidity.   
As stated previously, the stepwise-selected PZN-resistant mutants accumulated mutations in 
genes upstream of the CL synthase gene. We next analyzed the transcriptional response within the cls 
locus, including the upstream regulators/transporters and observed a dramatic increase in the expression 
of several cls genes in PR09-1 and PR09-4, including CL synthase itself and the transporters, but not the 
predicted response regulator and histidine kinase genes (Table S13). In contrast, there was no differential 
expression of any tested gene in the PR10-4 strain. Upon CL quantification, we did not detect differences 
in CL content between B. anthracis and the Δbas4114-4117 strain; however, only mutant PR10-4 
contained a proportionally increased level of CL (Table B.9). This suggests that CL does play a role in the 
activity of PZN, although there is not a straightforward relationship between CL content composition and 
PZN susceptibility. Based on our findings, we expect that in addition to CL, other membrane-associated 
biomolecules contribute to the ability of PZN to destabilize B. anthracis cell membranes. 
PZN colocalizes with cardiolipin and regions of increased fluidity 
The genetic and functional association with CL implicates the membrane as the most probable 
target for PZN. The lipid dye 10-N-nonyl acridine orange (NAO) approximates regions of the cell 
membrane enriched in CL.
60
 In B. subtilis, NAO organizes into distinct foci at the septa and the poles,
61
 
but it appears that in B. anthracis Sterne, NAO labels distinct foci throughout the entirety of the cell 
membrane (Figure B.16). CL has the potential to dramatically alter membrane architecture and may 
contribute to the susceptibility of B. anthracis through punctate localization throughout the cell. We 
therefore equilibrated B. anthracis cells with PZN-Cy5 and NAO to investigate if PZN localized to CL-
rich regions in the cell membrane. There existed a clear but imperfect colocalization of the two dyes, 
suggesting a possible interaction with CL in the bacterial membrane (Figure B.16). Thus, B. anthracis 
appears to have a unique distribution of CL that facilitates an interaction with PZN and leads to cell death, 
whereas CL localization within other species may not facilitate the lytic activity of PZN. Additionally, 
1,1’-Didodecyl-3,3,3’,3’-tetramethylindocarbocyanine perchlorate, (DilC12(3)), is a dye reported to 
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associate with regions of increased fluidity (RIF) within cell membranes of B. subtilis, and may also be 
indicative of CL localization.
62
 RIFs are transiently weakened regions within the bacterial membrane that 
affect lipid homeostasis and membrane fluidity. We observed colocalization of DilC12(3) and PZN-Cy5, 
consistent with PZN and CL co-associating with B. anthracis RIFs (Figure B.16). 
 
 
Figure B.16. PZN colocalizes with CL- and RIF-specific dyes. (A) From left to right, the channels for 
NAO, Cy5, DIC, and a merged image are shown to illustrate the co-localization of NAO (yellow) and 
PZN (red). (B) Same as panel A but with DilC12(3) replacing NAO. Scale bars, 2 μm. 
 
In this paper, we report a MOA for PZN bioactivity involving cell membrane depolarization in a 
CL-enhanced manner. Due to the advance in genomics, B. anthracis, the causative agent of anthrax, can 
be distinguished from the other members of the B. cereus sensu lato group by whole genome sequencing, 
multilocus sequence typing, the presence of chromosomal lambdoid prophages, and the presence of a 
characteristic nonsense mutation in plcR.
16, 27
 An alternative approach to B. anthracis identification now 
includes susceptibility to PZN, which is a natural product exhibiting potent and specific activity for B. 
anthracis under standard laboratory conditions. Our data demonstrate that the species selectivity of PZN 
is even more discriminating than that of the reputedly selective γ phage.23, 24, 26, 27 Additionally, the 
compound on its own does not contribute to B. amyloliquefaciens FZB42 antifungal or nematicidal 
activity. B. anthracis is very similar to other members of the B. cereus sensu lato family as described, but 
strains of B. anthracis designed to analyze key genetic differences retain their respective susceptibility to 
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PZN. Gene expression analysis, together with confocal and STORM microscopy, reveals that PZN 
operates by a different MOA than previously described cell envelope-targeting antibiotics. Thus, we 
present a model for PZN activity wherein PZN takes advantage of a locally weakened cell membrane, 
whether due to RIFs, CL-dependent membrane deformation, or some combination thereof. PZN 
accumulates to such membrane defects, which results in membrane depolarization and eventual lysis of B. 
anthracis in a species-specific manner. The activity of PZN suggests homeland security applications, 
where it could be further developed as a rapid B. anthracis detection test. 
Methods 
Strain and growth conditions 
All strain references are displayed in Table S1. All strains were grown in Luria-Bertani (LB) 
broth unless otherwise described (10 g/L tryptone, 5 g/L yeast extract, 10 g/L (0.34 M) NaCl). Biosafety 
level 3 strains of B. anthracis were grown on Mueller-Hinton agar. Neisseria strains were grown in 
gonococcal medium base supplemented with Kellogg’s I and II.63 Streptomyces endospores were isolated 
on mannitol soybean flour agar (20 g/L mannitol, 20 g/L soybean flour, 1.5% agar) and used to determine 
PZN susceptibility in ISP2 (4 g/L yeast extract, 10 g/L malt extract, 4 g/L dextrose). Yeast strains were 
grown in YPD medium (10 g/L yeast extract, 20 g/L peptone, 20 g/L dextrose). C. elegans was cultured 
on nematode growth medium with E. coli OP50. Cultures were supplemented with 1.25 mM CaCl2 when 
assaying daptomycin susceptibility. In cases where increased osmolarity was desired, the LB was 
supplemented with additional NaCl (final concentration of 1.84 M). 
PZN Bioactivity 
PZN and Me2-Arg-Az5 bioactivity was determined via microbroth dilution assay as described in 
the Clinical and Laboratory Standards Institute manual.
64
 The optical density (OD600) of a stationary 
phase culture was adjusted to 0.01 and added to a microtiter plate containing serially diluted PZN. Wells 
were visually inspected for turbidity, and the minimum inhibitory concentration (MIC) was determined as 
the lowest compound concentration that incurred no growth after 16 h. MICs were determined in LB 
unless growth conditions required an alternative medium (see above). The S. aureus media-dependent 
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PZN susceptibility was analyzed using LB, Brain-Heart Infusion (BHI, Bacto), and Mueller-Hinton 
(BBL) broths. When indicated, cardiolipin (CL) was added to the medium at 100 μg/mL. 
A B. anthracis growth curve was generated using Tecan Infinite M200 Pro. B. anthracis Sterne 
7702 cultures were grown in LB to stationary phase at 37 ˚C. Cultures were diluted to OD600 of 0.05 with 
fresh LB and allowed to recover to an OD600 of 0.35. Cultures were aliquoted into 96-well plates 
containing PZN and incubated at 37 ˚C with orbital shaking. OD600 was measured every 2 min. Values 
were normalized to an initial OD600 of 0.35 and adjusted to a 1 cm path length.  Error bars represent 
standard deviation of two independent experiments. 
A growth curve in the presence of Me2-Arg-Az5 was generated as described above with the 
following differences: B. anthracis Sterne 7702 and S. aureus USA300 cultures were grown in duplicate 
to OD600 1.0 and aliquoted into 96-well plates. Wells were treated with 1:1 dilutions of Me2-Arg-Az5 at a 
maximum concentration of 12 µM. The plate was incubated at 37 °C with orbital shaking and OD600 was 
measured every 2 min. Values were normalized to an initial OD600 of 1.0, adjusted to a 1 cm path length, 
and averaged at each time point. 
Gamma (γ) phage sensitivity 
γ phage were propagated as described previously23 using B. anthracis Sterne 7702 cells on brain 
heart infusion (BHI) agar plates, with no visible loss in infectivity. Phage infectivity was tested against a 
panel of B. cereus and B. anthracis strains using a serial dilution assay. Stationary phase cultures were 
adjusted to an OD600 of 0.1 and 100 µL was plated on BHI plates. 5 µL of phage stock (2.6 × 10
8 
plaque 
forming units/mL) was serially diluted (2-fold) and spotted onto the plates and allowed to dry. After 
incubation at 37 °C for 16 h, plates were removed and visually inspected for plaques. 
RNA isolation and transcriptional profiling of PZN-treated Sterne cells 
For the compound-treated samples, independent 3 mL cultures of B. anthracis Sterne 7702 cells 
were grown to an OD600 of 0.4, and 0.25 × MIC of PZN, 0.25 × MIC Me2-Arg-Az5,
13
 or an equivalent 
volume of DMSO was added and allowed to incubate for 10 min at 37 °C. Together with resistant mutant 
PR06, RNA was isolated and prepared as described previously 
4
.  RNA-Seq libraries were created using 
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the TruSeq Stranded RNA Sample Prep kit (Illumina, San Diego, CA) after rRNA depletion using the 
RiboZero Bacteria kit (Epicentre, Madison, WI). Sequencing was performed for 1 × 100 cycles on a 
HiSeq 2000 with Version 3 Chemistry. Transcriptomic data was processed with the Rockhopper version 
1.30 pipeline
65
 using B. anthracis Sterne and B. anthracis Ames Ancestor plasmid pXO1 (NC_007322.2) 
as references. Default values (allowed mismatches 0.15, minimum seed length 0.33, minimum expression 
of UTRs and ncRNAs 0.5) were used, with the exception that reverse complement reads were used for 
mapping. The RNA-Seq data discussed in this publication have been deposited in NCBI's Gene 
Expression Omnibus and is accessible through GEO Series accession number GSE73343 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73343).  
Membrane depolarization 
Three independent stationary phase cultures of B. anthracis Sterne 7702 were used to inoculate 
fresh LB and grown to OD600 0.5 at 37 ˚C with shaking. Aliquots (10 µL) were diluted to 1 mL in PBS 
containing 3 mM DiOC2(3) (3,3’-diethyloxacarbocyanine iodide) and compounds (DMSO - vehicle, 5 
µM carbonyl cyanide m-chlorophenyl hydrazone (CCCP), 3.0 µM daptomycin, 0.5 µM PZN, 1.0 µM 
PZN). Cells were mixed at 21 °C for 30 min prior to analysis by flow cytometry (BD LSR II Flow 
Cytometry Analyzer). Voltages for fluorescein isothiocyanate (FITC) and propidium iodide (PI) 
fluorescence were set so that average counts per cell were between 10
3
 and 10
4
. Geometric means for 
fluorescence ratios were normalized to the control DiOC2(3) samples.  
Confocal microscopy 
In general, cells were prepared by inoculating 5 mL LB with 200 µL of a stationary phase culture. 
After growing to an OD600 of 0.5 at 37 °C with shaking, 1 mL aliquots were centrifuged (3 min, 8000 × 
g), decanted, and resuspended in sterile PBS. Slides were prepared by mixing 1:1 (v/v) cell suspensions in 
PBS and liquefied low gelling temperature agarose (Sigma-Aldrich, 2% w/v in water). All microscopy 
images were obtained using a Zeiss LSM 700 Confocal microscope with a 63×/1.4 Oil DIC objective and 
processed using Zen 2012 software. Laser intensity and gain were kept at a minimum and held constant 
for all experiments. Linear contrast was equally applied during image processing. To localize PZN, B. 
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anthracis Sterne 7702 was treated in PBS with 0.2 µM PZN-Cy5 for 30 min at 22 °C. After washing in 
PBS (3 × 500 µL), cells were resuspended in a final volume of 250 µL PBS. Competition experiments 
were performed using PR06 (PZN-resistant) in PBS treated with DMSO (vehicle) or 1 µM PZN for 20 
min at 22 °C before the addition of 0.05 µM PZN-Cy5. After 20 min at 21 °C, the cells were washed in 
PBS (3 × 500 µL) and resuspended in a final volume of 250 µL PBS. Sterne underwent co-treatment in 
PBS with 0.2 µM PZN-Cy5 for 25 min before the addition of other fluorescent compounds. After 5 min 
additional treatment, cells were washed in PBS (5 × 500 µL) and resuspended in a final volume of 250 µL 
PBS. Concentrations used: NAO (Sigma-Aldrich), 1 µM; Dil-C12, 1 µM; BODIPY-vancomycin, 1 µM; 
Bocillin-FL, 1 µM. For CL experiments, cells were treated with EtOH (vehicle), 10 µg/mL CL, or 100 
µg/mL CL in addition to 0.2 µM PZN-Cy5 for 30 min. 
Super-resolution microscopy (STORM) 
Cells for 3D super-resolution microscopy were grown and treated with PZN-Cy5 as described for 
confocal microscopy. The cells were immobilized on Nunc® Lab-Tek® 8-well chambered coverglass 
(Sigma-Aldrich) coated with 0.1% (w/v) poly-L-lysine (Sigma-Aldrich). After 10 min incubation, 
unattached cells were removed by washing chambers with sterile PBS. Chambers were filled with 500 µL 
imaging buffer (10 mM NaCl, 50 mM Tris-HCl (pH 8.5), 10% w/v glucose). Immediately prior to 
imaging, cysteamine (Sigma-Aldrich, 10 mM final concentration), catalase (EMD Millipore, 909 U/mL), 
and pyranose oxidase (Sigma-Aldrich, 4.44 U/mL) were added to the imaging buffer. 3D super-resolution 
microscopy was performed as described previously.
66, 67
 Briefly, samples were imaged using an Olympus 
IX-71 inverted microscope outfitted with a 100× NA 1.4 SaPo oil objective. Mechanical shutters (LS6T2, 
Unibliz) were used to alternatively excite the sample with a red laser (DL640-100-AL-O, Crystalaser) and 
reactivate Cy5 with a violet laser (405 nm, 20 mW, Spectra Physics Excelsor). The lasers were expanded 
by 7.5×, reflected by a dichoroic mirror (Semrock FF408/504/581/667/762-Di01-25X36), and sent to the 
sample chamber with a focusing lens that also creates an incidental angle slightly smaller than the total 
internal reflection angle, reducing the background signal while allowing illumination of several hundred 
nm along the z-axis. The emission signal from the sample was passed through an emission filter (Semrock 
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FF01-594/730-25) and two additional notch filters (Semrock NF01-568/647-25X5.0 and NF01-568U-25), 
and was imaged on an EMCCD camera (DV887ECS-BV, Andor Tech). A cylindrical lens (SCX-50.8-
1000.0-UV-SLMF-520-820, CVI Melles Griot, 2 m focal length) in the emission beam path induced 
astigmatism for 3D detection.
47
  ASI CRISP (Applied Scientific Instrumentation) and a piezo-objective 
(PI P-721.10) were used to compensate for vertical drift during data collection. The horizontal drift was 
corrected in the post data acquisition step by the analysis software utilizing the correlation function.
68
 The 
data analysis software was provided by Xiaowei Zhuang
66
 and modified for 3D imaging.  
Selection of spontaneous PZN-resistant mutants 
Spontaneous PZN-resistant mutants were generated by plating 2 × 10
8 
B. anthracis Sterne 7702 
cells grown to stationary phase onto a PZN plate containing 4 × PZN MIC. Surviving colonies were 
tested for sustained PZN resistance via microbroth dilution as described above. Resistant mutants PR01, 
PR02, PR05, and PR06 were subjected to genomic DNA isolation as follows: 3 × 10 mL cultures of each 
strain were grown to stationary phase, harvested, and resuspended in 400 µL of water. Cells were lysed 
with 50 µL of 10% SDS and 5 µL of 20 mg/mL RNase solution at 22 °C for 5 min. DNA was isolated via 
25:24:1 phenol/chloroform/isoamyl alcohol extraction, followed by addition of 24:1 chloroform/isoamyl 
alcohol. DNA precipitation via cold isopropyl alcohol and a subsequent 70% ethyl alcohol wash resulted 
in purified gDNA. 
After genetic deletion of bas4114-4117 (described in the supporting methods), a second round of 
spontaneously resistant mutants to PZN were selected and isolated as above. Serial-passage mutants were 
isolated as previously described,
52
 starting with three independent cultures of an OD600 of 0.1 B. anthracis 
Sterne 7702 Δbas4114-4117 in 0.25 μg/mL (0.25 × MIC) PZN LB. Cultures that grew were diluted to an 
OD600 of 0.1 and subjected to increased concentrations of PZN, until cultures were resistant to 64 µg/mL. 
Cultures were serially passaged onto PZN-free medium to confirm mutant stability. Genomic DNA was 
isolated as described above. All mutants derived from the Δbas4114-4117 deletion strain were sequenced 
as described and assembled via CLC Genomics Workbench and SNP analysis was performed with Mauve 
version 2.3.1. 
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Whole genome sequencing and assembly 
Genomic libraries for resequencing were prepared using the TruSeq DNAseq Sample prep kit 
(Illumina, San Diego, CA). Sequencing was performed on a HiSeq 2000 with Version 3 Chemistry for 
1×100 cycles. SNP and DIP discovery was performed with two different methods. Regarding PR02, 
PR05, and PR06, CLC Genomics Workbench SNP and DIP discovery pipelines were employed using 
with the publicly available B. anthracis str. Sterne genome NC_005945.1 as a reference. PR01 required 
de novo assembly with IDBA UD version 1.0.9, followed by whole genome alignment and SNP 
discovery using Mauve version 2.3.1. Resistant mutants PR03 and PR04 were selected separately and 
underwent Sanger sequencing after PCR amplification of bas4114 and sequencing with the BamHI-
BAS4114-f primer (Table S2). The WGS data discussed in this publication have been deposited in 
NCBI's GenBank and are accessible via BioProject accession number PRJNA295544. Within this 
BioProject are individual accession numbers for each B. anthracis strain (taxId:1392) for which whole 
genome sequencing was performed: CP012720, PR01; CP012721, PR02; CP012722, PR05; CP012723, 
PR06; CP012724, PR07; CP012725, PR08; CP012726, PR09-1; CP012727, PR09-4; CP012728, PR10-4; 
CP012730, Parent1 (for PR01 through PR06); CP012729, Parent2 (for PR07 through PR10-4. 
Effect of cardiolipin on fluorescence intensity 
Three independent stationary phase cultures of B. anthracis Sterne 7702 were used to inoculate 
fresh LB (200 µL into 5 mL LB) and the new cultures were grown to OD600 0.5 at 37 ˚C with shaking. 
Samples were prepared by diluting 10 µL aliquots of culture to 1 mL in PBS containing 1 nM PZN-Cy5 
and vehicle (EtOH), 10 µg/mL CL (Sigma Aldrich), or 100 µg/mL CL. After mixing at 22 °C for 30 min, 
cells were analyzed by flow cytometry as described above for differences in PZN-Cy5 fluorescence 
intensity. Geometric means were normalized to the control samples. 
Cardiolipin quantification from total lipid extracts 
Cultures of B. anthracis Sterne 7702, B. anthracis Δbas4114-4117, B. anthracis PR09-4, B. 
anthracis PR10-4, B. subtilis 168, E. faecium U503, and S. aureus USA300 (three independent 10 mL 
cultures for each strain) were grown for 20 h at 37 ˚C. LB containing an additional 1.5 M NaCl was 
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inoculated with 200 µL aliquots of stationary phase cultures of B. subtilis 168, E. faecium U503, and S. 
aureus USA300 (three independent 10 mL cultures for each strain) and grown for 40 h at 37 °C. The cells 
were harvested by centrifugation (4000 × g, 10 min, 4 °C) and resuspended in 5 mL 2:1 CHCl3:MeOH 
and 1.25 mL PBS, and then extracted for 1 h at 22 °C. The supernatant was removed after centrifugation 
(4000 × g, 10 min, 4 °C) and layers were washed with 1 mL CHCl3 and 1 mL PBS. The organic layer was 
removed and dried by speed vacuum. The crude lipids were redissolved in 200 µL CHCl3 and transferred 
to microfuge tubes, then dried again. The lipids were then dissolved in 20 µL CHCl3 and separated by 
preparative TLC (Analtech Silica Gel G) using 2:1 CHCl3:MeOH. The CL-containing spots were 
removed and extracted with 200 µL 2:1 CHCl3:MeOH for 15 min with shaking. The extracts were dried 
by speed vacuum and redissolved in 20 µL CHCl3. Each sample was spotted (0.5 µL) onto Merck Silica 
Gel 60 F254 analytical TLC plates and separated using 80:20:5 CHCl3:MeOH:AcOH. The plates were 
developed in iodine and imaged using a Bio-Rad ChemiDoc XRS+. ImageJ was used to subtract 
background and measure spot density to determine percent CL out of total lipid content. 
Additional Methods 
PZN production 
Stationary phase cultures of RSpMarA2 (Δsfp, yczE, degU)4 were grown in LB with 7 µg/mL 
kanamycin and 7 µg/mL chloramphenicol. Sterilized aluminum sheet cake pans were prepared with M9 
agar medium supplemented with BME vitamin mix and ATCC trace mineral solution and the 
aforementioned antibiotics. Cake pans were inoculated with 1.5 mL stationary phase RSpMarA2 and 
incubated 48 h at 37 °C. Bacterial lawns were loosened from the agar and resuspended in Tris-buffered 
saline (TBS) (150 mL/pan). The bacteria were then harvested via centrifugation (11,000 x g, 20 min). The 
supernatant was decanted and the cell pellets were stored at -20 °C until extraction. 
PZN purification 
PZN was extracted from bacterial pellets by resuspending in 150 mL MeOH/tray of cells with 
intermittent vortexing for 15 min at 22 °C. The cells were harvested by centrifugation as above. The 
supernatant was vacuum filtered using Whatman filter paper, rotary evaporated, and subsequently 
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lyophilized to dryness. The dried, crude PZN was resuspended in MeOH (1 mL/tray of extract) and 
centrifuged to remove insoluble debris (4,000 × g, 10 min). The supernatant was then injected onto a 
RediSep Rf High Performance 15.5 g HP C18 cartridge (Teledyne Isco) and purified by MPLC using a 
Combiflash Rf 200 system (25-100% MeOH/10 mM aqueous NH4HCO3 over 120 column volumes). The 
fractions containing PZN were pooled, rotary evaporated, and lyophilized to dryness, yielding roughly 5 
mg/tray. PZN was dissolved in DMSO at concentrations of 30-50 mg/mL and stored at -80 ˚C for later 
use. 
Bacterial endospore preparation and susceptibility screening 
B. anthracis Sterne 7702
2
 endospores were prepared as described previously.
3
 Briefly, B. 
anthracis Sterne 7702 cells were incubated overnight in LB at 37 °C. Difco Sporulation Media agar plates 
(8 g Nutrient Broth, 1 g KCl, 0.25 g MgSO4 + 7H2O, and 17 g agar, per liter) was inoculated with 150 μL 
of the stationary phase culture and incubated at 30 °C for 5 days. Lawns were recovered by resuspension 
in sterile H2O and filtered using 3.1 and 1.2 μm filters to remove vegetative cells and aggregated 
endospores. Endospore filtrate was incubated at 65 °C for 1 h to remove any remaining vegetative cells. 
Endospores were harvested by centrifugation at 8000 × g for 25 min at 4 °C. After decanting the 
supernatant, the endospores were washed 3 times with 40 mL of H2O, harvesting by centrifugation. 
Endospores were stored at 4 °C in H2O and quantified by serial dilution. Endospores were screened for 
PZN activity by incubating 1 × 10
9
 endospores
 
with PZN (0-16 μg/mL) in H2O for 20 h at 37 °C. 
Endospores were subsequently incubated at 65 °C for 1 h to destroy any contaminating vegetative cells, 
and then 4 °C for 4 h to recover, and followed by serial dilution onto LB agar plates to assess 
germination. Plate counts represent the average of two trials. 
C. elegans nematicidal assays 
Wild-type N2 C. elegans were cultured on E. coli OP50 using standard techniques.
4
 Eggs were 
isolated from gravid hermaphrodites using standard bleaching protocols
5
 and incubated for 18 h at 20 °C 
to obtain synchronized L1 larvae. Cultures were then transferred to new NGM plates seeded with OP50 E. 
coli and incubated for 48 h at 25 °C. Resulting L4 larvae were used for assays adapted from Liu et al.
4
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Slow killing assays were performed using 12-well cell culture dishes with wells containing 1 mL 
NGM agar amended with 64 μg/mL PZN dissolved in DMSO or an equivalent volume (2 μL) of DMSO 
alone. One half of the slow killing assay wells were also seeded with 10 µL of OP50 E. coli. The effect of 
DMSO alone on mortality was also tested and found to be negligible. Subsequently, 40-60 L4 
hermaphrodites were transferred to each well, incubated at 25 °C and checked every 24 h for 3 days. Each 
treatment was performed with two biological replicates, each having three technical replicates.  Liquid 
fast killing assays were also performed using 12-well cell culture dishes with wells containing 1 mL M9 
buffer combined with 64 μg/mL PZN dissolved in DMSO or DMSO alone. 40-60 L4 larvae were 
transferred into each well and incubated at 25 °C for 24 h. Fast killing assays were replicated similarly to 
the slow killing assay (two biological, three technical replicates). For the duplicate assay, an additional 
control of M9 buffer was included. In both fast and slow killing assays, animals were scored according to 
criteria shown in Liu et al. Mortality rates were also calculated using identical ratios.  
cDNA construction and qRT-PCR analysis 
cDNA was generated using the published protocol from the Promega Improm-II system, 
replacing the reverse transcriptase with Invitrogen m-MLV reverse transcriptase. qRT-PCR was 
performed with iTaq universal SYBR Green Supermix and following manufacturer’s instructions using a 
Roche Lightcycler 480 System. Fold changes upon PZN treatment were calculated as described 
previously.
7
 
Compound preparation 
Me2-Arg-Az5. Me2-Arg-Az5 was synthesized as previously described.
7
  
PZN-Cy5. PZN (500 µg, 3.74 x 10
-7
 mol) in 20 µL dimethylformamide (DMF) was mixed with 5 
µL N,N’-diisopropylethylamine (DIPEA), 10 µL of a 190 mM solution of 1-hydroxybenzotriazole 
(HOBt) in DMF, and 10 µL of a 190 mM solution of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC) in DMF for 15 min at 21 °C. Then 29.3 µL of a 10 µg/µL solution of Cy5 amine (Lumiprobe) in 
DMF was added. The reaction was protected from light and stirred at 22 °C for 24 h. The sample was 
dried by speed vacuum, redissolved in 5% MeOH, and purified on a Sep-Pak C18 cartridge (Waters) on a 
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gradient from 0 – 100% MeOH. Fractions containing PZN-Cy5, as determined by MALDI-TOF mass 
spectrometry, were combined and their purity assessed by analytical HPLC (Thermo BetaSil C18 column 
[250 mm × 4.6 mm], 40 – 95% MeOH). Concentration was determined using the extinction coefficient of 
Cy5 in DMSO (ε646 = 250,000 L cm
-1
 mol
-1
). 
Daptomycin-Cy5. A 1 mg/mL solution of daptomycin in DMSO was prepared and 33 µL was 
mixed with 2 µL of 10 mM Cy5 NHS ester (Lumiprobe) and stirred at 22 °C, protected from light, for 4 
h. Labeled compound was purified by reverse-phase chromatography on a Perkin Elmer Flexar HPLC 
outfitted with a Thermo Scientific BetaSil C18 column (250 mm × 4.6 mm I.D., 5 µm particle size) using 
10 mM NH4HCO3 as the aqueous phase on a 45 min gradient from 25 – 95% MeCN at a flow rate of 1 
mL/min. Absorbance monitoring at 647 nm was used to identify the fraction containing daptomycin-Cy5, 
which was confirmed by MALDI mass spectrometry. Purity was determined by a second analytical HPLC 
run using the same solvents on a 30 min gradient from 40 – 95% MeOH. Concentration was determined 
using the extinction coefficient of Cy5 in DMSO. 
Biotin-PZN (N-terminal label). A 100 mM solution of EZ-link N-hydroxysuccinimide (NHS) 
Biotin (Thermo Scientific) in 80% MeCN, 10 mM MOPS (pH 8.0) was prepared. DesmethylPZN (200 
µg, 1.53 × 10
-7
 mol) was dissolved in 24 µL of the same buffer and treated with 6 µL EZ-link NHS biotin 
solution for 4 h at 22 °C. The solvent was removed by speed vacuum and the sample was dissolved in 
MeOH for purification by HPLC (BetaSil C18 column, 250 mm × 4.6 mm, 1 mL/min, 50 – 95% MeOH 
over 60 min, 10 mM NH4HCO3 aqueous phase, monitored at 254 nm). Fractions containing purified 
biotin-PZN were combined, dried, and redissolved in DMSO. B. anthracis Sterne 7702 susceptibility was 
determined to be >32 µg/mL using a standard microbroth dilution assay.  
PZN-Biotin (C-terminal label). PZN (500 µg, 3.74 × 10
-7
 mol) was dissolved in 10 µL DMF and 
1 µL DIPEA was added to the sample. A solution of 2.0 mM EDC and 2.0 mM HOBt in DMF was 
prepared and 2 µL was added to the PZN. After 5 min stirring, 1.0 mg biotin cadaverine was added to the 
reaction and allowed to proceed at 22 °C for 30 h. The reaction was dried by speed vacuum, redissolved 
in MeOH, and purified by HPLC (BetaSil C18 column, 250 mm × 4.6 mm, 1 mL/min, 50 – 95% MeOH 
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over 60 min, 10 mM NH4HCO3 aqueous phase, monitored at 254 nm). Fractions containing purified PZN-
biotin were combined, dried, and redissolved in DMSO. B. anthracis Sterne 7702 susceptibility was 
determined to be 32 µg/mL by a standard microbroth dilution assay. 
PZN-diazirine-alkyne. PZN (6.68 mg, 5.0 × 10
-6
 mol) was dissolved in 75 µL DMF and 1.4 µL 
Et3N was added with stirring. The sample was cooled in an ice bath to 0 ˚C. HOBt (0.95 mg, 0.007 mmol) 
and EDC (1.1 mg, 0.007 mmol) were dissolved in 100 µL DMF and added to the PZN. 2-(2-azidoethyl)-
2-(but-3-ynyl)-1,3-dioxolane (0.96 mg, 0.007 mmol)
50
 was dissolved in 200 µL DMF and 24 µL was 
added after 10 min at 0 ˚C with stirring, protected from light. The reaction was allowed to warm to 22 ˚C 
and allowed to proceed for 24 h. The solvent was removed by speed vacuum and the sample was 
redissolved in MeOH. The sample was purified by HPLC (BetaSil C18 column, 250 mm × 4.6 mm, 1 
mL/min, 50 – 95% MeOH over 60 min, 10 mM NH4HCO3 aqueous phase, monitored at 254 nm). 
Fractions containing purified PZN-diazirine-alkyne were combined, dried, and redissolved in DMSO. B. 
anthracis Sterne 7702 susceptibility was determined to be 32 µg/mL using a standard microbroth dilution 
assay. 
Structural characterization of PZN derivatives 
Purified samples were dried by speed vacuum and dissolved in 50% MeCN supplemented with 
1% (v/v) acetic acid. The diluted samples were directly infused using an Advion Nanomate 100 to an 
LTQ-FT hybrid linear ion trap-FTMS system (ThermoFisher) operating at 11 T. The MS was calibrated 
weekly using calibration mixture following the manufacturer's instructions, and tuned daily with Pierce 
LTQ Velos ESI Positive Ion Calibration Solution (ThermoFisher). Spectra were collected in profile mode 
with a resolution of 100,000. The singly charged ions were targeted for CID using an isolation width of 
5 m/z, a normalized collision energy of 35, an activation q value of 0.4, and an activation time of 30 ms. 
Data analysis was performed using Thermo Xcalibur software. 
Affinity purification using PZN-Biotin 
LB (200 mL) was inoculated with 10 mL stationary phase B. anthracis Sterne 7702. The culture 
was grown with shaking at 37 °C to OD600 0.5. The sample was divided into 100 mL aliquots, 
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centrifuged, and individually resuspended in 1.5 mL lysis buffer (50 mM Tris, 500 mM NaCl, 2.5% v/v 
glycerol, 0.1% v/v Triton X-100, pH 7.5) with 500 mU mutanolysin. After equilibrating for 30 min at 22 
°C, the samples were sonicated (4 × 30 s, 50% amplitude) and harvested by centrifugation (17,000 × g, 10 
min). The insoluble fractions were resuspended in 1.5 mL 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS) buffer (50 mM Tris-HCl, 150 mM NaCl, 1% w/v CHAPS, pH 7.5) and 
sonicated (10 s, 50% amplitude). One sample was treated with 1.0 × 10
-7
 mol PZN-biotin and the other 
was treated with vehicle (DMSO). The samples were treated for 30 min at 22 °C before the addition of 
100 µL streptavidin-agarose resin suspension (pre-equilibrated with Tris buffer, 50 mM Tris-HCl, 150 
mM NaCl, pH 7.5). After mixing for 3 h at 22 °C, samples were applied to Bio-Rad spin columns and the 
flow through was collected. The resin was washed (5 × 4 mL Tris buffer). The resin was then 
resuspended in 200 µL 1% SDS in PBS and boiled for 10 min. After cooling, the eluent was collected and 
analyzed by SDS-PAGE for the presence of unique bands in the sample containing PZN-biotin. Unique 
bands, as visualized by Coomassie and silver stain, were not found compared to the vehicle-treated 
sample (data not shown). Samples were also analyzed by Western blot using the following procedure: 
proteins were transferred by electroblot to a polyvinylidene fluoride (PVDF) transfer membrane (EMD 
Millipore). The membrane was blocked overnight at 4 °C in TBS containing 0.1% (v/v) Tween-20 (TBST 
buffer), treated for 1 h at 4 °C with 1/3,000 dilution of streptavidin-HRP in TBST, and then washed (2 × 
30 s then 5 × 5 min) with TBST. After washing once in PBS (1 × 30 s), the membrane was treated with 
1:1 hydrogen peroxide solution:luminol solution (Bio-Rad) for imaging. 
Photoaffinity purification using PZN-diazirine-alkyne 
The procedure used for photoaffinity purification studies was similar to that of affinity 
purification experiments, except that the samples were incubated with PZN-diazirine-alkyne or vehicle 
(DMSO) for 4 h at 4 °C, protected from light. The cells were then exposed to UV (4 W, 365 nm) for 15 
min at 22 °C to induce crosslinking. The samples were pelleted and resuspended in PBS containing 1 mM 
CuSO4, 128 µM tris(3-hydroxypropyltriazolylmethyl)amine, 1.2 mM sodium ascorbate, and 50 µM 
biotin-azide for 1 h at 22 °C. The cells were then centrifuged (4,000 × g, 2 min), the supernatant was 
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decanted, and the cells were resuspended in PBS treated with 200 U/mL mutanolysin. After incubation 
for 1 h at 37 °C, cells were sonicated as previously described. The insoluble fraction was separated by 
centrifugation and resuspended as previously described. Clarified lysates and insoluble fractions were all 
enriched with streptavidin-agarose resin as previously described, and eluents were compared by SDS-
PAGE followed by Western blot and mass spectrometric analysis.  
Macromolecular synthesis assay 
Radiolabel incorporation into cellular macromolecules was carried out as previously described.
8
 
Briefly, identical B. anthracis Sterne 7702 cultures were grown to an OD600 of 0.6 in Luria Broth and 
diluted to a final OD600 of 0.3. Radiolabelled precursor was added to a final concentration of 0.1 μCi, and 
compound (either PZN or control) was added to 1×, or 2× the MIC. Samples were taken at 60 min post-
compound addition. OD600 at each time point was determined using identically treated cultures lacking 
radioactive compound. The macromolecules of the cultures treated with radiation were precipitated using 
trichloroacetic acid on glass filter disks and washed with dilute acid and ethanol successively. The filters 
were placed in scintillation vials with Ultima Gold scintillation cocktail. Radioactive counts were 
determined using a liquid scintillation analyzer (PerkinElmer Tri-Carb 2910 TR). The macromolecules, 
radiolabelled precursors, and their corresponding control antibiotics were as follows:  
 cell wall: [1,6-
3
H (N)] N-acetyl-D-glucosamine (ARC, ART 0142), vancomycin control  protein: 
[U-
14
C] L-amino acid mixture (MP, 1014750), chloramphenicol control  
 RNA: [
14
C(U)] uridine (ARC, ARC 0154), rifampicin control 
 fatty acid: acetic acid [1-
14
C] sodium salt (ARC, ARC 0101A), triclosan control 
2D Projection analysis 
2D projection analysis was used to determine spatial localization of PZN on B. anthracis cells. A 
total of 11 cells imaged by super-resolution microscopy were aligned lengthwise along the y-axis, and 
then sectioned to remove poles and septa. Cells were projected onto the XZ plane and divided into units 
of 30 × 30 nm
2
. Within each unit, spot density was determined and color-mapped. The probability of 
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finding a dye molecule a certain distance R from the y-axis was calculated for radial windows with a 20 
nm bin size and normalized to the area of the radial window.  
PZN-Cy5 cluster analysis 
A density-based clustering analysis algorithm, DBSCAN,
9
 was used as previously reported
10, 11
 to 
analyze super-resolution images of PZN-Cy5-treated B. anthracis. Briefly, spots in super-resolution 
images of 14 cells were grouped into clusters based on spatial density. The required Npts and Eps 
parameters were set to 19 and 40 nm, respectively, and used to identify core points in high density spots. 
Parameter values empirically set such that core points within a cluster were within Eps distance of each 
other and surrounded by at least Npts points. Cluster borders were defined by points located with Eps 
distance to any core point. Cluster size was calculated as twice the average distance between the cluster 
center and every point in the cluster. 
Genetic deletion of bas4114-bas4117 
Markerless genetic deletions were created in B. anthracis Sterne 7702 as described previously.
12
 
The 500 base pairs upstream and downstream the bas4114-4117 gene cluster were cloned into the 
homologous recombination vector pBKJ236 using Gibson cloning (New England Biolabs) with the 
BamHI and NotI restriction sites. The pBKJ236 constructs were transformed into the E. coli dam dcm 
strain SCS110. Overnight cultures of the vector-containing SCS110 strain grown in LB containing 500 
µg/mL erythromycin were used for conjugation along with overnight cultures of the conjugation helper 
strain E. coli SS1827 grown in LB with 200 µg/mL ampicillin and B. anthracis Sterne 7702 grown in 
BHI. From the stationary phase cultures, 400 µL were removed and washed twice by pelleting and 
suspending in 500 µL of LB to remove residual antibiotic. The pellets were resuspended in 200 µL of LB, 
then mixed thoroughly in equal volumes, and 150 µL of the mixture was inoculated onto a BHI agar plate 
without spreading. The inoculum was allowed to dry and the plate was incubated at 22 °C for 24 h. The 
entire growth was then carefully removed from the plate, resuspended in 200 µL of LB, and spotted onto 
a BHI agar plate containing 5 µg/mL erythromycin and 60 U/mL polymyxin B (BHIep). The culture was 
allowed to dry and then subsequently plated to achieve single colonies. The plate was incubated at 22 °C 
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until single colonies of B. anthracis Sterne 7702 were visible (~48 h). A single colony was used to 
inoculate a 2 mL culture of BHI containing 5 µg/mL erythromycin, and the culture was incubated with 
shaking at 22 °C overnight. The saturated culture was used to inoculate a fresh culture of BHI containing 
5 µg/mL at a 1:1000 dilution. This culture was incubated at 37 °C with shaking until saturation (~8 h), 
then 150 µL of the culture was spotted onto a BHIep plate and allowed to dry. The spot was streaked for 
single colonies and the plate was incubated at 37 °C overnight. A single colony was picked and used to 
make competent cells as previously described.
13
 Briefly, a colony was used to inoculate a 1 mL culture of 
LB containing 0.1% glucose (LBG). The culture was incubated at 37 °C without shaking for 10 min, and 
then used to inoculate 25 mL of LBG in a 250 mL sealable Erlenmeyer flask. The culture was incubated 
with shaking at 100 rpm at 37 °C until it reached an OD600 of 0.20, at which point it was transferred to a 
50 mL conical tube and pelleted at 4000 × g at 4 °C for 10 min. The spent media was discarded and the 
pellet was washed with ice cold electroporation buffer (EB; 10% w/v sucrose, 15% v/v glycerol, 2 mM 
potassium phosphate, pH 7.8) twice. The cells were resuspended in 400 µL of cold EB, transferred to a 
0.4 cm gap electroporation cuvette (USA Scientific), and incubated on ice for 10 min. A plasmid 
encoding the I-SceI restriction enzyme, pSS4332,
14
 was added as 10 µL of a 500 ng/µL stock and the 
cells were pulsed one time at 2.5 kV, 25 µF, 200 Ω (mean time constant of 4.4 ms). The cells were then 
placed on ice for 10 min before being diluted with 600 µL LBG. The cells were recovered at 37 °C for 2 h 
and then plated on LBG agar plates containing 25 µg/mL kanamycin. Colonies were pooled and passaged 
repeatedly on BHI agar plates containing 25 µg/mL kanamycin until erythromycin sensitive colonies 
could be isolated. Sensitive colonies with the desired genes deleted were determined by PCR 
amplification with the cloning primers and were then repeatedly streaked on antibiotic free BHI agar 
plates until kanamycin sensitive colonies were isolated. Gene deletion was confirmed by PCR 
amplification with gene specific primers (Fig. S13) and the strains were confirmed to be sensitive to both 
kanamycin and erythromycin by plating on the appropriate antibiotic containing BHI agar plates. 
Supporting Tables 
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Table S1. Minimum inhibitory concentrations reveal the species specificity of plantazolicin (PZN) 
Strain MIC (μg/mL) 
MIC 
(μM) 
Source 
B. cereus group 
   
B. anthracis Sterne 34F2 1 0.75 S. Blanke (UIUC) 
B. anthracis Sterne 7702 1 0.75 USDA 
B. anthracis Sterne 7702 Δbas4114-
4117 
1 0.75 This study 
B. anthracis Sterne 7SBON30 1 0.75 
15
 
B. anthracis Sterne 7SBON40 1 0.75 
16
 
B. anthracis Sterne 7SDG30 1 0.75 
16
 
B. anthracis Sterne 7SBTR30 1 0.75 
17
 
B. anthracis Sterne 7SBONTO 1 0.75 
18
 
B. anthracis Sterne 7SBTRTO 1 0.75 
19
 
B. anthracis Sterne 7SBTO30 1 0.75 
20
 
B. anthracis BSL3 strains 2 – 16 1.5 – 12 USAMRIID 
B. anthracis CDC 684 2 1.5 USAMRIID 
B. anthracis Sterne 34F2 A0517-1 1 0.75 BEI 
B. anthracis Sterne 34F2 A0517-2 2 1.5 BEI 
B. anthracis Sterne 34F2 ΔblsO 1 0.75 21 
B. anthracis Sterne 34F2 ΔcsaB 1 0.75 22 
B. anthracis Sterne 34F2 Δsap 1 0.75 20 
B. anthracis Sterne 34F2 Δeag 1 0.75 22 
B. anthracis Sterne 34F2 Δanthrose 1 0.75 
C. Turnbough (U. 
Alabama Birmingham) 
B. anthracis Sterne 34F2 ΔbclA 1 0.75 23 
B. anthracis Sterne BA850 
(Δpetrobactin)  
1 0.75 
24
 
B. anthracis Sterne BA781 1 0.75 BEI 
B. anthracis Weybridge 1 0.75 BEI 
B. cereus 14579 >64 >48 USDA 
B. cereus 541 (ΔplcR) >64 >48 4 
B. cereus ATCC 7064   >64 >48 ATCC 
B. cereus ATCC 13472   >64 >48 BGSC 
B. cereus BAG4x2-1 >64 >48 BEI 
B. cereus E33L >64 >48 BEI 
B. cereus G9241 8 6 BEI 
B. cereus GP7 >64 >48 BGSC 
B. cereus Rock3-44 64 48 NMRS    
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B. cereus VD014 >64 >48 BEI 
B. cereus VD115 >64 >48 BEI 
B. mycoides 96/3308 >64 >48 BGSC 
B. samanii C1   >64 >48 BEI 
B. thuringiensis Konkukian 97-27   >64 >48 BEI 
B. thuringiensis israelensis ATCC 
35646 
  >64 >48 BEI 
B. thuringiensis subsp. thuringiensis >64 >48 BGSC 
Atypical gamma phage sensitivity 
   
B. cereus ATCC 4342   >64 >48 BEI 
B. cereus CDC 32805 >64 >48 
7
 
B. cereus 2002013145 >64 >48 CDC 
B. cereus 2002013146 >64 >48 CDC 
B. cereus 2002013100 >64 >48 CDC 
B. cereus 2000031002 >64 >48 CDC 
Non B. cereus group 
   
B. amyloliquefaciens FZB42   >64 >48 BGSC 
B. amyloliquefaciens B-14393T   >64 >48 BGSC 
B. megaterium 899 32 24 BGSC 
B. pumilus SAFR-032   >64 >48 BGSC 
B. subtilis    
AKP4 (Δdes) >64 >48 
D. de Mendoza (U. 
Nacional de Rosario) 
AKP21 (ΔdesRK) >64 >48 
D. de Mendoza (U. 
Nacional de Rosario) 
BSU-LIKE1 (ΔliaIH) >64 >48 BGSC 
HB0042 >64 >48 Personal Collection 
HB0934 (ΔliaGFSR) >64 >48 J. Helmann (Cornell) 
HB5126 (ΔliaIH) >64 >48 J. Helmann (Cornell) 
str. 168 >64 >48 J. Wells (USCF) 
Brevibacillus formosus SS 86-3 >64 >48 BGSC 
Brevibacillus laterosporus ATCC 
9141 
>64 >48 BGSC 
Neisseria meningititis serotype C >64 >48 
4
 
Neisseria sicca >64 >48 ATCC 
Staphylococcus aureus    
12608 >64 >48 P. Hergenrother (UIUC) 
29213 64 48 P. Hergenrother (UIUC) 
33591 64 48 P. Hergenrother (UIUC) 
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USA300 >64 >48 P. Hergenrother (UIUC) 
Streptomyces coelicolor >64 >48 USDA 
Streptomyces lividans >64 >48 USDA 
Eukaryotic organisms 
   
Caenorhabditis elegans N2 >64 >48 CGC 
Saccharomyces cerevisiae  >64 >48 H. Zhao (UIUC) 
Talaromyces stipitatus >64 >48 H. Zhao (UIUC) 
    
 
a
n ≥ 3 replicates 
b
Highlighted strains were tested for gamma phage susceptibility and are displayed in the main text 
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Table S2. PZN is not antibacterial against B. anthracis endospores 
 
[PZN] (μg/mL) CFU/mLa 
    Vehicle 9.8E+08 
    0.5 4.3E+08 
    1 8.3E+08 
    2 6.8E+08 
    4 3.4E+08 
    8 6.5E+08 
    16 3.5E+08 
    
      aColony forming units per mL of endospore suspension 
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Table S3. MICs of representative strains demonstrating PZN activity in various rich media 
 
 
                         MIC (μg/mL) 
 Strain LB
a
 MH BHI 
Bacillus anthracis Sterne 1 1 1 
Bacillus cereus CDC32805 >64 >64 >64 
Bacillus cereus ATCC 4242 >64 >64 >64 
Bacillus sp. Al Hakam >64 >64 >64 
Bacillus amyloliquefaciens FZB42 >64 >64 >64 
Bacillus subtilis strain 168 >64 >64 >64 
Enterococcus faecium U503 >64 >64 >64 
Listeria monocytogenes 4b >64 >64 >64 
Staphylococcus aureus ATCC 12608 >64 16 32 
Staphylococcus aureus ATCC 29213 64 8 16 
Staphylococcus aureus ATCC 33591 64 8 16 
Staphylococcus aureus USA300 >64 >64 >64 
     aLuria-Bertani (LB), Mueller-Hinton (MH), Brain Heart Infusion (BHI) 
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Table S4. Complete RNA-Seq analysis of differentially expressed B. anthracis genes after PZN treatment 
Locus Tag Gene Description Fold Change q-value 
BAS1222 ywcJ
a
 
formate/nitrite transporter family 
protein -7 3.19E-38 
BAS0577 lldp-1 L-lactate permease -7 2.14E-24 
BAS4869 ldh3 L-lactate dehydrogenase -6 6.40E-27 
BAS0169 
 
hypothetical protein -6 1.30E-25 
BAS4146 
 
hypothetical protein -5 3.66E-19 
BAS4762 ldh2 L-lactate dehydrogenase -4 1.19E-13 
BAS1089 yjzC
a
 hypothetical protein -4 5.38E-16 
BAS1615 yfmQ
a
 hypothetical protein -3 1.49E-05 
BAS3917 
 
hypothetical protein -3 9.12E-04 
BAS4690 cydA-2 
cytochrome d ubiquinol oxidase 
subunit I -3 4.40E-04 
BAS0513 bdbD hypothetical protein -3 1.00E-03 
BAS1942 sdpI
a
 hypothetical protein 2 5.98E-03 
BAS3405 
 
ahpC/TSA family protein 2 6.00E-03 
BAS2363 
 
hypothetical protein 2 1.27E-03 
BAS2776 yetG
a
 hypothetical protein 2 9.17E-04 
BAS1163 
 
hypothetical protein 3 2.06E-03 
BAS0730 yfhC
a
 nitroreductase family protein 3 6.85E-03 
BAS4453 
 
hypothetical protein 3 4.90E-04 
BAS2568 
 
TetR family transcriptional regulator 3 1.43E-03 
BAS2566 kynB hypothetical protein 3 2.83E-03 
BAS0683 yqgI
a
 phosphate ABC transporter permease 3 7.44E-04 
BAS4452 
 
hypothetical protein 3 2.81E-05 
BAS2565 kynA 
tryptophan 2,3-dioxygenase family 
protein 3 3.85E-03 
BAS3439 hutG
a
 formimidoylglutamase 3 1.17E-03 
BAS3871 
 
hypothetical protein 3 1.35E-05 
BAS0214 lagB invasion protein LagB 3 2.21E-04 
BAS1691 fabH2 3-oxoacyl-ACP synthase 3 6.35E-04 
BAS4502 ytpI
a
 hypothetical protein 3 2.71E-06 
BAS1573 
 
hypothetical protein 3 8.18E-03 
BAS0849 
 
hypothetical protein 3 1.49E-06 
BAS1346 liaF
a
 hypothetical protein 3 1.77E-04 
BAS0525 yuaG
a
 hypothetical protein 3 6.06E-04 
BAS0610 rocE
a
 amino acid ABC transporter permease 3 1.77E-04 
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BAS4777 sodC superoxide dismutase, Cu-Zn 3 6.63E-08 
BAS0524 yuaF
a
 hypothetical protein 4 2.77E-07 
BAS0848 yhaR
a
 enoyl-CoA hydratase 4 1.25E-07 
BAS4173 pstC phosphate ABC transporter permease 4 9.53E-06 
BAS4172 pstA phosphate ABC transporter permease 4 2.15E-07 
BAS4171 pstB 
phosphate transporter ATP-binding 
protein 4 7.63E-07 
BAS1307 ilvE1 
branched-chain amino acid 
aminotransferase 4 1.40E-08 
BAS4560 acsA acetyl-CoA synthetase 4 5.09E-06 
BAS3772 ylbP
a
 hypothetical protein 4 2.05E-05 
BAS0464 rocR-1 
arginine utilization regulatory protein 
RocR 4 1.01E-09 
BAS4877 fadN
a
 3-hydroxyacyl-CoA dehydrogenase 4 1.18E-09 
BAS0624 dppC
a
 
oligopeptide ABC transporter 
permease 4 7.90E-08 
BAS4174 phoX 
phosphate ABC transporter substrate-
binding protein 4 1.87E-08 
BAS5194 fadF
a
 ferredoxin, 4Fe-4S 4 1.32E-07 
BAS1894 dppE
a
 
oligopeptide ABC transporter 
substrate-binding protein 4 1.46E-08 
BAS1070 
 
hypothetical protein 4 1.73E-10 
BAS4778 
 
hypothetical protein 5 5.76E-14 
BAS0681 pstS
a
 
phosphate ABC transporter substrate-
binding protein 5 1.12E-16 
BAS4512 
 
hypothetical protein 5 1.76E-24 
BAS3440 hutI imidazolonepropionase 5 3.49E-21 
BAS2288 
 
hypothetical protein 6 7.47E-08 
BAS0625 
appB, 
oppB
a
 
oligopeptide ABC transporter 
permease 6 3.26E-20 
BAS2146 yokU
a
 hypothetical protein 6 5.30E-39 
BAS0626 
appF, 
oppF
a
 
oligopeptide ABC transporter ATP-
binding protein 6 2.29E-19 
BAS2145 kamA L-lysine 2,3-aminomutase 7 4.12E-35 
BAS3024 
 
arsR family transcriptional regulator 7 1.17E-52 
BAS2188 mmgD citrate synthase 3 8 2.67E-54 
BAS3441 hutU urocanate hydratase 8 5.49E-50 
BAS2649 
 
hypothetical protein 9 5.16E-42 
BAS2650 
 
hypothetical protein 9 2.30E-45 
BAS3442 hutH histidine ammonia-lyase 10 9.17E-104 
BAS0627 
appD, 
oppD
a
 
ABC transporter nucleotide-binding 
protein 11 1.62E-95 
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BAS2287 yaaN
a
 hypothetical protein 13 4.38E-93 
BAS1521 gerN germination protein gerN 28 0 
BAS3456 
 
hypothetical protein 40 0 
BAS5200 
yvfU, 
desR
a
 DNA-binding response regulator 49 0 
BAS5201 
yvfT, 
desK
a
 sensor histidine kinase 56 0 
BAS5202 yvfS
a
 ABC transporter permease 130 0 
BAS5203 yvfR
a
 ABC transporter ATP-binding protein 135 0 
BAS1345 liaH
a
 PspA/IM30 family protein 1084 0 
BAS1344 liaI
a
 membrane protein 1407 0 
     aGenes are annotated by sequence homology to the corresponding Bacillus subtilis gene 
The q-value is an adjusted p-value, taking in to account the false discovery rate 
  
354 
 
Table S5. RNA-Seq and qRT-PCR analysis of PZN-treated Bacillus anthracis 
 
  
Fold Change 
Locus Tag Gene Description RNA-Seq qRT-PCR
a
 
BAS0577 lldp-1 L-lactate permease -7 -7 ± 2 
BAS4869 ldh3 L-lactate dehydrogenase -6 -24 ± 14 
BAS4762 ldh2 L-lactate dehydrogenase -4 -3 ± 1 
BAS3439 hutG formimidoylglutamase 3 3 ± 1 
BAS3440 hutI imidazolonepropionase 5 4 ± 0 
BAS3441 hutU urocanate hydratase 8 3 ± 0 
BAS3442 hutH histidine ammonia-lyase 10 5 ± 2 
BAS0627 appD, oppD
b
 
ABC transporter nucleotide-
binding protein 
11 6 ± 3 
BAS1521 gerN germination protein 28 14 ± 9 
BAS5200 yvfU, desR
b
 DNA-binding response regulator 49 37 ± 30 
BAS5201 yvfT, desK
b
 sensor histidine kinase 56 94 ± 36 
BAS1345 liaH
b
 PspA/IM30 family protein 1084 138 ± 10 
BAS1344 liaI
b
 membrane protein 1407 352 ± 191 
 
a Error is given as standard deviation with n ≥ 3 replicates 
b 
Gene annotations are derived from sequence homology to the given B. subtilis gene 
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Table S6. Primers used in this study 
 
Confirmation of LLNL A0517_1 pXO1 plasmid loss 
pXO1_0172 lef RT-r GATGCGAAAGTAGTGCCAAAGA 
pXO1_0172 lef RT-r CCACAGCATGTCCAAATTCG 
 
Confirmation of spontaneous mutants 
BamHI-BAS4114-f AAAAGGATCCATGACAGCAAACCGCATTAAAG 
NotI-BAS4114-r AAAAGCGGCCGCTCAGTTTGAAAGGCCTCGC 
 
Generation and confirmation of the bas4114-4117 deletion strain 
G236Tet-up-vec-f 
TGGAGCTCCACCGCGGTGGCAGGCGTTTGCTGATAC
AC 
G236Tet-up-down-r TAAAAAAGGACAGTTTCATCCCCTACCTACC 
G236Tet-down-up-f GGGGATGAAACTGTCCTTTTTTATATTCATTCAGAC 
G236Tet-down-vec-r 
TCGACCTGCAGCCAAGGACGCATCTGTCTTTGTTTC
AGTG 
TetR-f GCAAACCGCATTAAAGCTGTAGC 
TetR-r CAGTTTGAAAGGCCTCGCC 
SugE4115-f GGCATGGATTTATGTAATCTTAGCTGG 
SugE4115-r GCCTCCTTCGCTTCTTTTTCTTC 
SugE4116-f GGCTTGGGTATTTTTAATTCTAGCTGG 
SugE4116-r CTTAATAGTTTTAAGCCAACAGCGCC 
BAS4117-f GTGGAAAGAAAAAGGGAAGCAACTG 
BAS4117-r GTTCAGAAGAACTGTCCTTTTTAAATAACTTATTCC 
 
RT-qPCR  
Banth 16S qRT-f CGGAATTATTGGGCGTAAAG 
Banth 16S qRT-r TCTCCCAGTTTCCAATGACC 
BAS0577 lldp-1 qRT-f TGGTTCACTATTCGCACCAC 
BAS0577 lldp-1 qRT-r TTTGCTATTGTGCCACCAAC 
BAS0627 appD qRT-f ACGAATTATCTGGCGGAATG 
BAS0627 appD qRT-r AGCCGTTGTTGGCTCATC 
BAS1344 liaI qRT-f GGAGCAGGAGTTGTGTACTGG 
BAS1344 liaI qRT-r GATGGACAAGCCGATTAAACC 
BAS1345 liaH qRT-f ATCAAAGCAAGCGCTTATCG 
BAS1345 liaH qRT-r TTCTAATCGAGTTACTTGCCCTTC 
BAS1521 gerN qRT-f ACGAATGACTGGATTTGATGC 
BAS1521 gerN qRT-r GAAAGTCCTGTTCCTGCAATG 
BAS1659 CitB RR qRT-f AACGACGTTCGATGATGATG 
BAS1659 CitB RR qRT-r TTATCGCATCACGAATACGC 
BAS1660 Sensor HK qRT-f TGAAAGCATTCGGATTACATTG 
BAS1660 Sensor HK qRT-r TCATGCTTACTGGCAAATTCC 
BAS1661 ABC trans qRT-f TGCGAAGATGAATATTGGTGTC 
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BAS1661 ABC trans qRT-r ACCCGTACAGTCCAGCAAAG 
BAS1662 ABC trans qRT-f CGGTTGTAATGACGACGATG 
BAS1662 ABC trans qRT-r TAGGCGCAGCAATAAGGTG 
BAS1663 ABC trans qRT-f TATGGGAATGTAGGGCAAGG 
BAS1663 ABC trans qRT-r AGAAATTTCACCGTATCATTTGC 
BAS1664 minor cls ClsB qRT-f TGGCACAACAAACTTTACTTCG 
BAS1664 minor cls ClsB qRT-r AACGCCTTATTAACTTGCCCTAC 
BAS1842 asbE qRT-f GGGTATTTGCTTTCTGGTCTTG 
BAS1842 asbE qRT-r TTTCACGGAAGTATGCAAAGG 
BAS1843 asbF qRT-f CAGATCCAGTTGACAGCTTCC 
BAS1843 asbF qRT-r CGGTTCGAACACATGTAAATAATC 
BAS3439 hutG qRT-f TAACGGGCTTTGCAAACAG 
BAS3439 hutG qRT-r CATTTGACGGACCACCATC 
BAS3440 hutI qRT-f TGACCCGCATACTCATCTTG 
BAS3440 hutI qRT-r AAGAATACCTCCGCCTTGTTC 
BAS3441 hutU qRT-f ATTTGTTGGCTTGGTTACGG 
BAS3441 hutU qRT-r CACGACCGATAACGATTGG 
BAS3442 hutH qRT-f TGCGATGGTTGCTCTTACAG 
BAS3442 hutH qRT-r AAAGAACTCCTTGCGCTGTC 
BAS4762 ldh2 qRT-f AATCGTTCGCGGTATTATGG 
BAS4762 ldh2 qRT-r TGGTAGACCAGATTCTTTCCAAG 
BAS4869 ldh3 qRT-f AATCATGAACGTGCAGTTGG 
BAS4869 ldh3 qRT-r TTGCAGTCTTCATAGCTTCCTG 
BAS5033 ftsX qRT-f CGGAAAGACGTTTGAGTTATTTG 
BAS5033 ftsX qRT-r TCGCAATTGTTGCTGTATCTG 
BAS5034 ABC ftsE qRT-f TCTTGAAGATCGTGCAGACG 
BAS5034 ABC ftsE qRT-r ATCGGCAATTACGACTTTCG 
BAS5200 desR qRT-f TTGAAGTAATTGGGCAAGCTG 
BAS5200 desR qRT-r TCTAACCCGCTTTGAATTGG 
BAS5201 desK qRT-f GCAGTGACGAATGTTGTAAAGC 
BAS5201 desK qRT-r CCAATTCCGTTATCTTCTACCG 
BAS5288 TetR reg qRT-f AAGATGAGGAATTGCTTGTTACG 
BAS5288 TetR reg qRT-r CTTGTATAACCGGAATCCTTGG 
BAS5289 transporter qRT-f CGGAGCTCTTGTTGCCTTAC 
BAS5289 transporter qRT-r AAGCACGATTGCGTTTGTTAC 
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Table S7. Minimum inhibitory concentrations (μM) of Me2-Arg-Az5 reveal a broader spectrum of activity 
than PZN 
 
Strain MIC (μM)a 
Bacillus anthracis Sterne 7702 3 
Bacillus anthracis PR06 3 
Bacillus anthracis A0517-1 3 
Bacillus cereus ATCC 4342 6 
Bacillus megaterium 899 3 
Bacillus subtilis 168 6 
Escherichia coli DH5a >48 
Enterococcus faecium U503 48 
Listeria monocytogenes 4b >48 
Neisseria sicca ATCC 29256 >48 
Staphylococcus aureus USA300 3 
Streptococcus pyogenes M1 48 
Pseudomonas putida >48 
  
aMinimum inhibitory concentration, determined my microbroth dilution assay, measured in μM 
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Table S8. Common differentially expressed genes after PZN and Me2-Arg-Az5 treatment 
 
   
Fold Change 
Locus Tag Gene Description PZN Me2-Arg-5Az 
BAS0169 
 
hypothetical protein -6 -4 
BAS0513 bdbD hypothetical protein -3 -2 
BAS0577 lldp-1 L-lactate permease -7 -7 
BAS1089 
 
hypothetical protein -4 -4 
BAS1222 ywcJ formate/nitrite transporter family protein -7 -7 
BAS1615 
 
hypothetical protein -3 -3 
BAS3917 
 
hypothetical protein -3 -2 
BAS4146 
 
hypothetical protein -5 -5 
BAS4690 cydA-2 cytochrome d ubiquinol oxidase subunit I -3 -2 
BAS4762 ldh2 L-lactate dehydrogenase -4 -4 
BAS4869 ldh3 L-lactate dehydrogenase -6 -4 
BAS5200 ycfU,desR DNA-binding response regulator 49 6 
BAS5201 yvfT, desK sensor histidine kinase 56 5 
BAS5202 yvfS ABC transporter permease 130 13 
BAS5203 yvfR ABC transporter ATP-binding protein 135 12 
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Table S9 Complete RNA-Seq analysis of differentially expressed B. anthracis genes after Me2-Arg-Az5 
treatment  
Locus Tag Gene Description Fold Change qValue 
BAS0577 lldp-1 L-lactate permease -7 5.95E-90 
BAS1222 ywcJ
a
 
formate/nitrite transporter family 
protein -7 1.30E-59 
BAS4134 
 
hypothetical protein -7 1.61E-116 
BAS4146 
 
hypothetical protein -5 6.09E-31 
BAS4711 
 
hypothetical protein -5 3.53E-31 
BAS0169 
 
hypothetical protein -4 9.57E-21 
BAS1089 yjzC
a
 hypothetical protein -4 2.76E-23 
BAS1357 hmp nitric oxide dioxygenase -4 6.57E-12 
BAS4762 ldh2 L-lactate dehydrogenase -4 1.24E-16 
BAS4869 ldh3 L-lactate dehydrogenase -4 3.46E-17 
BAS1023 
 
hypothetical protein -3 3.80E-06 
BAS1349 
 
hypothetical protein -3 1.12E-08 
BAS1615 yfmQ
a
 hypothetical protein -3 1.28E-06 
BAS4990 cggR 
gapA transcriptional regulator 
CggR -3 0.004179 
BAS0070 pabC 4-amino-4-deoxychorismate lyase -2 0.003344 
BAS0513 bdbD hypothetical protein -2 8.87E-04 
BAS0547 maeN
a
 
citrate cation symporter family 
protein -2 0.002003 
BAS0566 rapD, rapI
a
 transcriptional regulator -2 0.004179 
BAS0631 rbsR ribose operon repressor -2 6.17E-05 
BAS1024 
 
hypothetical protein -2 8.87E-04 
BAS1185 
 
hypothetical protein -2 0.007387 
BAS1273 
 
ABC transporter permease -2 8.71E-05 
BAS1666 gltT
a
 
proton/sodium-glutamate symport 
protein -2 5.37E-04 
BAS2706 
 
hypothetical protein -2 0.003549 
BAS2707 
 
ABC transporter ATP-binding 
protein -2 8.05E-04 
BAS3173 
 
transcriptional regulator -2 8.18E-07 
BAS3917 
 
hypothetical protein -2 8.14E-04 
BAS4414 
 
succinate dehydrogenase, 
cytochrome b558 subunit -2 0.003007 
BAS4690 cydA-2 
cytochrome d ubiquinol oxidase 
subunit I -2 0.004179 
BAS4922 nupC
a
 
NupC family nucleoside 
transporter -2 0.004085 
BAS5002 whiA hypothetical protein -2 0.007026 
BAS5316 yycI
a
 YycI protin -2 7.74E-04 
BAS0982 fadR, yvdT
a
 
TetR family transcriptional 
regulator 3 8.50E-04 
BAS4115 sugE-1 sugE protein 4 4.42E-10 
BAS5201 yvfT, desK
a
 sensor histidine kinase 5 2.03E-21 
BAS5200 yvfU, desR
a
 DNA-binding response regulator 6 4.21E-26 
BAS0375 yuxN, yfiR
a
 TetR family transcriptional 8 2.92E-37 
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regulator 
BAS0902 atpI
a
 ATP synthase protein I 8 2.99E-46 
BAS5203 yvfR
a
 
ABC transporter ATP-binding 
protein 12 1.66E-119 
BAS5202 yvfS
a
 ABC transporter permease 13 2.82E-151 
BAS0376 ykuC, yfiS
a
 
major facilitator family transporter 
protein 181 0 
     aGenes are annotated by sequence homology to the corresponding Bacillus subtilis gene 
The q-value is an adjusted p-value, taking in to account the false discovery rate 
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Table S10. B. anthracis Sterne mutations conferring PZN-resistance accumulate in bas4114, an AcrR 
family transcriptional regulator 
 
Strain Mutation Consequence 
Sterne Wild type DALEAFLCLLDGLMVELLFAGLNRFETRLNASWQVFWRGLSN
a
 
PR01
c
 457G→T DAL*b 
PR02 492^T DALEAFLCLLDGLMV* 
PR03 495^AG DALEAFLCLLDGLMVESYYSQV* 
PR04 504^C DALEAFLCLLDGLMVELLFRRFKSL* 
PR05 506^GC DALEAFLCLLDGLMVELLFAQV* 
PR06 507^ATTCGCA DALEAFLCLLDGLMVELLFAIRRFKSL* 
 
a 
Amino acids 150-191 of BAS4114. Bold residues represent the predicted transmembrane region, as 
defined by Spoctopus (Figure S12)
23
 
b 
Asterisk (*) represents the termination of the protein sequence due to the nonsense mutation. 
c 
MICs for the PZN-resistant (PR) mutants are ≥ 32 μg/mL PZN, compared to 1 μg/mL for the wild type. 
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Table S11. Upregulation of bas4114-4117 in PZN-resistant mutant, B. anthracis PR06 
Gene Annotation Fold change 
BAS4114 acrR family transcriptional regulator 34 
BAS4115 emrE drug efflux pump 152 
BAS4116 emrE drug efflux pump 47 
BAS4117 hypothetical protein 62 
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Table S12. MICs (μg/mL) of selected antibiotics against PZN-resistant mutant, B. anthracis PR06 
Compound 
B. anthracis 
Sterne 
B. anthracis 
PR06 
Plantazolicin 1 64 
Tetracycline 0.125 0.125 
Vancomycin 1 1 
Triclosan 1 1 
Nisin 2 2 
Kanamycin 4 4 
Cerulenin 4 8 
Spectinomycin 8 4 
Chloramphenicol 8 4 
Daptomycin 8 8 
Ethidium Bromide 16 16 
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Table S13. qRT-PCR of cls locus in step-wise evolved PZN-resistant mutants 
 
 
Fold change 
Gene PR09-1 PR09-4 PR10-4 
BAS1659  NS  NS  NS
a
 
BAS1660  NS  NS  NS 
BAS1661 21 ± 7 48 ± 26  NS 
BAS1662 23 ± 13  NS  NS 
BAS1663 24 ± 9 48 ± 26  NS 
BAS1664 (cls) 39 ± 7 74 ± 26  NS 
BAS1842 (asbE) - -  NS 
BAS1843 (asbF) - -  NS 
    
a
NS not significant 
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Supporting Figures 
 
 
 
Figure S1. Chemical structures of plantazolicin (PZN) (A), Me2-Arg-Az5 (B), Biotin-PZN (C), PZN-
Biotin (D), PZN-photoaffinity probe (E), PZN-Cy5 (F), daptomycin (Dap)-Cy5 (G) NAO, nonyl acridine 
orange (H), and DilC12(3) perchlorate (I). 
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Figure S2. Confirmation of plasmid loss in B. anthracis 34F2 LLNL A0517-1. (Top) PCR of a conserved 
chromosomal gene, bas4114. (Bottom) pXO1 encoded gene lef is not present in A0517-1 or the select B. 
cereus strains. 
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Figure S3. PZN is not toxic to Caenorhabditis elegans using two different experiments. PZN was 
subjected to purified PZN during both liquid fast killing (A) and slow killing assays (B-C). Animals were 
treated with 64 μg/mL PZN and analyzed by live/dead screening over the course of the experiments. P-
values were generated using the Log-rank (Mantel-Cox) test. 
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Figure S4. Mass spectrometry structural characterization of biotin-PZN. (A) Mass spectrum of the 
[M+H]
2+
 species by LTQ-FT-MS, which was used to calculate exact mass. (B) CID spectrum of the 
singly charged ion acquired by LTQ-FT-MS. Labeled peaks correspond to identified fragments of biotin-
PZN, shown on the structure in panel (C). 
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Figure S5. | Mass spectrometry structural characterization of PZN-biotin. (A) Mass spectrum of the 
[M+H]
2+
 species by LTQ-FT-MS, which was used to calculate exact mass. (B) CID spectrum of the 
singly charged ion acquired by LTQ-FT-MS. Labeled peaks correspond to identified fragments of PZN-
biotin, shown on the structure in panel (C). 
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Figure S6. Mass spectrometry structural characterization of PZN-photoaffinity probe. (A) Mass spectrum 
of the [M+H]
2+
 species by LTQ-FT-MS, which was used to calculate exact mass. (B) CID spectrum of the 
m/z 1427 species, corresponding to the loss of N2 from the original molecule. Labeled peaks correspond 
to identified fragments, shown on the structure in panel (C). 
  
371 
 
Figure S7. PZN treatment results in the 
inhibition of three out of four analyzed 
macromolecular pathways. B. anthracis cells 
were treated with 1 × or 2 × MIC PZN and the 
appropriate radiolabelled precursor to the 
macromolecule of interest. After incubation for 
1 h, macromolecules were precipitated and 
radiolabelled precursor incorporation into 
protein (A), fatty acid (B), peptidoglycan (C), or 
RNA (D) was measured. Each experiment 
included samples treated with a control 
compound that is known to affect a particular 
pathway (protein: chloramphenicol; fatty acid: 
triclosan; peptidoglycan: vancomycin; RNA: 
rifampicin. All compounds were added at 1 × or 
2 × MIC, except rifampicin, which required 
significantly lower concentrations to achieve 
medial inhibition. Percent inhibition was 
determined by comparing radioactive 
incorporation between cells containing 
compound vs. vehicle. Error is reported as 
standard deviation with n = 3. 
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Figure S8. The B. anthracis gene expression profile with Me2-Arg-Az5 differs from PZN treatment. (A) 
A volcano plot represents the set of differentially regulated genes in response to treatment with 0.25 × 
MIC of Me2-Arg-Az5. Red (upregulated) and green (downregulated) points are significantly expressed 
genes in response to Me2-Arg-Az5, while black genes did not meet the q-value (< 0.01) threshold. Genes 
where the q-value = 0 were given a value of E-155. Abbreviations: # – hypothetical, * – transporter, ^ – 
transcriptional regulator, atpI – ATP synthase protein I, hmp – nitric oxide dioxygenase, lldP-1 – L-lactate 
permease, ldh2/3 – L-lactate dehydrogenase, sugE-1 – EmrE protein (cationic drug membrane 
transporter), RR – response regulator, HK: histidine kinase , § – remaining upregulated. All genes are 
summarized in Table S9. (B) Venn diagram demonstrating the commonality of the PZN and Me2-Arg-Az5 
expression profiles. The compilation of common genes is located in Table S8. 
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Figure S9. Growth curves of PZN and Me2-Arg-Az5 reveal different phenotypes. (A) B. anthracis cells 
treated with PZN undergo rapid decrease in optical density with concentrations above the minimum 
inhibitory concentration (MIC, determined from microbroth dilution assays). Time points were collected 
every two minutes and adjusted to a 1-cm path length. Error is reported as standard deviation with n = 3. 
(B) B. anthracis treated with Me2-Arg-Az5. Reduction in optical density is observed briefly at 4 × MIC. 
Both growth curves were measured in duplicate and normalized to OD600 0.35 (A) and 1.0 (B). 
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Figure S10. Mass spectrometry characterization of PZN-Cy5. (A) Mass spectrum of the [M+H]
2+
 species 
by LTQ-FT-MS, which was used to calculate exact mass. (B) CID spectrum of the singly charged ion 
acquired by LTQ-FT-MS. Labeled peaks correspond to identified fragments of PZN-Cy5, shown on the 
structure in panel (C). 
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Figure S11. Cluster analysis of B. anthracis treated with PZN-Cy5 and imaged by super-resolution 
microscopy. (A) Representation of cell alignment used in subsequent analyses. (B) PZN-Cy5 color 
density map of a representative cell projected onto the XZ plane. (C) Probability density of PZN-Cy5 
increases as distance from the center of the cell (R) increases, reaching a maximum at the cell membrane. 
(D) Cluster analysis of two representative B. anthracis cells (top) shows identified clusters (bottom) used 
in subsequent size calculations. 
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Figure S12. Hydropathy plot of BAS4114 reveals a single transmembrane helix. (A) The amino acid 
sequence of BAS4114 was analyzed using SPOCTOPUS, which predicted a transmembrane domain from 
residues 151-171. (B) Corresponding amino acids for each predicted membrane association. Green, inside 
the membrane; Red, transmembrane; Blue, outside the membrane. 
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Figure S13. Confirmation of bas4114-4117 deletion in B. anthracis Sterne. Specific primers for each 
deleted gene were used to confirm their absence by PCR amplification. 1, bas4114 in wild type Sterne 
(WT); 2, bas4114 in deletion strain; 3, bas4115 in WT; 4, bas4115 in deletion strain; 5, bas4116 in WT; 
6, bas4116 in deletion strain; 7, bas4117 in WT; 8, bas4117 in deletion strain. 
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Figure S14. Mass spectrometry characterization of daptomycin-Cy5. (A) Mass spectrum of the [M+2H]
2+
 
species by LTQ-FT-MS, which was used to calculate exact mass. (B) CID spectrum of the doubly 
charged ion acquired by LTQ-FT-MS. Labeled peaks correspond to identified fragments of daptomycin-
Cy5, shown on the structure in panel (C). 
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Appendix C: Crystal structures of nelfinavir analogs 
 
This chapter is taken in part from Maxson et al. and is reproduced with permission from Acta 
Crystallographica Section E. 
 
Crystal structure and absolute configuration of (3S,4aS,8aS)-N-(tert-butyl)-2-((S)-3-(2-chloro- 4-
nitro-benzamido)-2-hy-droxy-propyl)-deca-hydro-iso-quinoline-3-carboxamide and (3S,4aS,8aS)- 
N-(tert-butyl)-2-((S)-2-((S)-1-(2-chloro-4-nitro-benzoyl)-pyrrolidin-2-yl)-2-hy-droxy-ethyl)-deca- 
hydro-iso-quinoline-3-carboxamide 
 
Abstract 
The crystal structure and absolute configuration of two new nelfinavir analogs, (3S,4aS,8aS)-N-
(tert-butyl)-2-((S)-3-(2-chloro-4-nitro-benzamido)-2-hy-droxy-propyl)-deca-hydro-iso-quinoline-3-
carboxamide (I) and (3S,4aS,8aS)-N-(tert-butyl)-2-((S)-2-((S)-1-(2-chloro-4-nitro-benzoyl)- pyrrolidin-2-
yl)-2-hy-droxy-ethyl)-deca-hydro-iso-quinoline-3-carboxamide (II), have been determined. Each of these 
molecules exhibits various disordered moieties as well as both intra- and inter-molecular hydrogen 
bonding. The intra-molecular hydrogen bonding inter-actions in (I) [O—H···O] and in (II) [N—H···O] 
are between the two chains coming off of the deca-hydro-iso-quinoline group. The inter-molecular 
hydrogen bonding in (I) [O—H···O; N—H···O] leads to two-dimensional sheets extending along the ac-
plane. The inter-molecular hydrogen bonding in (II) [O—H···O] leads to one-dimensional chains 
extending along the a-axis. 
C.1 Chemical context 
Nelfinavir (Viracept) is an FDA approved HIV protease inhibitor identified through structure-
based design with a low nanomolar inhibitory concentration against the HIV aspartyl protease (Kaldor et 
al., 1997). Although nelfinavir is no longer recommended as a first line treatment against HIV due to its 
inferior efficacy compared to alternative protease inhibitors (Panel on Anti-retroviral Guidelines, 2015), it 
has been found to have a number of additional biological activities that may have therapeutic utility 
including anti-viral (against other human viruses) (Yamamoto et al., 2004; Kalu et al., 2014), anti-cancer 
(Gantt et al., 2013; Koltai, 2015), and anti-virulence activity (Maxson et al., 2015). However, nelfinavir 
was originally designed with only the HIV protease active site in mind and the structure is likely not 
optimal for binding to the alternative targets involved in these other activities. We recently reported on 
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the synthesis of a collection of nelfinavir analogs that may be of inter-est for efforts to repurpose the drug 
(Maxson et al., 2015). 
The syntheses of the title compounds were achieved through a previously reported route that 
utilizes the configuration of the amino acid starting material to control the stereochemical outcome of the 
sodium borohydride reduction of the chloro-methyl ketone (Kaldor et al., 1997). However, the reduction 
of compound (I), derived from achiral glycine, results in a racemic mixture (Figure C.1) while the 
reduction of compound (II), derived from L-proline, does not benefit from a strong directing influence 
from the existing chiral center (Figure C.2). The products of the two reductions were carried forward 
through the remainder of the synthesis to generate the title compounds. The absolute configurations of 
compounds (I) and (II) as well as the conformations they adopt due to the increased flexibility and 
rigidity, respectively, relative to nelfinavir was investigated through X-ray diffraction. 
Figure C.1. Scheme showing the synthesis of (I). 
 
Figure C.2. Scheme showing the synthesis of (II). 
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C.2 Structural commentary 
The core molecular structures of (I) and (II) are comprised of N-(tert-butyl)-2-(2-
hy-droxy-alkyl)-deca-hydro-iso-quinoline-3-carboxamide groups. The difference between the two species 
comes from the substitution at the N position of the deca-hydro-iso-quinoline group. Compound (I) has a 
(2-chloro-4-nitro-benzamido)-2-hy-droxy-propyl group at the N position of the deca-hydro-iso-quinoline, 
Figure C.3. Compound (II) has a (2-chloro-4-nitro-benzoyl)-pyrrolidin- 2-yl)-2-hy-droxy-ethyl group at 
the N position, Figure C.4. 
 
Figure C.3. Plot showing 35% probability ellipsoids for non-H atoms and circles of arbitrary size for H 
atoms for (I). Only the major component of disordered sites is shown. 
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Figure C.4. Plot showing 35% probability ellipsoids for non-H atoms and circles of arbitrary size for H 
atoms for (II). Only the major component of disordered sites is shown. 
 
There is disorder of the Cl group in (I) over two positions with the site occupancies refining to 
0.941 (8):0.059 (8) for Cl1 and Cl1B respectively. The nitro group is disordered over two positions with 
the site occupancies for each orientation refining to 0.60 (2):0.40 (2). The NO2 group in one orientation is 
essentially co-planar with the phenyl ring [O1B—N1B—C4—C3; t = 1(2)°] and in the other orientation is 
twisted slightly more out of plane [O1—N1—C4—C3; t = -9.0 (13)°]. Both six-membered rings of the 
deca-hydro-iso-quinoline group in (I) adopt a chair conformation, the dihedral angle between the best fit 
planes of the cyclo-hexyl and piperidine moieties is 119.9 (15)°. There is one intra-molecular hydrogen 
bonding inter-action in (I) between the two chains coming off of the deca-hydro-iso-quinoline group 
(N2—H2···O5), Table C.1. The Flack x parameter of -0.008 (18) and the Hooft y parameter of -0.010 
(19) indicate that the absolute configuration of (I) has been assigned correctly. 
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 D—H···A D—H H···A D···A D—H···A 
O4—H4B···O5i 0.87 (4) 1.94 (4) 2.791 (2) 169 (3) 
N2—H2···O5 0.83 (3) 2.11 (3) 2.928 (3) 169 (3) 
N4—H4···O3ii 0.84 (3) 2.15 (3) 2.964 (2) 161 (3) 
 
Table C.1. Hydrogen-bond geometry (Å, º) for (I) 
Symmetry codes:  (i) x, y, z+1;  (ii) x+1/2, -y+3/2, -z+2. 
 
There are multiple disordered moieties in (II), the nitro group is disordered over two positions 
with the site occupancies for the two orientations refining to 0.967 (6):0.033 (8). In both orientations the 
NO2 group is twisted out of the plane of the phenyl ring; the major orientation is twisted out of the plane 
less [O1—N1—C3—C2 t = 10.9 (4)°] than the minor orientation [O1B—N1B—C3—C2 t = -26 (6)°]. 
The carbonyl group C7—O3 is disordered over two positions with the site occupancies refining to 0.58 
(2):0.42 (2). In the minor orientation the CO group is nearly normal to the plane of the phenyl ring 
[O3B—C7B—C6—C5 t = -89 (3)°], while the major orientation is significantly less out of plane [O3—
C7—C6—C5 t = -44 (3)°]. The final two disordered moieties of (II) are a portion of the pyrrolidin-2-yl 
group and the three methyl groups of the t-butyl. The carbon atoms C10 and C11 of the pyrrolidin-2-yl 
are disordered over two positions, site occupancies 0.669 (16):0.331 (16). The t-butyl methyl groups also 
disorder over two positions via a slight rotation around the N4—C24 bond, the site occupancies refine to 
0.811 (17):0.189 (17). Similar to (I), both six-membered rings of the deca-hydro-iso-quinoline group in 
(II) adopt a chair conformation with the dihedral angle between the best fit planes of the cyclo-hexyl and 
piperidine moieties of 116.3 (17)°. There is one intra-molecular hydrogen bonding inter-action in (II) 
between the two chains coming off of the deca-hydro-iso-quinoline group (N4—H4C···O4), Table C.2. 
The Flack x parameter of 0.036 (19) and the Hooft y parameter of 0.03 (2) indicate that the absolute 
configuration of (II) has been assigned correctly. 
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 D—H···A D—H H···A D···A D—H···A 
N4—H4C···O4 0.88 (3) 2.60 (3) 3.219 (3) 129 (3) 
O4—H4B···O5i 0.82 (1) 1.89 (2) 2.709 (2) 170 (4) 
 
Table C.2. Hydrogen-bond geometry (Å, º) for (II) 
Symmetry code:  (i) x-1, y, z. 
 
C.3 Supra-molecular features 
The extended structure of (I) is a two-dimensional sheet of hydrogen bonded molecules extending 
along the ac-plane, Figure C.5a. Each molecule of (I) is inter-molecularly hydrogen bonded to four 
neighboring molecules via O—H···O and N—H···O inter-actions, the details of these inter-actions can be 
found in Table C.1. The two-dimensional layers stack in an ABAB pattern along the crystallographic b-
axis, Figure C.5b. The layers are separated by the bulky deca-hydro-iso-quinoline groups which protrude 
above and below the sheets. The layers alternate between these bulky groups pointing "left" and "right", 
this along with a slight offset between the A and B layers allows them to inter-digitate. 
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Figure C.5. A plot of the packing of (I) viewed a) along the b axis showing a hydrogen bonded two-
dimensional sheet overlain with the unit cell; and b) along the c axis showing how two layers stack 
together along the b axis. Only the major component of disordered sites is shown. Red dashed lines 
indicate intermolecular hydrogen bonding; blue dashed lines indicate intramolecular hydrogen bonding. 
 
The extended structure of (II) is a one-dimensional chain of hydrogen bonded molecules 
extending along the crystallographic a-axis, Figure C.6a. Each molecule of (II) is inter-molecularly 
hydrogen bonded to two neighboring molecules via O—H···O inter-actions, the details of these 
inter-actions can be found in Table C.2. The one-dimensional chains are separated by the bulky 
deca-hydro-iso-quinoline groups and the t-butyl groups which prevent the chains from linking via further 
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hydrogen bonding inter-actions, Figure C.6b. 
 
Figure C.6. A plot of the packing of (II) viewed a) along the c axis showing a hydrogen bonded one-
dimensional chain; and b) along the a axis showing how the one-dimensional chains pack together 
overlain with the unit cell. Only the major component of disordered sites is shown. Red dashed lines 
indicate intermolecular hydrogen bonding; blue dashed lines indicate intramolecular hydrogen bonding. 
 
C.4 Database survey 
A search of the Cambridge Crystallographic Database (Groom & Allen, 2014) returns only three 
crystal structures with the N-(tert-butyl)-deca-hydro-iso-quinoline-3-carboxamide core. One of the 
structures is the N-(tert-butyl)-deca-hydro-iso-quinoline-3-carboxamide molecule [CSD code COVYAO] 
(Zhao et al., 2006). The other two molecules are nelfinavir derivatives like (I) and (II) which were 
isolated during optimization of the synthesis. The difference between these two molecules comes via the 
substitution at the N position of the deca-hydro-iso-quinoline group. 
One compound has a 3-amino-2-hy-droxy-4-(phenyl-thio)-butyl group in this position [CSD code 
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QONJUY] (Inaba et al., 2000) and the other has a 3-acet-oxy-2-(3-acet-oxy-2- methyl-benzoyl-amino)-4-
(phenyl-thio)-butyl group at the N position [CSD code GONKOJ] (Inaba et al., 1998). Each of these 
molecules has intra-molecular hydrogen bonding between the two chains coming off of the 
deca-hydro-iso-quinoline group, similar to (I) and (II), involving the N—H of the carboxamide and an 
oxygen atom on the adjacent chain. The core structure of each of these previously reported materials is 
similar to (I) and (II) in that both six-membered rings of the deca-hydro-iso-quinoline groups adopt chair 
conformations. The dihedral angle between the best fit planes of the cyclo-hexyl and piperidine moieties 
for the 3-amino-2-hy-droxy-4-(phenyl-thio)-butyl substituted molecule is 117.1 (18)°. Similarly, this 
angle for the 3-acet-oxy-2-(3-acet-oxy-2-methyl-benzoyl-amino)-4-(phenyl-thio)-butyl substituted 
molecule is 116.8 (14)°. 
C.5 Synthesis and crystallization 
Compound (I) was synthesized through the inter-mediate chloro-methyl hydroxyl 4 (Figure C.1). 
Chloro-methyl ketone 3 (571 mg, 2.36 mmol) was dissolved in di-chloro-methane (7 mL) and methanol 
(4 mL) under nitro-gen. The reaction was cooled to 0 °C and sodium borohydride (63 mg, 1.65 mmol) 
was added in one portion. The reaction was stirred cold for 1h before being quenched by the slow 
addition of 2 M HCl (2 mL). The reaction was dried and the solid was dissolved in ethyl acetate. The 
product was washed twice with water and once with brine, dried over sodium sulfate, and concentrated by 
rotary evaporation. The product was purified by silica flash column chromatography (gradient of 0-8% 
EtOAc in DCM) to yield racemic 4 as a colorless oil (423 mg, 75% yield). 
1
H NMR (500 MHz, CDCl3) d 
ppm 7.33-7.28 (complex, 5H), 5.63 (t, J = 6 Hz, 1H), 5.06 (s, 2H), 3.88 (s, 2H), 3.48 (m, 2H), 3.39 (m, 
1H), 3.22 (m, 1H). 
13
C NMR (500 MHz, CDCl3) d ppm 157.23, 135.93, 128.36, 128.06, 127.91, 70.52, 
66.90, 46.44, 43.96. HRMS (m/z): [M + H]
+
 calc. for C11H15NO3Cl, 244.0740; observed, 244.0741. For 
the synthesis of compound (I), compound 5 (104 mg, 0.233 mmol) was dissolved in methanol (15 mL) 
with 10% palladium on carbon (74 mg, 0.070 mmol). The solution was degassed for 30 min before being 
placed under 1 atm of hydrogen and stirred for 2 h at room temperature. The reaction was filtered through 
celite, dried to a solid, and taken up in tetra-hydro-furan (5 mL). 2-chloro-4-nitro-benzoic acid (52 mg, 
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0.256 mmol), 1- ethyl-3-(3-di-methyl-amino-propyl)-carbodiimide hydro-chloride (49 mg, 0.256 mmol), 
and hydroxy-benzotriazole hydrate (42 mg, 0.256 mmol) were added and the reaction was stirred at room 
temperature overnight. The reaction was taken up in ethyl acetate, washed once with sodium bicarbonate 
and once with brine, and dried over sodium sulfate. The product was purified by silica flash column 
chromatography (gradient of 0-3% MeOH in DCM) to yield (I) as a yellow solid (77 mg, 67%). Crystals 
suitable for X-ray diffraction were obtained from the vapor diffusion of pentane into a solution of 
compound (I) in ethyl acetate at room temperature. 1H NMR (500 MHz, CDCl3) d ppm 8.41 (q, J = 4 Hz, 
1H), 8.24 (d, J = 2 Hz, 1H), 8.13 (dd, J1 = 2 Hz, J2 = 8.5 Hz, 1H), 7.76 (d, J = 8.5 Hz, 1H), 5.60 (s, 1H), 
4.04 (m, 2H), 3.47 (dt, J1 = 4 Hz, J2 = 14 Hz, 1H), 3.35 (br, 1H), 2.71 (dd, J1 = 2 Hz, J2 = 11.5 Hz, 1H), 
2.49 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 2.36 (dd, J1 = 10 Hz, J2 = 12.5 Hz, 1H), 2.22 (dd, J1 = 5 Hz, J2 = 
12.5 Hz, 1H), 2.18 (dd, J1 = 3 Hz, J2 = 11.5 Hz, 1H), 1.95 (q, J = 12 Hz, 1H), 1.80-1.08 (complex, 20H). 
13C NMR (500 MHz, CDCl3) d ppm 174.16, 167.06, 148.39, 142.00, 132.80, 130.18, 124.96, 121.56, 
70.40, 68.29, 59.09, 57.54, 51.27, 43.27, 35.83, 33.55, 31.02, 30.86, 28.39, 26.19, 25.52, 20.18. HRMS 
(m/z): [M + H]+ calc. for C24H36N4O5Cl, 495.2374; observed, 495.2376. 
Compound (II) was synthesized through the inter-mediate chloro-methyl hydroxyl 7 (Figure C.2). 
Chloro-methyl ketone 6 (860 mg, 3.05 mmol) was dissolved in di-chloro-methane (7 mL) and methanol 
(4 mL) under nitro-gen. The reaction was cooled to 0 °C and sodium borohydride (81 mg, 2.14 mmol) 
was added in one portion. The reaction was stirred cold for 1h before being quenched by the slow 
addition of 2 M HCl (2 mL). The reaction was dried and the solid was dissolved in ethyl acetate. The 
product was washed twice with water and once with brine, dried over sodium sulfate, and concentrated by 
rotary evaporation. TLC analysis showed two diastereomers with the higher Rf compound being the (S,R) 
product. Both diastereomers were purified by silica flash column chromatography (gradient of 0-10% 
EtOAc in DCM) to yield the (S,S)-isomer as a white solid (279 mg, 32%) and (S,R)-isomer (7) as a white 
solid (429 mg, 50%). Characterization of the (S,R)-isomer (7): 1H NMR (500 MHz, CDCl3) d ppm 7.37-
7.28 (complex, 5H), 5.13 (dd, J1 = 12.5 Hz, J2 = 16 Hz, 2H), 4.95 (d, J = 2 Hz, 1H), 4.11 (m, 1H), 3.81 
(br s, 1H), 3.72 (d, J = 11 Hz, 1H), 3.55 (m, 2H), 3.37 (m, 1H), 2.03 (m, 1H), 1.89 (m, 1H), 1.81 (m, 1H), 
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1.72 (m, 1H). 13C NMR (500 MHz, CDCl3) d ppm 157.52, 136.04, 128.27, 127.87, 127.65, 74.69, 67.22, 
60.57, 47.91, 47.05, 28.12, 23.94. HRMS (m/z): [M + H]+ calc. for C14H19NO3Cl, 284.1053; observed, 
284.1055. For the synthesis of compound (II), compound 8 (218 mg, 0.620 mmol) was dissolved in 
tetra-hydro-furan (6 mL) with 2-chloro-4-nitro-benzoic acid (138 mg, 0.682 mmol), 1-ethyl-3-(3-
di-methyl-amino- propyl)-carbodiimide hydro-chloride (131 mg, 0.682 mmol), and 
hydroxy-benzotriazole hydrate (111 mg, 0.682 mmol). The reaction was stirred at room temperature 
overnight. The reaction was taken up in ethyl acetate, washed once with sodium bicarbonate and once 
with brine, and dried over sodium sulfate. The product was purified by silica flash column 
chromatography (gradient of 0-5% MeOH in DCM) to yield (II) as a yellow solid (248 mg, 72%). 
Crystals suitable for X-ray diffraction were obtained by layering pentane over a solution of compound (II) 
in di-chloro-methane at room temperature. 1H NMR (500 MHz, CDCl3) d ppm 8.31 (d, J = 2 Hz, 1H), 
8.20 (dd, J1 = 2 Hz, J2 = 8.5 Hz, 1H), 7.54 (d, J = 8.5 Hz, 1H), 6.87 (s, 1H), 5.31 (s, 1H), 4.36 (m, 1H), 
3.99 (m, 1H), 3.24 (m, 2H), 2.91 (d, J = 11 Hz, 1H), 2.63 (m, 2H), 2.18-1.13 (complex, 26H). 13C NMR 
(500 MHz, CDCl3) d ppm 173.83, 172.95, 148.31, 142.45, 128.53, 124.96, 122.35, 121.69, 69.81, 69.73, 
60.88, 58.37, 57.98, 50.55, 50.51, 49.05, 35.84, 33.23, 31.07, 30.80, 28.56, 28.20, 26.20, 25.46, 24.53, 
20.16. HRMS (m/z): [M + H]+ calc. for C27H40N4O5Cl, 535.2687; observed, 535.2692. 
C.6 Refinement 
Crystal data, data collection and structure refinement details for (I) and (II) are summarized in  
 (I) (II) 
Crystal data 
Chemical formula C24H35ClN4O5 C27H39ClN4O5 
Mr 495.01 535.07 
Crystal system, space group Orthorhombic, P21212 Monoclinic, P21 
Temperature (K) 193 168 
a, b, c (Å) 18.8408 (7), 20.2263 (8), 
6.7923 (3) 
6.4341 (7), 20.280 (2), 
11.0377 (12) 
a, b, g (°) 90, 90, 90 90, 105.248 (1), 90 
 
Table C.3. Experimental details 
396 
 
V (Å
3
) 2588.41 (18) 1389.5 (3) 
Z 4 2 
Radiation type Mo Ka Mo Ka 
m (mm
-1
) 0.19 0.18 
Crystal size (mm) 0.37 × 0.36 × 0.29 0.86 × 0.65 × 0.15 
 
Data collection 
Diffractometer Siemens Platform/ApexII 
CCD  
diffractometer 
Siemens Platform/ApexII 
CCD  
diffractometer 
Absorption correction Integration  
SHELXTL/XPREP V2005/2 
(Bruker, 2014) 
Integration  
SHELXTL/XPREP V2005/2 
(Bruker, 2014) 
 Tmin, Tmax 0.953, 0.960 0.892, 0.980 
No. of measured, 
independent and 
 observed [I > 2s(I)] 
reflections 
30342, 5243, 4694   16374, 5627, 5222   
Rint 0.027 0.024 
(sin q/l)max (Å
-1
) 0.623 0.625 
 
Refinement 
R[F
2
 > 2s(F
2
)], wR(F
2
), S 0.035,  0.085,  1.03 0.032,  0.082,  1.04 
No. of reflections 5243 5627 
No. of parameters 333 377 
No. of restraints 53 14 
H-atom treatment H atoms treated by a mixture 
of independent and 
constrained refinement 
H atoms treated by a mixture 
of independent and 
constrained refinement 
Dρmax, Dρmin (e Å
-3
) 0.34, -0.43 0.24, -0.21 
Absolute structure Flack (1983),  2720 Friedels  
Hooft, Straver and Spek 
(2008) 
Flack (1983),  2720 Friedels  
Hooft, Straver and Spek 
(2008) 
Absolute structure parameter -0.008 (18) 0.036 (19) 
 
Table C.3. (cont.) 
Computer programs: APEX2 V2010.11-3 (Bruker, 2014), SAINT V7.68A (Bruker, 2014), SAINT V7.68A, 
XPREP V2005/2, SADABS V2008/2 (Bruker, 2014), SHELX2014-4 (Sheldrick, 2015), SHELX2014-6 
(Sheldrick, 2015), SHELXTL V6.12 (Sheldrick, 2015), CrystalMaker v2.1.3 (CrystalMaker, 1994), XCIF 
V6.12 (Bruker, 2014), publCIF (Westrip, 2010). 
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Structural models consisting of the target molecules were developed for (I) and (II). Several 
disordered sites on each molecule were modelled with disorder. In each case, like distances were 
restrained to be similar. Since the major and minor components of each disordered site are in such close 
proximity to each other, the displacement parameters were constrained to be equal. Methyl H atom 
positions, R—CH3, were optimized by rotation about R—C bonds with idealized C—H, R–H and H–H 
distances. All hydroxyl and amine H atoms were found in the difference map in good hydrogen bonding 
environments (Hamilton & Ibers 1968) and their distances were allowed to refine. The O4—H4B distance 
in (II) was restrained to be 0.84Å (esd 0.02). Remaining H atoms were included as riding idealized 
contributors. Methyl, hydroxyl and amine H atom U's were assigned as 1.5 times Ueq of the carrier atom; 
remaining H atom U's were assigned as 1.2 times carrier Ueq. On the basis of 2237 unmerged Friedel 
opposites, the fractional contribution of the racemic twin was negligible (Flack, 1983; Flack & 
Bernardinelli, 2000) for (I). The absolute structure parameter y was calculated using PLATON (Spek, 
2009). The resulting value was y=-0.010 (19) indicating that the absolute structure has been determined 
correctly (Hooft, Straver and Spek, 2008). On the basis of 2720 unmerged Friedel opposites, the 
fractional contribution of the racemic twin was negligible (Flack, 1983; Flack & Bernardinelli, 2000) for 
(II). The absolute structure parameter y was calculated using PLATON (Spek, 2009). The resulting value 
was y=0.03 (2) indicating that the absolute structure has been determined correctly (Hooft, Straver and 
Spek, 2008). 
C.7 Supporting information 
Computing details 
For both compounds, data collection: APEX2 V2010.11-3 (Bruker, 2014); cell refinement: SAINT 
V7.68A (Bruker, 2014); data reduction: SAINT V7.68A, XPREP V2005/2, SADABS V2008/2 (Bruker, 
2014); program(s) used to solve structure: SHELX2014-4 (Sheldrick, 2015); program(s) used to refine 
structure: SHELX2014-6 (Sheldrick, 2015); molecular graphics: SHELXTL V6.12 (Sheldrick, 2015), 
CrystalMaker v2.1.3 (CrystalMaker, 1994); software used to prepare material for publication: XCIF 
398 
 
V6.12 (Bruker, 2014), publCIF (Westrip, 2010). 
(I) 
Crystal data 
 C24H35ClN4O5 F(000) = 1056 
Mr = 495.01 Dx = 1.270 Mg m
-3
 
Orthorhombic, P21212 Mo Ka radiation, l = 0.71073 Å 
Hall symbol:  P 2 2ab Cell parameters from 9966 reflections 
a = 18.8408 (7) Å q = 2.3–24.5° 
b = 20.2263 (8) Å m = 0.19 mm
-1
 
c = 6.7923 (3) Å T = 193 K 
V = 2588.41 (18)  Å
3
 Prism, colourless 
Z = 4 0.37 × 0.36 × 0.29 mm 
 
Data collection 
 Siemens Platform/ApexII CCD  
diffractometer 
5243 independent reflections 
Radiation source: normal-focus sealed tube 4694 reflections with I > 2s(I) 
Graphite monochromator Rint = 0.027 
profile data from f and w scans qmax = 26.3°, qmin = 1.5° 
Absorption correction: integration  
SHELXTL/XPREP V2005/2 (Bruker, 2014) 
h = -23®23 
Tmin = 0.953, Tmax = 0.960 k = -25®25 
30342 measured reflections l = -8®8 
 
Refinement 
 Refinement on F
2
 Hydrogen site location: mixed 
Least-squares matrix: full H atoms treated by a mixture of 
independent and constrained refinement 
R[F
2
 > 2s(F
2
)] = 0.035  w = 1/[s
2
(Fo
2
) + (0.0355P)
2
 + 0.5785P]   
where P = (Fo
2
 + 2Fc
2
)/3 
wR(F
2
) = 0.085 (D/s)max = 0.001 
S = 1.03 Dρmax = 0.34 e Å
-3
 
5243 reflections Dρmin = -0.43 e Å
-3
 
333 parameters Absolute structure:  Flack (1983),  2720 
Friedels  Hooft, Straver and Spek (2008) 
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53 restraints Absolute structure parameter: -0.008 (18) 
 
Special details 
 Experimental. One distinct cell was identified using APEX2 (Bruker, 2014).  Four  
frame series were integrated and filtered for statistical outliers  using SAINT (Bruker, 
2014) then corrected for absorption by  integration using SHELXTL/XPREP V2005/2 
(Bruker, 2014) before using  SAINT/SADABS (Bruker, 2014) to sort, merge, and scale  
the combined data  No decay correction was applied. 
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes)   are 
estimated using the full covariance matrix.  The cell esds are taken   into account 
individually in the estimation of esds in distances, angles   and torsion angles; 
correlations between esds in cell parameters are only   used when they are defined by 
crystal symmetry.  An approximate (isotropic)   treatment of cell esds is used for 
estimating esds involving l.s. planes. 
Refinement. Structure was phased by direct (Sheldrick, 2015).  Systematic  conditions 
suggested the ambiguous space group.  The space group choice was confirmed by 
successful convergence of the  full-matrix least-squares refinement on F
2
.  The final map 
had no  significant features.  A final analysis of  variance between observed and 
calculated structure factors showed no  dependence on amplitude or resolution. 
 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å
2
) 
 x y z Uiso*/Ueq Occ. (<1) 
Cl1 0.29551 (15) 0.69804 (7) 0.67519 (15) 0.0735 (5) 0.941 (8) 
Cl1B 0.326 (2) 0.6888 (7) 0.664 (3) 0.0735 (5) 0.059 (8) 
O1 0.3558 (8) 0.8988 (8) 0.2519 (16) 0.086 (2) 0.60 (2) 
O2 0.4046 (8) 0.9713 (5) 0.445 (2) 0.116 (3) 0.60 (2) 
N1 0.3808 (6) 0.9169 (5) 0.4064 (12) 0.0715 (17) 0.60 (2) 
O1B 0.3725 (13) 0.9134 (12) 0.271 (3) 0.086 (2) 0.40 (2) 
O2B 0.4360 (11) 0.9754 (7) 0.453 (3) 0.116 (3) 0.40 (2) 
N1B 0.3991 (9) 0.9260 (7) 0.431 (2) 0.0715 (17) 0.40 (2) 
C1 0.38040 (11) 0.78173 (14) 0.8790 (4) 0.0477 (6)  
C2 0.34335 (12) 0.77084 (14) 0.7057 (4) 0.0520 (7)  
C3 0.34488 (14) 0.81498 (16) 0.5532 (4) 0.0585 (7)  
H3A 0.3207 0.8062 0.4333 0.070*  
C4 0.38270 (16) 0.87247 (16) 0.5797 (5) 0.0635 (8)  
C5 0.41913 (17) 0.88668 (15) 0.7505 (5) 0.0675 (8)  
H5A 0.4439 0.9272 0.7658 0.081*  
C6 0.41831 (14) 0.84036 (15) 0.8974 (5) 0.0594 (7)  
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H6A 0.4443 0.8485 1.0148 0.071*  
C7 0.38161 (12) 0.73281 (14) 1.0445 (4) 0.0478 (6)  
O3 0.32755 (9) 0.71943 (11) 1.1373 (3) 0.0644 (5)  
O4 0.48956 (9) 0.73984 (10) 1.4849 (3) 0.0534 (5)  
H4B 0.5165 (17) 0.7479 (17) 1.585 (5) 0.080*  
O5 0.56221 (7) 0.75831 (7) 0.8387 (2) 0.0372 (3)  
N2 0.44567 (10) 0.70759 (11) 1.0807 (3) 0.0438 (5)  
H2 0.4786 (16) 0.7171 (15) 1.005 (5) 0.066*  
N3 0.60919 (9) 0.66293 (9) 1.1177 (3) 0.0368 (4)  
N4 0.67223 (10) 0.80363 (9) 0.8528 (3) 0.0417 (4)  
H4 0.7145 (16) 0.7950 (14) 0.884 (4) 0.063*  
C8 0.46111 (12) 0.66114 (13) 1.2385 (4) 0.0459 (6)  
H8A 0.4766 0.6186 1.1805 0.055*  
H8B 0.4172 0.6528 1.3145 0.055*  
C9 0.51828 (11) 0.68604 (12) 1.3772 (3) 0.0420 (5)  
H9A 0.5310 0.6499 1.4712 0.050*  
C10 0.58565 (11) 0.70901 (12) 1.2713 (3) 0.0386 (5)  
H10A 0.5767 0.7528 1.2109 0.046*  
H10B 0.6242 0.7144 1.3691 0.046*  
C11 0.65713 (11) 0.69212 (11) 0.9715 (3) 0.0380 (5)  
H11A 0.7036 0.7026 1.0353 0.046*  
C12 0.66899 (13) 0.64166 (11) 0.8056 (4) 0.0410 (5)  
H12A 0.6230 0.6318 0.7413 0.049*  
H12B 0.7010 0.6610 0.7054 0.049*  
C13 0.70138 (14) 0.57736 (12) 0.8829 (4) 0.0494 (6)  
H13A 0.7500 0.5880 0.9326 0.059*  
C14 0.70957 (16) 0.52528 (13) 0.7203 (4) 0.0590 (7)  
H14A 0.7303 0.5467 0.6025 0.071*  
H14B 0.7434 0.4910 0.7656 0.071*  
C15 0.64047 (16) 0.49205 (14) 0.6624 (4) 0.0611 (7)  
H15A 0.6503 0.4565 0.5661 0.073*  
H15B 0.6089 0.5248 0.5988 0.073*  
C16 0.60342 (19) 0.46287 (13) 0.8419 (5) 0.0696 (9)  
H16A 0.6333 0.4276 0.8999 0.084*  
H16B 0.5576 0.4430 0.8019 0.084*  
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C17 0.59030 (17) 0.51683 (13) 0.9945 (4) 0.0610 (8)  
H17A 0.5575 0.5502 0.9387 0.073*  
H17B 0.5671 0.4971 1.1115 0.073*  
C18 0.65836 (16) 0.55060 (13) 1.0574 (4) 0.0550 (7)  
H18A 0.6883 0.5165 1.1243 0.066*  
C19 0.64454 (15) 0.60538 (13) 1.2068 (4) 0.0505 (6)  
H19A 0.6145 0.5878 1.3143 0.061*  
H19B 0.6902 0.6196 1.2650 0.061*  
C20 0.62618 (10) 0.75493 (11) 0.8828 (3) 0.0354 (5)  
C21 0.65543 (13) 0.87079 (12) 0.7767 (4) 0.0480 (6)  
C22 0.60827 (17) 0.90585 (14) 0.9239 (5) 0.0679 (8)  
H22A 0.5644 0.8805 0.9422 0.102*  
H22B 0.5967 0.9501 0.8746 0.102*  
H22C 0.6332 0.9097 1.0500 0.102*  
C23 0.62113 (16) 0.86682 (14) 0.5736 (5) 0.0606 (8)  
H23A 0.5739 0.8468 0.5852 0.091*  
H23B 0.6507 0.8397 0.4866 0.091*  
H23C 0.6167 0.9114 0.5184 0.091*  
C24 0.72639 (15) 0.90696 (15) 0.7599 (6) 0.0682 (9)  
H24A 0.7496 0.9079 0.8890 0.102*  
H24B 0.7182 0.9523 0.7145 0.102*  
H24C 0.7569 0.8838 0.6655 0.102*  
 
Atomic displacement parameters (Å
2
) 
 U
11
 U
22
 U
33
 U
12
 U
13
 U
23
 
Cl1 0.0607 (12) 0.1010 (6) 0.0588 (5) -0.0165 (6) -0.0109 (5) -0.0190 (5) 
Cl1B 0.0607 (12) 0.1010 (6) 0.0588 (5) -0.0165 (6) -0.0109 (5) -0.0190 (5) 
O1 0.088 (6) 0.100 (6) 0.068 (2) 0.018 (4) -0.011 (3) 0.008 (3) 
O2 0.141 (8) 0.076 (2) 0.130 (3) -0.009 (4) -0.021 (6) 0.021 (2) 
N1 0.071 (4) 0.068 (2) 0.075 (3) 0.023 (2) -0.011 (3) -0.005 (2) 
O1B 0.088 (6) 0.100 (6) 0.068 (2) 0.018 (4) -0.011 (3) 0.008 (3) 
O2B 0.141 (8) 0.076 (2) 0.130 (3) -0.009 (4) -0.021 (6) 0.021 (2) 
N1B 0.071 (4) 0.068 (2) 0.075 (3) 0.023 (2) -0.011 (3) -0.005 (2) 
C1 0.0257 (10) 0.0711 (16) 0.0463 (14) 0.0075 (10) -0.0005 
(10) 
-0.0111 
(13) 
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C2 0.0330 (12) 0.0761 (18) 0.0471 (14) 0.0110 (12) -0.0037 
(10) 
-0.0142 
(14) 
C3 0.0463 (15) 0.0788 (19) 0.0505 (15) 0.0225 (14) -0.0057 
(12) 
-0.0146 
(15) 
C4 0.0602 (17) 0.0701 (19) 0.0601 (18) 0.0332 (15) 0.0033 (15) -0.0002 
(15) 
C5 0.0662 (19) 0.0567 (17) 0.079 (2) 0.0106 (14) -0.0035 
(17) 
-0.0068 
(16) 
C6 0.0464 (14) 0.0732 (19) 0.0586 (17) 0.0057 (14) -0.0091 
(13) 
-0.0124 
(15) 
C7 0.0284 (11) 0.0747 (17) 0.0404 (13) -0.0032 
(11) 
-0.0024 
(10) 
-0.0109 
(12) 
O3 0.0297 (8) 0.1063 (15) 0.0571 (11) -0.0049 (9) 0.0044 (8) 0.0005 (12) 
O4 0.0413 (9) 0.0750 (13) 0.0440 (9) 0.0114 (9) -0.0038 (8) -0.0169 (9) 
O5 0.0280 (7) 0.0430 (8) 0.0407 (8) -0.0008 (6) -0.0039 (6) 0.0031 (7) 
N2 0.0275 (9) 0.0655 (14) 0.0384 (10) -0.0050 (9) -0.0011 (8) -0.0050 
(10) 
N3 0.0375 (9) 0.0411 (10) 0.0318 (9) 0.0061 (8) -0.0012 (8) 0.0013 (8) 
N4 0.0298 (9) 0.0432 (10) 0.0521 (12) -0.0032 (8) -0.0044 (9) 0.0001 (10) 
C8 0.0373 (12) 0.0565 (14) 0.0440 (13) -0.0060 
(11) 
0.0017 (10) -0.0014 
(12) 
C9 0.0383 (12) 0.0525 (13) 0.0352 (11) 0.0052 (10) -0.0004 (9) -0.0039 
(11) 
C10 0.0334 (11) 0.0482 (13) 0.0342 (11) 0.0029 (9) -0.0056 (9) -0.0047 
(10) 
C11 0.0282 (10) 0.0457 (12) 0.0400 (12) 0.0033 (9) -0.0032 (9) -0.0016 
(10) 
C12 0.0393 (12) 0.0460 (12) 0.0378 (12) 0.0059 (10) 0.0050 (10) 0.0019 (10) 
C13 0.0482 (13) 0.0531 (14) 0.0470 (14) 0.0192 (12) 0.0032 (12) 0.0006 (12) 
C14 0.0673 (17) 0.0557 (16) 0.0540 (16) 0.0224 (14) 0.0116 (14) 0.0021 (13) 
C15 0.0818 (19) 0.0466 (14) 0.0549 (16) 0.0096 (13) 0.0141 (15) -0.0024 
(14) 
C16 0.097 (2) 0.0436 (14) 0.069 (2) 0.0034 (15) 0.0223 (19) 0.0010 (15) 
C17 0.085 (2) 0.0426 (14) 0.0550 (16) 0.0062 (14) 0.0222 (15) 0.0059 (12) 
C18 0.0689 (17) 0.0510 (14) 0.0451 (14) 0.0261 (14) 0.0048 (13) 0.0117 (12) 
C19 0.0580 (15) 0.0566 (15) 0.0369 (13) 0.0178 (12) -0.0022 
(12) 
0.0067 (12) 
C20 0.0301 (10) 0.0414 (11) 0.0348 (11) 0.0002 (9) -0.0006 (9) -0.0043 (9) 
C21 0.0411 (13) 0.0378 (12) 0.0653 (17) -0.0065 -0.0019 -0.0007 
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(10) (12) (12) 
C22 0.0653 (18) 0.0512 (15) 0.087 (2) 0.0017 (14) 0.0045 (17) -0.0127 
(16) 
C23 0.0665 (18) 0.0475 (14) 0.0678 (19) -0.0086 
(13) 
-0.0126 
(15) 
0.0125 (14) 
C24 0.0540 (16) 0.0529 (16) 0.098 (2) -0.0193 
(13) 
-0.0009 
(16) 
0.0024 (17) 
 
Geometric parameters (Å, º) for (I) 
Cl1—C2 1.739 (3) C11—C20 1.522 (3) 
Cl1B—C2 1.716 (12) C11—C12 1.536 (3) 
O1—N1 1.207 (7) C11—H11A 1.0000 
O2—N1 1.217 (7) C12—C13 1.529 (3) 
N1—C4 1.482 (7) C12—H12A 0.9900 
O1B—N1B 1.226 (9) C12—H12B 0.9900 
O2B—N1B 1.228 (10) C13—C14 1.534 (4) 
N1B—C4 1.511 (9) C13—C18 1.535 (4) 
C1—C2 1.386 (3) C13—H13A 1.0000 
C1—C6 1.390 (4) C14—C15 1.517 (4) 
C1—C7 1.498 (4) C14—H14A 0.9900 
C2—C3 1.368 (4) C14—H14B 0.9900 
C3—C4 1.376 (5) C15—C16 1.524 (4) 
C3—H3A 0.9500 C15—H15A 0.9900 
C4—C5 1.379 (5) C15—H15B 0.9900 
C5—C6 1.368 (4) C16—C17 1.525 (4) 
C5—H5A 0.9500 C16—H16A 0.9900 
C6—H6A 0.9500 C16—H16B 0.9900 
C7—O3 1.228 (3) C17—C18 1.514 (4) 
C7—N2 1.333 (3) C17—H17A 0.9900 
O4—C9 1.418 (3) C17—H17B 0.9900 
O4—H4B 0.87 (4) C18—C19 1.525 (4) 
O5—C20 1.244 (2) C18—H18A 1.0000 
N2—C8 1.455 (3) C19—H19A 0.9900 
N2—H2 0.83 (3) C19—H19B 0.9900 
N3—C11 1.467 (3) C21—C22 1.514 (4) 
N3—C10 1.467 (3) C21—C23 1.526 (4) 
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N3—C19 1.471 (3) C21—C24 1.528 (3) 
N4—C20 1.329 (3) C22—H22A 0.9800 
N4—C21 1.487 (3) C22—H22B 0.9800 
N4—H4 0.84 (3) C22—H22C 0.9800 
C8—C9 1.517 (3) C23—H23A 0.9800 
C8—H8A 0.9900 C23—H23B 0.9800 
C8—H8B 0.9900 C23—H23C 0.9800 
C9—C10 1.531 (3) C24—H24A 0.9800 
C9—H9A 1.0000 C24—H24B 0.9800 
C10—H10A 0.9900 C24—H24C 0.9800 
C10—H10B 0.9900   
    
O1—N1—O2 127.3 (9) H12A—C12—H12B 107.9 
O1—N1—C4 121.0 (9) C12—C13—C14 112.2 (2) 
O2—N1—C4 111.6 (9) C12—C13—C18 110.74 (19) 
O1B—N1B—O2B 120.6 (14) C14—C13—C18 111.5 (2) 
O1B—N1B—C4 111.2 (14) C12—C13—H13A 107.4 
O2B—N1B—C4 128.1 (14) C14—C13—H13A 107.4 
C2—C1—C6 118.1 (3) C18—C13—H13A 107.4 
C2—C1—C7 122.7 (2) C15—C14—C13 113.9 (2) 
C6—C1—C7 119.2 (2) C15—C14—H14A 108.8 
C3—C2—C1 121.9 (3) C13—C14—H14A 108.8 
C3—C2—Cl1B 120.7 (7) C15—C14—H14B 108.8 
C1—C2—Cl1B 113.0 (8) C13—C14—H14B 108.8 
C3—C2—Cl1 118.2 (2) H14A—C14—H14B 107.7 
C1—C2—Cl1 119.8 (2) C14—C15—C16 110.9 (3) 
C2—C3—C4 117.6 (3) C14—C15—H15A 109.5 
C2—C3—H3A 121.2 C16—C15—H15A 109.5 
C4—C3—H3A 121.2 C14—C15—H15B 109.5 
C3—C4—C5 123.0 (3) C16—C15—H15B 109.5 
C3—C4—N1 113.4 (5) H15A—C15—H15B 108.0 
C5—C4—N1 123.7 (5) C15—C16—C17 109.9 (2) 
C3—C4—N1B 128.6 (7) C15—C16—H16A 109.7 
C5—C4—N1B 108.1 (7) C17—C16—H16A 109.7 
C6—C5—C4 117.7 (3) C15—C16—H16B 109.7 
405 
 
C6—C5—H5A 121.1 C17—C16—H16B 109.7 
C4—C5—H5A 121.1 H16A—C16—H16B 108.2 
C5—C6—C1 121.6 (3) C18—C17—C16 112.2 (3) 
C5—C6—H6A 119.2 C18—C17—H17A 109.2 
C1—C6—H6A 119.2 C16—C17—H17A 109.2 
O3—C7—N2 124.9 (3) C18—C17—H17B 109.2 
O3—C7—C1 121.2 (2) C16—C17—H17B 109.2 
N2—C7—C1 113.9 (2) H17A—C17—H17B 107.9 
C9—O4—H4B 109 (2) C17—C18—C19 111.8 (2) 
C7—N2—C8 124.3 (2) C17—C18—C13 112.8 (2) 
C7—N2—H2 118 (2) C19—C18—C13 110.4 (2) 
C8—N2—H2 117 (2) C17—C18—H18A 107.2 
C11—N3—C10 114.32 (17) C19—C18—H18A 107.2 
C11—N3—C19 108.55 (18) C13—C18—H18A 107.2 
C10—N3—C19 110.33 (18) N3—C19—C18 112.3 (2) 
C20—N4—C21 126.27 (19) N3—C19—H19A 109.2 
C20—N4—H4 115 (2) C18—C19—H19A 109.2 
C21—N4—H4 119 (2) N3—C19—H19B 109.2 
N2—C8—C9 112.7 (2) C18—C19—H19B 109.2 
N2—C8—H8A 109.1 H19A—C19—H19B 107.9 
C9—C8—H8A 109.1 O5—C20—N4 123.7 (2) 
N2—C8—H8B 109.1 O5—C20—C11 120.82 (19) 
C9—C8—H8B 109.1 N4—C20—C11 115.44 (18) 
H8A—C8—H8B 107.8 N4—C21—C22 108.9 (2) 
O4—C9—C8 107.70 (19) N4—C21—C23 110.9 (2) 
O4—C9—C10 109.00 (19) C22—C21—C23 111.9 (2) 
C8—C9—C10 113.42 (19) N4—C21—C24 106.1 (2) 
O4—C9—H9A 108.9 C22—C21—C24 109.8 (2) 
C8—C9—H9A 108.9 C23—C21—C24 109.2 (2) 
C10—C9—H9A 108.9 C21—C22—H22A 109.5 
N3—C10—C9 113.06 (18) C21—C22—H22B 109.5 
N3—C10—H10A 109.0 H22A—C22—H22B 109.5 
C9—C10—H10A 109.0 C21—C22—H22C 109.5 
N3—C10—H10B 109.0 H22A—C22—H22C 109.5 
C9—C10—H10B 109.0 H22B—C22—H22C 109.5 
406 
 
H10A—C10—H10B 107.8 C21—C23—H23A 109.5 
N3—C11—C20 111.60 (17) C21—C23—H23B 109.5 
N3—C11—C12 108.59 (18) H23A—C23—H23B 109.5 
C20—C11—C12 108.67 (18) C21—C23—H23C 109.5 
N3—C11—H11A 109.3 H23A—C23—H23C 109.5 
C20—C11—H11A 109.3 H23B—C23—H23C 109.5 
C12—C11—H11A 109.3 C21—C24—H24A 109.5 
C13—C12—C11 111.81 (19) C21—C24—H24B 109.5 
C13—C12—H12A 109.3 H24A—C24—H24B 109.5 
C11—C12—H12A 109.3 C21—C24—H24C 109.5 
C13—C12—H12B 109.3 H24A—C24—H24C 109.5 
C11—C12—H12B 109.3 H24B—C24—H24C 109.5 
    
C6—C1—C2—C3 1.8 (4) C19—N3—C10—
C9 
-77.0 (2) 
C7—C1—C2—C3 -177.6 (2) O4—C9—C10—N3 -165.33 (18) 
C6—C1—C2—Cl1B 158.4 (14) C8—C9—C10—N3 -45.4 (3) 
C7—C1—C2—Cl1B -20.9 (14) C10—N3—C11—
C20 
-52.4 (2) 
C6—C1—C2—Cl1 179.7 (2) C19—N3—C11—
C20 
-176.07 (18) 
C7—C1—C2—Cl1 0.3 (3) C10—N3—C11—
C12 
-172.21 (17) 
C1—C2—C3—C4 -2.3 (4) C19—N3—C11—
C12 
64.2 (2) 
Cl1B—C2—C3—C4 -157.2 (15) N3—C11—C12—
C13 
-59.4 (2) 
Cl1—C2—C3—C4 179.8 (2) C20—C11—C12—
C13 
178.98 (19) 
C2—C3—C4—C5 0.7 (4) C11—C12—C13—
C14 
176.8 (2) 
C2—C3—C4—N1 -179.8 (5) C11—C12—C13—
C18 
51.5 (3) 
C2—C3—C4—N1B 173.4 (9) C12—C13—C14—
C15 
-75.8 (3) 
O1—N1—C4—C3 -9.0 (13) C18—C13—C14—
C15 
49.0 (3) 
O2—N1—C4—C3 168.9 (8) C13—C14—C15— -54.1 (3) 
407 
 
C16 
O1—N1—C4—C5 170.5 (10) C14—C15—C16—
C17 
57.2 (3) 
O2—N1—C4—C5 -11.6 (11) C15—C16—C17—
C18 
-57.7 (3) 
O1B—N1B—C4—
C3 
1 (2) C16—C17—C18—
C19 
178.8 (2) 
O2B—N1B—C4—
C3 
-175.8 (15) C16—C17—C18—
C13 
53.7 (3) 
O1B—N1B—C4—
C5 
174.8 (17) C12—C13—C18—
C17 
77.4 (3) 
O2B—N1B—C4—
C5 
-2 (2) C14—C13—C18—
C17 
-48.3 (3) 
C3—C4—C5—C6 1.4 (4) C12—C13—C18—
C19 
-48.5 (3) 
N1—C4—C5—C6 -178.1 (6) C14—C13—C18—
C19 
-174.2 (2) 
N1B—C4—C5—C6 -172.6 (8) C11—N3—C19—
C18 
-64.1 (3) 
C4—C5—C6—C1 -2.0 (4) C10—N3—C19—
C18 
170.0 (2) 
C2—C1—C6—C5 0.5 (4) C17—C18—C19—
N3 
-70.8 (3) 
C7—C1—C6—C5 179.9 (2) C13—C18—C19—
N3 
55.7 (3) 
C2—C1—C7—O3 -65.7 (3) C21—N4—C20—
O5 
4.6 (4) 
C6—C1—C7—O3 115.0 (3) C21—N4—C20—
C11 
-177.1 (2) 
C2—C1—C7—N2 115.6 (3) N3—C11—C20—
O5 
-41.3 (3) 
C6—C1—C7—N2 -63.7 (3) C12—C11—C20—
O5 
78.4 (3) 
O3—C7—N2—C8 -1.1 (4) N3—C11—C20—
N4 
140.4 (2) 
C1—C7—N2—C8 177.5 (2) C12—C11—C20—
N4 
-99.9 (2) 
C7—N2—C8—C9 -122.8 (3) C20—N4—C21—
C22 
64.5 (3) 
N2—C8—C9—O4 69.4 (2) C20—N4—C21—
C23 
-59.1 (3) 
408 
 
N2—C8—C9—C10 -51.3 (3) C20—N4—C21—
C24 
-177.5 (2) 
C11—N3—C10—
C9 
160.33 (18)   
 
Hydrogen-bond geometry (Å, º) for (I) 
 D—H···A D—H H···A D···A D—H···A 
O4—H4B···O5i 0.87 (4) 1.94 (4) 2.791 (2) 169 (3) 
N2—H2···O5 0.83 (3) 2.11 (3) 2.928 (3) 169 (3) 
N4—H4···O3ii 0.84 (3) 2.15 (3) 2.964 (2) 161 (3) 
 
Symmetry codes:  (i) x, y, z+1;  (ii) x+1/2, -y+3/2, -z+2. 
(II) 
Crystal data 
 C27H39ClN4O5 F(000) = 572 
Mr = 535.07 Dx = 1.279 Mg m
-3
 
Monoclinic, P21 Mo Ka radiation, l = 0.71073 Å 
Hall symbol:  P 2yb Cell parameters from 7806 reflections 
a = 6.4341 (7) Å q = 2.8–26.3° 
b = 20.280 (2) Å m = 0.18 mm
-1
 
c = 11.0377 (12) Å T = 168 K 
b = 105.248 (1)° Plates, colourless 
V = 1389.5 (3)  Å
3
 0.86 × 0.65 × 0.15 mm 
Z = 2  
 
Data collection 
 Siemens Platform/ApexII CCD  
diffractometer 
5627 independent reflections 
Radiation source: normal-focus sealed tube 5222 reflections with I > 2s(I) 
Graphite monochromator Rint = 0.024 
profile data from f and w scans qmax = 26.4°, qmin = 1.9° 
Absorption correction: integration  
SHELXTL/XPREP V2005/2 (Bruker, 2014) 
h = -8®8 
Tmin = 0.892, Tmax = 0.980 k = -25®25 
16374 measured reflections l = -13®13 
409 
 
 
Refinement 
 Refinement on F
2
 Hydrogen site location: mixed 
Least-squares matrix: full H atoms treated by a mixture of 
independent and constrained refinement 
R[F
2
 > 2s(F
2
)] = 0.032  w = 1/[s
2
(Fo
2
) + (0.0447P)
2
 + 0.1276P]   
where P = (Fo
2
 + 2Fc
2
)/3 
wR(F
2
) = 0.082 (D/s)max < 0.001 
S = 1.04 Dρmax = 0.24 e Å
-3
 
5627 reflections Dρmin = -0.21 e Å
-3
 
377 parameters Absolute structure:  Flack (1983),  2720 
Friedels  Hooft, Straver and Spek (2008) 
14 restraints Absolute structure parameter: 0.036 (19) 
 
Special details 
 Experimental. One distinct cell was identified using APEX2  (Bruker, 2014).  Four 
frame series were integrated and filtered  for statistical outliers using SAINT (Bruker, 
2014) then corrected  for absorption by integration using SHELXTL/XPREP V2005/2  
(Bruker, 2014) before using SAINT/SADABS (Bruker, 2014) to sort,  merge, and scale 
the combined data.  No decay correction was applied. 
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes)   are 
estimated using the full covariance matrix.  The cell esds are taken   into account 
individually in the estimation of esds in distances, angles   and torsion angles; 
correlations between esds in cell parameters are only   used when they are defined by 
crystal symmetry.  An approximate (isotropic)   treatment of cell esds is used for 
estimating esds involving l.s. planes. 
Refinement. Structure was phased by direct (Sheldrick, 2015) methods.  Systematic  
conditions suggested the ambiguous space group.  The space group choice was confirmed 
by successful convergence of the  full-matrix least-squares refinement on F
2
.  The  final 
map had no significant features.  A final analysis of  variance between observed and 
calculated structure factors showed little  dependence on amplitude and resolution. 
 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å
2
) 
 x y z Uiso*/Ueq Occ. (<1) 
Cl1 0.18218 (12) 0.27617 (3) 0.58986 (6) 0.05313 (19)  
O1 0.7185 (5) 0.41190 (18) 0.9393 (3) 0.0657 (8) 0.967 (8) 
O2 0.5309 (5) 0.48339 (16) 1.0083 (3) 0.0796 (11) 0.967 (8) 
O1B 0.658 (13) 0.391 (2) 0.970 (8) 0.0657 (8) 0.033 (8) 
O2B 0.605 (14) 0.4966 (13) 0.961 (9) 0.0796 (11) 0.033 (8) 
410 
 
N1 0.5493 (4) 0.43973 (13) 0.9347 (2) 0.0521 (6)  
O3 -0.3816 (17) 0.3687 (9) 0.5659 (16) 0.064 (2) 0.58 (2) 
C7 -0.1974 (15) 0.3696 (13) 0.5438 (6) 0.044 (3) 0.58 (2) 
O3B -0.341 (3) 0.3487 (9) 0.584 (2) 0.064 (2) 0.42 (2) 
C7B -0.209 (2) 0.3832 (18) 0.5437 (8) 0.044 (3) 0.42 (2) 
O4 -0.0271 (3) 0.50975 (9) 0.45504 (16) 0.0466 (4)  
H4B -0.124 (4) 0.5375 (14) 0.441 (3) 0.070*  
O5 0.6776 (3) 0.60681 (10) 0.43924 (17) 0.0497 (5)  
N2 -0.1962 (3) 0.38062 (11) 0.4242 (2) 0.0434 (5)  
N3 0.1541 (3) 0.56188 (9) 0.25105 (17) 0.0349 (4)  
N4 0.3515 (3) 0.61688 (10) 0.48165 (17) 0.0354 (4)  
H4C 0.211 (5) 0.6126 (16) 0.452 (3) 0.053*  
C1 0.1816 (4) 0.34965 (12) 0.6715 (2) 0.0407 (6)  
C2 0.3653 (5) 0.36560 (13) 0.7648 (2) 0.0419 (5)  
H2A 0.4918 0.3393 0.7794 0.050*  
C3 0.3571 (4) 0.42136 (13) 0.8359 (2) 0.0425 (6)  
C4 0.1757 (5) 0.46054 (15) 0.8176 (3) 0.0515 (7)  
H4A 0.1728 0.4977 0.8697 0.062*  
C5 -0.0004 (5) 0.44390 (15) 0.7217 (3) 0.0505 (6)  
H5A -0.1264 0.4703 0.7071 0.061*  
C6 0.0008 (4) 0.38941 (13) 0.6450 (2) 0.0417 (6)  
C8 -0.0147 (4) 0.40027 (12) 0.3737 (2) 0.0355 (5)  
H8A 0.1254 0.3883 0.4342 0.043*  
C9 -0.0526 (4) 0.35761 (14) 0.2539 (3) 0.0481 (6)  
H9A -0.0348 0.3849 0.1829 0.058*  
H9B 0.0544 0.3214 0.2674 0.058*  
C10 -0.2747 (10) 0.3296 (4) 0.2237 (6) 0.0504 (15) 0.669 (16) 
H10A -0.2719 0.2816 0.2401 0.060* 0.669 (16) 
H10B -0.3527 0.3379 0.1350 0.060* 0.669 (16) 
C11 -0.3755 (11) 0.3670 (4) 0.3125 (7) 0.0423 (15) 0.669 (16) 
H11A -0.4415 0.4086 0.2737 0.051* 0.669 (16) 
H11B -0.4878 0.3400 0.3353 0.051* 0.669 (16) 
C10B -0.2980 (17) 0.3525 (8) 0.2257 (15) 0.0504 (15) 0.331 (16) 
H10C -0.3618 0.3898 0.1705 0.060* 0.331 (16) 
H10D -0.3439 0.3114 0.1777 0.060* 0.331 (16) 
411 
 
C11B -0.392 (2) 0.3527 (9) 0.3383 (12) 0.0423 (15) 0.331 (16) 
H11C -0.5191 0.3818 0.3268 0.051* 0.331 (16) 
H11D -0.4263 0.3079 0.3630 0.051* 0.331 (16) 
C12 -0.0208 (4) 0.47423 (12) 0.3446 (2) 0.0370 (5)  
H12A -0.1522 0.4846 0.2757 0.044*  
C13 0.1800 (4) 0.49527 (12) 0.3056 (2) 0.0380 (5)  
H13A 0.3061 0.4945 0.3799 0.046*  
H13B 0.2073 0.4636 0.2433 0.046*  
C14 0.3607 (3) 0.59631 (12) 0.2673 (2) 0.0357 (5)  
H14A 0.4542 0.5706 0.2250 0.043*  
C15 0.3232 (4) 0.66580 (12) 0.2091 (2) 0.0369 (5)  
H15A 0.2424 0.6925 0.2564 0.044*  
H15B 0.4642 0.6874 0.2172 0.044*  
C16 0.1982 (4) 0.66434 (13) 0.0704 (2) 0.0380 (5)  
H16A 0.2901 0.6415 0.0230 0.046*  
C17 0.1487 (4) 0.73367 (15) 0.0150 (2) 0.0462 (6)  
H17A 0.2833 0.7598 0.0349 0.055*  
H17B 0.0968 0.7302 -0.0776 0.055*  
C18 -0.0196 (4) 0.76982 (15) 0.0644 (2) 0.0470 (6)  
H18A 0.0388 0.7786 0.1552 0.056*  
H18B -0.0528 0.8127 0.0209 0.056*  
C19 -0.2244 (4) 0.72936 (14) 0.0435 (2) 0.0451 (6)  
H19A -0.2910 0.7249 -0.0478 0.054*  
H19B -0.3279 0.7527 0.0807 0.054*  
C20 -0.1805 (4) 0.66089 (12) 0.1020 (2) 0.0381 (5)  
H20A -0.3159 0.6351 0.0816 0.046*  
H20B -0.1306 0.6652 0.1945 0.046*  
C21 -0.0090 (4) 0.62377 (13) 0.0539 (2) 0.0374 (5)  
H21A -0.0699 0.6159 -0.0380 0.045*  
C22 0.0428 (4) 0.55715 (13) 0.1167 (2) 0.0396 (5)  
H22A -0.0929 0.5322 0.1070 0.048*  
H22B 0.1344 0.5321 0.0736 0.048*  
C23 0.4782 (3) 0.60558 (11) 0.4055 (2) 0.0359 (5)  
C24 0.4216 (4) 0.62935 (12) 0.6177 (2) 0.0390 (5)  
C25 0.2182 (7) 0.6384 (4) 0.6614 (5) 0.0498 (13) 0.811 (17) 
412 
 
H25A 0.1300 0.5984 0.6430 0.075* 0.811 (17) 
H25B 0.1361 0.6760 0.6173 0.075* 0.811 (17) 
H25C 0.2573 0.6467 0.7521 0.075* 0.811 (17) 
C26 0.5534 (13) 0.5704 (3) 0.6839 (4) 0.0572 (14) 0.811 (17) 
H26A 0.4678 0.5300 0.6631 0.086* 0.811 (17) 
H26B 0.5913 0.5773 0.7750 0.086* 0.811 (17) 
H26C 0.6853 0.5662 0.6559 0.086* 0.811 (17) 
C27 0.5599 (11) 0.6921 (3) 0.6388 (7) 0.0569 (15) 0.811 (17) 
H27A 0.4787 0.7283 0.5894 0.085* 0.811 (17) 
H27B 0.6918 0.6842 0.6124 0.085* 0.811 (17) 
H27C 0.5977 0.7037 0.7281 0.085* 0.811 (17) 
C25B 0.227 (4) 0.6608 (14) 0.651 (3) 0.0498 (13) 0.189 (17) 
H25D 0.0945 0.6390 0.6040 0.075* 0.189 (17) 
H25E 0.2201 0.7078 0.6299 0.075* 0.189 (17) 
H25F 0.2418 0.6558 0.7415 0.075* 0.189 (17) 
C26B 0.461 (5) 0.5602 (8) 0.678 (2) 0.0572 (14) 0.189 (17) 
H26D 0.3258 0.5351 0.6569 0.086* 0.189 (17) 
H26E 0.5122 0.5647 0.7697 0.086* 0.189 (17) 
H26F 0.5692 0.5369 0.6465 0.086* 0.189 (17) 
C27B 0.612 (4) 0.6761 (14) 0.659 (3) 0.0569 (15) 0.189 (17) 
H27D 0.7446 0.6534 0.6543 0.085* 0.189 (17) 
H27E 0.6262 0.6903 0.7457 0.085* 0.189 (17) 
H27F 0.5895 0.7148 0.6037 0.085* 0.189 (17) 
 
Atomic displacement parameters (Å
2
) 
 U
11
 U
22
 U
33
 U
12
 U
13
 U
23
 
Cl1 0.0715 (4) 0.0369 (3) 0.0546 (4) -0.0005 (3) 0.0230 (3) -0.0055 (3) 
O1 0.0580 (14) 0.0857 (18) 0.0498 (14) 0.0073 (14) 0.0076 (10) -0.0005 
(13) 
O2 0.0664 (16) 0.097 (2) 0.0719 (18) -0.0101 
(14) 
0.0123 (14) -0.0422 
(16) 
O1B 0.0580 (14) 0.0857 (18) 0.0498 (14) 0.0073 (14) 0.0076 (10) -0.0005 
(13) 
O2B 0.0664 (16) 0.097 (2) 0.0719 (18) -0.0101 
(14) 
0.0123 (14) -0.0422 
(16) 
N1 0.0564 (14) 0.0602 (15) 0.0405 (12) -0.0036 0.0143 (10) 0.0005 (11) 
413 
 
(12) 
O3 0.041 (4) 0.092 (8) 0.068 (4) -0.008 (3) 0.029 (4) -0.011 (4) 
C7 0.0435 (16) 0.040 (10) 0.0557 (16) -0.004 (3) 0.0269 (13) -0.0166 
(16) 
O3B 0.041 (4) 0.092 (8) 0.068 (4) -0.008 (3) 0.029 (4) -0.011 (4) 
C7B 0.0435 (16) 0.040 (10) 0.0557 (16) -0.004 (3) 0.0269 (13) -0.0166 
(16) 
O4 0.0528 (11) 0.0454 (10) 0.0399 (10) 0.0172 (8) 0.0090 (8) -0.0097 (8) 
O5 0.0298 (8) 0.0613 (12) 0.0524 (11) 0.0106 (8) 0.0011 (7) -0.0171 (9) 
N2 0.0344 (11) 0.0495 (13) 0.0480 (12) -0.0039 (9) 0.0136 (9) -0.0135 
(10) 
N3 0.0322 (10) 0.0374 (11) 0.0333 (10) 0.0008 (8) 0.0054 (8) -0.0082 (8) 
N4 0.0306 (9) 0.0423 (11) 0.0300 (10) 0.0024 (8) 0.0022 (7) -0.0053 (8) 
C1 0.0582 (15) 0.0342 (12) 0.0379 (13) -0.0028 
(11) 
0.0273 (12) -0.0015 
(10) 
C2 0.0528 (14) 0.0417 (13) 0.0363 (12) 0.0041 (11) 0.0208 (11) 0.0064 (10) 
C3 0.0525 (14) 0.0448 (14) 0.0336 (12) -0.0042 
(11) 
0.0174 (10) 0.0019 (10) 
C4 0.0611 (17) 0.0552 (16) 0.0424 (15) 0.0031 (13) 0.0213 (13) -0.0126 
(12) 
C5 0.0487 (15) 0.0599 (17) 0.0469 (15) 0.0071 (13) 0.0196 (12) -0.0097 
(13) 
C6 0.0450 (14) 0.0477 (14) 0.0394 (13) -0.0040 
(11) 
0.0233 (11) -0.0054 
(11) 
C8 0.0330 (11) 0.0394 (12) 0.0350 (12) 0.0029 (9) 0.0104 (9) -0.0048 
(10) 
C9 0.0539 (15) 0.0443 (14) 0.0461 (15) 0.0056 (12) 0.0131 (12) -0.0130 
(12) 
C10 0.073 (2) 0.037 (4) 0.0420 (16) -0.021 (3) 0.0166 (17) -0.018 (3) 
C11 0.0325 (16) 0.035 (3) 0.058 (3) -0.0071 
(18) 
0.0089 (19) -0.004 (2) 
C10B 0.073 (2) 0.037 (4) 0.0420 (16) -0.021 (3) 0.0166 (17) -0.018 (3) 
C11B 0.0325 (16) 0.035 (3) 0.058 (3) -0.0071 
(18) 
0.0089 (19) -0.004 (2) 
C12 0.0375 (12) 0.0394 (12) 0.0330 (11) 0.0083 (10) 0.0072 (9) -0.0068 (9) 
C13 0.0360 (12) 0.0345 (12) 0.0410 (12) 0.0050 (9) 0.0059 (9) -0.0089 
(10) 
C14 0.0265 (10) 0.0438 (13) 0.0364 (12) 0.0029 (9) 0.0077 (9) -0.0106 (9) 
C15 0.0291 (11) 0.0472 (14) 0.0357 (12) -0.0043 0.0111 (9) -0.0062 
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(10) (10) 
C16 0.0304 (11) 0.0535 (15) 0.0325 (12) -0.0009 
(10) 
0.0128 (9) -0.0049 
(10) 
C17 0.0409 (13) 0.0614 (16) 0.0383 (13) -0.0066 
(12) 
0.0139 (10) 0.0040 (12) 
C18 0.0487 (14) 0.0487 (14) 0.0450 (14) -0.0002 
(12) 
0.0148 (11) 0.0057 (12) 
C19 0.0378 (13) 0.0583 (16) 0.0398 (13) 0.0056 (12) 0.0111 (10) 0.0010 (12) 
C20 0.0272 (10) 0.0520 (14) 0.0355 (12) -0.0009 
(10) 
0.0089 (9) -0.0009 
(10) 
C21 0.0322 (11) 0.0523 (14) 0.0267 (11) -0.0045 
(10) 
0.0061 (8) -0.0095 
(10) 
C22 0.0365 (12) 0.0462 (14) 0.0346 (12) -0.0017 
(10) 
0.0066 (9) -0.0137 
(10) 
C23 0.0315 (11) 0.0353 (12) 0.0387 (12) 0.0057 (9) 0.0052 (9) -0.0079 
(10) 
C24 0.0422 (13) 0.0420 (13) 0.0295 (11) 0.0017 (10) 0.0037 (9) -0.0019 (9) 
C25 0.0545 (17) 0.062 (4) 0.0341 (18) -0.001 (2) 0.0141 (12) -0.008 (3) 
C26 0.054 (3) 0.066 (2) 0.0469 (18) 0.007 (2) 0.005 (2) 0.0227 (17) 
C27 0.072 (3) 0.058 (3) 0.039 (3) -0.015 (3) 0.012 (2) -0.015 (2) 
C25B 0.0545 (17) 0.062 (4) 0.0341 (18) -0.001 (2) 0.0141 (12) -0.008 (3) 
C26B 0.054 (3) 0.066 (2) 0.0469 (18) 0.007 (2) 0.005 (2) 0.0227 (17) 
C27B 0.072 (3) 0.058 (3) 0.039 (3) -0.015 (3) 0.012 (2) -0.015 (2) 
 
Geometric parameters (Å, º) for (II) 
Cl1—C1 1.742 (2) C12—H12A 1.0000 
O1—N1 1.215 (3) C13—H13A 0.9900 
O2—N1 1.228 (3) C13—H13B 0.9900 
O1B—N1 1.210 (15) C14—C23 1.525 (3) 
O2B—N1 1.219 (15) C14—C15 1.541 (3) 
N1—C3 1.466 (3) C14—H14A 1.0000 
O3—C7B 1.236 (18) C15—C16 1.531 (3) 
O3—C7 1.271 (11) C15—H15A 0.9900 
C7—O3B 1.20 (2) C15—H15B 0.9900 
C7—N2 1.341 (7) C16—C17 1.533 (4) 
C7—C6 1.512 (7) C16—C21 1.536 (3) 
O3B—C7B 1.271 (14) C16—H16A 1.0000 
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C7B—N2 1.343 (10) C17—C18 1.522 (4) 
C7B—C6 1.513 (10) C17—H17A 0.9900 
O4—C12 1.425 (3) C17—H17B 0.9900 
O4—H4B 0.824 (14) C18—C19 1.518 (4) 
O5—C23 1.239 (3) C18—H18A 0.9900 
N2—C8 1.475 (3) C18—H18B 0.9900 
N2—C11 1.476 (5) C19—C20 1.526 (4) 
N2—C11B 1.477 (10) C19—H19A 0.9900 
N3—C22 1.470 (3) C19—H19B 0.9900 
N3—C14 1.470 (3) C20—C21 1.541 (3) 
N3—C13 1.471 (3) C20—H20A 0.9900 
N4—C23 1.336 (3) C20—H20B 0.9900 
N4—C24 1.472 (3) C21—C22 1.515 (4) 
N4—H4C 0.88 (3) C21—H21A 1.0000 
C1—C6 1.382 (4) C22—H22A 0.9900 
C1—C2 1.387 (4) C22—H22B 0.9900 
C2—C3 1.385 (4) C24—C25 1.520 (4) 
C2—H2A 0.9500 C24—C27B 1.524 (13) 
C3—C4 1.382 (4) C24—C27 1.535 (5) 
C4—C5 1.374 (4) C24—C26 1.535 (4) 
C4—H4A 0.9500 C24—C25B 1.536 (13) 
C5—C6 1.393 (4) C24—C26B 1.545 (12) 
C5—H5A 0.9500 C25—H25A 0.9800 
C8—C12 1.532 (3) C25—H25B 0.9800 
C8—C9 1.545 (3) C25—H25C 0.9800 
C8—H8A 1.0000 C26—H26A 0.9800 
C9—C10 1.492 (6) C26—H26B 0.9800 
C9—C10B 1.531 (11) C26—H26C 0.9800 
C9—H9A 0.9900 C27—H27A 0.9800 
C9—H9B 0.9900 C27—H27B 0.9800 
C10—C11 1.514 (7) C27—H27C 0.9800 
C10—H10A 0.9900 C25B—H25D 0.9800 
C10—H10B 0.9900 C25B—H25E 0.9800 
C11—H11A 0.9900 C25B—H25F 0.9800 
C11—H11B 0.9900 C26B—H26D 0.9800 
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C10B—C11B 1.519 (11) C26B—H26E 0.9800 
C10B—H10C 0.9900 C26B—H26F 0.9800 
C10B—H10D 0.9900 C27B—H27D 0.9800 
C11B—H11C 0.9900 C27B—H27E 0.9800 
C11B—H11D 0.9900 C27B—H27F 0.9800 
C12—C13 1.526 (3)   
    
O1B—N1—O2B 126 (3) N3—C14—C23 112.03 (19) 
O1—N1—O2 123.3 (3) N3—C14—C15 110.24 (17) 
O1B—N1—C3 110 (3) C23—C14—C15 106.64 (18) 
O1—N1—C3 119.0 (2) N3—C14—H14A 109.3 
O2B—N1—C3 124 (3) C23—C14—H14A 109.3 
O2—N1—C3 117.8 (3) C15—C14—H14A 109.3 
C7B—O3—C7 13 (3) C16—C15—C14 112.51 (19) 
O3B—C7—O3 22.9 (9) C16—C15—H15A 109.1 
O3B—C7—N2 128.8 (12) C14—C15—H15A 109.1 
O3—C7—N2 116.0 (12) C16—C15—H15B 109.1 
O3B—C7—C6 113.6 (12) C14—C15—H15B 109.1 
O3—C7—C6 120.7 (10) H15A—C15—H15B 107.8 
N2—C7—C6 117.5 (7) C15—C16—C17 112.4 (2) 
C7—O3B—C7B 13 (3) C15—C16—C21 109.89 (19) 
O3—C7B—O3B 22.8 (9) C17—C16—C21 111.2 (2) 
O3—C7B—N2 118.4 (11) C15—C16—H16A 107.7 
O3B—C7B—N2 122.9 (19) C17—C16—H16A 107.7 
O3—C7B—C6 123.1 (11) C21—C16—H16A 107.7 
O3B—C7B—C6 109.5 (15) C18—C17—C16 113.0 (2) 
N2—C7B—C6 117.2 (9) C18—C17—H17A 109.0 
C12—O4—H4B 112 (2) C16—C17—H17A 109.0 
C7—N2—C7B 12 (3) C18—C17—H17B 109.0 
C7—N2—C8 128.8 (4) C16—C17—H17B 109.0 
C7B—N2—C8 128.2 (5) H17A—C17—H17B 107.8 
C7—N2—C11 125.8 (5) C19—C18—C17 110.9 (2) 
C8—N2—C11 105.0 (4) C19—C18—H18A 109.5 
C7—N2—C11B 110.1 (7) C17—C18—H18A 109.5 
C7B—N2—C11B 112.6 (8) C19—C18—H18B 109.5 
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C8—N2—C11B 119.2 (6) C17—C18—H18B 109.5 
C22—N3—C14 109.84 (18) H18A—C18—H18B 108.1 
C22—N3—C13 109.01 (18) C18—C19—C20 111.8 (2) 
C14—N3—C13 112.62 (18) C18—C19—H19A 109.3 
C23—N4—C24 126.7 (2) C20—C19—H19A 109.3 
C23—N4—H4C 118.8 (19) C18—C19—H19B 109.3 
C24—N4—H4C 114.2 (19) C20—C19—H19B 109.3 
C6—C1—C2 121.8 (2) H19A—C19—H19B 107.9 
C6—C1—Cl1 120.4 (2) C19—C20—C21 111.6 (2) 
C2—C1—Cl1 117.8 (2) C19—C20—H20A 109.3 
C3—C2—C1 117.3 (2) C21—C20—H20A 109.3 
C3—C2—H2A 121.3 C19—C20—H20B 109.3 
C1—C2—H2A 121.3 C21—C20—H20B 109.3 
C4—C3—C2 122.9 (2) H20A—C20—H20B 108.0 
C4—C3—N1 118.5 (2) C22—C21—C16 110.13 (19) 
C2—C3—N1 118.6 (2) C22—C21—C20 111.7 (2) 
C5—C4—C3 117.7 (2) C16—C21—C20 112.0 (2) 
C5—C4—H4A 121.2 C22—C21—H21A 107.6 
C3—C4—H4A 121.2 C16—C21—H21A 107.6 
C4—C5—C6 121.9 (3) C20—C21—H21A 107.6 
C4—C5—H5A 119.1 N3—C22—C21 113.16 (18) 
C6—C5—H5A 119.1 N3—C22—H22A 108.9 
C1—C6—C5 118.2 (2) C21—C22—H22A 108.9 
C1—C6—C7 120.0 (10) N3—C22—H22B 108.9 
C5—C6—C7 121.4 (9) C21—C22—H22B 108.9 
C1—C6—C7B 130.1 (13) H22A—C22—H22B 107.8 
C5—C6—C7B 111.7 (13) O5—C23—N4 124.3 (2) 
C7—C6—C7B 11 (2) O5—C23—C14 120.3 (2) 
N2—C8—C12 111.36 (19) N4—C23—C14 115.23 (18) 
N2—C8—C9 102.10 (19) N4—C24—C25 106.6 (3) 
C12—C8—C9 112.3 (2) N4—C24—C27B 114.8 (14) 
N2—C8—H8A 110.3 N4—C24—C27 107.9 (3) 
C12—C8—H8A 110.3 C25—C24—C27 111.4 (4) 
C9—C8—H8A 110.3 N4—C24—C26 109.6 (3) 
C10—C9—C8 109.3 (3) C25—C24—C26 110.9 (3) 
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C10B—C9—C8 97.7 (6) C27—C24—C26 110.3 (3) 
C10—C9—H9A 109.8 N4—C24—C25B 105.5 (12) 
C8—C9—H9A 109.8 C27B—C24—C25B 108.3 (18) 
C10—C9—H9B 109.8 N4—C24—C26B 104.9 (9) 
C8—C9—H9B 109.8 C27B—C24—C26B 114.1 (13) 
H9A—C9—H9B 108.3 C25B—C24—C26B 108.9 (13) 
C9—C10—C11 102.3 (6) C24—C25—H25A 109.5 
C9—C10—H10A 111.3 C24—C25—H25B 109.5 
C11—C10—H10A 111.3 H25A—C25—H25B 109.5 
C9—C10—H10B 111.3 C24—C25—H25C 109.5 
C11—C10—H10B 111.3 H25A—C25—H25C 109.5 
H10A—C10—H10B 109.2 H25B—C25—H25C 109.5 
N2—C11—C10 105.1 (5) C24—C26—H26A 109.5 
N2—C11—H11A 110.7 C24—C26—H26B 109.5 
C10—C11—H11A 110.7 H26A—C26—H26B 109.5 
N2—C11—H11B 110.7 C24—C26—H26C 109.5 
C10—C11—H11B 110.7 H26A—C26—H26C 109.5 
H11A—C11—H11B 108.8 H26B—C26—H26C 109.5 
C11B—C10B—C9 116.4 (11) C24—C27—H27A 109.5 
C11B—C10B—
H10C 
108.2 C24—C27—H27B 109.5 
C9—C10B—H10C 108.2 H27A—C27—H27B 109.5 
C11B—C10B—
H10D 
108.2 C24—C27—H27C 109.5 
C9—C10B—H10D 108.2 H27A—C27—H27C 109.5 
H10C—C10B—
H10D 
107.3 H27B—C27—H27C 109.5 
N2—C11B—C10B 94.0 (9) C24—C25B—H25D 109.5 
N2—C11B—H11C 112.9 C24—C25B—H25E 109.5 
C10B—C11B—
H11C 
112.9 H25D—C25B—
H25E 
109.5 
N2—C11B—H11D 112.9 C24—C25B—H25F 109.5 
C10B—C11B—
H11D 
112.9 H25D—C25B—
H25F 
109.5 
H11C—C11B—
H11D 
110.3 H25E—C25B—
H25F 
109.5 
O4—C12—C13 108.45 (19) C24—C26B—H26D 109.5 
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O4—C12—C8 108.7 (2) C24—C26B—H26E 109.5 
C13—C12—C8 110.82 (18) H26D—C26B—
H26E 
109.5 
O4—C12—H12A 109.6 C24—C26B—H26F 109.5 
C13—C12—H12A 109.6 H26D—C26B—
H26F 
109.5 
C8—C12—H12A 109.6 H26E—C26B—
H26F 
109.5 
N3—C13—C12 111.04 (18) C24—C27B—H27D 109.5 
N3—C13—H13A 109.4 C24—C27B—H27E 109.5 
C12—C13—H13A 109.4 H27D—C27B—
H27E 
109.5 
N3—C13—H13B 109.4 C24—C27B—H27F 109.5 
C12—C13—H13B 109.4 H27D—C27B—
H27F 
109.5 
H13A—C13—H13B 108.0 H27E—C27B—
H27F 
109.5 
    
C7B—O3—C7—
O3B 
154 (6) O3B—C7B—C6—
C5 
-89 (3) 
C7B—O3—C7—N2 -77 (3) N2—C7B—C6—C5 125 (2) 
C7B—O3—C7—C6 76 (3) O3—C7B—C6—C7 87 (5) 
O3—C7—O3B—
C7B 
-26 (5) O3B—C7B—C6—
C7 
67 (4) 
N2—C7—O3B—
C7B 
-88 (4) N2—C7B—C6—C7 -80 (4) 
C6—C7—O3B—
C7B 
88 (3) C7—N2—C8—C12 -100.6 (15) 
C7—O3—C7B—
O3B 
-25 (5) C7B—N2—C8—
C12 
-85 (2) 
C7—O3—C7B—N2 83 (4) C11—N2—C8—
C12 
86.4 (4) 
C7—O3—C7B—C6 -84 (4) C11B—N2—C8—
C12 
96.6 (9) 
C7—O3B—C7B—
O3 
153 (6) C7—N2—C8—C9 139.3 (15) 
C7—O3B—C7B—
N2 
68 (4) C7B—N2—C8—C9 155 (2) 
C7—O3B—C7B—
C6 
-76 (3) C11—N2—C8—C9 -33.6 (4) 
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O3B—C7—N2—
C7B 
95 (4) C11B—N2—C8—
C9 
-23.5 (9) 
O3—C7—N2—C7B 72 (4) N2—C8—C9—C10 14.1 (5) 
C6—C7—N2—C7B -81 (4) C12—C8—C9—
C10 
-105.3 (4) 
O3B—C7—N2—C8 -174 (2) N2—C8—C9—
C10B 
29.1 (7) 
O3—C7—N2—C8 163.8 (14) C12—C8—C9—
C10B 
-90.3 (7) 
C6—C7—N2—C8 11 (3) C8—C9—C10—
C11 
10.2 (8) 
O3—C7—N2—C11 -25 (3) C7—N2—C11—
C10 
-131.3 (15) 
C6—C7—N2—C11 -177.9 (10) C8—N2—C11—
C10 
42.0 (7) 
O3B—C7—N2—
C11B 
-10 (4) C9—C10—C11—
N2 
-31.3 (9) 
O3—C7—N2—
C11B 
-32 (3) C8—C9—C10B—
C11B 
-31.8 (15) 
C6—C7—N2—
C11B 
174.6 (15) C7—N2—C11B—
C10B 
-161.4 (15) 
O3—C7B—N2—C7 -87 (5) C7B—N2—C11B—
C10B 
-174 (2) 
O3B—C7B—N2—
C7 
-61 (4) C8—N2—C11B—
C10B 
4.3 (16) 
C6—C7B—N2—C7 80 (4) C9—C10B—
C11B—N2 
18.3 (18) 
O3—C7B—N2—C8 174.9 (19) N2—C8—C12—O4 55.0 (2) 
O3B—C7B—N2—
C8 
-159.1 (18) C9—C8—C12—O4 168.76 (19) 
C6—C7B—N2—C8 -18 (4) N2—C8—C12—
C13 
174.05 (19) 
O3—C7B—N2—
C11B 
-7 (4) C9—C8—C12—
C13 
-72.1 (2) 
O3B—C7B—N2—
C11B 
19 (4) C22—N3—C13—
C12 
-85.1 (2) 
C6—C7B—N2—
C11B 
161 (2) C14—N3—C13—
C12 
152.70 (18) 
C6—C1—C2—C3 3.5 (3) O4—C12—C13—
N3 
-73.4 (2) 
Cl1—C1—C2—C3 -174.92 (18) C8—C12—C13— 167.38 (18) 
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N3 
C1—C2—C3—C4 0.3 (4) C22—N3—C14—
C23 
177.20 (18) 
C1—C2—C3—N1 -179.6 (2) C13—N3—C14—
C23 
-61.1 (2) 
O1B—N1—C3—C4 155 (6) C22—N3—C14—
C15 
58.6 (2) 
O1—N1—C3—C4 -168.9 (3) C13—N3—C14—
C15 
-179.68 (18) 
O2B—N1—C3—C4 -36 (7) N3—C14—C15—
C16 
-56.0 (2) 
O2—N1—C3—C4 10.2 (4) C23—C14—C15—
C16 
-177.86 (18) 
O1B—N1—C3—C2 -26 (6) C14—C15—C16—
C17 
176.37 (19) 
O1—N1—C3—C2 10.9 (4) C14—C15—C16—
C21 
52.0 (2) 
O2B—N1—C3—C2 144 (7) C15—C16—C17—
C18 
-70.8 (3) 
O2—N1—C3—C2 -169.9 (3) C21—C16—C17—
C18 
52.9 (3) 
C2—C3—C4—C5 -2.2 (4) C16—C17—C18—
C19 
-55.0 (3) 
N1—C3—C4—C5 177.7 (2) C17—C18—C19—
C20 
55.7 (3) 
C3—C4—C5—C6 0.4 (4) C18—C19—C20—
C21 
-55.3 (3) 
C2—C1—C6—C5 -5.2 (4) C15—C16—C21—
C22 
-51.3 (2) 
Cl1—C1—C6—C5 173.2 (2) C17—C16—C21—
C22 
-176.4 (2) 
C2—C1—C6—C7 -179.1 (6) C15—C16—C21—
C20 
73.6 (2) 
Cl1—C1—C6—C7 -0.7 (6) C17—C16—C21—
C20 
-51.5 (3) 
C2—C1—C6—C7B 176.1 (9) C19—C20—C21—
C22 
177.21 (19) 
Cl1—C1—C6—C7B -5.5 (10) C19—C20—C21—
C16 
53.1 (3) 
C4—C5—C6—C1 3.2 (4) C14—N3—C22—
C21 
-61.1 (2) 
422 
 
C4—C5—C6—C7 177.0 (7) C13—N3—C22—
C21 
175.09 (19) 
C4—C5—C6—C7B -177.9 (8) C16—C21—C22—
N3 
57.2 (2) 
O3B—C7—C6—C1 105 (2) C20—C21—C22—
N3 
-67.9 (2) 
O3—C7—C6—C1 129 (2) C24—N4—C23—
O5 
-3.2 (4) 
N2—C7—C6—C1 -79 (2) C24—N4—C23—
C14 
-178.2 (2) 
O3B—C7—C6—C5 -69 (3) N3—C14—C23—
O5 
149.4 (2) 
O3—C7—C6—C5 -44 (3) C15—C14—C23—
O5 
-89.9 (2) 
N2—C7—C6—C5 107.5 (16) N3—C14—C23—
N4 
-35.4 (3) 
O3B—C7—C6—
C7B 
-95 (4) C15—C14—C23—
N4 
85.3 (2) 
O3—C7—C6—C7B -71 (4) C23—N4—C24—
C25 
-179.4 (4) 
N2—C7—C6—C7B 81 (4) C23—N4—C24—
C27B 
43.0 (15) 
O3—C7B—C6—C1 110 (3) C23—N4—C24—
C27 
60.9 (4) 
O3B—C7B—C6—
C1 
90 (2) C23—N4—C24—
C26 
-59.3 (5) 
N2—C7B—C6—C1 -57 (3) C23—N4—C24—
C25B 
162.1 (12) 
O3—C7B—C6—C5 -69 (3) C23—N4—C24—
C26B 
-83.0 (13) 
 
Hydrogen-bond geometry (Å, º) for (II) 
 D—H···A D—H H···A D···A D—H···A 
N4—H4C···O4 0.88 (3) 2.60 (3) 3.219 (3) 129 (3) 
O4—H4B···O5i 0.82 (1) 1.89 (2) 2.709 (2) 170 (4) 
 
Symmetry code:  (i) x-1, y, z. 
Document origin: publCIF [Westrip, S. P. (2010). J. Apply. Cryst., 43, 920-925]. 
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